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ABSTRACT OF THE THESIS 
This thesis examined the in vitro and in vivo anti-oxidative and anti-diabetic activities of five 
African medicinal plants which are traditionally used for the treatment of diabetes mellitus viz; 
Ziziphus mucronata, Cassia singueana, Parkia biglobosa, Khaya senegalensis and Vitex 
doniana. Ethanol, ethyl acetate and aqueous crude extracts of the stem bark, root and leaf 
samples of each of the plants (a total of 45 crude extracts) were investigated for detailed anti-
oxidative activity and the most active crude extract from each plant was selected for further 
fractionation with solvents of increasing polarity. Subsequently, the solvent fractions derived 
from these crude extracts (a total of 21 fractions) were also subjected to the anti-oxidative assays 
as well as α-glucosidase and α-amylase inhibitory activities assays. Results from these assays 
revealed that the butanol fractions from crude extracts of Z. mucronata, P. biglobosa, K. 
senegalensis and V. doniana and the acetone fraction from the crude extract of C. singueana 
were the most bioactive. Kinetic delineation of the types of enzyme inhibitions exerted by these 
most active fractions as well as measurement of relevant kinetic parameters (KM, Vmax and Ki) 
were done using Lineweaver-Burke’s plot. Furthermore, the most active fractions were also 
subjected to GC-MS analysis and in vivo intervention trial in a type 2 diabetes (T2D) model of 
rats (except fraction from V. doniana). The in vivo studies revealed that all the fractions 
possessed potent in vivo anti-T2D activity (to varying extent) and the possible mechanisms of 
actions were proposed.  Furthermore, most of the fractions were able to ameliorate the T2D-
associated complications. Analysis of in vivo oxidative stress markers such as glutathione, 
thiobarbituric acid reactive substances, superoxide dismutase and catalase in the serum, liver, 
kidney, heart and pancreas of the animals also gave a clue in to the possible mechanism of 
action. Bioassay guided isolation was used to track the bioactive anti-diabetic compounds from 
these fractions via column chromatography. The isolated compounds were characterized by 1H 
NMR, 13C NMR, 2D NMR (in two cases) and mass spectroscopy (in one case). From this study, 
2,7-dihydroxy-4H-1-benzopyran-4-one, 3β-O-acetyl betulinic acid, lupeol and 
bicyclo[2.2.0]hexane-2,3,5triol were identified as the possible bioactive compounds from Z. 
mucronata, C. singueana, P. biglobosa, K. senegalensis solvent fractions respectively. The 
findings of this work are important for the relevant government agencies, pharmaceutical 
industries, scientific community and poor diabetic patients because it might open an avenue for 
the development of viable and cost effective anti-diabetic herbal products and/or novel plant-
derived anti-diabetic drugs. 
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INTRODUCTION AND LITERATURE REVIEW 
 
1.0 DIABETES MELLITUS 
Diabetes mellitus could be defined as a heterogeneous group of a complex metabolic disorder associated 
with high blood glucose concentrations (hyperglycemia) and alterations in the metabolism of major 
macromolecules resulting from impairments in the secretion of insulin or its action [1, 2]. Diabetes is 
commonly accompanied with polydipsia, polyuria, microvascular problems involving eyes, kidney and 
peripheral nerves as well as cardiovascular problems such as hypertension [3, 4]. These complications 
affect about 50% of diabetic patients and can lead to their death [5, 6] thereby making diabetes a 
recognized fatal disease in different parts of the world for centuries.  
 
Insulin is a hormone synthesized by the β-cells at the pancreatic isles of Langerhans and its primary role 
is to tightly control blood glucose levels which usually rise after dietary intake. Thus, insulin is released 
from the pancreatic β-cells to normalize the glucose level. Therefore, in diabetic patients, anomalies in the 
production of insulin and/or its utilization cause hyperglycemia. Insulin is also vital to carbohydrates and 
lipids metabolism because it lowers blood glucose levels by enhancing the glucose uptake by cells and by 
stimulating glycogenesis as well as inhibiting glycogenolysis. It also retards the breakdown of fats to free 
fatty acids and ketone bodies [7]. This hormone also encourages the storage of fat into the adipose tissues 
and reduces gluconeogenesis in liver and kidneys. 
At present, diabetes is the fifth major cause of death in the world affecting 366 million individuals 
globally and this figure is projected to increase to a staggering 552 million by the year 2030 as reported 
by the International Diabetes Federation [8]. It is also projected that the greatest number of diabetic 
patients are between 40-59 years of age and about 50% of diabetic cases are still undiagnosed [8]. In 2011 
alone, 4.6 million deaths were attributed to diabetes and about USD 465 billion dollars were spent as 
healthcare expenditures due to diabetes [8]. In Africa, the prevalence rate of diabetes is 4.3% and the 
region was reported to have the highest mortality rate due to the disease [9].  More specifically, South 
African population is greatly affected by diabetes because it is the fourth major cause of death in the 
country [10] affecting all race groups. However, the Indian origin-South Africans have the highest 
prevalence because of a gene pool that predisposes them to diabetes [10, 11]. Also the black community 
is at risk because of rapid lifestyle and cultural changes [12].  
1.1 CLASSIFICATION 
Diabetes mellitus is broadly classified, based on the clinical manifestations, into two main types such as 
type 1 diabetes (T1D) or insulin-dependent diabetes mellitus (IDDM) and type 2 diabetes (T2D) or non-
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insulin dependent diabetes mellitus (NIDDM). However, a number of authors have also recognized a third 
category called gestational diabetes or type 3 diabetes [13, 14]. Apart from these common types of 
diabetes, another type of diabetes is also found rarely called diabetes insipidus where the synthesis, 
transport or release of anti-diuretic hormone (vasopressin) are impaired resulting in polyuria and 
polydipsia [15]. 
 
1.1.1 Type 1 Diabetes 
Type 1 diabetes (T1D) is responsible for approximately 5-10% of the total diabetic patients worldwide. It 
is caused by destruction of the insulin-secreting pancreatic β-cells by cellular mediated autoimmunity 
which leads to complete deficiency of insulin in the circulation. A number of factors have been proposed 
for the autoimmune destruction of the β-cells which includes immunological, genetic and environmental 
factors. The first proposal on the pathogenesis of T1D was made by George Eisenbarth in 1986 that 
observed the presence of one or more autoantibodies to islet cells in diabetic patients with polyendocrine 
deficiencies and consequently proposed a chronic autoimmune process caused by unknown factors as the 
basis for the destruction of the β-cells by autoreactive lymphocytes [16]. Subsequently, autoantibodies to 
insulin, glutamic acid decarboxylase and tyrosine phosphatases were also implicated [17] in the 
pathogenesis of T1D. On the other hand, the most powerful genetic risk factor for the disease 
pathogenesis is associated with human leukocyte antigen (HLA) locus which is categorized into class I 
and II. The class II HLA locus is the high-risk which represents the strongest genetic association with 
T1D [18]. However, apart from HLA loci, over 40 non-HLA polymorphisms that are associated with T1D 
have also been identified through genome-wide association studies and other novel loci have also been 
confirmed in prospective population-based studies [18]. The environmental factors involved in the 
pathogenesis of T1D include parasites, viruses and bacteria which mediate the direct infection of the 
pancreatic β-cells or shape the immune system to mutually benefit the parasite and the host [19, 20].  
 
Apart from hyperglycemia, diabetic ketoacidosis is another hallmark of T1D which is caused by 
decreased glucose utilization by body tissues with concomitant increase in lipid catabolism to compensate 
for the body energy demand [21]. Prolonged lipid catabolism leads to the accumulation of acetyl coA 
which could trigger ketogenesis with concomitant disturbances in the body’s pH homoestatic mechanism 
(ketoacidosis) and death could result if proper action is not taken. Other important features of T1D are 
polyuria, polydipsia, polyphagia, unexplained weight loss, lethargy, fatigue and abdominal pain [21]. 
Insulin therapy is the most predominantly and commonly used method for the treatment of T1D. 
However, because of the very low prevalence of T1D, most of the diabetes related deaths are caused by 




1.1.2 Type 2 Diabetes 
Type 2 diabetes (T2D) could be defined as a complex metabolic disorder that is associated with a gradual 
loss in the action of insulin (insulin resistance), followed by the failure of pancreatic β-cells to account for 
the insulin resistance (β-cell dysfunction) [2].  
 
T2D is a product of a complex interaction between environmental and genetic factors. The genetic factors 
are insulin resistance and β-cell dysfunction, whereas weight gain, physical inactivity or sedentary life 
style and oxidative stress exacerbate these metabolic abnormalities. At present, a two-step process has 
been proposed for the pathogenesis of T2D [22].   In step one, normal individuals progress to impaired 
glucose tolerant (IGT) individuals with insulin resistance as the primary marker. Blood insulin levels are 
increased, and β-cell function is usually impaired [23]. In the second step, IGT progresses to T2D due to a 
decline in β-cell function. 
This dissertation intends to mainly focus on T2D and therefore the pathogenesis of the two main features 
of the disease (insulin resistance and pancreatic β-cell dysfunction) are elaborated below. Furthermore, all 
subsequent sub-headings (within this chapter) and indeed other chapters will mainly focus on T2D. 
1.1.2.1 Insulin resistance  
Insulin resistance could be defined as impaired insulin-mediated glucose uptake in skeletal muscle and 
inhibition of hepatic glucose synthesis. However, in the fasting state, the muscle is also responsible for a 
small percentage of glucose disposals (less than 20%) while endogenous glucose production accounts for 
all the glucose that enters the blood circulation. Endogenous glucose production is elevated in T2D 
patients or impaired fasting glucose [24]. Therefore, the driving force of hyperglycemia in T2D is hepatic 
insulin resistance. Research findings have indicated that a number of factors act individually or 
synergistically in the development of insulin resistance [2]. These factors include obesity, molecular 
defects in insulin signaling and oxidative stress. 
 
 Obesity 
Sedentary life style, physical inactivity and obesity are important causes of insulin resistance in the 
developed world. The mechanisms involved appeared to be complex but cytokines and circulating 
hormones as well as metabolic fuels such as non-esterified fatty acids (NEFA) in the adipocyte are 
implicated in the modulation of insulin activity. An increase in the mass of stored triglycerides in adipose 
tissues usually leads to large adipocytes which resist the insulin action towards retarding lipids 
breakdown. Consequently, an elevation in the levels of glycerol and circulating NEFA occurs and these 
are known to stimulate insulin resistance in liver and skeletal muscle [25]. Although the mechanism of 
fatty acid-induced insulin resistance is not completely understood, the most important concept is that fatty 
acids interfere with insulin signaling events via serine phosphorylation of insulin receptor substrate-1 
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(IRS-1) by protein kinase C [26]. Another molecular target involved in the inhibition of insulin action is 
tumor necrosis factor- (TNF-) which blocks insulin signaling by altering the interactions between IRS-
1 and insulin receptor [27]. Resistin is also another adipocyte-associated factor linked to the obesity-
mediated insulin resistance which acts via deactivation of AMP-kinase and consequently impairs the 
normal effects of this enzyme on transcriptionally regulated gluconeogenic enzymes.  This suggests that 
resistin has an important regulatory role over hepatic glucose production in obese subjects.  
 
 Molecular mechanisms involved in insulin resistance 
In order to understand how molecular defects in insulin signaling causes insulin resistance, some basic 
understanding into the molecular mechanisms involved in insulin signaling pathway is paramount.  
 
The molecular events via which insulin promotes glucose uptake by target cells commences with the 
binding of the hormone to specific cell surface receptors with tyrosine kinase activity that are located on 
insulin target tissues [28]. Once the insulin binds the receptor, second messengers are generated which 
eventually initiate a chain of phosphorylation-dephosphorylation reactions that promote glucose 
metabolism inside the cells. The first event in intracellular glucose metabolism is the activation of glucose 
transport system (GLUT4) which leads to influx of glucose into the cells. Upon entry, the free glucose is 
metabolized by a cascade of enzymatic reactions in glycolytic and TCA cycle pathways. Most of these 
enzymatic reactions are also directly regulated by insulin. Among these, the most important are 
hexokinase which catalyze the phosphorylation of glucose, glycogen synthase which catalyzed glycogen 
synthesis, phosphofructokinase which regulate glycolysis.  
Thus, insulin resistance also results due to blockage of one or more of the molecular insulin signaling 
events listed below. 
 Insulin receptor tyrosine kinase  activity [28] 
 Phosphorylation and dephosphorylation of insulin receptor substrate (IRS) proteins [29] 
 Translocation of GLUT 4 and glucose transport [2] 
 NFkB activity  
 Oxidative stress 
The involvement of oxidative stress in the different aspect of T2D pathology has been the subject of 
intensive clinical and biomedical investigations. More specifically, the involvement of oxidative stress in 
the pathogenesis of insulin resistance also appears to be complicated and poorly understood at the 
moment. In vitro studies have provided evidence that H2O2, a reactive oxygen species (ROS), can cause a  
marked decrease in the insulin stimulation of the insulin signaling proteins (such as IRS and AkT) and of 
5 
 
course, glucose transport activity thereby leading to insulin resistance [30] (Figure 1.1). Studies have also 
shown that other stress-activated serine kinases are involved in the pathogenesis of oxidant-induced 
insulin resistance. For example, serine kinase IκB kinaseβ (IKKβ) controls the function of the redox-
sensitive transcription factor NF-κB which leads to stimulation of the expression of proinflammatory 
genes as well as modulate cell survival, immune responses and metabolic regulation. Interestingly, IKKβ 
could also be activated by ROS and inhibition of IKKβ is related with diminished insulin resistance [31]. 
Interestingly, these studies are strongly supported by several other studies which showed that excess 
mitochondrial H2O2 productions play a pivotal role in causing insulin resistance in the skeletal muscle of 
individuals with excess energy [31]. On the other hand, the renin-angiotensin system is also associated 
with skeletal muscle insulin resistance and T2D (Figure 1.1). Angiotensin II (ANG II) is an important 
component of the system and was reported to stimulate the activity of NADPH oxidase to produce 
superoxide ions through a reduction of oxygen and the oxidation of NADPH (Figure 1.1). Interestingly, 
these NADPH-derived superoxides were found to be critical in the ANG-II induced impairment of insulin 
signaling systems as well as insulin resistance [31].   
 
Figure 1.1: The involvement of oxidative stress in the development of insulin resistance. Excess 
generation of ROS from NADPH oxidase and other mitochondrial sources in muscle leads to the 
attenuation of stress-activated kinases and consequently diminish insulin- signaling molecular events as 
well as reduce glucose transport process (Adapted without permission from Henriksen et al. [31]) 
Apart from in vitro experiments, studies with animal models have provided strong evidence for the 
connection of oxidative stress and insulin resistance. Antioxidant (-lipoic acid) was found to improve 
insulin sensitivity in animal models of diabetes and was also reported to have a direct stimulatory effect 
on GLUT 4 translocation or activation. Furthermore, many clinical trials have revealed that 
administration of antioxidant vitamins (C and E) or glutathione stimulate insulin sensitivity in human 
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subjects with insulin resistance [32]. All these findings portray the vital role of oxidative stress-mediated 
events in causing insulin resistance.   
 
1.1.2.2 Pancreatic β-cell dysfunction 
Pancreatic β-cell dysfunction is a gradual progressive decline in insulin secretion and the failure of the β-
cells to account for the insulin resistance [33]. Several studies have been carried out to understand the 
mechanism of β-cell dysfunction in T2D but none of the proposed mechanisms is widely accepted by the 
experts in the field. However, the hypotheses which have been put forward are briefly discussed below. 
 
 Glucose-induced β-cell toxicity  
Considerable evidences suggest that hyperglycemia in type 2 diabetic patients contribute to pancreatic β-
cell dysfunction although the direct toxic effects of glucose is still an issue of controversy. However, 
abnormally high glucose level has been reported to impair with the functions of important genes, key 
enzymes and every major metabolic pathway in the pancreatic β-cells [34]. This suggests that high 
glucose level is detrimental to the components of insulin producing β-cells leading to decline in insulin 
secretion.  
 
 Beta-cell exhaustion 
Several studies have been carried out in animal models and humans that support the β-cell exhaustion. 
Deterioration of insulin secretion over time has been partly attributed to functional exhaustion in β-cells. 
Chronic hyperglycemia causes a nonsustainable compensatory increase in insulin secretion which 
consequently depletes some cellular components for continued insulin secretion [34].  
 
 Lipid-induced β-cell toxicity 
The effect of lipids on β-cell dysfunction is complex and poorly understood at the moment. However, two 
mechanisms have been proposed to be involved. The concentrations of free fatty acids are usually 
increased in type 2 diabetic patients as a result of increased adipocyte lipolysis. The presence of high 
glucose level inhibits the β-oxidation of these free fatty acids which consequently will lead to the 
accumulation of long chain fatty acyl coA [35]. Subsequently, the accumulated fatty acyl coA interferes 
with the normal potassium channel activity and activates uncoupling protein-2 which would uncouple 
electron transport chain from oxidative phosphorylation leading to diminished ATP production and 
decreased insulin secretion [36]. Another proposed mechanism for lipid-induced β-cell toxicity involves 
the biosynthesis of ceramide from free fatty acids. Ceramide was reported to inhibit the expression of 




 Role of oxidative stress on β-cell dysfunction  
Oxidative stress appears to be the common unifying pathogenic factor for the glucose and lipid-induced 
β-cell dysfunction.  The pancreatic β-cells are the most susceptible cells to oxidative stress-induced 
damages [38] among other cells in the body. This is partly because the β-cells have very low amount of 
ROS detoxifying enzymes (catalase and superoxide dismutase) as well as redox-regulating enzyme, 
glutathione peroxidase [39]. It was suggested that hyperglycemia leads to the generation of high amount 
of ROS via stimulation of mitochondrial electron transport chain resulting in the overproduction of 
superoxide anions. Also, autooxidation of glucose in the presence of transition metals as well as the 
generation of advanced glycation end products (AGE) are other various mechanisms of hyperglycemia-
induced generation of ROS [40]. On the other hand, in vitro and in vivo investigations have provided 
evidences that diminished secretion of insulin and β-cell dysfunction are associated with free fatty acids-
induced ROS production [41]. These ROS from the above mentioned sources attack vital cellular 
components leading to β-cell dysfunction. This is further supported by an in vitro study where high blood 
glucose levels induce mitochondrial ROS and diminished the initial phase of glucose-induced insulin 
secretion via the suppression of glyceraldehyde-3-phosphate dehydrogenase [42]. An additional 
mechanism of oxidative stress-induced β-cell dysfunction is via the stimulation of NFkB which is majorly 
a pro-apoptotic process in β-cells [38]. 
 
 Pancreatic islet amyloid 
The involvement of amyloidogenic process in the pathophysiology of β-cell dysfunction is not clear at the 
moment. Islet amyloid is made up of islet amyloid polypeptide deposits called amylin which is 
simultaneously secreted with insulin and was proposed to act via inhibition of insulin action and/or 
secretion as well as the inhibition of glucagon. Small aggregates of amyloid polypeptides were found to 
be cytotoxic to β-cells due to ‘’channel formation’’ as well as calcium influx into the cells [43]. Thus, it is 
possible that hyperglycemia promotes amylin aggregation which is in turn cytotoxic to the β cells.  
 
Summarily, although hundreds of studies have been conducted in vitro and in vivo in order to understand 
the pathogenesis of β-cell dysfunction, but a number of knowledge-gap still exists in the area. Therefore, 
more research work is needed to solve some of the puzzles.  
1.2 COMPLICATIONS OF TYPE 2 DIABETES 
T2D-induced complications affect more than 50% of diabetic patients and accounts for more than 70% of 
all case-fatalities making these complications the leading mortality cause among type 2 diabetic patients 
[5, 44]. A number of theories have been put forward to explain the pathophysiology of the vascular 
complications in T2D which include increase in the metabolic flux of polyol (sorbitol) pathway [45], 
formation of high amounts of AGE as well as activation of protein kinase C [46]. Interestingly, all these 
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processes lead to the induction of oxidative stress. Therefore, oxidative stress-mediated events are 
considered the most important unifying pathogenic factors responsible for the initiation and progression 
of T2D-associated complications.  
 
1.2.1 Oxidative stress and T2D: focus on ROS generating pathways 
Oxidative stress is the most important mechanism that unites the pathogenesis of all diabetic 
complications and indeed plays a role in all other aspects of diabetes pathology. Therefore, in this sub 
chapter, oxidative stress will be briefly reviewed in the context of T2D with emphasis on the multiple 
pathways responsible for the induction of this stress.  
 
Oxidative stress refers to the presence of free radicals and ROS which are produced in normal body 
processes and are usually neutralized by a chain of endogenous antioxidants systems. However, when 
there is an excess generation of ROS or the antioxidants are inactivated, the ROS/antioxidants equilibrium 
usually shift in favor of stress, thereby making the ROS become harmful to the body [40]. The most 
important ROS are superoxides, hydroxyl radicals and peroxides while the endogenous antioxidants are 
divided into enzymatic (examples are superoxide dismutase, catalase, and glutathione peroxidase) and 
non-enzymatic (examples are glutathione, vitamins A, C and E). In T2D, hyperglycemia induces 
oxidative stress via multiple pathways which include glucose autooxidation, increased metabolic flux of 
the polyol (sorbitol) pathway, increased  production of AGE, activation of protein kinase C  as well as 
increased flux of the hexosamine pathway [3, 47]. 
1.2.1.1 Glucose autooxidation 
This is the single hyperglycemia-induced unifying process that links other pathogenic mechanisms of 
diabetic complications [48]. In T2D, hyperglycemia leads to the overdrive of the TCA cycle with 
concomitant increase in the number of electron donors (NADH and FADH2) that enter the electron 
transport chain. Consequently, the differences in voltage across the membranes of the mitochondria shoot 
up until a critical threshold is attained when the transfer of electrons within complex III is blocked 
making the electrons to revert to coenzyme Q. Subsequently, the coenzyme Q donates the electrons, one 
after the other, to molecular oxygen, thereby producing high amounts of superoxide [48] that cannot be 
completely be neutralized by the mitochondrial SOD (Figure 1.2). It is generally accepted that this 
mitochondrial-derived overproduction of superoxides is the unifying hypothesis that account for the 





Figure 1.2: Hyperglycemia induced excess generation of superoxides in the mitochondrial electron 
transport chain (Adapted from Brownlee [48]) 
1.2.1.2 Increased metabolic flux of polyol pathway 
The role of this pathway as a major player in the T2D-associated oxidative stress was first described by 
Gabbay et al. [49]. Under normal condition, toxic aldehydes are converted to inactive alcohols by 
NADPH-dependent aldose reductase (AR) but upon elevation of glucose concentration, the glucose first 
undergoes reduction to produce its sugar alcohol sorbitol catalyzed by AR. Subsequently, NAD-
dependent sorbitol dehydrogenase oxidized the sorbitol to fructose (Figure 1.3). Hyperactivity of the 
polyol pathway under diabetic situation leads to high levels of intracellular sorbitol that results in osmotic 
stress and production of fructose, which is 10 times more powerful as an agent of glycation than glucose 
[45]. Another biochemical consequence of increased polyol pathway is the consumption of NADPH by 
AR which consequently affects the regeneration of the most important endogenous non-enzymatic 
antioxidant, reduced glutathione (Figure 1.3). The overall effect of these events is increased susceptibility 
to intracellular oxidative stress [48].  
 
Figure 1.3: Relationship between hyperglycemia, increased polyol pathway and oxidative stress in T2D 
(Adapted from Brownlee [3]). 
10 
 
1.2.1.3 Increased generation of advanced glycation end products (AGE) 
The concept of AGE as biological drivers to T2D-associated oxidative stress started manifesting in 1970s. 
AGE are a complex group of compounds formed from a non-enzymatic covalent bonding of aldehyde or 
ketone groups of reducing sugars to the free amine groups on proteins, lipids, or nucleic acids. Research 
findings have revealed that the major AGE produced in vivo is formed from oxoaldehydes or dicarbonyls 
such as glyoxal, 3-deoxyglucosone and methylglyoxal which are established highly reactive intermediate 
carbonyl groups. Common examples of AGE in humans are N-carboxymethyl-lysine and pentosidine 
[50]. The generation of AGEs which is associated by ROS-generating reactions at different steps [51] and 
under diabetic condition, high glucose stimulates AGEs generation and consequently leads to the 
overproduction of ROS which cannot be completely neutralized by endogenous antioxidants resulting in 
oxidative stress. Another ROS-generating step associated with AGEs occurs during binding of the AGEs 
to various receptors called RAGE [52]. AGEs play a cardinal role in causing biological damages to cells 
by modifying intracellular proteins involved in gene transcription or modifying extracellular matrix 
molecules as well as blood proteins like albumin [48]. 
 
1.2.1.4 Activation of protein kinase C (PKC) 
PKC is a threonine/serine kinase that performs a vital role in signal transduction processes and respond to 
specific neuronal, hormonal and growth factor stimuli. This enzyme catalyzes the transfer of phosphate 
moieties from ATP to various substrate proteins, while the enzyme itself undergoes a series of complex 
phosphorylation steps before it is activated and translocated from the cytosol to the cell membrane [53]. 
Under normal physiological state, the activation of PKC is achieved in cells through pathways that 
produce diacyl glycerol (DAG). In hyperglycemic or diabetic situation, there is usually an increase in the 
metabolic flux of glycolysis which increases the levels of the glycolytic intermediate, dihydroxyacetone 
phosphate (DHAP). The DHAP is reduced to glycerol-3-phosphate, which subsequently promotes the de 
novo synthesis of DAG [54] leading to profound activation of PKC (Figure 1.4). Apart from this major 
PKC activation pathway, this enzyme is activated by oxidants such as H2O2 in a manner unrelated to lipid 
second messengers and by mitochondrial superoxide induced by elevated glucose levels [55].  
 
The activation of PKC has been linked to the induction of oxidative stress and a number of metabolic and 
functional aberrations in T2D. Upon activation of PKC under diabetic condition, NADPH oxidase which 
is the most important source of ROS production in blood vessels is consequently activated by PKC-
dependent mechanisms (Figure 1.4) and this is thought to be the most essential path responsible for 
increased ROS production in blood vessels [56]. Furthermore, the pathway has been implicated as a vital 
process in the increased vascular permeability and neovascularization as well as decreased Na+-K+ 
ATPase activity observed in diabetic animals [57]. Indeed, most of the diabetes-induced vascular 
complications are associated, at least in part, with the PKC-dependent increase in ROS [53, 55]. A 
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schematic representation of the biological effects of PKC activation under diabetic condition is provided 
below. 
  
Figure 1.4: Multiple effects of PKC activation in diabetic animals. (Adapted from Geraldes and King 
[55]).  
1.2.1.5 Hexosamine pathway 
The role of increased metabolic flux of the hexosamine pathway in the pathophysiology of diabetic 
complications started coming out in the 1990s. Under hyperglycemic condition, glucose is metabolized 
through glycolysis while generating fructose-6-phosphate as an intermediate [48]. Some of the fructose-6-
phosphate becomes chanelled from the glycotic pathway in to a signaling pathway, the hexosamine 
pathway. The first step of the hexosamine pathway involves the conversion of fructose-6-phosphate to 
glucosamine-6-phosphate in the presence of glutamine:fructose-6-phosphate amidotransferase (GFAT) 
which is the rate-limiting enzyme for the pathway [58]. Subsequently, the glucosamine-phosphate is 
converted to UDP N acetyl-glucosamine (UDP GlcNAc) which happens to be a good substrate for O- and 
N-glycosylation of protein [59]. Thus, increased hexosamine flux leads to high O-linked glycosylation of 
proteins and/or inhibition of the hexose monophosphate shunt and this is responsible for the detrimental 
effects of hyperglycemia in various situations. On the other hand, the glucosamine phosphate could 
competitively inhibit glucose-6-phosphate dehydrogenase (G6PDH), the rate limiting enzyme of the 
hexose monophosphate shunt. G6PDH activity is linked to the reduction of NADP+ to NADPH which is 
most important redox-regulator because it is a cofactor for glutathione reductase. This enzyme catalyzes 
the conversion of oxidized glutathione (GSSG) to reduced glutathione (GSH) as well as enhances the 
activity of catalase which decomposes H2O2 to H2O. The foregoing could explain, at least in part, the 
influence of the increased hexosamine pathway in the induction of oxidative stress under diabetic state. 
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Indeed, it was reported that high activity of hexosamine pathway induces oxidative stress during chronic 
exposure to hyperglycemia and leads to β-cell deterioration [60]. 
 
Based on the above discussions on the oxidative stress-induction pathways under diabetic condition, the 
following figure (Figure 1.5) is provided to give an interconnection between the different pathways.  
 
Figure 1.5: Interrelationship between hyperglycemia and oxidative stress-induced pathways in type 2 
Diabetes (Adapted from Ceriello [61]). 
We now have an insight into the multiple oxidative stress generating pathways, thus, we can now turn the 
focus to the complications of T2D themselves. 
Broadly speaking, all complications associated with T2D are categorized into two broad classes; 
microvascular and macrovascular complications.  
1.2.2 Microvascular complications 
These involve small vessels such as capillaries and the most common, and perhaps most important, forms 
of these complications are called diabetic nephropathy, diabetic retinopathy and diabetic neuropathy. 
 Diabetic nephropathy 
This is also referred to as nodular diabetic glomerulosclerosis or Kimmelstiel-Wilson syndrome. It is a 
serious and progressive complication of T2D that affect approximately 25% of people with T2D [62]. The 
primary marker for this pathological change is microalbuminuria which usually progresses to full 
albuminuria and eventually to renal failure. Several mechanisms contribute to diabetic nephropathy which 
includes hemodynamic pathways such as the renin-angiotensin-aldosterone systems, non-enzymatic 
protein glycosylation, increased PKC activity as well as impaired polyol pathway [63]. However, 
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oxidative stress is the common theme to all these pathways. The oxidative stress elicits multiple negative 
biological effects including modulation of nephron functionality, membrane lipids peroxidation, proteins 
oxidation, DNA damage and renal vasoconstriction [63]. All these effects of oxidative stress eventually 
lead to the pathological features associated with T2D-induced nephropathy. This is supported by a study 
where histological analysis of type 2 diabetic patients’ kidney showed deposits of glycation and lipid 
oxidation products in the mesangial matrix and glomeruli which were not detected in non-diabetic 
individuals [63]. 
 Diabetic neuropathy 
Diabetic neuropathy is a complex disorder that impairs both peripheral and autonomic nervous system. 
Several possible pathogenic mechanisms have been proposed for diabetic neuropathy but the pathogenesis 
still remains unclear suggesting that the overall mechanism could be complex and perhaps multifactorial 
[64]. A number of vascular and metabolic factors have been implicated in the development of T2D-
related neuropathy. These include: 
 Increase in the metabolic flux of polyol pathway which leads to high levels of sorbitol and 
fructose, as well as diminished Na+-K+ ATPase activity. 
 Distortions in the membrane structure of the nerves as well as hemorrheologic and microvascular 
anomalies due to impairments in the metabolism of essential fatty acid and prostaglandin 
 Activation of the NF-kB, and increased activity of PKC, endoneural microvascular deficits with 
ischemia and hypoxia. 
 Reduced levels of neurotrophic  agents, including neurotrophin-3, nerve- and insulin like growth 
factors, which causes a decline in neurotrophism and distortions in axonal transport 
 High levels of non-enzymatic AGE on nerve and vessel proteins 
 Generation of auto-antibodies against sympathetic ganglia, vagal nerve and adrenal medulla as 
well as inflammatory changes [65]. 
 Diabetic retinopathy 
This is a microvascular complication that impairs normal function of the peripheral retina and/or the 
macula. It causes visual disability as well as partial or complete blindness in patients with T2D. The 
primary marker for this complication is the loss of pericytes which affect capillary constriction, new 
capillary generation and indeed other continuous exposure to noxious molecules [66]. Consequently, 
these would lead to partial or total loss of vision via a retinal detachment or vitreous hemorrhage [67].  
 
Currently, the pathogenesis of diabetic retinopathy is unclear. However, multiple biochemical events 
appear to interplay in causing this complication. These include activation of PKC, high activity of the 
polyol pathway, high amount of AGE, high expression of growth factors such as insulin-like growth 
factor-1 (IGF-1) and vascular endothelial growth factor (VEGF), activation of the renin-angiotensin-
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aldosterone system, haemodynamic changes and sub clinical inflammation and capillary occlusion [68]. 
However, a close analysis of the possible contributory role of each of the mechanisms suggests that 
oxidative stress is the most important biological phenomenon to the pathogenesis of T2D-related 
retinopathy [69].  Evidences from animal studies suggest that there is a diminished activity of ROS-
detoxifying enzymes in the retina and the prevention of experimental diabetic retinopathy by the use of 
antioxidants [70]. It was proposed that the ROS induces DNA damage which could activate poly-(ADP-
ribose)-polymerase (PARP) and reduce the activity of glyceraldehyde phosphate dehydrogenase leading 
to the accumulation of glycolysis metabolites. These metabolites could activate the polyol pathway 
leading to impaired function of the lens [45]. Furthermore, the ROS were found to activate 
metalloproteinase-2 in the development of diabetic retinopathy and this is believed to elicit death of the 
retinal cells [68]. Although hundreds of animal and human-based studies have unequivocally show 
oxidative stress as the most vital pathogenic mechanism for the development of diabetic retinopathy, but 
more specific details on the ROS-mediated molecular events that actually leads to visual impairments are 
still unknown. 
1.2.3. Macrovascular complications 
This involves large vessels such as arteries and veins and is sometimes referred to as cardiovascular 
complications because cardiovascular events are the most predominant forms of the complications.  
 
1.2.3.1 Cardiovascular complications 
Cardiovascular disease (CVD) accounts for >70% of death among people with T2D [44] and therefore 
CVD is regarded as the leading cause of death in type 2 diabetic patients. Research investigations have 
provided evidence that type 2 diabetic patients have a four-fold higher risk for developing CVD compared 
to non-diabetic human subjects after the traditional risk factors for CVD such as tobacco use, age, 
dyslipidemia, obesity, and hypertension are controlled. This indicates that T2D is an independent risk 
factor for CVD [71]. At present, the mechanism(s) of pathogenesis of T2D-associated CVD is poorly 
understood despite extensive research activities in the area. However, a number of plausible biological 
mechanisms have been proposed as possible explanations to the development of atherosclerosis in T2D. 
 
 Endothelial cells dysfunction 
Endothelial cells refer to a mono layer of cells that line the inner portion of blood vessels and play a 
crucial role in vessel homeostasis. The endothelial cells are known to perform crucial functions in the 
regulation of blood flow, nutrient delivery, leukocyte trafficking and vascular smooth muscle cell 
proliferation and migration [44]. Therefore, dysfunction of the endothelial cells is a highly detrimental 




A number of experiments have been carried out to determine the cause(s) of endothelial dysfunction in 
T2D but it is generally agreed based on evidences from such experiments that oxidative stress is the major 
cause of endothelial dysfunction in T2D [44]. High blood glucose levels lead to the generation of AGE 
with concomitant stimulation of PKC which in turn stimulate endothelial NADPH oxidase activity [56]. 
Subsequently, the increased NADPH oxidase activity uncouples eNOS and directs electron transfer to 
oxygen rather than L-arginine to generate superoxide (Figure 1.6) instead of nitric oxide radicals [47]. 
Thus, the bioavailability of nitric oxide is decreased and this is associated with impairment of endothelial-
directed vasodilation. Another mechanism of oxidative stress-mediated endothelial dysfunction is through 
stimulation of platelet-derived growth factor and plasminogen activator-1 activation of NFkB as well as 
vascular permeability [47]. 
 Vascular smooth muscle 
Atherosclerosis is associated with vascular smooth muscle proliferation and migration. In T2D, 
hyperglycemia increase superoxide generation in vascular smooth muscle cells which reacts with nitric 
oxide from endothelial cells and consequently impair with smooth muscle relaxation (Figure 1.6), 
vasodilation and enhance the formation of atherosclerotic lesions [47].  
 
 Inflammatory cells 
Monocytes and macrophages penetrate into damaged endothelial cells and move to the inner vessels to 
ingest oxidized LDL and generate foam cells (Figure 1.6).  These foam cells become the most important 
component of an early marker of macrovascular disease, atherosclerotic fatty streaks. The levels of 
adhesion molecules are also elevated type 2 diabetic patients, thereby aggravating the phenomenon of 
foam cell formation [72]. 
 
 Oxidized LDL 
Oxidized low density lipoproteins play a pivotal role in vascular cell injury and atherosclerosis [47]. This 
is because the influx and maintainance of lipoproteins in the vascular wall is an important step in 
atherogenesis. LDL in diabetic patients easily undergoes oxidative modification through oxidative stress-
dependent processes which consequently increased the rate of LDL transvascular transport (Figure 1.6) 




Figure 1.6: The role of oxidative stress in T2D-associated cardiovascular complications (Adapted from 
Jay et al. [47]). 
1.3 CURRENT TREATMENTS OF TYPE 2 DIABETES 
Several clinical and experimental studies have provided strong evidences that T2D and its related 
complications can be controlled, prevented or delayed by achieving tight glycemic control. Therefore 
much effort has been devoted to the search and development of optimal therapeutic agents for the 
management of T2D. However, the most commonly used approach is via oral therapies and at present, 
several classifications exist for the currently available oral anti-T2D drugs (depending on the approach) 
but for the sake of simplicity and ease of understanding, these drugs will be classified into six classes in 
this dissertation based on their mechanism of actions. These are the sulfonylureas, biguanides, 




This class of anti-T2D drugs became available since 1954 and act to lower blood glucose mainly by 
stimulating insulin release from functioning pancreatic β-cells [73]. Sulfonylureas bind, with high 
affinity, to their specific receptors on the pancreatic β-cells surface which are associated with ATP-
sensitive potassium channel that inhibits the efflux of potassium ions through the channel resulting in 
depolarization of the cell membrane [73]. Subsequently, depolarization causes the opening of a voltage-
gated calcium channel that leads to calcium entry and insulin release from secretory granules within the 
cell.  Insulin sensitivity is not directly influenced by sulfonylureas and the potentiation in insulin 
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sensitivity usually observed after using these drugs is only as a result of better control of metabolic 
processes [74]. 
  
Sulfonylureas are generally divided into first and second generation sulfonylureas. The first generation 
includes chlorpropamide, tolbutamide, acetohexamide, and tolazamide while the second generation 
includes glyburide, glipizide, glimepiride and glibenclamide. The second generation drugs are more 
powerful and safer compared to the first generation drugs [75].  
Despite interesting anti-T2D activity, the sulfonylureas are not without side effects. Hypoglycemia and 
weight gain are the major adverse effects of these drugs. The sulfonylureas-associated hypoglycemia 
results from the direct stimulation of insulin secretion from the pancreatic β-cells regardless of blood 
glucose concentrations [74]. On the other hand, the weight gain could also be detrimental, especially to 
obesity prone patients. Other side effects of the sulfonylureas are skin rash, hyponatreamia and alcohol-
induced flushing. 
1.3.2 Biguanides 
So far, three types of biguanides have been introduced into the market. The first two, phenformin and 
buformin, were introduced into the markets since 1970s but they were withdrawn from circulation 
because of their association with lactic acidosis [76]. However, the third biguanide, metformin was later 
introduced into the market in 1995 after safety concerns were cleared. Metformin was originally derived 
from the French lilac, Galega officinalis L., a perennial herb used for centuries to reduce the diabetic 
symptoms. The active compound is galegine, a guanidine derivative. 
 
At present, the mechanism of action of metformin is not completely known. However, the predominant 
mechanism of lowering blood glucose levels is via decreasing hepatic glucose production in the presence 
of insulin, primarily by decreasing gluconeogenesis [77]. Metformin also decreases the peripheral insulin 
resistance to a lesser extent and this is achieved by increasing insulin-mediated glucose uptake [73]. It is 
therefore considered as an insulin sensitizer. Another proposed mechanism of action of metformin is 
delaying glucose absorption in the gastrointestinal tract. Metformin has no effect on insulin secretion and 
therefore it does not cause hypoglycemia when applied in monotherapy. 
Metformin therapy has side effects which include gastrointestinal discomfort, such as nausea, abdominal 
pain, bloating, anorexia and diarrhea in approximately 50% of patients [78] and the reasons for these 
effects is not completely known. In some patients, metformin also causes weight loss [79] and the risk of 
lactic acidosis observed with earlier biguanides is also reported, though rarely in some patients. 





Thiazolidinediones is a recently introduced class of oral antidiabetic drug that enhances insulin 
sensitivity. In 1997, the first thiazolidinediones was introduced in the United Kingdom, United States and 
Japan but was later withdrawn from the circulation due to high risk of liver failure. At present, the two 
commercially available thiazolidinediones are rosiglitazone and pioglitazone. These agents improve the 
sensitivity of muscle and adipose tissue to insulin via a unique mechanism which is not completely 
understood.  
 
Thiazolidinediones are pharmacological ligands for a nuclear receptor called peroxisome-proliferator-
activated receptor gamma (PPARϒ). These nuclear receptors bind with response elements on DNA to 
alter the expression of vital genes responsible for the control of carbohydrate and lipid metabolism. 
Indeed, insulin-stimulated uptake of glucose in the skeletal muscle cells is profoundly increased by 
thiazolidinediones. Thus, thiazolidinediones improve insulin sensitivity in peripheral tissues. Glucose 
production in the liver is also reduced but only occurs when high doses are administered. The PPARϒ 
activation also facilitates adipocyte differentiation and decreases lipid breakdown. It is also noteworthy 
that the adipocytes produced the highest amount of the nuclear receptors compared to other tissues. 
Therefore, stimulation of muscle glucose uptake is an indirect effect elicited as a result of the drugs 
interaction with adipocytes. Other biomolecules affected by thiazolidinediones are tumor necrosis factor, 
free fatty acids, leptin, resistin and adiponectin [75]. Apart from the above-mentioned mode of action, 
some authors have postulated that thiazolidinediones improve β-cell function by reducing free fatty acids. 
Furthermore, thiazolidinediones were reported to decrease the proinsulin-insulin ratio in T2D indicating 
an improvement in β-cell function [81].  
Thiazolidinediones are highly costly and usually regarded as the most expensive anti-T2D drugs. In 
addition, they have multiple side effects which include anemia, edema, weight gain and congestive heart 
failure, thereby making it highly unsuitable for patients with hepatic impairments [75]. 
1.3.4 -Glucosidase inhibitors 
The commercially available -glucosidase inhibitors were first introduced in 1996. These drugs do not 
target any specific mechanism of diabetic pathogenesis. Rather, they act by decreasing the rate of 
absorption of products of carbohydrates digestion (monosaccharides) in the small intestine. The -
glucosidase inhibitors inhibits the activity of -glucosidases located at the brush border of the small 
intestine as well as -amylase found in the pancreas in a competitive manner. The -Amylase breakdown 
starch and other polysaccharides to oligosaccharides whereas -glucosidases hydrolyze these 
oligosaccharides into absorbable glucose. Therefore, these agents interact with the carbohydrate-binding 
region of these enzymes and inhibit the digestion of the ingested carbohydrates [73].  Consequently, the 
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absorption of monosaccharides (mainly glucose) derived from dietary carbohydrates is delayed. This 
impedes the entry of glucose into the bloodstream and reduces postprandial blood glucose levels [74]. A 
number of -glucosidase isoenzymes exist but the crucial ones are sucrase, glucoamylase, maltase, and 
isomaltase. 
The side effects of -glucosidase inhibitors are mainly gastrointestinal problems which include flatulence, 
abdominal discomfort, diarrhea and bloating [74].  
1.3.5 Dipeptidyl peptidase (DPP) IV inhibitors 
This class of anti-T2D drugs was first introduced into the market in 2006. Sitagliptin was the first drug to 
be introduced followed by vildagliptin, saxagliptin, linagliptin, and alogliptin.  
 
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are incretin 
hormones that cause glucose-dependent insulin secretion, increase β- cells mass and decrease glucagon 
secretion. They also retard gastric emptying and induce satiety [82]. However, these incretin hormones 
are rapidly inactivated by DPP IV thereby making the half-life of the active forms of these hormones to 
be approximately 1-2 minutes [82]. Therefore, the therapeutic basis of DPP-IV inhibitors depends on their 
ability to bind and inhibit DPP-IV and consequently increase the half-life of the hormones thereby 
elevating the levels of the biologically active form of the incretin hormones in circulation. These would 
obviously have multiple advantages on metabolic processes [83] such as a more sustained potentiation of 
insulin secretion and suppression of glucagon release.  
The most frequently encountered adverse effects of DPP IV inhibitors are headache, nausea, 
hypersensitivity and skin reactions as well as nasopharyngitis [84]. 
1.3.6 SGLT 2 inhibitors 
These are most likely the next generation of anti-T2D drugs that may flood the diabetic market because 
several of them are currently at advance stages of clinical trials. They use an insulin-independent 
approach and based on the inhibition of renal glucose reabsorption. Canagliflozin has been approved in 
the USA while Dapagliflozin was rejected by FDA but marketed in Europe. Ipragliflozin, Tofogliflozin 
and Empagliflozin are at phase III clinical trials. 
 
Glucose transport into the cells is mediated via two main families of glucose transporters, SGLT and 
GLUT. The SGLT family has 12 members which are usually situated at the renal tubular cells and also at 
the brush border membrane of the gut epithelium. In enterocytes, the main glucose transporter is SGLT 1 
which simultaneously transports glucose and sodium with a stoichiometry of 1:2. However, this 
transporter is thought to possess another vital function in the kidney which is to reabsorb about 10% of 
glucose in the straight S3 segment of the proximal renal tubule. Apart from SGLT 1, scientific findings 
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have revealed that a complementary role of SGLT 2 is greatly required for the filtered glucose to be 
reabsorbed in the kidney. By contrast, the expression of SGLT 2 occurs mainly at the S1 segment of the 
proximal renal tubule, where it simultaneously transports glucose and sodium using a stoichiometry of 1:1 
and with 50% efficiency in humans. Interestingly, apart from the kidney, SGLT 2 is also synthesized in 
other tissues [85]. Therefore, SGLT 2 inhibitors act via modulating the function of SGLT 2 in proximal 
convoluted tubules of the kidney and consequently block the glucose reabsorption. This leads to excretion 
of the glucose in urine (glycosuria). Thus, SGLT 2 inhibitors induce glycosuria which leads to a decrease 
in blood glucose concentrations. They also cause a net decrease of body calories and maintain an overall 
negative energy balance [86].  
Interestingly, these drugs present other multiple advantages such as prevention of blood pressure 
elevation in hypertensive prone patients because of reduced sodium reabsorption thereby causing a 
decrease in the activity of the renin-angiotensin-aldosterone system. 
Despite interesting reports on several potential beneficial effects of these drugs, they are still not without  
adverse effects. The most recognized side effect of SGLT 2 inhibitors is increased risk of genitourinary 
infections which are more prevalent in females than males [85]. Furthermore, these drugs do not seem to 
optimally act in patients with some renal impairment because of their dependence of glomerular filtration 
and other kidney dependent processes. Thus, they find more application in early diagnosed T2D cases 
where complications have not been fully developed. Clinical trials have provided evidence of the risk of 
developing mild form of secondary hyperparathyroidism with SGLT 2 inhibitors. 
Based on the above discussion on the currently available anti-diabetic drugs, it is evident that all the drugs 
have detrimental side effects and therefore the search for alternative therapies is appealing. 
1.4 THE ROLE OF TRADITIONAL HERBAL MEDICINES IN THE TREATMENT OF T2D 
1.4.1 Medicinal plants as sources of therapeutics  
Throughout the history of mankind, nature has been the primary source of all kinds of medicines for the 
treatment of wide spectrum of diseases. Among all the natural sources of medicines, plants have 
particularly been the most important source of complex traditional medicine systems. The earliest records 
of traditional use of plants for treating diseases dates back to 2600 BCE where approximately 1000 plant 
materials were documented in the traditional medicine system of Mesopotamia [87]. Also, the Egyptian 
traditional medicine dates back to 2900 B.C with over 700 plant-derived drugs used in their traditional 
medicine. Furthermore, Chinese system of traditional medicine dates back to 1100 B.C. with over 850 
plant-derived materials in use since then [87]. On the other hand, Africa has a rich diversity of plants 
harbouring about 25% of the total numbers of higher plants in the world where more than 5400 medicinal 
plants have been found to have over 16,300 medicinal uses [88]. Unfortunately however, African 
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traditional system, though as old as others, is verbal and therefore some of the precious information about 
the plants and their medicinal values along with dates was not recorded leading to the loss of the 
information over the course of time. Based on the above, it appears therefore that the use of herbal 
products in the treatment of wide array of diseases is as old as human existence itself. 
 
Interestingly, in this modern era, the use of these herbal products also continues to play a crucial role in 
the healthcare delivery systems of many parts of the world [89]. Indeed, according to World Health 
Organization [90], 60% of the total population of the world relies on traditional medical systems directly 
or indirectly, while 80% of the population in developing countries depends almost exclusively on 
traditional medical practices, more specifically, plant medicines for their primary health care needs [91]. 
Reports from developed countries also indicated that a number of patients of some chronic disease are 
gradually turning to herbal remedies as alternatives to modern synthetic drugs [92] because of the toxic 
side effects and high cost of the modern drugs as well as the more perceived effectiveness of the plant-
based remedies. 
 
An investigation of plant-originated pure compounds used as drugs in countries with WHO-Traditional 
Medicine Centers indicated that, out of the 122 compounds so far identified, 80% were applied for the 
same or similar ethno-medical purposes and were obtained from 94 plant species only. Relevant examples 
of currently used drugs which are originally derived from medicinal plants are quinine and artemisinin for 
treating malaria, reserpine for treating hypertension, khellin as bronchodilator, salbutamol and salmetrol 
for treating asthma and more relevant to this dissertation, the widely used anti-T2D drug metformin was 
originally developed from medicinal plant [87].  In fact, 75% of the anti-infectious agents and 60% of the 
anticancer drugs approved from 1981-2002, are originally derived from natural sources [93] whereas 61% 
of all new chemical compounds marketed as drugs worldwide during the same period are also derived 
from natural products [94]. In another report by Newman and Cragg [95], from 1981 to 2010, a total of 
1130 new drugs were approved for the treatment of 61 diseases and an impressing number of 543 of those 
drugs were directly derived from medicinal plants. Therefore, in view of the impressive role of medicinal 
plants in drug discovery, biochemists, pharmacologists, medicinal chemists, pharmacists, microbiologists 
and botanists from all over the world have intensify efforts on investigating medicinal plants for novel 
phytochemicals and lead compounds that could be developed for the treatment of various diseases. 
1.4.2 African medicinal plants in the treatment of T2D 
At present, medicinal plants are extensively used in the treatment of diabetes mellitus in all the sub-
regions of Africa and perhaps by all African cultures as well. This is evident by the number of 
publications on ethnobotanical surveys for medicinal plants used in local diabetes therapy from different 
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geographical regions of the continent. These reports could further denote that most diabetic patients in the 
region perhaps depend on medicinal plants for the treatment of the disease.  
 
Starting from West Africa, Gbolade [96] reported that fifty medicinal plants from different families are 
exploited in the local treatment of diabetes in Lagos state, Nigeria. These herbal recipes are often orally 
taken without serious adverse effects. Among the fifty plants prescribed, the most highly cited medicinal 
plants by the diabetes trado-specialists are Vernonia amygdalina, Ocimum gratissimum, Carica papaya, 
Citrus aurantifolia and Bidens pilosa. Another study from the South Western part of Nigeria where one 
hundred traditional medicine practitioners were interviewed revealed that thirty one medicinal plants are 
the most commonly used for the treatment of diabetes mellitus [97]. Among these plants, Vernonia 
amygdalina, Cassia alata and Momordica charantia top the list. In another ethnobotanical survey from 
the North Western part of Nigeria, one hundred and twenty eight herbalists were interviewed [98]. These 
herbalists have no formal education and inherited these indigenous knowledge systems from their 
ancestors.  From the study, thirty four medicinal plants were cited by the traditional practitioners and 
based on informant consensus, Vernonia amygdalina, Mangifera indica, Calotropis procera, Khaya 
senegalensis and Cassia singueana were ranked highest among other plants. Available ethnobotanical 
study from another West African country comes from Guinea [99]. A total of one hundred and twelve 
people were interviewed where one hundred and forty six plant species belonging to fifty five families 
were recommended for the treatment of diabetes mellitus. The most cited plant species were Anacardium 
occidentale, Aframomum melegueta, Ficus glumosa and Ficus capensis.  
From Southern Africa, Oyedemi et al. [100] conducted a survey on anti-diabetic plants in the Eastern 
Cape Province of South Africa. Results from the study indicated that fifteen different plant species 
belonging to thirteen families are used by the traditional healers while Strychnos henningsii and Leonotis 
leonorus were the most cited plants in the study. In a more recent report from South Africa, though from 
the Limpopo Province, fifty two traditional healers were interviewed where they recommended twenty 
four plant species belonging to twenty families for the treatment of diabetes mellitus [101]. The most 
repeatedly mentioned plants by the healers were Mimusops  zeyheri,  Helichrysum  caespititium,  
Plumeria  obtuse,  Aloe  marlothii, Hypoxis  iridifolia  and  Moringa  oleifera. Another ethnobotanical 
study for anti-diabetic plants from the Southern sub-region of Africa was from DR Congo [102]. Thirty 
one plant species were cited by the traditional healers of Kisangani city of the country and among them, 
Catharanthus roseus, Aloe vera, Morinda lucida, Morinda morindoides and Cassia occidentalis were the 
most highly cited. 
Available data from Eastern Africa emanates from the Lower eastern Province of Kenya [103]. In this 
study, thirty-nine plant species belonging to thirty three genera and twenty six families were reported to 
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be used in the local therapy of of diabetes mellitus. The most frequently cited plants were Cassia 
abbreviate, Zanthoxylum chalybeum, Azadirachta indica and Cactus species.  
Reports from Morocco (North Africa) indicated that about ninety four medicinal plants belonging to thirty 
eight families are used in the traditional management of diabetes mellitus and hypoglycemic effects of 
some of the plants have been confirmed by Morroccan researchers [104]. Members of Compositae, 
Lamiaceae, Leguminosae and Liliaceae families are generally the most commonly used anti-diabetic 
plants in Morocco. In an ethnopharmacological survey from the South Eastern Morocco [105], a total of 
four hundred people were interviewed and forty five medicinal plant species were mentioned as potent 
anti-diabetic plants used for diabetes treatment in the area. From the results of the study, the most 
frequently cited plants to treating diabetes include Nigella sativa, Allium cepa, Rosmarinus officinalis 
Artemisia herba-alba, Carum carvi, Peganum harmala, Ajuga iva, Lepidium sativum, Olea europaea, 
Zygophyllum gaetulum and Phoenix dactylifera 
Based on the above discussions, it is obvious that medicinal plants play a fundamental role in the 
treatment of diabetes in Africa. However, most of the above-mentioned plants are used by traditional 
healers as simple concoction and not standardized by relevant authorities. In order to further portray the 
crucial role of phytomedicines in diabetes therapy, some standardized herbal products are investigated 
and approved for sales in the South African market. A brief run-down of these standardized herbal 
products present in South African market is given below. 
The most commonly used standardized herbal products in South Africa are probetix, DiaviteTM,  
Diabecinn and Cinnachrome.  
Probetix is a herbal supplement developed from the leaf extract of South African Sutherlandia frutescens. 
Scientific findings have confirmed that this herbal product has anti-diabetic activity which is mediated 
through decreasing intestinal glucose uptake as well as maintaining normoinsulineamic state in diabetic 
subjects [106]. Furthermore, the extract was found to normalize some physico-metabolic abnormalities 
associated with diabetes. In another study, this extract was found to have a profound effect on the 
development of insulin resistance by reducing the levels of free fatty acid [107]. In a more recent study 
[108], this herbal product was also reported to directly affect the biosynthesis of lipid and mitochondrial 
activity and consequently restore insulin sensitivity via modulation of fatty acid biosynthesis. 
Interestingly, findings from a clinical trial revealed that no indication of toxicological effects is associated 
with treatment of 800 mg/day of this herbal product for a period of three months [109]. The possible 
bioactive agents identified are pinitol, asparagines, L-arginine, g-aminobutyric acid, L-canavinine, g-
sitosterol, saponin, parabens and -lipoic acid [110]. 
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DiaviteTM is an anti-diabetic food supplement developed from the dried and ground pods of Prosopis 
glandulosa, commonly known as honey mosquito. Scientific findings have indicated that this herbal 
supplement reduces blood glucose levels as well as the glycemic index value of foods. Furthermore, 
DiaviteTM was found to stimulate insulin secretion, improves insulin sensitivity of cardiomyocytes as well 
as confers some protection to β-cells [111].   
Another anti-diabetic herbal product in the South African market is Diabecinn. This product is water 
based cinnamon bark extract that may reduce blood sugar levels, triglycerides and cholesterol in type 2 
diabetic patients. Scientific investigation done with the cinnamon extract showed that the extract prevents 
the development of insulin resistance and lowers plasma glucose concentrations by enhancing insulin 
signaling process [112]. In a more recent study by Couturier et al. [113], polyphenols were found to be 
main bioactive agents that decrease blood glucose levels, improves insulin sensitivity and alters body 
composition. 
Cinnachrome is another cinnamon-derived herbal product that is used by diabetic patients in South 
Africa. Apart from the cinnamon extract, this herbal preparation also contains chromium polynicotinate 
which is a natural form of chromium that provides free chromium and niacin. [114]. The bioactive agent 
was proposed to be methyl-hydroxy chalcone polymer.  
Based on the above discussions coupled with ethnobotanical revelations (described in earlier part of this 
sub-section), it is obvious that Africa is naturally blessed with huge medicinal plant resources that could 
be exploited either directly as standardized anti-T2D herbal products or indirectly by providing novel 
chemical leads for the development of newer alternative therapies for the treatment of T2D. 
Unfortunately, these abundant African medicinal plant natural resources remain largely untapped in both 
respects. 
Therefore, there is a crucial need for thorough studies on the anti-diabetic potential of a number of 
African medicinal plants with a view to harness their potentials as anti-diabetic herbal products or as 
possible providers of chemical leads for the development of novel and more effective chemotherapeutic 
agents against T2D. 
1.5 AIM OF THE STUDY 
The aim of this study is to conduct a thorough investigation on the anti-oxidative, anti-diabetic potentials 
and possible toxicological effects of five African medicinal plants namely; Ziziphus mucronata, Parkia 
biglobosa, Khaya senegalensis, Cassia singueana and Vitex doniana using a number of in vitro and in 





The research objectives are: 
1. To evaluate the in vitro anti-oxidative activities of aqueous, ethanol and ethyl acetate crude 
extracts of various parts (stem barks, roots and leaves) of the Ziziphus mucronata, Parkia 
biglobosa, Khaya senegalensis, Cassia singueana and Vitex doniana 
2. Based on the results of the in vitro anti-oxidative studies above, the best crude extracts from each 
plant will further be partitioned and the fractions will be investigated for the in vitro anti-
oxidative activities as well as α-glucosidase and α-amylase inhibitory effects, which are crucial 
carbohydrates-hydrolyzing enzymes. 
3. Based on the results of the in vitro anti-oxidative as well as α-glucosidase and α-amylase 
inhibitory effects of the fractions, the best fraction from each plant will be subjected to a 
comprehensive study on the in vivo anti-diabetic activity of the fractions in a T2D model of rats 
as well as their possible mechanism of actions. 
4. To identify the possible bioactive agents in the extracts and fractions from each plant using GC-
MS. 
5. To isolate the possible bioactive anti-T2D compounds in their pure forms, characterize them 
using NMR and MS and subject them to the α-glucosidase and α-amylase inhibitory activities 
assays. 
1.5.2 STRUCTURE OF THE DISSERTATION 
Chapter 1:  This chapter gives detailed background introduction and literature review on diabetes 
mellitus. Epidemiology, classification, pathogenesis, complications, role of oxidative stress, currently 
available oral anti-diabetic drugs and their limitations as well as the role of African medicinal plants in 
the treatment of diabetes mellitus are discussed. 
Chapter 2: This chapter describes the materials and methods used in the study 
Chapter 3: The in vitro and in vivo anti-diabetic activities of Ziziphus mucronata have been described in 
this chapter. Identification, isolation and characterization of the possible bioactive compounds are also 
discussed.  
Chapter 4: The in vitro and in vivo anti-diabetic activities of Cassia singueana have been described in this 




Chapter 5: The in vitro and in vivo anti-diabetic activities of Parkia biglobosa have been described in this 
chapter. Identification, isolation and characterization of the possible bioactive compound are also 
discussed.  
Chapter 6: The in vitro and in vivo anti-diabetic activities of Khaya senegalensis have been described in 
this chapter. Identification, isolation and characterization of the possible bioactive compound are also 
discussed.  
Chapter 7: The in vitro anti-oxidative and anti-diabetic activities of Vitex doniana have been described in 
this chapter.  
Chapter 8: This chapter gives a general discussion of all the findings of the study and the conclusions 
drawn from the study. Recommendations are also suggested in this chapter. 
Chapter 9: Appendices  
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Figure 2.1: Flow charts to describe how the experiment was systematically arranged and executed  
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2.1 Chemicals and reagents 
Streptozotocin, yeast α-glucosidase, porcine pancreatic amylase, p-nitrophenyl-α-D-glucopyranoside 
(pNPG), p-nitrophenol, acarbose, 1,1-diphenyl-2-picrylhydrazyl radical (DPPH), 6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid (trolox), 6-hydroxydopamine, 5,5′-dithiobisnitrobenzoic acid 
(DTNB), 2 deoxy-D-ribose, diethylenetriaminepentaacetic acid (DETAPAC), ascorbic acid, gallic acid 
and potassium ferricyanide were obtained from Sigma-Aldrich through Capital Lab Supplies, New 
Germany, South Africa. Starch, dinitrosalicylic acid (DNS), maltose, absolute ethanol, ethyl acetate, 
trichloroacetic acid, hydrogen peroxide, ferric chloride, Griess reagent, sodium nitroprusside, 
thiobarbituric acid, reduced glutathione, Folin ciocalteau reagent, deuterated chloroform and deuterated 
methanol were purchased from Merck Chemical Company, Durban, South Africa. An ultra sensitive rat 
insulin ELISA kit was purchased from Mercodia AB, Uppsala, Sweden. Reagents to analyze the other 
blood parameters were from Labtest Diagnostics (Costa Brava, Lagoa Santa, Brazil) purchased via 
Replamed Company Ltd., Centurion, South Africa. 
 
2.2 Equipment 
Buchi Rotavapor II, Buchi, Germany, Shimadzu UV mini 1240 spectrophotometer (Shimadzu 
Corporation, Kyoto, Japan), microcentrifuge, Bruker AvanceIII 400 MHz NMR spectrometer (Bruker 
BioSpin, Rheinstetten, Germany), GC-MS 6890 series (Agilent Technologies, USA), Glucoplus 
glucometer (Glucoplus Inc., Saint-Laurent, Que., Canada), Automated Chemistry Analyzer (Labmax 
Plenno, Labtest Co. Ltd., Lagoa Santa, Brazil), multi-plate ELISA reader (Biorad-680, BIORAD Ltd., 
Japan), Leica slide Scanner  SCN 4000, (Leicabiosystems Germany) and portable tissue homogenizer. 
 2.3 Collection and preparation of plant materials 
 The stem bark, root and leaf samples of Ziziphus mucronata Willd, Parkia biglobosa A. Jacq, Khaya 
senegalensis A. Juss, Cassia singueana Delile and Vitex doniana Sweet were collected in January 2011 
from Zaria, Kaduna state, Nigeria. The plant samples were authenticated at the herbarium unit of the 
Department of Biological Science, Ahmadu Bello University, Zaria, Nigeria. The herbarium voucher 
specimens were deposited and assigned the repository numbers  154 (Z.mucronata), 3017 (P. biglobosa), 
900081 (K. senegalensis), 6863 (C. singueana) and 1162 (V. doniana). The stem bark, root and leaves 
were immediately washed and shade-dried for about 2-4 weeks (depending on the plant material) to attain 
constant weights. The dried samples were pounded to fine powder using a kitchen blender, and then 
stored individually in air-tight containers for transport to the University of KwaZulu-Natal, Westville 






2.4 Preparation of the crude extracts  
Forty (40) grams of the fine powdered sample from each part of the plant were separately defatted with 
hexane. The defatted materials were sequentially extracted with ethyl acetate, ethanol and water by 
soaking for 48 hours in 200 ml of the respective solvent followed by shaking for 2 hours at 200 rpm. 
After filtration through Whatmann filter paper (No 1), respective solvents were evaporated in vacuum 
using a rotary evaporator at 40 oC under reduced pressure to obtain the solvent crude extracts. Aqueous 
extracts were however dried on a water bath at 50 oC (Figure 2.1). The extracts in each case were 
weighed, transferred to micro tubes and refrigerated at 4 oC until needed.  
2.5 In vitro anti-oxidative activities of crude extracts from the various parts of the selected plants 
2.5.1 Estimation of total phenolic content 
The total phenolic content of each extract was estimated (as gallic acid equivalent) using the method 
described by McDonald et al. [1] with slight modifications. Briefly, 200 µL of the extract (240 µg/mL) 
was incubated with 1 mL of 10 times diluted Folin ciocalteau reagent and 800 µL of 0.7 M Na2CO3 for 30 
minutes at room temperature.  Then, the Absorbance values were measured at 765 nm on a Shimadzu UV 
mini 1240 spectrophotometer (Shimadzu Corporation, Kyoto, Japan). All measurements were done in 
triplicate. 
 2.5.2 Ferric cyanide (Fe3+) reducing antioxidant power (FRAP) assay  
The total reducing power of the extracts were measured using the FRAP method of Oyaizu [2] with slight 
modifications. To perform this assay,  1 mL of each extract (15–240 µg/mL) was incubated with 1 mL of 
sodium phosphate buffer ( 0.2 M, pH 6.6) and 1% potassium ferricyanide at 50 oC for 30 minutes. 
Thereafter, 1 mL of 10% trichloroacetic acid was used to acidify the the reaction mixtures. After the 
acidification, 1 mL of the sample was mixed with 1 mL of distilled water and 200 µL of 0.1% FeCl3. The 
absorbance of the resulting solution was read at 700 nm in a spectrophotometer. The absorbance of the 
samples is proportional to the reduction capability of the extracts [3]. The results were expressed as a 
percentage of the absorbance of the sample to the absorbance of gallic acid.  
Ferric reducing antioxidant power  % =
Absorbance of sample
Absorbance of gallic acid
  X 100 
2.5.3 Free radical scavenging activity  
The free radical scavenging activity of the extracts or standards (ascorbic and gallic acids as well as 
trolox) was determined using a slightly modified method described by Tuba and Gulcin [4]. A 0.3 mM 
solution of DPPH was prepared in methanol and 500 µL of the DPPH solution was added to 1 mL of the 
extracts at various concentrations (15–240 µg/mL). These solutions were mixed and incubated in the dark 
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for 30 minutes at room temperature. The absorbance was read at 517 nm against blank samples lacking 
scavenger. 
 2.5.4 Nonsite-specific hydroxyl radical mediated 2-deoxy-D-ribose degradation assay 
Ascorbate–EDTA– H2O2 system (Fenton reaction) generate hydroxyl radicals which could degrade 
deoxyribose and measured as products degradation reaction. Thus, the hydroxyl radical scavenging 
activity was determined by studying the competition between the extracts and deoxyribose for the 
generated hydroxyl radicals as described by Hinnerburg et al. [5].  The assay was performed by adding 
200 µL of premixed 100 µM FeCl3 and 100 µM EDTA (1:1 v/v) solution, 100 µL of 10 mM H2O2, 360 
µL of 10 mM 2-deoxy-D-ribose, 1 mL of different extract concentrations (15–240 µg/mL), 400 µL of 
phosphate buffer (50 mM, pH 7.4) and 100 µL of 1 mM ascorbic acid in sequence. This followed by the 
incubation of the mixture at 50 oC for 2 hours. Thereafter, 1 mL of TCA (2.8%) and 1 mL of 1.0% 
thiobarbituric acid (in 25 mM NaOH) were transferred to the reaction tubes. The samples were further 
incubated in a water bath at 50 oC for 30 minutes to develop the pink chromogen. The extent of oxidation 
was determined from the absorbance of the samples at 532 nm and the hydroxyl radical scavenging 
activity of the extract was reported as percentage inhibition of deoxyribose degradation. 
 2.5.5 Nitric oxide (NO) radical scavenging assay  
This assay is based on the ability of aqueous solution of sodium nitroprusside at physiological pH to 
spontaneously produce nitric oxide (NO), which could interact with oxygen to generate nitrite ions that 
can be measured using Griess reagent. All agents that can scavenge NO compete with oxygen, resulting in 
decreased NO generation [6]. The assay was carried out by incubating 500 µL of 10 mM sodium 
nitroprusside in sodium phosphate buffer (pH 7.4) and 500 µL of different extract concentrations (15-240 
µg/mL) at 37 oC for 2 hours. Thereafter, 500 µL of Griess reagent was transferred to the reaction mixture.  
Diazotization of nitrite with sulphanilamide produce a chromophore that can be measured at 546 nm. The 
percentage inhibition of NO generated was measured by comparing with the absorbance value of a 
control (10 mM sodium nitroprusside in phosphate buffer). 
All assays were carried out in triplicate. The scavenging activities of the plant extracts in the case of 
DPPH, hydroxyl and nitric oxide radicals scavenging assays were calculated by using the following 
formula:  
 Scavenging activity  % =  1 −  As
Ac
  x 100 




2.5.6 Gas chromatography-mass spectrometric (GC-MS) analysis  
Based on the results of anti-oxidative assays, the most active extract from each part of the plants (except 
Z. mucronata) were subjected to GC-MS analysis. The GC-MS analysis was conducted with an Agilent 
technologies 6890 GC coupled with (an Agilent) 5973 mass selective detector and driven by Agilent 
chemstation software. A HP-5MS capillary column was used (30 m x 0.25 mm internal diameter x 0.25 
μm film thickness). The carrier gas was ultra-pure helium at a flow rate of 1.0 mL/minute and a linear 
velocity of 37 cm/second. The injector temperature was set at 250 °C. The initial oven temperature of 60 
°C which was programmed to 280 °C at the rate of 10 °C/minute with a hold time of 3 minutes. Injections 
of 1 μL were made in a split mode with a split ratio of 20:1.The mass spectrometer was operated in the 
electron ionization mode at 70 eV and electron multiplier voltage at 1859 V. Other MS operating 
parameters were as follows: ion source temperature 230 °C, quadruple temperature 150 °C, solvent delay 
4 minutes and scan range 50-700 amu. Compounds were identified by direct comparison of the retention 
times and mass fragmentation pattern data with those in the National Institute of Standards and 
Technology (NIST) library.  
 
2.6 In vitro anti-oxidative and anti-diabetic activities of solvent fractions derived from the crude 
extracts 
2.6.1 Solvent fractionation of the most active crude extracts from each plant 
Based on the results of the preliminary anti-oxidative assays (described above), the most active crude 
extract from each plant was selected for further fractionation (Figure 2.1). The selection was made in 
relation to the crude extracts of the same plant (intra) and not across the plants (inter). The selected 
extracts were ethanolic extract of the root (Z. mucronata), ethanolic extract of the leaves (P. biglobosa), 
ethanolic extract of the root (K. senegalensis), ethyl acetate extract of the stem bark (C. singueana) and 
ethanolic extract of the leaves (V. doniana). For each crude extract, a 10 g of the extracts was dissolved in 
a 200 mL of distilled water : methanol (9:1) and successively partitioned with hexane (2 x 200 mL), 
dichloromethane (2 x 200 mL), ethyl acetate (2 x 200 mL) and n-butanol (2 x 200 mL). However, the n-
butanol was replaced with acetone during the fractionation of the ethyl acetate extract of the stem bark of 
C. singueana and it was also observed during the fractionation of the ethanolic extract of the leaves of V. 
doniana that the n-butanol completely dissolved the remaining aqueous fraction after ethyl acetate 
partitioning and therefore the fraction was regarded as aqueous fraction (Figure 2.2). All the resulting 
fractions were evaporated to dryness at 40 oC under reduced pressure whereas the remaining aqueous 
fractions were dried on a water bath. The fractions in each case were weighed, transferred to micro tubes 





Figure 2.2: Protocol for the solvent-solvent fractionation of the crude extracts  
2.6.2 Determination of α-glucosidase inhibitory activity of solvent fractions  
The α-glucosidase inhibitory activity was measured according to the method described by Ademiluyi and 
Oboh [7] with slight modifications. Briefly, 250 µL of each fraction or acarbose at different 
concentrations (30-240 µg/mL) was incubated with 500 µL of 1.0 U/mL α-glucosidase solution in 100 
mM phosphate buffer (100mM, pH 6.8) at 37 °C for 15 minutes. Thereafter, 250 µL of pNPG solution (5 
mM) in phosphate buffer (100 mM, pH 6.8) was added and the reaction mixture was further incubated at 
37 oC for 20 minutes.  The absorbance of the released p-nitrophenol was measured at 405 nm and the 
inhibitory activity was expressed as percentage of the control without the inhibitors.  
 2.6.3 Determination of α-amylase inhibitory activity of the solvent fractions  
The procedure described by Shai et al. [8] with slight modifications was used to determine the α-amylase 
inhibitory activity of the fractions. A volume of 250 µL of each fraction or acarbose at different 
concentrations (30-240 µg/mL) was incubated with 500 µL of porcine pancreatic amylase (2 U/mL) in 
phosphate buffer (100 mM, pH 6.8) at 37 °C for 20 minutes. Thereafter, 250 µL of 1% starch dissolved in 
100 mM phosphate buffer (pH 6.8) was further added to the reaction mixture and incubated at 37° C for 1 
hour.  Dinitrosalicylate colour reagent (1 mL) was then added and boiled for 10 minutes.  The absorbance 
of the resulting mixture was read at 540 nm and the inhibitory activity was expressed as percentage of a 
control without the inhibitors.  
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All assays were carried out in triplicate. The inhibitory activities of the fractions on the α-glucosidase and 
α-amylase were calculated by using the following formula: 
 Inhibitory activity  % =  1 −  As
Ac
 x 100 
Where As is the absorbance in the presence of the sample and Ac is the absorbance of the control. 
 2.6.4 Mechanism of α-glucosidase and α-amylase inhibition 
Based on the results of α-glucosidase and α-amylase inhibitory assays, the most active fraction from the 
solvent fractions of each plant was further subjected to kinetic experiments to determine the type of 
inhibition exerted on α-glucosidase and α-amylase. The experiment was conducted according to the 
protocols as described above at a constant concentration of the sample fraction with a variable 
concentration of substrate as described below. For the α-glucosidase inhibition assay, 0.625-5 mM of 
pNPG was used and 0.125-1% of starch was used for the α-amylase inhibition assay. The initial rates of 
the reactions were determined from calibration curves constructed using varying concentrations of p-
nitrophenol and maltose for the α-glucosidase and α-amylase inhibition assays respectively. The initial 
velocity data obtained were used to construct Lineweaver-Burke’s plot to determine the KM (Michaelis 
constant) and Vmax (maximum velocity) of the enzyme and the type of inhibition for both enzymes. 
2.6.5 Anti-oxidative activities of the solvent fractions 
All the solvent fractions were investigated for anti-oxidative activities using the four models described in 
sub chapters 2.5.2 – 2.5.5 above.  
2.6.6 GC-MS analysis of the most active fractions 
The phytochemical components of the most active fraction from the solvent fractions of each plant were 
analysed using the GC-MS protocol described in 2.5.6 above. 
2.7 In  vivo antidiabetic activity of the most active fractions in a type 2 diabetes rats model  
Based on the results of the anti-oxidative activities as well as α-glucosidase and α-amylase inhibitory 
activities, butanol fractions from the aforementioned extracts (see 2.6.1 above) of Z. mucronata,  P. 
biglobosa and K. senegalensis  and the acetone fraction from C. singueana (see 2.6.1 above)  were the 
most active and therefore selected for in vivo studies. The selection was made by comparing the activities 
of solvent fractions derived from a plant and not across plants (see Figure 2.1 above). The 
aforementioned most active fractions from each plant was re-prepared as described in subchapters 2.4 and 
2.6.1 above but the starting material was three kilograms (3 kg) because of the large quantity of the 
fractions needed for the in vivo studies. Unfortunately, due to the a low yield and unavailability (for 
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further extraction) of the leaves of V. doniana when needed, the most active (aqueous) fraction derived 
from the ethanolic extract of the leaves of this plant was not subjected to the in vivo study.  
2.7.1 Experimental animals 
Male Sprague-Dawley (six-week-old) rats were obtained from the Biomedical Resource Unit  (BRU)  
located at  the  University  of KwaZulu-Natal  (Westville  Campus),  South  Africa  with  initial  mean 
body weight  (BW)  207.60  ±  4.27  g. The rats were maintained as 2  in  one medium size poly-
carbonated  cage  in  a  humidity and temperature controlled  room  with  a 12  hour  light–dark  cycle.  A 
standard rat  pellet  diet was  supplied  ad libitum  for the whole duration of the experiment. The rules and 
regulations of the Committee for Experimental Animal Ethics of the University of KwaZulu-Natal, South 
Africa (Ethical approval number: 022/12/Animal) were followed in maintaining the rats. 
2.7.2 Animal grouping and induction of type 2 diabetes 
The rats were randomly divided into six groups of eight animals each namely:  
Normal Control (NC) : Normal rats (non diabetic and not treated) 
Diabetic Control (DBC): These are diabetic and untreated control 
Diabetic + fraction low dose (DFL): diabetic rats treated with 150 mg/kg BW of the fraction.  
Diabetic + fraction high dose (DFH): diabetic rats treated with 300 mg/kg BW of the fraction.  
Diabetic + metformin (DMF): diabetic rats treated with 300 mg/kg BW of metformin 
Non-diabetic fraction control (NFT): non-diabetic rats treated with 300 mg/kg BW of the fraction.  
The same procedure and arrangement was done for the four fractions derived from the four plants (Figure 
2.3). After one-week adaptation period, the animals in DBC, DFL, DFH and DMF groups were supplied 
with a 10% fructose solution ad libitum for two weeks to induce insulin resistance which was followed by 
an overnight fast and subsequently, a single injection (i.p.) of streptozotocin (40 mg/kg BW) dissolved in 
citrate buffer (pH 4.5) was injected to the animals in DBC, DFL, DFH and DMF groups to induce partial 
pancreatic beta-cell dysfunction (Figure 2.3). The rats in NC and NFT groups were given normal 
drinking water and injected with citrate buffer instead of 10% fructose and STZ, respectively [9]. One 
week after the STZ injection, the nonfasting blood glucose (NFBG) levels of all the rats were measured in 
the blood collected from the tail vein by using a portable glucometer (Glucoplus Inc., Saint-Laurent, 
Quebec, Canada). The rats with NFBG level > 17 mM were considered as diabetic [10] while rats with 
NFBG level < 17 mM were excluded from the study.  
2.7.3 Intervention trial 
After the confirmation of diabetes, a respective dose of the fraction was orally administered five days in a 
week by using a gastric gavage needle to the rats in DFL and DFH and NFT groups while the rats in 
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controls (NC and DBC) and DMF groups were treated with a similar volume of the vehicle and 
metformin respectively for a 4 week experimental period. During this period, daily food and fluid intakes 
as well as weekly body weight changes and NFBG concentrations were measured in all animal groups.  
2.7.4 Oral glucose tolerance test (OGTT) 
The OGTT was conducted in the last week of the 4-week intervention period to measure the glucose 
tolerance ability of each animal. To perform this test, a single dose of glucose solution (2 g/kg BW) was 
orally ingested into each animal and the levels of blood glucose were measured at 0 (just before the 
ingestion of glucose), 30, 60, 90 and 120 minutes after the dose of glucose. 
2.7.5 Collection of blood and organs  
The rats were euthanized by halothane anesthesia at the end of the experimental period and blood and 
organ samples were collected (Figure 2.3). Cardiac puncture was used to collect the whole blood of each 
rat which was immediately preserved in a refrigerator until further processing. The blood samples were 
centrifuged at 3000 rpm for 15 minutes and serum from each blood sample was separated and kept at –30 
°C for subsequent analysis. The liver, kidney and heart were collected from each rat, rinsed with normal 
saline, wiped with filter paper, weighed and kept at –30 °C until further analysis. A small portion of the 
pancreas sample from each rat was cut and immersed into a 10% neutral buffered formalin and stored at 
room temperature for histopathological analysis. The neutral buffered formalin of each samples was 
changed weekly during the entire preservation period.  
2.7.6 Analytical methods 
The concentrations of serum insulin were measured by an enzyme-linked immunosorbent assay (ELISA) 
method using an ultrasensitive rat insulin ELISA kit (Mercodia, Uppsala, Sweden) in multi-plate ELISA 
reader (Biorad-680, BIORAD Ltd., Japan). The serum lipid profile (total cholesterol, HDL- and LDL-
cholesterols, and triglycerides), fructosamine, urea and creatinine concentrations as well as liver function 
enzymes; aspartate and alanine aminotransferases (AST and ALT) and alkaline phosphatase (ALP) were 
measured with an Automated Chemistry Analyzer (Labmax Plenno, Labtest Co. Ltd., Lagoa Santa, 
Brazil) with commercial assay kits for these analyses from the same company. Computation of the 
homeostatic model assessment (HOMA-IR and HOMA-β) using were conducted using serum insulin and 
FBG concentrations measured at the end of the experimental period using the formula below: 
HOMA − IR =
Serum insulin in U/L X Blood glucose in mmol/L 
22.5
 
HOMA − β cell function =
20 X Serum insulin in U/L




Conversion factor: insulin (1U/L = 7.174 pmol/L) 
The liver glycogen concentrations were determined using a phenol-sulfuric acid procedure of Lo et al. 
[11]. 
2.7.7 Histopathological analysis of the pancreas 
A standard laboratory protocol for paraffin embedding was followed in processing the formalin preserved 
pancreatic tissues. Sections were cut to a size of 4 µm. Thereafter,  p-xylene was used to deparaffinize the 
slides which were then rehydrated in ethanol concentration gradient (100%, 80%, 70%, 50%) and rinsed 
with tap water. Subsequently, the hematoxylin was used to stain the slides for 5 minutes which was rinsed 
with water. This is followed by counterstaining using eosin, Finally, the slides were mounted in DPX, 







Figure 2.3: Flow charts to describe the overall experimental flow for the in vivo anti-diabetic activies of 
the selected solvent fractions from the four plants 
2.7.8 In vivo anti-oxidative studies 
In order to understand the possible contributory role of anti-oxidative activity to the observed anti-
diabetic activity,  the in vivo anti-oxidative activities of the fractions were investigated in the serum and 
organs of the animals using four in vivo oxidative stress markers namely; reduced glutathione, 
thiobarbituric acid reactive substances (TBARS) levels, catalase and superoxide dismutase activities. 
To perform these assays, homogenates of the organs (liver, kidney, heart and pancreas) were initially 
prepared by homogenising 0.5 g of the sample in 4 mL of homogenization buffer (50 mM sodium 
phosphate buffer with triton X-100, pH 7.5) using a portable tissue homogenizer. Thereafter, the mixture 
was transferred to a microtube and spinned for 15 minutes at 15000 rpm in a microcentrifuge. The 
supernatant was then collected in another micro centrifuge and stored at -20 oC for further analysis.  
2.7.8.1 Determination of reduced glutathione 
The reduced glutathione levels were determined using the procedure described by Ellman [12] with slight 
modifications. A 0.5 mL of the serum or tissue homogenate was added to 0.5 mL of 10% TCA and 
centrifuged at 5000 rpm for 10 minutes. Thereafter, 0.5 mL of the supernatant was mixed with 0.5 mL of 
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Ellman’s reagent (19.80 mg of DTNB dissolved in 100 mL of 0.1% NaNO3) and 3 mL of  phosphate 
buffer (200 mM, pH 8.0). The mixture was incubated for 30 minutes at room temperature and the 
absorbance was measured at 412 nm. The concentration of the reduced glutathione in the samples was 
calculated from a standard glutathione curve.  
 
2.7.8.2 Determination of thiobarbituric acid reactive substance (TBARS) concentration as 
malondialdehyde (MDA) equivalent 
Thiobarbituric acid reactive substances, expressed as MDA concentration were measured to determine the 
extent of lipid peroxidation using the protocol described by Fraga et al. [13]. A 200 µL of the sample or 
MDA standards were thoroughly mixed with 200 µL of 8.1% SDS solution, 750 µL of 20% acetic acid, 2 
mL of 0.25% TBA and 850 µL of distilled water. Subsequently, the resulting mixture was heated in a 
water bath at 95 oC for 1 hour and allowed to cool to room temperature. The absorbance of the resulting 
solution was then read at 532 nm and the concentration of TBARS in the samples was calculated from the 
MDA standard curve. 
2.7.8.3 Determination of catalase activity 
This assay was carried out as described by Aebi [14]. A 340 µL of 50 mM sodium phosphate buffer (pH 
7.0) was mixed with 150 µL of 2 M H2O2. Thereafter, 10 µL of the sample was added and the decrease in 
absorbance at 240 nm was monitored for 3 minutes at 1 minute interval. 
2.7.8.4 Determination of superoxide dismutase activity 
This assay was carried out by transferring 1 mL of 0.1 mM diethylenetriaminepentaacetic acid 
(DETAPAC) and 90 µL of the sample into a quartz cuvette. Then a 90 µL of 1.6 mM 6-hydroxydopamine 
(6-HD) was added and the mixture was quickly mixed. Absorbance of the resulting mixture was recorded 
at 492 nm for 3 minutes at 1 minute interval . 
2.8 Isolation of the bioactive anti-diabetic compounds from the fractions 
A bioassay guided isolation protocol was used to isolate the pure bioactive anti-diabetic agent(s) from 
each of the most active fraction (from in vitro studies described in sub chapter 2.6.2 - 2.6.5) but the 
approach slightly differs from one fraction to another. 
2.8.1 Isolation of the bioactive compound from the butanol fraction of ethanolic extract of Ziziphus 
mucronata root 
The fraction was separated on a silica gel column using dichloromethane with an increasing gradient of 
methanol as the solvent system to give fifty seven fractions of 15 mL each. Fractions were monitored by 
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thin layer chromatography (TLC) and fractions with similar TLC profiles were pooled together and tested 
for α-glucosidase inhibitory activity. However, fraction 29 was found to have the best α-glucosidase 
inhibitory activity but it was a mixture of a chromone and polar aliphatic alcohol, which co-eluted in the 
same fraction and was unable to be separated despite several attempts.  The chromone was further 
characterized by 1H NMR, 13C NMR and two dimensional (2D) NMR. The sample was dissolved in 
deuterated chloroform (CDCl3, Merck South Africa) and transferred to 5 mm NMR tubes. 
2.8.2 Isolation of the bioactive compound from the butanol fraction of ethanolic extract of Parkia 
biglobosa leaves 
The fraction was subjected to silica gel column chromatography using a solvent system of 
dichloromethane with an increasing gradient of methanol to give fifty seven fractions of 15 mL each. 
Fractions were monitored by TLC and fractions with similar TLC profiles were pooled together and 
tested for α-glucosidase inhibitory activity. Fraction 11 however, was found to be a pure α-glucosidase 
inhibitory compound which was characterized by 1H and 13C NMR. The sample was dissolved in 
deuterated chloroform (CDCl3, Merck South Africa) and transferred to 5 mm NMR tubes. 
2.8.3 Isolation of the bioactive compound from the butanol fraction of ethanolic extract of Khaya 
senegalensis root 
The fraction was subjected to a column chromatrography on a silica gel column (100 mesh) eluted with 
ethyl acetate: methanol (8:2, 7:3, 6:4 and 1:1) as the mobile phase to obtain forty fractions of 20 mL each. 
Fractions were monitored by TLC and fractions with similar TLC profiles were pooled together and 
tested for α-glucosidase inhibitory activity. A combined fraction 10-14 displayed the highest α-
glucosidase inhibitory activity and was further subjected to silica gel column chromatography using 
methanol in dichloromethane (2%-10%) as the mobile phase. Thirty five fractions (I-XXXV) of 15 mL 
each were collected and fraction XIV was found to be a pure α-glucosidase inhibitory compound which 
was characterized by 1H, 13C and two dimensional (2D) NMR as well as mass spectroscopy. The sample 
was dissolved in deuterated methanol and transferred to 5 mm NMR tubes. 
2.8.4 Isolation of the bioactive compound from the acetone fraction of the ethyl acetate extract of  
Cassia singueana stem bark 
This fraction was also subjected to column chromatography on a silica gel column (100 mesh) eluted with 
hexane : ethyl acetate (8:2, 7:3 and 1:1) as the mobile phase to obtain fifteen fractions (I-XV). The 
fractions were monitored by TLC and were subsequently pooled according to their TLC profiles. 
Combined fractions XI-XIII displayed the highest α-glucosidase inhibitory activity and was further 
fractionated using methanol in dichloromethane (0%-10%) as the mobile phase. Sixty fractions of 15 mL 
47 
 
were collected. Fraction 34 was found to be the best α-glucosidase inhibitory compound which was 
further characterized by 1H and 13C NMR. The sample was dissolved in deuterated chloroform (CDCl3, 
Merck South Africa) and transferred to 5 mm NMR tubes. 
All the NMR experiments were performed on a Bruker AvanceIII 400 MHz spectrometer (Bruker 
BioSpin, Rheinstetten, Germany) at room temperature with all chemical shifts (δ) values recorded against 
the internal standard, tetramethylsilane (TMS). Chemical shifts for all NMR spectra are reported in parts 
per million (ppm). The NMR system was controlled by TopSpin 2.0 software.  
The α-glucosidase and α-amylase inhibitory activities as well as the mechanism of action of the pure 
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3.0 THE ANTI-OXIDATIVE AND ANTI-DIABETIC ACTIVITIES OF 
Ziziphus mucronata Willd IN VITRO AND IN VIVO  
3.1 Ziziphus mucronata Willd. (Rhamnaceae) 
 
Figure 3.1: Ziziphus mucronata Willd. (Rhamnaceae); Common names: buffalo thorn (English), Magarya 
(Hausa, Nigeria), Umlahlankosi (Zulu, South Africa), Chinanga (Shona, Zimbabwe), Omukekete  
(Oshiwambo, Namibia). Photo: Mr. Umar Gallah (2012), Zaria, Nigeria 
3.1.2 Background 
 Ziziphus mucronata is a deciduous tree with an irregular spiky canopy mostly supported by a single trunk 
but sometimes contains minor branches.   The plant is usually 8 – 10 m in height and the leaves are shiny 
and light green while the thorns are located at the base of the leaves.  The flowers are yellowish star-
shaped while the fruits are circular, about 2.5 cm in diameter, sub-globose drupe and green at younger 
stage but becomes shiny reddish-brown when riped. The plant is distributed throughout West and East 
African countries as well as some Central and Southern African countries [1]. 
 
3.1.3 Ethnomedicinal uses 
The high adaptabililty of this plant to the climates of most sub-Saharan countries makes it prone to 
exploitation for medicinal purposes by the traditional medicine practitioners of a number of African 
countries.  The powdered leaf and bark are used as for curing chest pain and cough by the Zulu tribe of 
South Africa. Furthermore, warm aqueous extract of the root, bark and leaf are applied topically for the 
treatment of sores, boils and swellings [2]. The roots are also used in the local treatment of dysentery, 
diarrhoea and stomach ulcers.  In Namibia, the leaf and root are used in the folkloric medicine for the 
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treatment of skin allergies and sores [3]. Indeed, all the parts including the fruits are used in different 
forms such as food, poultice and drinks for the treatment of so many tropical diseases [1]. However, more 
relevant to this dissertation, is that the stem bark of the plant is commonly used in the North Western 
region of Nigeria for the traditional management of diabetes mellitus [4]. Furthermore, decoction of the 
leaves is used for diabetes management by the traditional healers of South Africa [2]. 
 
3.1.4 Biological activities 
The first study on the scientifically investigated biological activity of Z. mucronata was antihelminthic 
effects [5]. Aqueous extract of the root bark of Z. mucronata was reported to be highly active against 
schistosomiasis (tapeworms) [5]. This finding was further confirmed in another antihelminthic studies 
where aqueous and organic extracts of the various parts of the plant were found possess strong activity 
against the levamisole strain of Caenorhabtidis elegans.  In a genotoxicity study, a 90% methanolic 
extract of Z. mucronata leaves was reported to be mutagenic in the presence of metabolic activation (6). 
Also, the anti-sickling activity of the aqueous and ethanolic extracts of different parts of the plant was 
demonstrated when a UV lamp and solar irradiations were used to induce photodegradation [7]. In order 
to validate the folkloric use of the plant for treating bacterial diseases, Coopoosamy et al. [8] studied the 
activity of various solvent extracts of the different parts of the plant against some pathogenic bacteria and 
reported that the leaves extracts had the greatest inhibitory properties on both gram positive and gram 
negative bacteria. In a related study, Olajuyigbe and Afolayan [9] reported that the ethanolic extract of the 
bark possessed strong synergistic effect with antibiotics against clinically important bacteria. The 
anticholinesterase and antioxidant activity of the root part of the plant was investigated [10] where the 
methanol and ethyl acetate extracts were reported to display good anticholinesterase and radical 
scavenging activities. Furthermore, the antioxidant activity of the bark extracts of the plant was 
investigated where the ethanolic extract was found to have the highest antioxidant activity among other 
solvent extracts of the plant [11]. 
3.1.5 Phytochemistry 
Information on the phytochemical contents of different parts of this plant is very scanty in the literature. 
Preliminary quantitative analysis revealed that the bark of the plant contain phenolics, flavonoids and 
proanthocyanidin [11] but the phenolics content was significantly higher than the flavonoids and 
proanthocyanidins.  The only isolated group of phytochemicals reported in Z. mucronata is the 
cyclopeptide alkaloids, predominantly mucronines. Auvin et al. [12] described the isolation and 
characterization of mucronine J along with abyssenine A and mucronine D from the dichloromethane 
extract of the root bark. Furthermore, frangufoline (sanjoinine A) with strong sedative property was 




The aim of this study is to comprehensively investigate the anti-diabetic activity of this plant using in 
vitro and in vivo models. To accomplish this, various solvent crude extracts of the stem bark, root and 
leaves of the plant were subjected to detailed in vitro anti-oxidative studies (using four models) from 
where the ethanolic extract of the root was found to have the best activity. Subsequently, the ethanolic 
extract of the root was fractionated across various solvents and the fractions were subjected to the anti-
oxidative and -glucosidase and -amylase inhibitory studies where the butanol fraction was found to 
have the best anti-oxidative and enzymes inhibitory activities. Thus, the butanol fraction was investigated 
for in vivo anti-diabetic activity in type 2 diabetic rats as well as the possible mechanism of action. A pure 






















3.2 Anti-oxidative activities of various extracts of stem bark, root and leaves 
of Ziziphus mucronata (Rhamnaceae) in vitro 
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Preface:  The in vitro anti-oxidative activities of the stem bark, root and leaves of the plant were 
investigated in this article. The article has already been accepted published in the Journal of Medicinal 
Plants Research, 2012, Vol 6 number 25 pages 4176-4184. 
 
3.2.1 Abstract 
The present study examined the anti-oxidative activities of extracts from different parts of Ziziphus 
mucronata. Stem bark, root and leaves samples were sequentially extracted with solvents of increasing 
polarity and tested for in vitro anti-oxidative activity using various models. Our results indicated that all 
the extracts had potent electron donating and 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical scavenging 
activities. However, the ethanolic extracts exhibited a significantly (P<0.05) more potent DPPH radical 
scavenging activity than other extracts and possessed lower IC50 values than ascorbic acid and trolox. The 
organic extracts of all the parts demonstrated hydroxyl radical scavenging activities but the ethyl acetate 
extracts of the stem bark and root as well as the ethanolic extract of the leaves displayed more powerful 
anti-OH* activity than trolox. All aqueous extracts were found to possess pro-oxidative activities in the 
hydroxyl radical scavenging method. Nitric oxide (NO) scavenging activities were observed in all the 
extracts tested except the aqueous extract of the roots that was found to be pro-oxidative at higher 
concentrations. Furthermore, a non-dose dependent NO scavenging activities were observed in the 
ethanolic extract of the stem bark and ethyl acetate extracts of the root and leaves as well as aqueous 
extract of the leaves. Data from this study suggest that the different parts of Z. mucronata, especially the 
ethanolic extracts possessed potent anti-oxidative activities that warrant further studies to identify the 
active key principles. 
3.2.2 Introduction 
The use of herbs and natural products in the treatment of various diseases is as old as human existence 
and continues to be an important component of health care delivery system, especially in African 
countries. Africa has a rich diversity of plants and about 25% of the total numbers of higher plants in the 
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world are found in Africa where more than 5400 medicinal plants were reported to have over 16,300 
medicinal uses [14]. Recent pharmaceutical and biological research findings suggest plants as good 
sources of compounds that could provide chemical leads for the development of new generation of drugs 
to treat various diseases [15], especially non-communicable chronic diseases such as diabetes. 
Diabetes mellitus is one of the major global health problems whose prevalence is currently on the increase 
at an alarming rate [16]. Mainly two types of diabetes are identified such as type 1 or insulin dependent 
diabetes mellitus (IDDM) and type 2 or non-insulin dependent diabetes mellitus (NIDDM). Among these 
types, type 2 is the most prevalent one and > 95% of the total diabetic patients are suffers from it. Type 2 
diabetes (T2D) is a complex heterogeneous disorder that is associated with a gradual decline in the action 
of insulin (insulin resistance), followed by the failure of pancreatic β-cells to account for the insulin 
resistance (β-cell dysfunction) [17]. A number of mechanisms are involved in the β-cell damage but 
oxidative stress is considered as one of the major contributor [18-20]. 
 Oxidative stress refers to the presence of free radicals and reactive oxygen species (ROS) that are 
generated in normal body processes but become harmful when not being quenched by the endogenous 
antioxidants systems. This usually occurs when there is an excess generation of ROS or when the 
antioxidants (AO) are inactivated, thereby altering the ROS/AO equilibrium in favor of stress [21, 22]. In 
T2D, various free radicals, including ROS, hydroxyl and nitric oxide radicals [23-25] are involved in the 
induction of oxidative stress induced pancreatic β-cell destruction [26] as well as the activation of all 
major pathways underlying the different components of vascular diabetic complications such as glycation, 
sorbitol pathways among others [27]. The foregoing therefore makes research on diabetes therapy and 
prevention to focus a lot of attention on the search for alternative agents with anti-oxidative properties 
that could be used to ameliorate the complications associated with T2D. 
Ziziphus mucronata (Rhamnaceae), commonly known as buffalo thorn, is native to northern Nigeria. The 
plant decoction is used traditionally in the treatment of diabetes mellitus [4] among the rural populace of 
northern Nigeria, however scientific report(s) on any pharmacological activity from this plant is scanty in 
the literature. Hence, this study was designed to evaluate the anti-oxidative activities of various extracts 
of stem bark, root and leaves of Z. mucronata initially in vitro.  
3.2.3 Materials and methods 







The percentage yield of the various extracts collected from the plant indicated that higher yields are 
obtained from the leaves extracts compared to roots and stem bark (Table 3.2.1). Furthermore, the 
ethanolic extracts of the stem bark and root contained significantly (P<0.05) higher amount of total 
polyphenols than other extracts from these parts of the plant whereas ethyl acetate extract of the leaves 
contained significantly (P<0.05) higher amount of the total polyphenols than other extracts in this part 
(Table 3.2.1). 
Table 3.2.1: Percentage yield and total phenolic content of various extracts of Z. mucronata parts 
 
Results are expressed as mean ± SD of triplicate determinations. a-fDifferent superscripts alphabets within 
a column indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The total reducing power (in terms of percentage gallic acid equivalent) of the various extracts of Z. 
mucronata was compared to ascorbic acid and trolox and presented in Figure 3.2.1. According to the 
results, the total reducing power of all extracts was found to increase steadily with increasing 
concentrations of the samples (Figure 3.2.1). However, the ethanolic extracts from the different parts of 
the plant demonstrated a significantly (P<0.05) higher Fe3+ to Fe2+ reductive ability, at least at higher 
concentrations, than other extracts and trolox.  
Plant Extracts % Yield Total phenolic (mg/g GAE) 
Stem bark   
Ethyl acetate 0.15 3.10 ± 0.13a 
Ethanolic 0.38 87.43 ± 2.87f 
Aqueous 1.46 25.01 ± 0.97b 
   
Root   
Ethyl acetate 0.34 2.38 ± 0.58a 
Ethanolic 0.29 77.41 ± 0.50e 
Aqueous 0.93 36.62 ± 0.46c 
   
Leaves   
Ethyl acetate 3.65 75.66 ± 1.21e 
Ethanolic 1.09 71.38 ± 1.81d 






Figure 3.2.1: Total reducing power (relative to gallic acid) of stem bark (A), root (B) and leaves (C) 
extracts of Z. mucronata. Results are expressed as mean±SD of triplicate determinations. a-dDifferent 
alphabets presented for a given concentration for each extract indicate significant difference (Tukey’s-


















































































































The DPPH radical scavenging activities of Z mucronata stem bark, root and leaves extracts are presented 
in Figure 3.2.2. The stem bark and root ethanolic extracts demonstrated powerful free radical scavenging 
activity (100% radical scavenging activity at 120-240 µg/ml) which were statistically similar with all the 
standard antioxidants used and significantly (P<0.05) higher than other extracts from the other plant parts. 
The IC50 values of 1.99, 1.38 and 1.68 µg/ml were obtained for stem bark, root and leaves ethanolic 
extracts respectively whereas 2.56, 1.27 and 5.04 µg/ml were found for ascorbic acid, gallic acid and 













Figure 3.2.2: DPPH radical scavenging activity of stem bark (A), root (B) and leaves (C) extracts of Z. 
mucronata. Results are expressed as mean±SD of triplicate determinations. a-eDifferent alphabets over the 
bars for a given concentration for each extract indicate significant difference (Tukey’s-HSD multiple 
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The results of the hydroxyl radical scavenging effects of extracts from Z. mucronata (Table 3.2.2) 
indicate that the ethyl acetate extracts derived from stem bark (IC50 1.07 µg/ml) and root (IC50 1.36 
µg/ml) samples exhibited a concentration dependent anti-OH activities which were also significantly 
(P<0.05) higher than the activities observed with the corresponding ethanolic extracts and trolox (IC50 
2.61 µg/ml) at all concentrations tested. Stem bark ethanolic extract demonstrated an anti-OH activity that 
inversely correlates with the concentration used while a non-dose dependent activity was observed with 
leaf ethanolic extract (Table 3.2.2). However, the aqueous extracts from all the plant’s parts showed pro-
oxidative rather than anti-oxidative activities at least in this model.  






15  30 60 120 240 
Stem bark      
Ethyl acetate 74.48 ± 0.50g 79.85 ± 1.78g 83.87 ± 0.18h 94.20 ± 0.12h 98.72 ± 0.42h 
Ethanolic 45.06 ±1.02b 38.65 ± 0.75c 23.64 ± 3.69c 16.45 ± 1.39d 1.09 ± 0.50d 
Aqueous -70.19 ± 2.37a -100.00 ± 0.00a -100.00 ± 0.00a -100.00 ± 0.00a -100.00 ± 0.00a 
      
Root      
Ethyl acetate 68.35 ± 1.39f 80.78 ± 0.57g 89.12 ± 1.71i 93.26 ± 1.09h 94.66 ± 0.64g 
Ethanolic 43.27± 3.41b 38.16 ± 3.71c 30.82 ± 0.22d 20.45 ± 0.93e 16.76 ± 7.54e 
Aqueous 0.00 ± 0.00b 0.00 ± 0.00b -10.63 ± 1.99b -23.58 ± 1.43c -51.14 ± 1.60b 
      
Leaves      
Ethyl acetate 49.42 ± 0.56c 47.10 ± 0.27d 48.30 ± 4.86e 28.81 ± 1.26f 16.24 ± 0.47e 
Ethanolic 60.89 ± 0.60d 67.52 ± 1.86e 80.67 ± 0.94g 82.41 ± 0.65g 78.52 ± 1.06f 
Aqueous 0.00 ± 0.00b 0.00 ± 0.00b -7.93 ± 1.36b -11.86 ± 0.86b -20.48 ± 3.22c 
      
Trolox 57.32 ± 2.95d 73.11 ± 1.44f 76.04 ± 2.05f 80.09 ± 3.93g 79.82 ± 3.50f 
Results are expressed as mean±SD values of triplicate determinations. a-iDifferent alphabets along a column indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Table 3.2.3 shows the NO radical scavenging activities of the various extracts of Z. mucronata. A non-
dose dependent NO inhibition effects with root and leaf ethyl acetate extracts as well as stem bark 
ethanolic extract were observed while root aqueous extract was found to be pro-oxidative in this model. 
On the other hand, dose dependent NO inhibition activities were observed for ethyl acetate and ethanolic 
extracts of stem bark section of this plant which were significantly higher (P<0.05) than the results of 






Table 3.2.3: Percentage of nitric oxide scavenging activities of extracts from various parts Z. mucronata  
Samples Concentration (µg/ml) 
15  30 60 120 240 
Stem bark      
Ethyl acetate 12.70 ± 0.62c 54.00 ±9.41ef 64.55 ± 4.74f 72.66 ± 4.80h 80.60 ± 1.26h 
Ethanolic 31.33 ± 1.27d 51.24 ± 4.93e 43.96 ±1.86e 41.24 ± 0.94e 40.60 ± 0.80e 
Aqueous 25.06 ± 6.91d 26.87 ± 3.23d 32.35 ±2.80d 41.59 ± 6.64ef 53.07 ± 2.09c 
      
Root      
Ethyl acetate 8.30 ± 3.12b 15.81± 2.95c 21.48±8.92bcd 15.61 ± 3.65c 38.75 ± 2.29e 
Ethanolic 0.00 ± 0.00a 0.00 ± 0.00a 15.17 ± 0.78b 44.36 ± 1.05f 48.10± 1.93f 
Aqueous 0.00 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.00a -66.70 ± 3.55a -100.00 ± 0.00a 
      
Leaves      
Ethyl acetate 62.45 ± 2.30g 60.99 ±8.60ef 69.94 ± 4.99a 24.00 ± 3.89d 14.24 ± 2.30b 
Ethanolic 0.00 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.00b 18.05 ±1.66c 
Aqueous 52.99 ± 1.47f 32.06± 3.60d 29.66 ± 1.09d 28.36± 9.70de 12.60 ± 0.97b 
      
Ascorbic acid 47.81 ± 0.51e 50.97 ± 1.35e 52.82 ± 1.35f 56.72 ± 3.69g 64.08 ± 4.25g 
Gallic acid 4.43 ± 2.69b 7.52 ± 1.11b 25.74 ± 0.44c 27.66 ± 1.91d 31.70 ± 2.51d 
Trolox 66.30 ± 1.23h 65.51 ±1.27f 63.39 ± 1.84f 59.53 ± 1.81g 52.21 ± 2.47f 
Results are expressed as mean±SD values of triplicate determinations. a-hDifferent alphabets along a 
column indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
























Nitric oxide radical 
scavenging activity 
Stem bark    
Ethyl acetate 122.16 1.07 43.34 
Ethanolic 1.99 12.18 56431.12 
Aqueous 35.36 P 239.10 
    
Root    
Ethyl acetate 553.33 1.36 1818.82 
Ethanolic 1.38 8.19 242.17 
Aqueous 24.64 P P 
    
Leaves    
Ethyl acetate 3.61 22.06 48.85 
Ethanolic 1.68 2.09 425039.14 
Aqueous 106.73 P 12.52 
    
Ascorbic acid 2.56 ND 26.28 
Gallic acid 1.27 ND 1026.45 




Ziziphus mucronata has been reported to be used in the traditional management of diabetes mellitus, a 
disease whose pathogenesis has, in part, been linked to the development of oxidative stress in affected 
humans. As per our knowledge, the antioxidant activities of all the parts of the plants within the Ziziphus 
genus have not been reported until now. This study investigated the anti-oxidative activities of various 
extracts from different parts of Z. mucronata as a prelude to find agent(s) that could be used to ameliorate 
T2D-associated abnormalities. We found in this study that some of the Z. mucronata extracts possess 
exceptionally very high anti-oxidative activities, at least with experimental models used in this study. 
Different models for in vitro anti-oxidative studies were used because a single method cannot give a 
comprehensive prediction of the anti-oxidative capacities of the different extracts under investigation. It 
was proposed that the electron donating ability which reflects the reducing power of phytochemicals is 
linked with antioxidant activity [28, 29]. Antioxidants can be reductants which can inactivate oxidants 
and the reaction can be described as a redox reaction in which one reaction species is reduced at the 
expense of the oxidation of the other. Thus, the presence of antioxidant substances in the samples causes 
the conversion of the Fe3+/ferricyanide complex to the Fe2+ form which can be measured at 700 nm [30]. 
The reducing power of the extracts increased with increasing concentration which suggests that the 
electron donating ability of the extracts is concentration dependent. The higher reducing power of the 
ethanolic extracts from different parts of this plant at almost all concentrations used suggest that the 
ethanol extractable phytochemical constituents of this plant has strong redox potentials that could act as 
reducing agents, hydrogen donors and singlet oxygen quenchers [31].  
The model of scavenging the stable DPPH radical is a widely used method to evaluate the antioxidant 
activity of extracts or pure compounds. DPPH is a free radical that can accept an electron or hydrogen 
radical to become a stable diamagnetic molecule. Hence, DPPH is usually used as a substrate to evaluate 
the free radical scavenging activity of antioxidative agents in vitro [32].  Using this model, the ethanolic 
extracts of all the parts of Z. mucronata also demonstrated remarkable anti-radical activities with IC50 
values lower than those of ascorbic acid and trolox. Although, a number of reports on the DPPH radical 
scavenging activity of extracts from plants belonging to different families and from parts of the world 
exist in the literature but only a few authors [33] reported such a low IC50 value as observed with the 
ethanolic extracts of this plant. This further suggests that these extracts contain powerful free radical 
scavenging phytochemicals that could have the ability to inhibit free radical upsurge as well as oxidative 
stress which consequently might ameliorate T2D-associated complications and indeed other oxidative 
stress associated metabolic disorders.  
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The hydroxyl radical is a highly potent free radical in living organism and has been implicated as a highly 
damaging species in free radical pathology that can damage all life essential biomolecules [34]. The 
hydroxyl radical scavenging activity is thus measured as the percentage of inhibition of these radicals 
generated in the Fenton’s reaction mixture (Fe3+/EDTA/ascorbate/H2O2) by studying the competition 
between deoxyribose and the plant extracts [35]. In this study, all the organic extracts from Z. mucronata 
contain phytochemicals with hydroxyl radical inhibition activity. However, the stem bark and root ethyl 
acetate extracts were found to be more effective in hydroxyl radical inhibition than the corresponding 
ethanolic extracts whereas leaves ethanolic extract was more effective in hydroxyl radical inhibition than 
the ethyl acetate extract.  The reciprocal hydroxyl radical inhibition pattern found in the ethanolic extracts 
of the stem bark and root samples as well as in the ethyl acetate extract of the leaves could be due to 
hormesis phenomenon exhibited by these extracts. Hormesis is a dose-response relationship for a single 
endpoint that is associated with reversal of response between high and low doses of biological molecule, 
chemicals, physical stressors, or any other agent that can initiate a response [36] and its occurrence has 
been documented in numerous biological, toxicological and pharmacological investigations [37]. The 
phenomenon could also account for the non-dose dependent response of the ethanolic extract of the leaves 
of this plant. Thus, these Z. mucronata extracts possess optimal points for effective inhibition of hydroxyl 
radical. On the other hand, the pro-oxidative tendencies of the aqueous extracts in the hydroxyl radical 
based anti-oxidative model further indicate the need to use a multi method approach before a definite 
statement can be made on the anti-oxidative effects of a plant extract. 
Nitric oxide is a very unstable species that has been implicated in the pathology of cancer, type 2 diabetes 
and several other diseases [23, 25, 38]. Ethyl acetate extracts of the stem bark and leaves of this plant 
displayed greater inhibitions against NO radical than the corresponding ethanolic extracts. This could 
indicate that the anti-oxidative principles extracted by the two solvents act via different antioxidant 
mechanisms. Further, the hormetic responses shown by some extracts towards scavenging NO indicate 
that the anti-NO principles have some optimal points of effective inhibitions and/or antagonism occur 
with other phytochemicals at certain concentrations. Considering all the anti-oxidative models used in this 
study, it is possible to surmise that the quantitative difference in the anti-oxidative activities among the 
plant parts could be attributed to the variation(s) in the concentrations and compositions of the anti-
oxidative principles in the different parts since distinct function(s) is performed by the parts and hence 
tend to produce slightly different chemical constituents.  
We therefore concluded that the various parts of Z. mucronata possessed anti-oxidative activities that 
could account for the forkloric use of the plant in the treatment of diabetes mellitus. Our results also 
suggest that the ethanolic extracts from different parts of the plant contain the most active anti-oxidative 
principles. Bioassay guided fractionation and evaluating the anti-T2D effects of the most active anti-
oxidative fraction from the ethanolic extracts will be the subject of our future investigations. 
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Postscript : From the above experiment, the ethanolic crude extract from the root was found to have 
relatively higher anti-oxidative activity that cuts across various types of radicals than other extracts. It was 


































3.3 Butanol fraction of Ziziphus mucronata (Willd) root ethanolic extract 
contains anti-oxidative agents and potent inhibitors α-glucosidase and α-
amylase 
 
M. A. Ibrahim1,3, N. A. Koorbanally2  and M. S. Islam1* 
1School of Life Sciences, 2School of Chemistry and Physics, University of KwaZulu-Natal (Westville 
Campus), Durban, 4000 South Africa. 
3Department of Biochemistry, Ahmadu Bello University, Zaria, Nigeria 
*Correspondence to: islamd@ukzn.ac.za or sislam1974@yahoo.com 
 
Preface: In this sub-chapter, solvent-solvent fractionation of the crude ethanol extract of the root was 
carried out and the solvent fractions were investigated for anti-oxidative and α-glucosidase and α-amylase 
inhibitory activities. This article has been submitted for publication to Indian Journal of Experimental 
Biology and is currently under review 
 
3.3.1 Abstract 
The in vitro anti-oxidative as well as the α-glucosidase and α-amylase inhibitory effects of various solvent 
fractions derived from the crude ethanol extract of Ziziphus mucronata root were investigated. Our 
findings indicated that butanol fraction contained a significantly higher (P < 0.05) amount of total 
phenolics, FRAP and DPPH radical scavenging activity than other solvent fractions. Furthermore, the 
butanol fraction elicited a significantly higher (P < 0.05) inhibitory effects on α-glucosidase (IC50=1.41 ± 
0.16 μg/ml) and α-amylase (IC50=105.86 ± 5.21 μg/ml) activities than other fractions. Steady state kinetic 
analysis revealed that the butanol fraction is a mixed inhibitor of both α-glucosidase and α-amylase 
altering both KM and Vmax of the enzymes. The computed index of physiological efficiency (Kcat) of the 
enzymes was also reduced in the presence of the fraction. Analysis of the butanol fraction using GC-MS 
indicated that the fraction contains mainly phenolics such as catechol, pyrogallol, 2,6-dimethoxy phenol 
and 2-methoxyhydroquinone. Data from the study suggest that the butanol fraction contains potent anti-
oxidative agents and inhibitors of α-glucosidase and α-amylase which could be exploited for developing 




Oxidative stress refers to the presence of free radicals and reactive oxygen species (ROS) that are 
generated in normal physiological processes. However, when there is an excess generation of ROS or the 
endogenous antioxidants (AO) systems are inactivated, the ROS/AO equilibrium is altered in favor of 
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stress and consequently the species become harmful [21, 22]. At present, the concept of oxidative stress 
as a major pathogenic phenomenon for a number of non-communicable chronic diseases and their 
associated complications is a favored hypothesis [39, 40]. Furthermore, oxidative stress is believed to be 
the most important biological phenomenon for both macrovascular and microvascular complications 
associated with type 2 diabetes (T2D) [41]. Thus, diabetes therapy targeted to reduce oxidative stress 
would be beneficial to the patients and other risk populations.  
 
On the other hand, the control of postprandial hyperglycemia is also considered as an important strategy 
for treatment of T2D and preventing its associated complications such as nephropathy, neuropathy, 
retinopathy and cardiomyopathy. Among the different therapeutic strategies to reduce postprandial 
hyperglycemia, delaying the digestion and absorption of carbohydrates by inhibiting carbohydrate-
hydrolyzing enzymes, such as α-amylase and α-glucosidase, in the digestive organs holds a strong 
potential [42]. α-Amylase hydrolyzes starch and other complex polysaccharides to oligosaccharides which 
are further hydrolyzed by intestinal α-glucosidase to liberate glucose which is then absorbed into the 
intestinal epithelium and enter blood circulation. Consequently, postprandial rise in blood glucose 
concentration could be retarded by inhibitors of these enzymes [43]. Thus, the amelioration of oxidative 
stress and the control of postprandial hyperglycemia offer a unique therapeutic strategy for the treatment 
of T2D and for reducing its associated complications [44]. Therefore, the search for alternative agents 
with potent anti-oxidative properties that could also decrease postprandial hyperglycemia via inhibiting 
carbohydrate digesting enzymes is an important therapeutic strategy that would provide a holistic avenue 
to control hyperglycemia and other diabetic complications resulting from oxidative stress. 
 
Traditional herbal medicines have been used throughout the world for the treatment of various diseases 
and are still considered to be an important component of health care delivery system, especially in Africa 
[14]. The World Health Organization (WHO) has also recommended herbal medicines as targets for 
scientific investigation in order to search for novel agents to treat different diseases [45]. This is because 
most modern medicines exert serious side effects. A typical example is the clinically used glucosidase 
inhibitors, acarbose and miglitol, mostly found to cause gastrointestinal disturbances such as diarrhea, 
other intestinal pain and flatulence [46]. Interestingly, glucosidase inhibitors derived from plants sources 
were reported to be more acceptable because they are cheap and relatively safer, including a lower 
tendencies of causing serious gastrointestinal discomfort [47, 48]. This makes the search of glucosidase 
inhibitors from plants an appealing alternative. 
 
Ziziphus mucronata Willd (Rhamnaceae), commonly referred to as ‘’buffalo thorn’’, is native to northern 
Nigeria. A decoction of the plant is used traditionally in the treatment of diabetes mellitus among the rural 
inhabitants of northern Nigeria [4]. In a recent study, we subjected the various crude solvents extracts 
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from the stem bark, root and leaf samples of the plant to a series of in vitro anti-oxidative assays and 
found that the ethanolic extract of the root had the most potent anti-oxidative activities that reasonably cut 
across various models [49]. In this study, we further fractionated the ethanolic extract of the root by 
solvent-solvent partitioning and then conducted a comprehensive investigation on the in vitro anti-
oxidative as well as the α-glucosidase and α-amylase inhibitory effects of the fractions.  
 
3.3.3. Materials and Methods 
Please refer to the chapter 2 sub-sections 2.6.1-2.6.6 pages 38-40 for detailed material and methods that 
involve Z. mucronata 
3.3.4 Results 
The total reducing power of the butanol fraction was significantly higher (P < 0.05) than all other 
fractions and the standard antioxidants used (Figure 3.3.1). All the fractions were found to scavenge the 
DPPH radical in a dose dependent fashion (Figure 3.3.2) but judging from the IC50 values, the butanol 
fraction also displayed a significantly (P < 0.05) more powerful DPPH radical scavenging activity than 
other fractions (Table 3.3.2).  
 
Figure 3.3.1: Total reducing power (relative to gallic acid) of different solvent fractions of Z. mucronata  
root ethanolic extract. The results are expressed as mean ± SD of triplicate determinations. a-fDifferent 
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Figure 3.3.2: Free radical scavenging activities of different solvent fractions of Z. mucronata root 
ethanolic extract. The results are expressed as mean ± SD of triplicate determinations. a-fDifferent 
alphabets over the bars for a given concentration indicate significant difference (Tukey’s-HSD multiple 
range post hoc test, P<0.05) 
 
The results of the HRS assay also showed that all the fractions contained phytochemicals that could 
scavenge hydroxyl radicals produced by Fenton’s reaction in a dose dependent manner (Table 3.3.1). 
However, the less polar fractions (ethyl acetate and dichloromethane) showed a significantly higher (P < 
0.05) HRS activity than the more polar fractions (butanol and water) as shown by the IC50 values (Table 
3.3.2). On the other hand, analysis of the total phenolic content of the fractions indicated that the butanol 
fraction had a significantly higher (P < 0.05) phenolic content than other fractions (Table 3.3.2). 





15  30 60 120 240 
Aqueous 35.15 ± 7.55b 51.63 ±1.24b 63.59 ±1.98b 71.36 ±0.52b 74.96 ± 0.41a 
Butanol 20.12 ± 1.24a 42.60 ±1.47a 56.59 ±2.85a 68.95 ±1.56a 75.61 ± 1.39a 
Ethyl acetate 52.28 ± 0.74c 64.11 ±0.71c 73.40 ±1.14c 78.55 ±0.30c 78.94 ± 0.56b 
Dichloromethane 49.73 ± 1.67c 62.21 ± .08c 71.30 ±1.14c 71.04 ±0.68a 74.63 ± 0.30a 
      
Trolox 57.32 ±2.95d 73.11 ±1.44d 76.04 ±2.05d 80.09 ±3.93c 79.82 ±3.50a,c 
The results are expressed as mean ± SD values of triplicate determinations. a-dDifferent superscript alphabets within 
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Table 3.3.2 : IC50 values of various solvent fractions of ethanolic extract of Z. mucronata root in different 
anti-oxidative models 
Fractions Total phenolics 
(mg/g GAE) 
IC50 (µg/ml) 
DPPH Hydroxyl radical 
Aqueous 143.06 ± 0.96c 14.57 ± 0.18d 34.00 ± 0.42c 
Butanol 150.39 ± 1.15d 9.17 ± 0.33c 52.31 ± 2.00d 
Ethyl acetate 95.56 ± 0.78b 53.01 ± 1.70e 8.00 ± 0.26b 
Dichloromethane 3.91 ± 0.80a 3.29 ± 0.63f* 9.11 ± 1.63b 
    
Ascorbic acid - 2.56 ± 0.26b ND 
Gallic acid - 1.40 ± 0.43a ND 
Trolox - 8.47 ± 2.88c 3.23 ± 0.49a 
Results are expressed as mean ± SD values of triplicate determinations. a-dDifferent superscript alphabets within a 
column for a given parameter indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05). 
*Unit is presented in mg/ml. 
 
The α-glucosidase and α-amylase inhibitory activities of the fractions are shown in Figure 3.3.3. All the 
solvent fractions inhibited α-glucosidase activity in vitro in a dose dependent pattern (Figure 3.3.3A). 
The more polar fractions demonstrated significantly higher (P < 0.05) α-glucosidase inhibitory activity 
than the less polar fractions and acarbose. However, within the more polar fractions, the inhibitory 
activity demonstrated by the butanol fraction was significantly higher (P < 0.05) than aqueous fraction as 
shown by the IC50 values (Table 3.3.3). Pancreatic α-amylase activity was also inhibited in vitro by all the 
fractions in a dose dependent fashion (Figure 3.3.3B) and the butanol fraction showed a significantly 







Figure 3.3.3: α-glucosidase (A) and α-amylase (B) inhibitory effects of different solvent fractions of 
ethanolic extract of Z.mucronata root. The results are expressed as mean±SD of triplicate determinations. 
a-dDifferent alphabets over the bars for a given concentration of each fraction indicate significant 
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Table 3.3.3: IC50 values for the inhibition of α-glucosidase and α-amylase by various solvent fractions of 
ethanolic extract of Z. mucronata root  
Fractions/standard IC50 (µg/ml) 
α-glucosidase α-amylase 
Aqueous  4.38 ± 1.08b 187.31 ± 15.99b 
Butanol 1.41 ± 0.16a 105.86 ± 5.21a 
Ethyl acetate 23.60 ± 2.33c 252.48 ± 2.56c 
Dichloromethane 43.91 ± 6.99d 306.97 ± 57.81c 
Acarbose 55.59 ± 5.22d 256.66 ± 20.52c 
The results are expressed as mean ± SD of triplicate determinations. a-eDifferent superscripts alphabets within a 
column for a given parameter indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05).  
 
Furthermore, a steady state kinetic analysis of both α-glucosidase and α-amylase at varied substrate 
concentrations in the presence and absence of 30 μg/ml of the butanol fraction was conducted. From the 
experiment, the butanol fraction exerted mixed inhibition pattern on both α-glucosidase and α-amylase 
with altered the KM and Vmax of both enzymes (Table 3.3.4). Interestingly, the computed index of 
physiological efficiency (Kcat) of both enzymes was reduced in the presence of the butanol fraction (Table 
3.3.4).  
Table 3.3.4: Effect of butanol fraction (30 μg/ml) of ethanolic extract of Z. mucronata root on some 
kinetic parameters of α-glucosidase and α-amylase 
 
Kinetic parameters α-glucosidase α-amylase 
Control + butanol fraction Control + butanol fraction  
KM  2.00*  1.17*  0.25#  6.66#  
Vmax (μmol/min) 655.09 19.64 33.70 223.21 
Kcat (min-1) 327.54 16.78 134.80 33.51 
 
The units for KM was mM (*) and % (#) 
 
Results from the GC-MS analysis of the butanol fraction revealed that it contains phenolic compounds 
such as catechol, pyrogallol, 2,6-dimethoxy phenol and 2-methoxyhydroquinone, sugars such as 
levoglucosan trimethyl ether and ethyl α-D-glucopyranoside, fatty acids and esters as well as other 
aromatics (Figure 3.3.4 and Table 3.3.5) which were identified by their fragmentation pattern in 
conjunction with the NIST library. The chemical structure of the identified components is presented in 










Table 3.3.5: Identified components of butanol fraction of Z. mucronata root ethanolic extract by GC-MS 




1 catechol 7.08 110.1 
2 2,6-dimethoxy phenol 9.13 154.1 
3 pyrogallol  9.63 126.0 
4 2,4-diisopropenyl-1-methyl-1-vinylcyclohexane 9.72 204.4 
5 2-methoxyhydroquinone 9.80 140.1 
6 levoglucosan trimethyl ether 11.18 204.2 
7 ethyl α-D-glucopyranoside 12.92 208.2 
8  palmitic acid, methyl ester 15.78 270.3 
9  palmitic acid 16.16 256.3 
10 2-(2-chlorobenzylidene)cyclohexanone 16.47 220.1 
11 [1-cyano-2-(3-methoxyphenyl)-vinyl]-phosphonic acid diethyl ester 21.03 295.1 
12 Phthalic acid mono -(2-ethylhexyl) ester 21.17 279.2 
 

































































Figure 3.3.5 :  Structures of some of the compounds identified in the butanol fraction of Z. mucronata 
root ethanolic extract by GC-MS. 
 
3.3.5 Discussion 
A viable strategy for T2D management is via the inhibition of α-glucosidase and α-amylase as well as the 
use of potent anti-oxidative agents [41, 42]. This is because the approach provides a holistic therapeutic 
option for the amelioration of hyperglycemia and chronic vascular complications associated with 
oxidative stress. Our findings revealed that the butanol fraction derived from the crude ethanolic extract 




Plants produce various classes of phytochemicals that could be polar or non-polar. Thus, the crude 
ethanolic extract of the root was sequentially fractionated to achieve good separation of all non-polar as 
well as polar components and thereby separately involving all components in the study. Different models 
for in vitro anti-oxidative studies were used because a single method cannot give a comprehensive 
prediction of the anti-oxidative capabilities of the different fractions tested. It was proposed that the Fe3+ 
to Fe2+ reducing ability of phytochemicals is associated with their anti-oxidative activity [29]. Using this 
model, the butanol fraction displayed consistently higher reducing power than other fractions. Free 
radicals are important contributory factors to a number of biological damages and DPPH is used to 
investigate the free radical scavenging activity of phytochemicals. Hydroxyl radicals are also extremely 
reactive species that could damage any biological molecule found in living systems [34].  All these 
radicals are implicated in the pathogenesis of T2D [41]. From the present study, the butanol fraction also 
demonstrated remarkable anti-radicals activities which could further suggest that the fraction contains 
powerful radical scavenging phytochemicals that could have the ability to inhibit free radical upsurge as 
well as oxidative stress which consequently might ameliorate T2D-associated complications and indeed 
other oxidative stress associated metabolic disorders.  
 
The process of digestion of carbohydrates in mammals involves rapid conversion of digestible starch into 
monosaccharide units (glucose) which are absorbed into the intestinal epithilium. Pancreatic and intestinal 
α-glucosidases perform disaccharides hydrolysis and in T2D, an increase in the rate of hepatic 
glycogenolysis and gluconeogenesis is linked with low glucose utilization by tissues and this is a vital 
mechanism underlying hyperglycemia [50]. Thus, inhibitors of liver α-glucosidase could inhibit α-1,6-
glucosidase of glycogen-debranching enzymes, reduce the glycogenolytic rate and consequently decrease 
hyperglycemia [50] whereas inhibitors of intestinal α-glucosidase  are  effective in delaying intestinal 
glucose uptake and consequently decrease postprandial hyperglycemia.  In this study, we found that the 
butanol fraction exhibited the most powerful inhibitory activity against the α-glucosidase through a mixed 
inhibition pattern. Thus, the fraction contains powerful (mixed) inhibitors that are able to bind both at the 
active site and at an allosteric site of the enzyme [51] which consequently decreased the computed index 
of physiological efficiency of the enzyme. These observations could further imply that the fraction is 
capable of binding to the different isozymes of α-glucosidase at saturation of the enzyme and cause a 
reduction in the hydrolysis of disaccharides/oligosaccharides to liberate glucose and consequently lower 
the postprandial blood glucose levels.  
 
The butanol fraction had the highest α-amylase inhibitory activity which is mediated through a mixed 
type of inhibition. In humans, two α-amylase isozymes (salivary and pancreatic) exist which are encoded 
by five genes, three for the salivary isozyme and two for the pancreatic isozyme. Both salivary and 
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pancreatic α-amylases are made up of 496 amino acids in a single polypeptide chain with an overall 
sequence similarity of 97% and 92% similarity in the catalytic domain [42]. These similarities connote 
that the butanol fraction could interact with both isozymes through a similar pattern to slow down the 
breakdown of complex carbohydrates to oligosaccharides, thereby diminishing the postprandial effect of 
carbohydrates consumption on blood glucose. Even though our study was carried out in vitro but the 
findings could be relevant in an in vivo situation. Some plant extracts were demonstrated to inhibit α-
glucosidase and α-amylase activities in both in vitro and in vivo models [52]. Furthermore, the in vitro 
and in vivo α-glucosidase and α- amylase inhibitory activities of some flavonoids and triazoles have been 
documented [53, 54].  
 
Phenolic compounds are the main plant’s constituents responsible for anti-oxidative activity [55]. These 
phytochemicals also interact with proteins and inhibit enzyme actions including α-glucosidase and α-
amylase activity [43]. The butanol fraction contained the highest amount of phenolics in addition to the 
observed high anti-oxidative and enzymes inhibitory activities. It could thus imply, although without a 
correlation analysis, that phenolics play a vital role in the α-glucosidase and α-amylase inhibitory 
activities of this fraction. Previous studies indicated that the α-amylase and α-glucosidase inhibitory 
effects of Ocimum basilicum, Citrus maxima, cinnamon and tea extracts are mediated by phenolics [43, 
56, 57]. Indeed, α-amylase inhibitory activities of some phenolics have been proposed to be through the 
hydrogen bonds formation between the -COO- groups of Asp197 and Glu233 in the active site of the 
enzyme and the hydroxyl groups of the phenolics [58]. Interestingly, our GC MS analysis also revealed 
that the butanol fraction contained an array of phenolics which includes catechol, 2,6-dimethoxy phenol, 
2-methoxyhydroquinone and pyrogallol. Thus, while not discounting the possible contribution of other 
components, it is possible to suggest that these phenolics act individually or synergistically to bring about 
the observed inhibitory effects.    
 
In conclusion, our data suggest that the butanol fraction of Z. mucronata root ethanolic extract contains 
potent anti-oxidative agents and inhibitors of α-glucosidase and α-amylase which could be exploited for 
the development of holistic therapeutic strategy for the control of postprandial blood glucose levels, T2D 
and chronic vascular complications. While phenolics appear to play a vital role on the observed activity, 
the possible contribution of other detected phytochemicals should not be discounted. Our future work will 
involve a detailed study on the antidiabetic activity of the butanol fraction in a T2D diabetes model of rats 
as well as isolating some pure compounds from it. 
 
Postscript: From the above studies, the butanol fraction had the best α-glucosidase and α-amylase effects 
and therefore it was selected for detailed in vivo anti-diabetic study 
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3.4 Effects of butanol fraction of Ziziphus mucronata root on glucose 
homeostasis, serum insulin, hepatic glycogen metabolism and diabetes-related 
complications in a type 2 diabetes model of rats 
 
M. A. Ibrahim1,2 N. A. Koorbanally and M. S. Islam1* 
1School of Life Sciences, , University of KwaZulu-Natal (Westville Campus), Durban, 4000 South Africa. 
2Department of Biochemistry, Ahmadu Bello University, Zaria, Nigeria 
*Correspondence to: islamd@ukzn.ac.za or sislam1974@yahoo.com 
Preface: This article reports the detailed in vivo anti-diabetic studies of the acetone fraction and it is 
currently awaiting revision before submission to a journal for publication. 
3.4.1. Abstract 
Ziziphus mucronata is currently used in the traditional treatment of diabetes mellitus in Nigeria. The 
present study investigated the effects of the butanol fraction of Z. mucronata root (ZMBF). 
Chromatographic investigation of the fraction led to the isolation of a chromone, 2,7-dihydroxy-4H-1-
benzopyran-4-one which strongly inhibited α-glucosidase and α-amylase using uncompetitive and non-
competitive inhibition patterns respectively. Subsequently, the effects of ZMBF treatments on 
polyphagia, polydipsia, body weight gain, glucose homeostasis, insulin secretion,  β cell function 
(HOMA-β), insulin resistance (HOMA-IR), serum fructosamine level, liver glycogen metabolism, serum 
lipid profile and biomarkers of hepatic and renal functions in a type 2 diabetes (T2D) model of rats. The 
ZMBF treatment, at 300 mg/kg bw, significantly (P<0.05) lowered blood glucose level, improved oral 
glucose tolerance ability, stimulated insulin secretion and hepatic glycogen synthesis. However, 
polyphagia, polydipsia, body weight gain, β cell function, insulin resistance, serum fructosamine level 
and hepatic and renal functions were not significantly (P>0.05) affected by the treatment. Findings from 
this study suggest that ZMBF treatment, at 300 mg/kg b.w, possess anti-diabetic activity but could 
slightly ameliorate some diabetes-associated complications in a T2D model of rats. 
 
3.4.2 Introduction 
The International Diabetes Federation (IDF) estimates that more than 366 million people worldwide are 
affected by the diabetes and this figure is projected  to reach a staggering 552 million by 2030 [59] while 
type 2 diabetes (T2D) accounts for >90% of all the diabetic cases. T2D is a complex and polygenic 
metabolic disorder characterized mainly by insulin resistance and pancreatic β cell dysfunction [60] 
which leads to chronic hyperglycemia. Several mechanisms have been proposed for the β-cell destruction 
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including oxidative stress [41]. Currently, T2D is predominantly managed with sulfonylureas and 
biguanides but the use of α-glucosidase inhibitors is also considered as an important approach for the 
treatment of the disease [61]. Unfortunately, the use of these synthetic anti-diabetic agents is beset with a 
number of side effects such as diarrhea, nausea and liver failure [46].  
For some few years back, research interest in traditional herbal medicine has tremendously grown 
especially for the care and management of diabetes and this happens in both developing and developed 
countries, due to their natural origin and lesser side effects [62, 63]. Indeed, traditional medicinal plants 
were listed by the World Health Organization (WHO) expert committee on diabetes as one of the methods 
for the treatment of diabetes which should be further investigated [64] to provide potential chemical leads 
for the development of novel anti-diabetic agents. In this context, African medicinal plants may provide 
the much needed chemical leads because of their multiple health benefits. 
Ziziphus mucronata Willd (Rhamnaceae), commonly referred to as ‘’buffalo thorn’’ is available in most 
parts of Africa. A decoction of the plant is used traditionally in the treatment of diabetes mellitus [4] 
among the rural inhabitants of northern Nigeria. In spite of this report, the anti-diabetic effects of the plant 
have not been scientifically validated either in humans or experimental animals. In fact, apart from few 
reports [7, 10, 65], information on the pharmacological actions of the plant is scanty in the literature.  In a 
recent study [49], we subjected the various crude solvents extracts from the stem bark, root and leaf 
samples of the plant to a series of in vitro anti-oxidative assays and reported that the ethanolic extract of 
the root had the most potent anti-oxidative activities that reasonably cuts across various models. Hence, in 
the present study, we isolated a chromone from the butanol fraction of the root and subjected it to an in 
vitro α-glucosidase and α-amylase inhibitory activity assays. Subsequently, we conducted a 
comprehensive investigation on the in vivo activity of the butanol fraction on T2D which is an oxidative 
stress-related metabolic disorder.  
3.4.3 Materials and methods 
Please refer to the chapter 2 sub-sections 2.3-2.4 (page 35-36); 2.6.1 (page 38); 2.7.1-2.7.7 (pages 40-43) 
and 2.8.1 (pages 45-46) for detailed material and methods that involve Z. mucronata. However, the group 
codes DFL, DFH and NFT used in the chapter two are replaced with DZL, DZH and NZT respectively. 
ZMBF refers to the butanol fraction derived from the crude ethanol extract of Z. mucronata root. 
3.4.4 Results 
The 1H NMR spectrum of fraction 29 indicated that it contained a mixture of an aromatic compound (1) 
and polar aliphatic chains.  The aromatic resonances were contained in the region of δ 6.50 to d 7.30 and 
the polar aliphatic chains had resonances between 0.80 and 1.60 as well as between δ 3.40 and 4.10, the 
latter indicating alcoholic functionality in the aliphatic chains.  It was clear that the side chains were not 
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part of the chromone as part of an ester as the integration of the respective resonances was not in 
agreement. While it was not possible to identify the aliphatic chains, it was possible to elucidate a 
structure for the chromone based on its NMR data.   
 
With regard to the aliphatic chains, it was difficult to ascertain the number of chains that co-eluted with 
the chromone, but alcoholic functionality could be identified by the methylene hydroxy peaks in the 1H 
NMR spectrum at δ 3.46 (2H, dd, J = 6.5, 4.1 Hz), 3.51 (2H, dd, J = 4.8, 4.8 Hz), 3.70 (2H, brt, J = 4.0 
Hz), coupled resonances at δ 3.92 (1H, d, J = 9.0 Hz), 4.00 (1H, d, J = 9.0 Hz) and a methine hydroxy 
peak at d 4.08 (s).  Their corresponding oxygenated carbon resonances further indicated alcoholic groups 
at δ 71.1, 71.7, 61.9 and 76.3 for the oxygenated methylene carbon atoms and at δ 75.8 for the methine 
hydroxyl carbon.  The methyl and methylene resonances of the aliphatic chains were present between δ 
0.80 and 1.60 in the 1H NMR spectrum and between δ 13.9 and 32.0 in the 13C NMR spectrum. 
 
The 1H NMR spectrum of compound 1 showed a characteristic NMR pattern for an A ring chromone 
system with ortho and meta coupled protons at δ 6.57 (d, J = 8.2 Hz, H-5), δ 7.04 (dd, J = 8.2, 2.4 Hz, H-
6) and δ 7.27 (d, J = 2.4 Hz, H-8).  The singlet resonance at δ 6.97 is attributed to H-3 on the pyranone 
ring.  The 3-hydroxy option was ruled out since an H-2 proton would appear as a singlet in the region of δ 
8.00 [66]. Furthermore, the NMR data were not consistent with Lai et al. [66] for 3,7-dihydroxy-4H-1-
benzopyran-4-one. Using the HSQC spectrum, C-5 was identified at δ 115.9, C-6 at δ 123.5, C-8 at δ 
124.1 and C-2 at δ 124.8.  The oxygenated aromatic carbon resonances were seen at 151.8, 155.6 and 
159.2 with the carbonyl resonance, C-4 being present at δ 177.2. The remaining carbon resonance of C-10 
could be seen at δ 130.9. Based on the above, the compound (1) was identified as 2,7-dihydroxy-4H-1-
benzopyran-4-one (Figure 3.4.1).  
The enzyme inhibitory studies revealed that 2,7-dihydroxy-4H-1-benzopyran-4-one inhibited -
glucosidase and -amylase catalyzed reactions with IC50 values of 39.01 ± 4.17 and 93.73 ± 5.43 µg/ml 
respectively. Using kinetics approach, the compound was found to be an uncompetitive inhibitor of -
glucosidase thereby decreasing both the Vmax and KM of the enzyme. The Vmax decreased from 655.09 
μmol/min to 48.16 μmol/min while the KM decreased from 2 mM to 0.9 mM. On the other hand, 2,7-
dihydroxy-4H-1-benzopyran-4-one inhibited -amylase in a non-competitive fashion with Vmax 

















Figure 3.4.1: Structure of 2,7-dihydroxy-4H-1-benzopyran-4-one  (1) isolated from ZMBF 
During the 4-week intervention period, feed and fluid intakes as well as body weight gain were not 
significantly (P<0.05) different between DBC, DZL and DZH groups (Figures 3.4.2 and 3.4.3). The 
ZMBF treatment also did not affect feed and fluid intakes of normal rats. Also, there was no significant 
difference between the NFBG levels of DZL and DBC groups throughout the experiment except for a 
sharp decline in the NFBG level of DZL group after the first week of treatment which was not 
subsequently sustained. On the other hand, the DZH group recorded a significantly lower (P<0.05) NFBG 
level than the DBC group during the entire experimental period (Figure 3.4.4).  
 
Figure 3.4.2: The effects of oral treatment of butanol fraction of Z. mucronata root on feed and fluid 
intakes of type 2 diabetic rats. The results are expressed as mean ± SD of eight rats. a-bDifferent alphabets 




































Figure 3.4.3: The effects of oral treatment of butanol fraction of Z. mucronata root on mean body weight 
gain of type 2 diabetic rats. The results are expressed as mean ± SD of eight rats. a-bDifferent alphabets for 
a given week indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Figure 3.4.4: The effects of ZMBF treatment on weekly blood glucose concentrations (post induction) of 
type 2 diabetic rats. The results are expressed as mean ± SD eight rats. a-dDifferent alphabets for a given 
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The data for the OGTT are shown in Figure 3.4.5. Although the results were not significantly different 
(P<0.05) but better glucose tolerance ability was recorded in the DZL group than the DBC group. 
Furthermore, DZH group had a significantly (P<0.05) better glucose tolerance ability compared to DBC 
and DZL groups.  
 
Figure 3.4.5: Oral glucose tolerance test (OGTT) for all groups of animals in the last week of 
experimental period. The results are expressed as mean ± SD of eight rats. a-cDifferent alphabets for a 
given time indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
Serum insulin levels and β-cell functions (HOMA-β) were significantly lower (P<0.05) while serum 
fructosamine concentrations and peripheral insulin resistance (HOMA-IR) were significantly (P<0.05) 
elevated in the DBC group than the NC group (Table 3.4.1). However, compared to the DBC group, the 
ZMBF treated diabetic groups had significantly higher (P<0.05) serum insulin concentrations, relatively 
higher β-cell functions but relatively lower insulin resistance and serum fructosamine concentrations. The 
serum level of AST was neither affected by the T2D nor the ZMBF treatments but serum ALT, ALP and 
urea levels were significantly elevated (P<0.05) in the DBC group compared to the NC group. However, 
ZMBF treatments did not statistically affect the serum ALT level but reduced the serum ALP and urea 
levels in diabetic rats (Table 3.4.1). No significant differences were observed between the NC and NZT 
groups for all these parameters. Relatively lower serum creatinine concentration was observed in the DBC 
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Table 3.4.1: Serum insulin and fructosamine concentrations, indices of hepatic and renal damages as well 
as computed HOMA-IR and HOMA-β scores for different animal groups at the end of the experiment 
 NC DBC DZL DZH DMF NZT 
Serum insulin 
(pmol/L) 




196.3±5.6a 258.4±10.9b 258.6±19.2b 234.2±20.0b 253.8±30.4b 189.8±61.0ab 
HOMA-IR 4.9±1.1a 16.2±5.65b 10.8± 5.7b 9.8±4.5b 9.8±3.8b 5.12±0.70a 
HOMA-β 304.1±53.7c 9.7±5.2a 24.9±14.5ab 13.6±7.9a 54.9±27.5b 253.4±30.9c 
AST (U/L) 88.00±14.88 73.6±7.6 91.2±26.3 71.8±6.6 88.7±17.8 89.16±15.49 
ALT (U/L) 56.25±12.55a 77.8±4.6ab 81.8±30.0ab 88.3±12.8b 63.3±18.2a 57.3±15.9a 
ALP (U/L) 188.8±19.8a 898.6±174.4c 578.0±163.4bc 510.5±94.3b 472.0±74.9b 214.4±78.2a 
Urea (mg/dl) 48.00±6.16a 93.0±16.4b 67.8±12.7b 59.3±22.9ab 42.0±11.8ab 47.7±9.0ab 
Creatinine 
(µg/dl) 
582.0±70.4ab 485.0±40.4a 563.3±51.6ab 550.0±74.3ab 675.0±95.2b 471.4±49.1a 
Results are expresed as mean ± SD of eight rats. a-cDifferent superscripts alphabets along a row indicate significant 
difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The data for the liver weights and liver glycogen concentration of the experimental animals are presented 
in Table 3.4.2. Relative liver weight was significantly higher in the DBC, DZL and DZH groups than the 
NC group with no significant difference between the DBC and ZMBF treated diabetic groups. 
Conversely, liver glycogen was significantly (P<0.05) depleted in the DBC group but the ZMBF 
treatment significantly (P<0.05) boosted the liver glycogen reserves in the DZH group only. 
 
Table 3.4.2: Liver weights and liver glycogen concentrations in different animal groups at the end of the 
experimental period 
 NC DBC DZL DZH DMF NZT 
Liver weight (g) 11.8±2.4 10.9±1.9 10.3±1.9  10.3±1.2 10.4±1.7 11.9±1.9 
Relative liver weight (%) 3.3±0.3a 3.9±0.2b 4.0±0.3b 3.8±0.1ab 3.7±0.1a 3.4±0.4a 
Liver glycogen (mg/g tissue) 3.5±0.8b 1.5±0.1a 2.2±0.9ab 2.4±0.5b 2.7±0.4b 2.9±1.0b 
Results are presented as mean ± SD of eight rats. a-bValues with different alphabets along a row are significantly 





Table 3.4.3 presents the effects of the ZMBF treatment on serum lipid profile of the experimental rats. 
Serum total and LDL-cholesterols were not significantly different among the animals groups. However, 
the DBC group recorded a significantly lower level of HDL-cholesterol which was increased in the 
ZMBF treated diabetic groups. Serum triglyceride concentration was significantly higher in the DBC 
group compared to the NC and NZT groups but the DZL group had a relatively lower and the DZH group 
had a relatively higher serum triglycerides compared to the DBC group.  
 
Table 3.4.3: The effects of ZMBF treatments on serum lipid concentrations of type 2 diabetic rats 
Serum lipids NC DBC DZL DZH DMF NZT 
(mg/dl) 
Total cholesterol 66.25±6.39 76.25±10.62 61.00±9.45 79.25±17.25 74.63±12.10 80.66±11.28 
HDL cholesterol 31.00±9.55b 19.80±1.64a 28.50±5.24ab 26.00±9.27ab 28.14±5.39ab 32.42±8.48b 
LDL cholesterol 19.85±5.35 27.45±4.34 18.60±8.47 16.50±6.90 25.98±7.43 30.57±8.48 
Triglycerides 102.5±27.5a 184.8±40.9ab 113.5±30.1a 198.4±7.5b 120.13±27.4a 92.00±14.22a 
Results are expressed as mean ± SD of eight rats. a-bDifferent superscript alphabets along a row indicate are 




Histopathological examination of the pancreatic sections revealed a reduction in the size of pancreatic 
islets as well as the number of cells per islet count in the DBC group compared to the NC group. No 
much difference was detected between DZL group and the DBC group. However, the DZH group had 
higher number of cells per islet than the DBC group (Figure 3.4.6). The NZT group had similar 








      
        
Figure 3.4.6: Representative sections of histopathological examinations of the pancreas from different 
animal groups. The NC group had high number cells per islet while the DBC and DZL group had smaller 
pancreatic islets with very few cells. The DZH had relatively higher number of cells per islet compared to 
DBC and DZL groups but far lower than the NC group. 
3.4.5 Discussion 
The role of medicinal plants in the health care delivery systems of many parts of the world has been duly 
recognized [15], However, the traditional use of a plant in the traditional management of a disease might 
not necessary be a reflection of its efficacy. This study reveals that the butanol fraction of Z. mucronata 
root, a plant traditionally used for the treatment of diabetes [4], contains potent -glucosidase and -
amylase inhibitory compound and elicited anti-hyperglycemic effects but slightly ameliorated the T2D-
associated complications in a rat model. 
The potent anti-oxidative activity of ethanolic extract of the root of Z. mucronata [49] prompted us to 
subject it to further studies. Solvent-solvent fractionation of the ethanolic extract led us to a butanol 
fraction with potent -glucosidase and -amylase inhibitory activity (see manuscript 3.3 above) and 
subsequent phytochemical analysis of the butanol fraction led to the isolation of a chromone, 2,7-
dihydroxy-4H-1-benzopyran-4-one. Apart from few reports on cyclopeptide alkaloids isolated from this 
plant [1, 12], no much information on the isolation and characterization of other phytochemical 
compounds from this plant have been reported in the literature. Interestingly, the chromone isolated in 
DZL DBC NC 
NZT DZH DMF 
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this study was found to be a dual inhibitor of the two enzymes (-glucosidase and -amylase) in an in 
vitro model which suggests that this compound could lead to delayed carbohydrate digestion and glucose 
absorption with concomitant reduction in postprandial hyperglycemic shoot up [67]. In previous studies, 
hydroxyl groups have been implicated as the vital structural features responsible for the inhibitory effects 
of most phytochemicals on α-glucosidase and -amylase proteins [58, 68]. In our study, kinetic 
delineation of α-glucosidase and -amylase inhibitions by 2,7-dihydroxy-4H-1-benzopyran-4-one 
revealed uncompetitive and non-competitive patterns respectively. These observations could suggest that 
one or more hydroxyl groups of the chromones interact individually or synergistically with the enzyme-
substrate complexes to inhibit the α-glucosidase and -amylase. 
After confirming the in vitro anti-hyperglycemic potentials of the chromone isolated from the ZMBF, we 
subjected the fraction to an in vivo study in a T2D model of rats. Polyphagia and polydipsia with 
concomitant reduction of body weight are major symptoms of diabetes mellitus [69] which were also 
evidently observed in the diabetic groups of our experiment. These parameters are usually linked to stable 
and prolong diabetic condition [70]. In our study, the treatment with ZMBF did not ameliorate the T2D-
induced polyphagia, polydipsia and weight loss possibly because other diabetic complications, especially 
metabolic parameters, were not significantly affected by the fraction. 
Elevated fasting or postprandial hyperglycemia causes life-threatening complications linked to diabetes. 
Consequently, maintaining glucose homeostasis is essential in preventing the detrimental effects of 
hyperglycemia and its associated complications [71]. At a dose of 300 mg/kg bw, the ZMBF displayed 
appreciable anti-hyperglycemic and insulinotropic effects, improved glucose tolerance but slightly 
prevented the T2D-induced β-cell dysfunction (HOMA- β) and the damage to pancreatic architecture. 
Taken together, it appears that the fraction slightly protected the β cell from destruction but remarkably 
potentiated the residual β-cells to secrete more insulin which consequently might promote more glucose 
uptake by the cells. However, the failure of the fraction to significantly decrease peripheral insulin 
resistance and at the same time, achieved significant anti-hyperglycemia suggests that, in addition to the 
observed insulinotropism, another mechanism probably an extrapancreatic retardation of intestinal 
glucose production could be involved. This hypothesis is supported by the potent -glucosidase and -
amylase inhibitory actions displayed by the ZMBF and the isolated chromone from it. On the other hand, 
the ability of the fraction to slightly protect pancreatic damage caused by the disease could be linked to its 
potent anti-oxidative activity (see manuscript 3.3 above) because the protection of pancreatic damage is 
usually mediated through an anti-oxidative dependent mechanism since oxidative stress is an important 




Another important feature of experimentally induced diabetes is a reduction in the liver glycogen level 
[70] which is caused by the modulation of glycogen synthase and glycogen phosphorylase activities. 
Previous studies have demonstrated that a number of plant materials [73, 74] and isolated flavonoids [75] 
elicited an anti-diabetic activity partly through stimulation of hepatic glycogenesis. Thus, the significantly 
higher liver glycogen content recorded in the DZH group than the DBC group (Table 3.4.2) indicated that 
the anti-hyperglycemic activity of the ZMBF at 300 mg/kg bw might be mediated not only by stimulating 
insulin secretion and/or retarding carbohydrates digestion but also by increasing hepatic glycogen 
synthesis. 
Lipids are vital  to the pathogenesis of experimentally induced diabetes and the level of serum lipids is 
usually elevated at diabetic state which is a risk factor for cardiovascular diseases associated with T2D 
[76]. Although the results were not significant, an increasing tendency in the serum total cholesterol and 
LDL-cholesterol was observed in the DBC group compared to NC group (Table 3.4.3). On the other 
hand, significant HDL-cholesterol level and hypertriglyceridemia were recorded in the DBC group 
compared to NC group. The ZMBF treatments displayed appreciable ameliorative effects towards the 
disease-induced alterations LDL- and HDL-cholesterols but not towards the other forms of lipids. 
Although a number of plant derived phytochemicals have been shown to possess hypolidemic activity in 
experimental diabetes [77-79] but findings from our study revealed that ZMBF did not contain powerful 
hypolipidemic phytochemicals. Results from other indices of diabetic complications also indicated that 
the T2D caused a significant increase in serum levels of ALT, ALP and urea. However, despite the potent 
anti-hyperglycemic effects of the fraction, a close look at the results of these biomarkers of hepatic and 
renal functions also indicated that ZMBF treatments slightly ameliorated the hepatic and renal damages 
caused by diabetes. Therefore, a further study is required in order to understand the basis of these 
observations.  Apart from assessing renal damage, creatinine was reported to be a predictor for T2D and 
insulin resistance and previous studies have demonstrated lower serum creatinine level in T2D human 
subjects compared to normal individuals [80, 81]. It is thus plausible to suggest that the relatively lower 
insulin resistance (HOMA-IR) of the ZMBF treated diabetic groups compared to DBC group is 
responsible for the relatively elevated serum creatinine levels recorded in these groups.  
On a general note, we observed that ZMBF treatment at 150 mg/kg bw was not able to show anti-diabetic 
activity for most of the parameters measured in this study. This might indicate that the amount of ZMBF 
has to reach a threshold level before the anti-diabetic activity could be manifested.  
 
We conclude that ZMBF, at a dose of 300 mg/kg, had anti-hyperglycemic activity but slightly alleviate 
most of the T2D-associated complications. Furthermore, 2,7-dihydroxy-4H-1-benzopyran-4-one could 
play a role in the anti-glycemic activity of the fraction. Our future work will focus on detailed studies on 
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the molecular mechanism(s) for the observed results as well as a more detailed phytochemistry of the 
fraction.  
 
Postscript: In order to further explore the possible mechanism of anti-diabetic action of the butanol 
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Preface: This article describes the in vivo anti-oxidative status of the serum and organs collected from the 
rats in the above experiment.  
3.5.1 Abstract 
The effects of oral administration of the butanol fraction of Ziziphus mucronata root (ZMBF) on 
antioxidant status of the liver, kidney, heart, pancreas and serum of type 2 diabetic animals were 
investigated. The in vivo oxidative stress markers measured were thiobarbituric acid reactive substances 
(TBARS), reduced glutathione, superoxide dismutase (SOD) and catalase. The ZMBF treatment 
significantly (P<0.05) increased the reduced glutathione levels in the serum and all the investigated 
organs compared to diabetic controls. Hepatic TBARS were significantly lowered while SOD and 
catalase were significantly (P<0.05) increased in the ZMBF treated rats compared to diabetic controls. 
However, diabetes-induced changes in kidney TBARS, SOD and catalase were not statistically affected 
by the ZMBF treatment. An insignificant (P>0.05) increase in the heart catalase level and a dose 
dependent decrease in the heart TBARS were observed in the ZMBF treated rats compared to diabetic 
controls. Also, diabetes-induced changes in pancreatic and serum TBARS, SOD and catalase levels were 
ameliorated by the treatment. Results from this study indicate that ZMBF possess in vivo anti-oxidative 
effects in a type 2 diabetic rats.  
3.5.2 Introduction 
Hyperglycemia is a major pathogenic feature of diabetes mellitus and is implicated in the pathogenesis of 
most of the secondary complications associated with the disease [82]. In type 2 diabetes (T2D), 
hyperglycemia induces oxidative stress via multiple pathways which include glucose autooxidation, 
increased metabolic flux of the polyol (sorbitol) pathway, activation of protein kinase C, increased 
generation of advanced glycation end products and increased flux of hexosamine pathway [83, 84]. The 
oxidative stress is thus considered as an important unifying mechanism that plays major roles in all 
aspects of T2D pathology that include pancreatic β cell dysfunction, microvascular and macrovascular 
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complications [84-86]. Therefore, modulation of in vivo oxidative stress is an important therapeutic 
mechanism that could ultimately benefit diabetic patients. 
In normal individuals, oxidative stress is suppressed by physiological enzymatic (superoxide dismutase, 
catalase and glutathione peroxidase) and non-enzymatic (glutathione, vitamins C and E) anti-oxidative 
defense system in vivo but in diabetic condition significant alterations in the serum and tissue anti-
oxidative defense system as well as, in lipid peroxidation occur [72]. Thus, anti-oxidative agents that 
could prevent these changes would offer protection against the long-term vascular complications 
associated with the disease. Indeed, some antioxidants have been reported to reduce the diabetic 
complications thereby affecting the overall outcome of the disease [87]. 
Ziziphus mucronata Willd (Rhamnaceae), commonly referred to as ‘’buffalo thorn’’ is available in most 
parts of Africa. A decoction of the plant is used traditionally in the treatment of diabetes mellitus among 
the rural inhabitants of northern Nigeria [4]. In a previous study [49], we subjected the various crude 
solvents extracts from the stem bark, root and leaf samples of the plant to a series of in vitro anti-
oxidative assays and reported that the ethanolic extract of the root had the most potent anti-oxidative 
activities that reasonably cuts across various models. Subsequently, we subjected the ethanolic extract of 
the root to solvent-solvent partiotioning and found that the butanol fraction contain the most potent anti-
oxidative and α-glucosidase and α-amylase inhibitory phytochemicals in in vitro models (see manuscript 
3.3 above). Based on these findings, a follow up comprehensive investigation was conducted on the in 
vivo activity of the butanol fraction in a T2D model of rats where the fraction exhibited anti-
hyperglycemic and insulinotropic effects but slightly ameliorate some diabetes-related complications (see 
manuscript 3.4 above).  In order to further understand the biochemical basis for the observed seemingly 
unusual effects, in the present study, we investigated the effects of the fraction on the serum and tissues 
(liver, kidney, heart and pancreas) anti-oxidative status of T2D model of rats. 
3.5.3 Materials and methods 
Please refer to the chapter two sub sections 2.3-2.4 (pages 35-36); 2.7.1-2.7.3 and 2.7.5 (pages 41-42) and 
2.7.8 (2.7.8.1-2.7.8.4) (pages 44-45) for material and methods that involve Z. mucronata. However, the 
group codes DFL, DFH and NFT used in the chapter two are replaced with DZL, DZH and NZT 
respectively. 
3.5.4 Results 
Diabetes was found to induce lipid peroxidation and deplete endogenous antioxidant reserves as 
manifested by the significantly higher (P<0.05) levels of TBARS with a corresponding lower levels of 
glutathione, SOD and catalase in the DBC group of all tissues compared to the NC group. However, the 
ZMBF treatments significantly (P<0.05) prevented the diabetes-induced lipid peroxidation in the hepatic 
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tissues. Also, the DBC group had significantly (P<0.05) decreased levels of hepatic glutathione, SOD and 
catalase which were significantly (P<0.05) boosted in the ZMBF-treated diabetic groups (Table 3.5.1).   
Table 3.5.1: Effects of ZMBF on hepatic lipid peroxidation and anti-oxidant status of type 2 diabetic rats 
 NC DBC DZL DZH DMF NZT 
TBARS (µM) 10.6±3.0a 33.9±4.9c 21.5±4.8b 21.3±4.5b 35.9±9.5c 14.2±5.4ab 
Glutathione (µM) 120.8±6.0c 29.9±9.3a  54.2±12.6b 69.2±5.4b 73.6±10.2b 70.8±11.6b 
Superoxide dismutase 
(nmol/min) 
25.5±5.3b 12.4±1.6a 20.8±5.3b 21.8±4.3b 17.5±5.2ab 23.9±5.5b 
Catalase (µmol/min) 16.5±0.9b 1.5±0.3a 12.9±4.8bc 8.4±2.7b 1.7±0.6a 9.2±2.0b 
Results are expressed as the mean ± SD of five rats. a-cDifferent superscript alphabets along a row indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
In the kidney, the TBARS levels in the DZL and DZH groups were lowered, though insignificantly 
(P>0.0.5) compared to the DBC group but the depletion in glutathione levels was significantly (P<0.05) 
ameliorated in the ZMBF-treated diabetic groups compared to DBC group (Table 3.5.2).  However, the 
kidney SOD and catalase levels were higher in the DZL and DZH groups in comparison to DBC group.   
 
Table 3.5.2: Effects of ZMBF on kidney lipid peroxidation and anti-oxidant status of type 2 diabetic rats 
 NC DBC DZL DZH DMF NZT 
TBARS (µM) 14.1±5.8a 40.8±12.5bc 42.8±9.8c 30.1±10.2bc 33.4±10.0bc 26.6±5.0b 
Glutathione (µM) 68.2±20.8ab 46.0±8.6a 93.3±14.3b  104.8±29.9b 70.8±10.4b 81.9±9.6b 
Superoxide dismutase 
(nmol/min) 
16.1 ±3.4b 6.8±1.5a 9.7±2.7a 8.3±2.8a 11.5±4.4ab 8.6±2.4a 
Catalase (µmol/min) 1.7±0.3b  0.88±0.21a 1.9±0.9b 1.0±0.2ab 1.6±0.4b 1.6±0.5b 
Results are expressed as the mean ± SD of five rats. a-cDifferent superscript alphabets along a row indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
In the heart, the TBARS level was significantly lower (P<0.05), the glutathione level was significantly 
higher (P<0.05) while the SOD and catalase were relatively elevated in the DZH group than the DBC 






Table 3.5.3: Effects of ZMBF on lipid peroxidation and anti-oxidant status in the heart of type 2 diabetic 
rats 
 NC DBC DZL DZH DMF NZT 
TBARS (µM) 9.4±2.6a 24.6±8.8b 20.9±8.8b 11.5±4.7ab 33.9±5.9b 8.6±3.2a 
Glutathione (µM) 122.2±22.0bc 48.5±14.6a 108.7±12.2b 134.2±7.1c 79.2±18.3ab 111.8±26.6b 
Superoxide dismutase 
(nmol/min) 
15.2±4.0b 5.8±1.2a 14.4±2.4b 6.4±2.2a 12.8±2.0ab 8.1±1.9a 
Catalase (µmol/min) 2.1±0.5b 0.9±0.2a 0.9±0.2a 1.1±0.2a 1.4±0.4ab 2.3± 0.2b 
Results are expressed as the mean ± SD of five rats. a-cDifferent superscript alphabets along a row indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
The data for the pancreatic in vivo antioxidant status also revealed that the DZH group had significantly 
lower (P<0.05) level of TBARS as well as significantly higher (P<0.05) levels of glutathione, SOD and 
catalase than the DBC group. The low dose significantly (P<0.05) attenuated these pancreatic parameters 
except glutathione (Table 3.5.4).  
Table 3.5.4: Effects of ZMBF on pancreatic lipid peroxidation and anti-oxidant status of type 2 diabetic 
rats  
 NC DBC DZL DZH DMF NZT 
TBARS (µM) 6.00±1.16a 35.73±9.13c 29.38±5.12c 23.09±4.83bc 18.35±4.37b 8.37±3.36a 
Glutathione (µM) 80.02±8.09c 6.22±3.49a 51.27±9.60b 54.36±9.81b 37.33±8.56b 48.44±8.49b 
Superoxide dismutase 
(nmol/min) 
2.61±0.45c 0.37±0.16a 3.12±1.36c 2.66±0.80c 1.03±0.46b 1.89±0.54bc 
Catalase (µmol/min) 0.65± 0.17bc 0.35±0.039a 0.55±0.08b 0.50±0.06b 1.11±0.20c 0.98±0.18c 
Results are expressed as the mean ± SD of five rats. a-cDifferent superscript alphabets along a row indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
The in vivo antioxidant status of the serum were also significantly (P<0.05) affected by the diabetes 
induction but the ZMBF treatments significantly (P<0.05) ameliorated the diabetes-induced depletion in 
glutathione, SOD and catalase but could not significantly (P<0.05) alleviate the disease-induced elevation 
in TBARS (Table 3.5.5). It is noteworthy that the in vivo antioxidant parameters of NZT group was not 






Table 3.5.5: Effects of ZMBF on serum lipid peroxidation and anti-oxidant status of type 2 diabetic rats 
 NC DBC DZL DZH DMF NZT 
TBARS (µM) 63.0±15.1a  201.1±19.3c 194.9±19.8bc 210.6±17.7c 142.0±32.0b 113.8± 26.1b 
Glutathione (µM) 84.4± 7.6d 19.8 ± 2.4a 47.6 ± 8.8b 57.4±9.4bc 65.2±6.7c 64.5± 16.0bcd 
Superoxide dismutase 
(nmol/min) 
18.0±2.4c 0.86±0.19a 2.2±0.9b  4.07±0.92b 3.2±0.7b 13.7±5.9c 
Catalase (µmol/min) 3.62±0.76c 1.54±0.39a 1.82±0.75ab 2.84±0.36bc 2.41±0.47b 1.95±0.57ab 
Results are expressed as the mean ± SD of five rats. a-dDifferent superscript alphabets along a row indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
3.5.5 Discussion 
A previous study from our lab has revealed that a high dose of ZMBF displayed significant anti-
hyperglycemic and insulinotropic effects but slightly prevented tissue damages caused by T2D. In the 
present study, we observed that modulation of in vivo anti-oxidant status could play a role in the 
previously observed effects and that the effect of the ZMBF on the antioxidant status of diabetic animals 
is organ-specific.  
Decreased glutathione and antioxidant enzymes with a concomitant increase in lipid peroxidation in all 
organs clearly demonstrate the development of oxidative stress in the diabetic animals. Alterations in the 
biomarkers of hepatic damage and insulin resistance are recognized features of experimentally induced 
diabetes and oxidative stress has been reported to be an important contributor to the hepatic damage and 
mediating insulin resistance in diabetic state [88, 89]. Thus, the ability of the ZMBF to significantly 
ameliorate the T2D-induced changes in hepatic antioxidant status whilst achieving less potent results for 
the liver function enzymes and insulin resistance suggests that the ZMBF mainly functions through an 
anti-oxidative dependent mechanism, thereby sparing other biological players of hepatic damage and 
insulin resistance to proceed. It is also possible that the experimental period is short for the amelioration 
of hepatic oxidative stress to be translated in to a complete reversal of hepatic damage and insulin 
resistance.  
Kidney plays an important in glucose homeostasis and therefore it is regarded as an important organ in 
diabetes management [90]. In the present study, oxidative stress was also induced in the kidney of the 
diabetic rats but the ZMBF treatments restore the depleted glutathione and slightly boosted the 
antioxidant enzymes reserves. It also slightly prevented lipid peroxidation in the kidney. Taken as a 
whole, it seems that ZMBF is not highly effective in modulating kidney-based oxidative stress during 
diabetes. Interestingly, this observation correlates with an insignificant reduction in the level of a 
biomarker of kidney function (serum urea) caused by ZMBF treatment in the diabetic rats (see manuscript 
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3.4 above).  This might further suggest that ZMBF mediates its effects in the kidney of diabetic animals 
through an anti-oxidative dependent mechanism. 
Cardiovascular complications are associated with T2D and are usually caused by alterations in serum 
lipids profile during diabetes [78]. Thus, exploration of the biochemical events occurring at cardiac 
tissues during diabetes may ultimately provide a clue to the management of cardiovascular diseases 
associated with T2D. At a dose of 300 mg/kg bw, the ZMBF ameliorated the diabetes-induced lipid 
peroxidation and depletion of endogenous antioxidant reserves. This observation might suggest that 
ZMBF could be beneficial in reducing the detrimental effects of hyperlipidemia because 
hypertriglyceridemia has been reported to be an important factor that enhances the formation of lipid 
peroxides [91]. Unfortunately however, ZMBF was found to cause a slight elevation in triglycerides in 
diabetic animals (see manuscript 3.4 above). Based on the above, we speculated that ZMBF was able to 
protect cardiac tissues from oxidative attack via an anti-oxidative mediated mechanism but at the same 
time could act elsewhere to stimulate lipids synthesis. 
An important pathogenic mechanism for pancreatic β cell dysfunction in T2D is via the induction of 
oxidative stress [72] and ZMBF treatments were found to replenish the depleted pancreatic glutathione, 
SOD and catalase as well as moderately prevented lipid peroxidation in this organ which suggests that the 
fraction could reduce pancreatic β cell dysfunction in diabetic patients and consequently improve the 
disease condition. This observation could further explain, at least in part, the biochemical basis for the 
increased β cell function (HOMA-β) and serum insulin concentration as well as higher number of β cells 
in ZMBF-treated diabetic rats compared to diabetic untreated rats (see manuscript 3.4 above).  
In conclusion, the results of this study demonstrate that ZMBF modulates T2D-induced oxidative stress in 
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4.0 THE ANTI-OXIDATIVE AND ANTI-DIABETIC ACTIVITIES OF 
Cassia singueana Delile IN VITRO AND IN VIVO  
4.1 Cassia singueana Delile (Caesalpiniaceae) 
 
Figure 4.1: Cassia singueana Delile (Caesalpiniaceae); synonym: Cassia goratensis; common names: 
golden shower tree (English), Runhu (Hausa, Nigeria), Rumfuhi (Fulani, Nigeria),  Isihaqa esincinyane 
(Ndebele, Zimbabwe), Mudyamhungu (Shona, Zimbabwe), Kalusapwe (Nyanja, Zambia). Photo: Mr. 
Umar Gallah (2012), Zaria, Nigeria 
4.1.2 Background  
It is a small tree 1-15 m high with trunks of up to 35 cm in diameter.  The leaves are compound, 2.5-5 cm 
long with 4-10 pairs of oval leaflets. The flowers are deep yellow, fragrant and could be up to 15 cm long.  
The species is distributed in the drier tropical countries of West, East and Southern Africa which include 
Niger, Nigeria, Mali, Angola, Zambia, Zimbabwe, Ethiopia, Tanzania and Kenya. It is often found in the 
thickets, deciduous woodland and savannah belts of these countries.  
 
4.1.3 Ethnomedicinal uses 
Different African cultures use this plant for different ethnobotanical practices. In Niger, the stem bark of 
the plant is used in the treatment of stomach ulcers whereas in northern Nigeria the plant is highly utilized 
for bathing recently delivered nursing mothers and also for treating feverish conditions, acute malaria and 
conjunctivitis [1] as well as against microbial infections [2]. In Tanzania, the root is used against 
gonorrhea, bilhazia, heartburn, constipation and snake bites but in northern Kenya, it is used against 
stomach disorders, sore throats and elephantiasis. Reports from the Southern part of Africa indicate that 
the leaves or root decoction is used for treating abdominal pains in Zimbabwe 
(http://www.africamuseum.be/collections/external/prelude/view_plant?pi=02690 accessed on 27th July, 
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2013). An ethnobotanical survey carried out in the northwestern Nigeria revealed that a decoction of the 
leaves of the plant is prescribed by traditional medicine practitioners for the treatment of diabetes mellitus 
[3]. 
4.1.4 Biological activities 
Most of the scientific investigation on the biological activities of C. singueana comes from Nigeria. In 
2003, Adzu et al. [4] reported that the methanolic extract of the root exhibits significant antimalarial, anti-
pyretic and antinociceptive activities but unfortunately, the same extract was found to contain potent 
neuropharmacological agents with significant sedative effects by reducing spontaneous motor activity and 
prolonging barbital hypnosis [5]. The traditional exploitation of the plant for the treatment of stomach 
ulcers prompted a research group to investigate the leaves of anti-ulcer activities. Findings from the 
studies revealed that the methanolic and ethanolic extracts of the leaves possess anti-ulcer effects in 
different rat models of gastric ulcer [6-8]. In another study, the methanol crude extract of the leaves 
demonstrated potent in vitro relaxant effects on histamine-induced pre-contracted rabbit jejenum [9]. 
Interestingly, the methanol extract of the leaves from this plant was found to be safe in a toxicological 
study [10]. Beside the above mentioned investigations, a study reported the preliminary in vitro 
antioxidant potential of the methanolic extract from the leaves of this plant [11] and the methanolic 
extract of the root bark was also reported to contain potent antioxidant, hepatoprotective and 
hypolipidemic agents [1]. 
4.1.5 Phytochemistry 
The only available information on the phytochemistry of C. singueana appearing in the literature was 
reported by Mutasa et al. [12] who described the isolation and characterization of 7-methylphyscion, 
Chrysophanol, Cassiamin A and lupeol as well as a fraction with a mixture of β-sitosterol, stigmasterol 
and campesterol. Using TLC, the presence of an unidentified flavonoid was demonstrated by Ode et al. 
[9] but detailed characterization and elucidation was not carried out which makes the data not weighty. 
 
In order to validate the folkloric claim for anti-diabetic activity of this plant (as earlier mentioned), a 
systematic and comprehensive investigation on the anti-diabetic activity of this plant using in vitro and in 
vivo models was carried out. Initially, various solvent crude extracts from the stem bark, root as well as 
the leaves of the plant were subjected to detailed in vitro anti-oxidative studies (using four models) from 
where the ethyl acetate extract of the stem bark had the best anti-oxidative activity. Subsequently, the 
crude stem bark ethyl acetate extract was fractionated across various solvents and the fractions were 
subjected to the anti-oxidative and -glucosidase and -amylase inhibitory studies where the acetone 
fraction was found to have the best anti-oxidative and enzymes inhibitory activities. Thus, the acetone 
fraction was investigated for in vivo anti-diabetic activity in a type 2 diabetic rats as well as the possible 
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Preface:  The in vitro anti-oxidative activities of the stem bark, root and leaves of the plant were 
investigated in this article. The article has already been published in the journal ‘’ Acta poloniae 
pharmaceutica – drug research’’ Vol 70 number 4; Pages 709-719. 
 
4.2.1 Abstract 
The present study was conducted to investigate the anti-oxidative activities of different solvent extracts of 
Cassia singueana parts. Our results indicate that all the extracts have reducing power (Fe3+- Fe2+) and 
DPPH radical scavenging abilities. However, the stem bark ethyl acetate extract has highest total reducing 
power whilst the ethanol extract of the stem bark has more potent free radical scavenging activity than all 
the other extracts. The ethyl acetate extract of the stem bark exhibited more powerful hydroxyl radical 
scavenging activity than other extracts whilst the aqueous extract of the leaves displayed more potent 
nitric oxide inhibition activity than other extracts. The GC-MS analysis of the ethyl acetate extract of the 
stem bark and the ethanol extract of the root and leaves indicated that several aromatic compounds, 
including phenolics, fatty acids, amino acids, triterpenoids were present in these extracts.  Data from this 
study suggest that the parts of C. singueana possessed anti-oxidative activities and it can be used as a 
potential alternative medicine for oxidative stress related non-communicable chronic diseases. Further 
experimental and clinical studies in this regard are warranted. 
4.2.2 Introduction 
Oxidative stress refers to the presence of free radicals and reactive oxygen species (ROS) that are 
generated in normal physiological processes but become harmful when they are not neutralized by the 
endogenous antioxidants systems. This usually occurs when there is an excess generation of ROS or when 
the antioxidants (AO) are inactivated, thereby altering the ROS/AO equilibrium in favor of stress [13]. 
Oxidative damage plays a vital pathological role in several non-communicable chronic diseases and 
metabolic disorders such as arthritis, atherosclerosis, cirrhosis, cancer and diabetes [14].  
 
Current research findings have provide strong evidences that anti-oxidative agents could be the most 
viable agents to neutralize the harmful effects of oxidative stress and  therefore, can retard the progress of 
many diseases [15, 16]. For this reason, research on therapy and prevention of oxidative stress mediated 
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non-communicable chronic diseases and metabolic disorders has focused attention on the search for 
agents with anti-oxidative activities that could be used to ameliorate the complications associated with the 
disease. 
 
The use of medicinal plants for the treatment of various diseases continues to be an important component 
of health care delivery systems, especially in Africa because the continent has a rich diversity of plants 
with about 25% of the total number of higher plants in the world where more than 5400 medicinal plants 
were reported to have over 16,300 medicinal uses [17].  The influence of these medicinal plants and 
natural products upon drug discovery is impressive because a number of clinically active drugs are either 
natural products or have a natural product pharmacophore [18].   
 
Cassia singueana (Caesalpiniaceae), commonly called golden shower, is native to northern Nigeria. The 
plant leaves are commonly used in the traditional circle of northern Nigeria to treat diabetes mellitus [3] 
and to bathe newly delivered mothers. The antipyretic and antiplasmodial activities of the root extract [4] 
and the anti-ulcer activity of leaf extract [8, 19] has been reported. Further, the methanol extract of the 
leaves from this plant was found to be safe in a toxicological study [10]. Beside the above mentioned 
informations, a most recent study reported the preliminary in vitro antioxidant potential of the methanolic 
extract from the leaves of this plant [11]. However, in order to completely understand the profile of the 
antioxidant capacity of any plant especially as a guide to a future pharmacological study, different 
solvents extracts from the various parts of the plant need to be investigated for antioxidant activity.   
 
We therefore conducted a comprehensive investigation of the stem bark, root and leaves of this plant for 
anti-oxidative activity by using several models with a view to finding compound(s) that could be used to 
ameliorate oxidative stress related metabolic disorders. We also analyzed the most highly anti-oxidative 
extracts by gas chromatography-mass spectrometric (GC-MS) analysis in order to identify the 
phytochemical components of these extracts. 
 
4.2.3 Materials and methods 
Please see chapter two; sub sections 2.3 – 2.5 pages 35-38 for details that affect C. singueana 
4.2.4 Results 
The yield of the various extracts collected from the plant indicated that higher yields are apparently 
obtained from the stem bark extracts. Furthermore, the stem bark extracts contained significantly 
(P<0.05) higher amount of total phenolics than extracts from other parts of the plant. Within the stem 
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bark, the ethyl acetate extract contained a significantly (P<0.05) higher amount of the total phenolics than 
the other solvents extracts (Table 4.2.1). 
Table 4.2.1: Percentage yield and total polyphenol concentrations of various solvent extracts of Cassia 
singueana parts 
 
Data are presented as mean ± SD values of triplicate determinations. a-gDifferent letters along a column are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The total reducing power (in terms of percentage gallic acid equivalent) of the various extracts of C. 
singueana was compared to ascorbic acid and trolox (Table 4.2.2). While all the solvent extracts from the 
various parts of C. singueana demonstrated Fe3+- Fe2+ reductive ability but the EtoAc extract of the stem 
bark exhibited a consistently higher reducing ability compared to all other extracts as well as a standard, 
trolox, though the difference was not significant (P>0.05) compared to EtOH extract of the same plant 
part at lower concentrations. With the exception of the EtOAc extract of the root, the total reducing power 









Samples % Yield Total polyphenol 
(mg/g GAE) 
   
Stem bark   
EtOAc 4.04 102.36±1.18a 
EtOH 6.90 91.53 ± 0.96b 
Aqueous 5.29 81.45 ± 0.15c 
   
Root   
EtOAc 0.63 75.65 ± 2.07d 
EtOH 2.21 77.59 ± 1.36d 
Aqueous 2.40 13.02 ± 1.93f 
   
Leaves   
EtOAc 0.78 5.55 ± 0.77g 
EtOH 1.34 28.84 ± 0.72e 
Aqueous 0.48 6.94 ± 0.33g 
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Table 4.2.2: Total reducing power (gallic acid equivalent) of solvent extracts from the different part of 





15  30 60 120 240 
Stem bark      
EtOAc 37.19 ± 2.39h 31.38 ± 4.18d 27.11 ± 4.58cd 44.47 ± 6.08d 69.03 ± 16.14ced 
EtOH 28.51 ± 3.30g 27.83 ± 5.06d 21.11 ± 2.18c 29.94 ± 4.41c 56.84 ± 1.62e 
Aqueous 0.00 ± 0.00a 6.04 ±0.97a 3.46 ± 1.02a 8.48 ± 1.91b 21.56 ± 4.34b 
      
Root      
EtOAc 20.63 ± 2.28f 17.21 ± 2.76c 15.96 ± 1.16b 26.45 ± 2.73c 45.54 ± 4.04c 
EtOH 1.99 ± 0.55b 8.14 ± 1.62ab 15.27 ± 2.13b 32.51 ± 3.68c 56.19 ± 8.53c 
Aqueous 3.53 ± 0.97c 10.00 ± 1.84b 3.49 ± 1.56a 6.82 ± 1.79a 11.93 ± 2.10a 
      
Leaves      
EtOAc 4.43 ± 0.40c 6.00 ± 1.01a 4.44 ± 0.49a 6.97 ± 0.93ab 10.70 ± 0.65a 
EtOH 7.62 ± 0.56d 6.62 ± 1.19a 5.20 ± 1.02a 9.82 ± 1.07b 15.68 ± 3.59ab 
Aqueous 10.23 ± 0.86e 5.65 ± 1.75a 3.56 ± 0.56a 4.57 ± 1.66a 13.28 ± 1.83a 
      
Ascorbic  acid 31.50 ± 4.92g 32.66 ± 3.00d 35.62 ± 5.51d 52.56 ± 5.43d 89.95 ± 6.21f 
Trolox 17.84 ± 1.86f 20.88 ± 7.33c 24.42 ± 3.95c 29.61 ± 1.96c 52.77 ± 0.90d 
Data are presented as mean ± SD values of triplicate determinations. a-hDifferent letters along a column are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Figure 4.2.1 shows the DPPH radical scavenging activities of the various solvent extracts of C. 
singueana parts. All the extracts had a tendency to quench DPPH free radicals as manifested by the 
concentration dependent increase in the percentage inhibitions. The EtOH extracts of the stem bark and 
root had a consistently higher DPPH radical scavenging ability than other extracts in these parts, although 
difference in some cases was insignificant. There was no difference between the free radical scavenging 
activity of most of stem bark and root extracts and the standard antioxidant used (Figure 4.2.1). On the 
contrary, the leaves extracts showed significantly lower free radical scavenging activity compared to the 












Figure 4.2.1: DPPH radical scavenging activities of various solvent fractions from stem bark (A), root 
(B) and leaves (C) of Cassia singueana. a-eValues with different letters over the bars for a given 
concentration for each extract are significantly different from each other (Tukey’s-HSD multiple range 
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The results of the hydroxyl radical inhibition of the solvent extracts of C. singueana parts indicated that 
all the other extracts inhibited hydroxyl radicals generated by Fenton’s reaction except the EtOH and 
aqueous extracts of the stem bark as well as the EtOAc extract of the root which showed pro-oxidative 
tendencies (Table 4.2.3). However, the EtOAc extract of the stem bark and EtOH extracts of the roots 
and leaves demonstrated significantly higher (P<0.05) anti-OH* activity than other extracts within the 
plant parts. The IC50 values of 1.56, 3.12 and 6.47 µg/ml were obtained for EtOAc extract of the stem 
bark and EtOH extracts of the roots and leaves respectively whereas 2.61µg/ml was found for trolox 
(Table 4.2.5).   





15  30 60 120 240 
Stem bark      
EtOAc 59.30 ± 14.42fg 78.06 ± 0.31g 81.37 ± 1.46g 84.07 ± 1.54h 82.24 ± 0.53f 
EtOH -5.81 ± 2.60b -15.20 ± 4.46b -30.67 ± 1.67b -52.47 ± 1.78b -100.00 ± 0.00a 
Aqueous -25.14 ± 7.42a -45.39 ± 1.48a -66.61 ± 0.81a -100.00 ± 0.00a -100.00 ± 0.00a 
      
Root      
EtOAc 0.00 ± 0.00c 0.00 ± 0.00c 0.00 ± 0.00c -13.94 ± 1.59c -33.08 ± 0.84b 
EtOH 62.23 ± 3.38g 71.01 ± 2.04f 74.47 ± 6.57fg 84.56 ± 0.71a 87.60 ± 0.56g 
Aqueous 42.50 ± 3.26e 37.37 ± 0.38e 35.18 ± 3.57e 35.49 ± 2.98f 29.17 ± 0.69d 
      
Leaves      
EtOAc 0.00 ± 0.00c 0.00 ± 0.00c 0.00 ± 0.00c 0.00 ± 0.00d 20.10 ± 4.62c 
EtOH 54.84 ± 1.17f 68.48 ± 1.01f 73.85 ± 0.76f 77.53 ± 0.93g 84.68 ± 2.23f 
Aqueous 11.85 ± 1.69d 18.40 ± 2.82d 21.37 ± 3.97d 27.99 ± 0.75e 35.77 ± 3.40e 
      
Trolox 57.32 ± 2.95fg 73.11 ± 1.44f 76.04 ± 2.05fg 80.09 ± 3.93gh 79.82 ± 3.50f 
Data are presented as mean ± SD values of triplicate determinations. a-hDifferent letters along a column are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The nitric oxide inhibition activities of the different solvent extracts of C. singueana parts are presented in 
Table 4.2.4. Apart from the EtOH extracts of the stem bark and root, all other extracts were found to 
exhibit nitric oxide scavenging activities. The EtOAc and aqueous extracts of the root as well as EtOAc 
and EtOH extracts of the leaves exhibited a non-concentration dependent NO inhibition effect. Aqueous 
extracts were found to possess lower IC50 values in the NO scavenging model than other extracts within 







Table 4.2.4: Nitric oxide scavenging activities of extracts from various parts Cassia singueana  
Samples Concentration (µg/ml) 
15  30 60 120 240 
Stem bark      
EtOAc 0.00± 0.00b 0.00 ± 0.00b 16.12 ± 0.85c 23.70 ± 1.66c 30.93 ± 4.20c 
EtOH -46.61±5.34a -100.00±0.00a -100.00±0.00a -100.00±0.00a -100.00±0.00a 
Aqueous 8.99±1.31c 12.70±0.59d 37.56±0.75e 44.91± 7.16e 50.24±1.88e 
      
Root      
EtOAc 36.01±0.31d 43.51±4.13f 53.36± 7.82fg 58.00± 1.08f 44.36±4.24de 
EtOH 0.00± 0.00b 0.00± 0.00b 0.00± 0.00b 0.00± 0.00b 0.00± 0.00b 
Aqueous 6.89±0.89c 17.20±2.09e 77.83±5.26h 80.87±2.89h 34.07±1.31c 
      
Leaves      
EtOAc 56.01±2.30f 52.93 ±13.42f 61.67±2.48fg 58.06 ± 1.84f 65.39 ± 4.17f 
EtOH 46.51±1.20e 37.66±10.97f 67.60±0.39h 65.33±2.60g 44.15± 1.94d 
Aqueous 9.19 ± 2.91c 16.36 ±0.89d 24.97±2.81d 26.03±0.37d 56.22±4.69e 
      
Ascorbic acid 47.81 ± 0.51e 50.97 ± 1.35f 52.82 ± 1.35f 56.72 ± 3.69f 64.08 ± 4.25f 
Gallic acid 4.43 ± 2.69c 7.52 ± 1.11c 25.74 ± 0.44d 27.66 ± 1.91d 31.70 ± 2.51c 
Trolox 66.30 ± 1.23g 65.51 ± 1.27g 63.39 ± 1.84g 59.53 ± 1.81f 52.21 ± 2.47e 
Data are presented as mean ± SD values of triplicate determinations. a-gDifferent letters along a column are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 













ND means not determined and P means the extract showed pro-oxidative properties in the experimental model 
Based on the high anti-oxidative activities, the EtOAc extract of the stem bark and the EtOH extracts of 
the root and leaves were analyzed by GC-MS analysis (Figure 4.2.2). The EtOAc extract of the stem bark 
was found to contain phenolic compounds such as resorcinol and 4-propylphenol, amino acids such as 
 
Samples 
 IC50 (µg/ml)  
DPPH Hydroxyl Nitric oxide 
Stem bark    
EtOAc 1.76 1.56 1116.40 
EtOH 1.20 P P 
Aqueous 34.05 P 188.78 
    
Root    
EtOAc 31.78 P 115.51 
EtOH 14.57 3.12 Nil 
Aqueous 2.58 2.05 87.73 
    
Leaves    
EtOAc 44.23 161016.65 4.57 
EtOH 35.88 6.47 29.56 
Aqueous 53.09 1439.25 2.81 
    
Ascorbic acid 2.56 ND 26.28 
Gallic acid 1.27 ND 1026.45 
Trolox 5.04 2.610 599.21 
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dehydroxylevodopa, sterols such as 6-dehydroestradiol and aromatic esters such as the methyl benzoates. 
The ethanol extracts of the roots was found to contain polyphenols such as resorcinol, anthralin, and a 
polyhydroxylated flavonoid, precursors to polyphenol compounds such as hydroxyphenyl pyruvic acid 
and aromatics such as benzylidenexanthene and methyl chrysene. The EtOH extract of the leaves 
contained phytol along with benzyl alcohols, fatty acids and their esters and precursors to triterpenoids 




Figure 4.2.2: GC-MS chromatogram of EtOAc extract of the stem bark (A) and EtOH extracts of the root 




























Table 4.2.6: Identified compounds of EtOAc extract of stem bark and EtOH extracts of root and leaves of 
Cassia singueana by GC-MS  





     
 EtOAc extract of stem bark  
1 2,3-dihydro benzofuran 7.67 120.15 4.08 
2 Resorcinol 8.52 110.10 54.03 
3 4-propylphenol  9.74 136.19 7.24 
4 Dehydroxylevodopa 12.59 179.10 ND 
5 3-methylanthralin 19.85 240.05 1.71 
6 2,3,5,7-tetramethylpyrrolo[2,3-f]quinolin-9-ol 21.12 240.00 ND 
7 2,2’-(m-phenylene) dithiophene 21.40 242.10 ND 
8 6-dehydroestradiol 22.41 270.36 2.62 
9 1-(4-methoxyphenyl)-2-(2-hydroxy-4-
methylphenyl)-diazene 
22.58 242.10 ND 
10 Methyl 3-(1-formyl-3,4-methylenedioxy) benzoate  23.42 284.06 9.28 
 EtOH extract of root  
2 Resorcinol 8.51 110.10 ND 
11 P-hydroxyphenyl pyruvic acid 9.74 180.15 ND 
5 3 methylanthralin 19.86 240.10 ND 
12 5,6 dimethyl-4-phenyl-3-cyanopyridine-2-thione 21.13 240.10 ND 
13 1-methyl chrysene 21.48 242.10 ND 
14 9-benzylidenexanthene  22.41 270.10 ND 
15 3’,7-dihydroxy-4-methoxy-flavonol 23.43 284.10 ND 
 EtOH extract of the leaves  
16 2-methoxy-4-vinylphenol 9.02 150.06 2.67 
17 1-(3,6,6-trimethyl-1,6,7,7-
tetrahydrocyclopenta[c]pyran-1-yl) ethanone 
10.16 191.10 ND 
18 4-methyl-2,5-dimethoxybenzaldehyde 12.17 180.10 ND 
19 Coniferyl alcohol 14.21 180.20 2.72 
20 *Long chain aromatic ester 15.52 194.20 ND 
21 Palmitic acid 16.50 256.42 5.50 
22 Phytol 17.95 296.53 23.70 
23 Linolenyl alcohol 18.20 264.44 3.92 
24 Stearic acid 18.39 284.48 1.73 
25 Linolenic acid ethyl ester 18.46 306.48 2.24 
26 Squalene 23.94 410.72 7.28 
27 Eicosane 24.88 282.55 3.32 
The compounds presented in the table are those which matched similar compounds in the NIST library software and 
which contained the molecular ion of the matching compound. *Compound had the fragment pattern characteristics 
of long chain aromatic esters. The aliphatic chain had a good hit with the library. ND means not determined while # 







Cassia singueana is currently utilized in the traditional treatment of diabetes mellitus in Nigeria whose 
pathogenesis has, in part, been linked to the development of oxidative stress. Apart from now, only a few 
authors have reported the antioxidant activities of the plants within the Cassia genus [20-22]. This study 
investigated the complete anti-oxidative profile of various solvent extracts from different parts of this 
plant as a prelude to finding agent(s) that could be used to ameliorate oxidative stress-associated 
complications. We found some of the C. singueana extracts to possess exceptionally high anti-oxidative 
activities, at least with the experimental models. 
 
Different anti-oxidative agents act via various mechanisms and therefore no single model can provide a 
full evaluation of the anti-oxidant potentials. Therefore, investigating the complex anti-oxidative activities 
mostly requires the use of multiple methods [23]. It was proposed that the ability to donate electrons by 
bioactive compounds which reflects their reducing power is linked to anti-oxidative activity [24, 25]. 
Antioxidants can be reductants, and inactivation of oxidants by reductants can be described as redox 
reactions in which one species is reduced at the expense of the oxidation of the other. Thus, the 
availability of reductants, like anti-oxidative agents  in the samples could cause the reduction of Fe2+ to 
Fe3+ which can be measured as the formation of Perl’s prussian blue at 700 nm. The FRAP assay 
therefore provides a reliable method to study the antioxidant activity of various extracts and/or 
compounds. In our experiment, the higher reducing power of the EtOAc extracts of the stem bark and root 
in most of the concentrations used suggest that the phytochemical constituents with high redox potential 
are more extractable with EtOAc. 
 
 
The DPPH radical is a widely used model to study the neutralizing effects of crude plant extracts, solvent 
fractions or pure compounds on free radicals. Antioxidants act on DPPH through their hydrogen donating 
ability [26]. Hence, DPPH is frequently used as a substrate to investigate the free radical scavenging 
activity of anti-oxidantive agents in vitro [27]. The high DPPH radical scavenging activities of the various 
solvent extracts which are comparable to standard antioxidants used suggest that the extracts have 
compounds with high proton donating ability and could serve as free radical inhibitors. However, the 
organic solvents extract from the stem bark demonstrated a more remarkable anti-radical activity with 
IC50 values lower than those of ascorbic acid and trolox. Although many reports on the DPPH radical 
scavenging activity of extracts from plants belonging to different families and from various parts of the 
world exist in the literature but only few authors [28] reported low IC50 values as was observed with these 
extracts. This further suggests that these extracts contain powerful free radical scavenging phytochemicals 
that could have the ability to inhibit free radical upsurge as well as oxidative stress which consequently 




Hydroxyl radicals are highly reactive species that causes damage to all life essential macromolecules [29].  
These radicals are extremely detrimental because they initiate auto-oxidation, polymerization and 
fragmentation of biomolecules. Thus, compounds with excellent scavenging effects towards hydroxyl 
radicals would be important for treating diseases such as T2D where oxidative stress is important for the 
disease initiation and/or progression. The hydroxyl radical scavenging effects is thus monitored as the 
percentage of inhibition of hydroxyl radicals produced in the Fenton’s reaction mixture by studying the 
competition between deoxyribose and the extracts for hydroxyl radicals generated from the 
Fe3+/EDTA/ascorbate/H2O2 system [30]. From the present study, the EtOAc extract of the stem bark and 
aqueous extract of the root are more effective in hydroxyl radical inhibitions, considering their lower IC50 
values. The pro-oxidative tendencies showed by the EtOH and aqueous extracts of the stem bark as well 
as the EtOAc extract of the root in the hydroxyl radical based anti-oxidative model further indicate the 
need to use a multi method approach before a definite statement can be made on the anti-oxidative effects 
of any plant extract or bioactive compound. 
 
Nitric oxide is a very unstable species that has been implicated in the pathology of cancer, T2D and 
several other disorders [31-33]. The lower IC50 values observed by the aqueous extracts in all the plant 
parts could indicate that the anti-oxidative principles extracted by the various solvents act via different 
antioxidant mechanism. On the other hand, the non-concentration dependent pattern of NO scavenging 
activity demonstrated by the EtOAc and aqueous extracts of the root as well as the organic solvent 
extracts of the leaves could be linked to a hormesis phenomenon exhibited by these extracts. Hormesis is 
a dose-response relationship for a single endpoint that is characterized by reversal of response between 
low and high doses of chemicals, biological molecules, physical stressors, or any other initiators of a 
response [34] and its occurrence has been documented in numerous biological, toxicological and 
pharmacological investigations [35]. Thus, these extracts possess optimal points for effective inhibition of 
NO radical and/or antagonism may occur with other phytochemicals at certain concentrations.  
Phenolics are very important constituents among other natural antioxidants because of their various 
pharmacological actions and direct contribution to anti-oxidative activity [29]. Although a correlation 
analysis was not performed, our data tends to suggest strong correlations between the total phenolic 
content and anti-oxidative capacity because most extracts with the highest phenolic content within a plant 
part displayed high anti-oxidative activity in most of the experimental models used and consequently 
these extracts were selected for GC-MS analysis. While not discounting the possible contributions of the 
other detected phytochemicals, it is possible to surmise that the main anti-oxidative agents of these 
extracts are simple phenolics, especially resorcinol in the stem bark and root as well as phytol in the 
leaves. However, the differences in the anti-oxidative activities among the extracts could be due to 
different qualitative and quantitative composition of their phenolics as well as other phytochemicals.  This 
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is because the antioxidant actions of phenolics and their derivatives depend on the number of hydroxyl 
groups in the molecule [36]. 
 
In conclusion, this work reveals that the various solvent extracts of C. singueana parts possessed strong 
anti-oxidative activities that could be relevant in the management of oxidative stress related non-
communicable chronic diseases, however further experimental and clinical studies are warranted. 
Phenolic compounds were found to be the main phytochemicals with resorcinol being more prominent 
than other compounds in the stem bark and root and phytol being more prominent than other compounds 
in the leaves. Bioassay guided fractionation and evaluating the in vivo anti-oxidative effects of some of 
the extracts will be the subject of our future study. 
Postscript: From the above experiment, the ethyl acetate crude extract from the stem bark was found to 
have relatively higher anti-oxidative activity that cuts across various types of radicals than other extracts. 
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Preface: In this sub-chapter, solvent-solvent fractionation of the crude stem bark ethyl acetate extract was 
carried out and the solvent fractions were investigated for anti-oxidative and α-glucosidase and α-amylase 
inhibitory activities. This article is yet to be submitted to the supervisors for comments and proof reading 
and eventual submission for publication 
 
4.3.1 Abstract 
The present study investigated the in vitro anti-oxidative as well as the α-glucosidase and α-amylase 
inhibitory activities of various solvent fractions derived from the crude ethyl acetate extract of Cassia 
singueana stem bark. Solvent-solvent fractionation was used to fractionate the crude ethyl acetate extract 
into hexane, dichloro methane, acetone and aqueous fractions. The acetone fraction had significantly 
higher (P<0.05) total phenolics, total reducing power and DPPH radical scavenging activity than other 
solvent fractions. Furthermore, the acetone fraction elicited a significantly more potent (P<0.05) 
inhibitory effects on α-glucosidase and α-amylase activities than other fractions. Steady state kinetic 
analysis revealed that the acetone fraction inhibited α-glucosidase in a non-competitive pattern with an 
inhibition binding constant (Ki) of 22.81 μg/ml and inhibited α-amylase in a competitive pattern with Ki 
of 8.57 μg/ml. GC-MS analysis of the acetone fraction revealed that the main bioactive components are 
phenolics such as resorcinol and 2’ 4’-dihydroxy chalcone.  It was concluded that the acetone fraction 
contains potent inhibitors of α-glucosidase and α-amylase while resorcinol and 2’ 4’-dihydroxy chalcone 
could be the main bioactive agents. 
4.3.2 Introduction 
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia with alterations in the 
metabolism of major macromolecules resulting from anomalies in the secretion of insulin or its action 
[37].  According to the International Diabetes Federation (IDF), about 366 million people are living with 
diabetes and this figure is projected to increase to 552 million by the year 2030 [38]. A number of 
hypotheses have been suggested to provide explanation on the different aspects of diabetes pathology 
among which oxidative stress, through a single unifying mechanism of reactive oxygen species 
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generation, is regarded as the common biological phenomenon that plays vital roles in all aspects of the 
disease pathogenesis such as insulin resistance, pancreatic β-cell dysfunction as well as macrovascular 
and microvascular complications [39-41].  Therefore, the use of antioxidants could be exploited in the 
treatment of T2D and prevention of its chronic vascular complications [42]. 
On the other hand, the control of postprandial hyperglycemia is also considered to be important in the 
management of diabetes and the prevention of its associated complications. At present, hyperglycemia is 
predominantly managed with sulfonylureas and biguanides but the use of α-glucosidase and α-amylase 
inhibitors is still considered as important line of treatment especially in the developing world [43]. α-
Amylase hydrolyzes starch and other complex polysaccharides to oligosaccharides which are further 
hydrolyzed by intestinal α-glucosidase to liberate glucose which is then absorbed into the intestinal 
epithelium and enter blood circulation.  Consequently, inhibitors of these enzymes will ultimately retard 
the release of glucose from dietary carbohydrates to the bloodstream, thereby impeding the postprandial 
hyperglycemia. Unfortunately, the clinically available α-glucosidase inhibitors, acarbose and miglitol, 
were frequently found to cause diarrhea and gastrointestinal side effects such as bloating, flatulence, 
cramping and abdominal pain [44]. These gastrointestinal disturbances have been reported to be the main 
reason for non-compliance and early withdrawal in randomized controlled trials [45]. Interestingly, 
glucosidase inhibitors derived from plants sources were reported to be more acceptable because they are 
cheap and relatively safer, including a lower tendency of causing serious gastrointestinal discomfort [46, 
47]. Based on the above, research on diabetes therapy has focus attention on the search for plant based 
agents with potent anti-oxidative activity and α-glucosidase inhibitory activities, thereby providing a 
holistic therapeutic avenue to control hyperglycemia and other diabetic complications resulting from 
oxidative stress.  
 
Cassia singueana Delile, also known as golden shower, is a member of the family Caesalpiniaceae and is 
commonly used by the traditional medicine practitioners of northern Nigeria to treat diabetes mellitus [3] 
as well as bathe nursing mothers. The antipyretic and antiplasmodial activities of the root extract [4] and 
the anti-ulcer activity of leaf extract [8, 19] have been reported. Furthermore, the methanol extract of the 
leaves from this plant was found to be safe in a toxicological study [10]. In a previous study, preliminary 
in vitro anti-oxidative potential of the methanolic extract from the leaves was reported [11].  However, in 
a most recent study, we subjected different solvent crude extracts of the stem bark, root and leaves of the 
plant to anti-oxidative activity assays using several models and reported that the ethyl acetate extract of 
the stem bark had the best anti-oxidative activity among all other extracts [48].  
 
In the present study, we further fractionated the ethyl acetate extract of the stem bark across solvents of 
varying polarity and then conducted a comprehensive study on the in vitro anti-oxidative as well as the α-
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glucosidase and α-amylase inhibitory activities of the fractions. Additionally, we subjected the most 
bioactive fraction to GC-MS analysis in order to identify the phytochemicals contained therein.   
 
4.3.3 Materials and methods 
Please see chapter two sub-sections 2.6.1-2.6.6 (pages 38-40) for detailed materials and methods that 
affect C. singueana 
4.3.4 Results 
The total phenolics content of the acetone fraction was significantly higher (P<0.05) than all other 
fractions. Also, the acetone fraction had a significantly higher (P<0.05) Fe3+- Fe2+ reducing power 
(Figure 4.3.1) and DPPH radical scavenging activity (Table 4.3.1) than other fractions. The results of 
hydroxyl radical scavenging activity also showed that all the fractions contained phytochemicals that 
could scavenge hydroxyl radicals generated by Fenton’s reaction but the aqueous fraction had the best 
activity in this model followed by the acetone fraction. NO radicals were also scavenged by all the 
fractions but the less polar fractions (hexane and dichloromethane) showed a significantly higher 
(P<0.05) NO radical scavenging activity than the more polar fractions (acetone and water) (Table 4.3.1).   
 
Figure 4.3.1:  Total reducing power (relative to gallic acid) of different solvent fractions of the ethyl 
acetate extract of C. singueana stem bark. Data are presented as mean ± SD of triplicate determinations. a-
eValues with different letters presented for a given concentration are significantly different from each 
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Table 4.3.1: IC50 values of various solvent fractions of ethyl acetate extract of C. singueana  stem bark  in 
different anti-oxidative models 
Fractions Total phenolics 
(mg/g GAE) 
IC50 (µg/ml) 
DPPH Hydroxyl radical NO 
Aqueous 167.49 ± 0.14c 5.07 ± 0.09c 169.58 ± 14.23b 322.81 ± 20.49c 
Acetone 193.69 ± 3.78d 1.95 ± 0.30a 194.05 ± 8.78c 346.44 ± 30.43c 
Dichloromethane 154.96 ± 11.06b 31.46 ± 8.67e 219.80 ± 14.21d 226.75 ± 45.47b 
Hexane 7.77 ± 0.94a 89.63 ± 0.44f 272.65 ± 8.99e 272.97 ± 47.08bc 
     
Ascorbic acid - 2.56 ± 0.26b ND 26.40 ± 6.46a 
Gallic acid - 1.40 ± 0.43a ND 1053.48 ± 239.92e 
Trolox - 8.47 ± 2.88d 3.23 ± 0.49a 629.76 ± 63.98d 
Data are presented as mean ± SD values of triplicate determinations. a-eDifferent letters along a column are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Figure 4.3.2 presents the α-glucosidase and α-amylase inhibitory effects of the fractions. With the 
exception of hexane fraction, all other fractions inhibited α-glucosidase in a dose dependent pattern 
(Figure 4.3.2A). The more polar fractions demonstrated significantly higher (P<0.05) α-glucosidase 
inhibitory effects than the less polar fractions However, within the more polar fractions, the α-glucosidase 
inhibitory activity demonstrated by the acetone fraction was significantly higher (P<0.05) than aqueous 
fraction. Pancreatic α-amylase activity was inhibited by all the fractions in a dose dependent fashion 
except the hexane fraction (Figure 4.3.2B) and the acetone fraction showed a significantly higher 
(P<0.05) α-amylase inhibitory effects than other fractions. Based on the high activity of the acetone 





Figure 4.3.2: α-glucosidase (A) and α-amylase (B) inhibitory activities of different solvent fractions of 
the ethyl acetate extract of C. singueana stem bark. Data are presented as mean ± SD of triplicate 
determinations. a-eValues with different letters over the bars for a given concentration are significantly 
different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
A steady state kinetic analysis of both α-glucosidase and α-amylase activities at varied substrate 
concentrations in the presence and absence of 60 μg/ml of the acetone fraction (the most active fraction) 
was further conducted to determine the mechanism of inhibition. From the experiment, the acetone 
fraction was found to be a non-competitive inhibitor of of α-glucosidase (Figure 4.3.3A) with Vmax 
decreasing from 655.09 μmol/min to 180.45μmol/min. The KM remained unchanged at 2.00 mM and the 
computed Ki value for inhibiting α-glucosidase was 22.81μg/ml (Table 4.3.2). Conversely, the 
mechanism of inhibition of α-amylase by the acetone fraction revealed a competitive inhibition pattern 






















































































respectively. The Vmax of the α-amylase was not affected (33.70 μmol/min) and Ki for inhibiting α-
amylase by the fraction was 8.57 μg/ml (Table 4.3.2).  
 
 
Figure 4.3.3: Lineweaver-Burke’s plot of α-glucosidase (A) and α-amylase (B) catalyzed reactions in the 
presence and absence of the acetone fraction derived from the ethyl acetate extract of C. singueana stem 
bark 
 
Table 4.3.2: Effects of the acetone fraction derived from the ethyl acetate extract of C. singueana stem 
bark (60 μg/ml) on some kinetic parameters of α-glucosidase and α-amylase 
Kinetic parameters α-glucosidase α-amylase 
control + acetone fraction control + acetone fraction  
KM  2.00*  2.00*  0.25#  2.00#  
Vmax (μmol/min) 655.09 180.45 33.70 33.70 
Ki (μg/ml) - 22.81 - 8.57 



















































The major peaks detected in the GC-MS chromatogram of the acetone fraction (Figure 4.3.4) were those 
of resorcinol, 2’ 4’-dihydroxy chalcone and 2-(3-carbethoxyphenylamino)-4,6-diphenylpyrimidine 
identified by their fragmentation patterns and in conjunction with the NIST library (Table 4.3.3).  The 
retention time and the molecular mass of these compounds are also provided in Table 4.3.3. 
 
Figure 4.3.4: GC-MS chromatogram of the acetone fraction derived from the ethyl acetate extract of C. 
singueana stem bark. 
 
Table 4.3.3: Identified components of the acetone fraction derived from the ethyl acetate extract of C. 
singueana stem bark by GC-MS 




1 Resorcinol 8.32 110.11 
2 2’ 4’-dihydroxy chalcone 21.13 240.25 
3. 2-(3-Carbethoxyphenylamino)-4,6-diphenylpyrimidine 22.75 395.50 
 
4.3.5 Discussion 
Phytochemicals or other chemotherapeutic agents with potent anti-oxidative as well as α-glucosidase and 
α-amylase inhibitory effects are useful in the management of postprandial hyperglycemia, T2D and 
related chronic vascular complications, thereby providing a holistic therapeutic strategy. In the present 
study, acetone fraction fractionated from the crude ethyl acetate of C. singueana stem bark elicited 







Plants have wide array of phytochemicals ranging from both nonpolar to polar. Thus, we fractionated the 
crude ethyl acetate extract to further narrow down on the phyto-components responsible for the observed 
high activity [48] and to also determine their in vitro anti-diabetic potentials. For the anti-oxidative 
activity of the fractions, different models for in vitro anti-oxidative studies were used because a single 
method cannot give a full evaluation of the anti-oxidative capabilities due to the involvement of multiple 
mechanisms in the induction of oxidative stress. The total reducing power of phytochemicals is 
considered as a reliable marker of their antioxidant effects. The reductants terminate the free radical chain 
reaction by donating hydrogen atoms to the radical molecules. Free radicals are known to be a major 
factor in cellular damages in biological systems and DPPH method has been used to investigate the free 
radical scavenging activity of natural anti-oxidative agents. On the other hand, hydroxyl radicals are also 
extremely reactive species that could damage any biomolecule in living systems [49] and NO is an 
unstable species which reacts with oxygen to generate the reactive nitrite and peroxynitrite anions [50]. 
All these radicals are implicated in the pathogenesis of T2D and associated complications [32, 51]. From 
the present study, the acetone fraction contains better group(s) of phytochemical(s) which could 
reasonably scavenge all the various forms of radicals. This further suggests the presence of powerful 
phytochemical(s) that might have the ability to inhibit free radical upsurge as well as oxidative stress. 
These phytochemicals, either in pure form or in combination could be useful therapeutic agents for 
treating oxidative stress related metabolic disorders such as T2D.  
 
Analysis of the α-glucosidase inhibitory activity of the fractions also demonstrated that the acetone 
fraction contains the most powerful inhibitors against this enzyme which could slow down the breakdown 
of disaccharides to liberate glucose; thereby reducing glucose absorption from the small intestine [52]. 
Consequently, this will decrease the flow of glucose into the bloodstream; thereby controlling 
postprandial hyperglycemia. The observation could be linked to the high phenolics content recorded in 
the fraction since phenolic fractions from plants have been reported to inhibit α-glucosidase activity and 
allow for a tight control of blood glucose levels [53]. Indeed, some isolated phenolics have been reported 
to be the main bioactive anti-diabetic agents of Brickellia cavanillesii [54] and Garcinia mangostana [55] 
and the activity was mediated through the inhibition of α-glucosidase. Furthermore, Mai et al. [56] 
demonstrated a strong positive correlation between polyphenolic content and α -glucosidase inhibitory 
effects of 28 extracts from Vietnamese edible plants which corroborates with this study. On the other 
hand, analysis of α-amylase inhibitory activity also revealed that the acetone fraction had the highest 
activity which suggests the presence of better group(s) of phytochemicals that could inhibit the 
breakdown of complex carbohydrates to oligosaccharides, thereby diminishing the effect of carbohydrate 




Kinetic delineation of the α-glucosidase inhibitory effects of the acetone fraction indicated that the 
mechanism of inhibition is non-competitive suggesting that the bioactive phytochemicals binds the α-
glucosidase at separate site(s) of the enzyme (rather than the active site) but caused conformational 
modification at the active site, thereby preventing effective binding of the substrate and consequently 
reduced the α-glucosidase activity [57]. On the contrary, the pattern of α-amylase inhibition by the 
fraction (competitive) suggests that the active site of the enzyme is directly involved in the inhibitory 
action and the fraction likely contains some phytochemical(s) that could serve as substrate analogues, 
thereby competing for the active site of the α-amylase [58].  
Phytochemical analysis of the acetone fraction revealed that phenolics such as resorcinol and 2’ 4’-
dihydroxy chalcone are the main bioactive agents of the fraction. This observation corroborates with our 
earlier assertion on the involvement of phenolics in the observed inhibitory effects.   
 
We concluded that the acetone fraction derived from the crude ethyl acetate extract of C. singueana stem 
bark contains powerful anti-oxidative agents and inhibitors of α-glucosidase and α-amylase which could 
be exploited for the development of holistic therapeutic strategy for the control of postprandial 
hyperglycemia, T2D and related complications while phenolics are the main bioactive agents responsible 
for the observed activities investigated in the study. We are currently working on a detailed study on the 
anti-diabetic activity of the acetone fraction in a T2D diabetes model of rats as well as isolating some pure 
compounds from it. 
 
Postscript: From the above studies, the acetone fraction had the best α-glucosidase and α-amylase effects 
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Preface: This article reports the detailed in vivo anti-diabetic studies of the acetone fraction and it has 




The present study examined the anti-diabetic activity of the acetone fraction of Cassia singueana stem 
bark (CSAF) in a type 2 diabetes (T2D) model of rats and the enzyme inhibitory activity of 3β-O-acetyl 
betulinic acid isolated from the fraction.  Rats were randomly allocated into six groups: normal control 
(NC), diabetic control (DBC), diabetic rats treated with 150 mg/kg bw (DCL) and 300 mg/kg bw (DCH) 
of CSAF, diabetic rats treated with 300 mg/kg bw of metformin (DMF) and normal rats treated with 300 
mg/kg bw of CSAF (NCT). T2D was induced by feeding the rats a 10% fructose solution for two weeks 
ad libitum followed by an intraperitoneal injection of streptozotocin (40 mg/kg b.w). After 4 weeks of 
intervention, non-fasting blood glucose levels were significantly (P<0.05) lowered and the glucose 
tolerance ability was significantly improved in the DCL and DCH groups compared to the DBC group. 
Furthermore, serum insulin concentrations, pancreatic β-cell function (HOMA-β) and liver glycogen level 
were significantly (P<0.05) increased while serum alanine transaminase, alkaline phosphatase and urea 
were significantly decreased in the CSAF treated diabetic rats compared to the DBC group. Other T2D-
induced abnormalities ameliorated, though insignificantly (P>0.05), by the CSAF treatments in diabetic 
rats were feed and fluid intakes, body weight changes, serum lipids alterations, serum fructosamine level 
and peripheral insulin resistance (HOMA-IR) Analysis of 3β-O-acetyl betulinic acid isolated from CSAF 
revealed that it is a potent non-competitive inhibitor of -glucosidase and -amylase activities. It was 
concluded that orally administered CSAF could ameliorate most of T2D-induced abnormalities and 3β-O-
acetyl betulinic acid is a possible anti-diabetic agent in the fraction.  
 
4.4.2 Introduction 
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia which results from 
anomalies in the secretion of insulin and/or its action [59]. According to a projection of the International 
Diabetes Federation (IDF),  approximately 366 million people are living with diabetes and this figure is 
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projected to increase to 552 million by the year 2030 [38].  Among the two major types of diabetes, type 2 
is more prevalent than type 1, with more than 90% of the total diabetic patients are suffering from it. Type 
2 diabetes (T2D) is a heterogeneous disorder characterized by a gradual decline in insulin action (insulin 
resistance) and subsequent failure of pancreatic β-cells to compensate for the insulin resistance (β-cell 
dysfunction) which leads to hyperglycemia with oxidative stress being a major contributor to the β-cell 
damage [60, 61].  
 
Hyperglycemia is a major factor responsible for the development of several chronic complications 
associated with T2D such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic 
cardiomyopathy, and diabetic foot diseases [62].  Approximately, 50% of people with T2D are affected 
with one or more above-mentioned complications [63]. The control of hyperglycemia is therefore of 
prime importance to impede the disease progression. At present, the use of insulin secretagogues and 
sensitizers constitutes the predominant line of therapy, however, the use of inhibitors of carbohydrate 
digesting enzymes in order to reduce the intestinal absorption of sugar is also vital as they do not interfere 
with the carbohydrate metabolism and help to control hyperglycemia in a noninvasive manner [64]. Alpha 
glucosidase inhibitors are the current class of inhibitors of intestinal absorption which are shown to 
control postprandial hyperglycemia. However, the clinically available glucosidase inhibitors, acarbose 
and miglitol, are frequently found to cause diarrhea and other gastrointestinal side effects such  as 
bloating, flatulence, cramping and abdominal pain [44]. Hence, research on diabetes therapy is focused on 
the search for alternative agents which could decrease postprandial hyperglycemia and other diabetic 
complications with fewer or no side effects.  
Cassia singueana Delile, also known as golden shower, is a member of the family Caesalpiniaceae and is 
commonly used by traditional medical practitioners to treat diabetes mellitus [3] as well as bathe nursing 
mothers. In a previous study, the in vitro anti-oxidative potential of the methanolic extract from the leaves 
was reported [11]. However, in a most recent study, we subjected different solvent crude extracts of the 
stem bark, root and leaves of the plant to anti-oxidative activity assays using several models and reported 
that the crude stem bark ethyl acetate extract had the best anti-oxidative activity among all other extracts 
[48]. 
In the present study, the ethyl acetate extract was further partitioned across solvents of different polarity 
and the acetone fraction derived from it was found to have the highest -glucosidase and -amylase 
inhibitory activities (among other solvent fractions). Subsequently, the acetone fraction was subjected to a 





4.4.3 Materials and methods 
Please see chapter two sub-sections 2.3-2.4 (pages 35-36); 2.6.1-2.6.3 pages 38-39; 2.7.1-2.7.7 pages 40-
43; and 2.8.4 (page 46) for detailed material and methods that affect C. singueana. However, the group 
codes DFL, DFH and NFT used in the chapter two are replaced with DCL, DCH and NCT respectively. 
CSAF refers to the acetone fraction derived from the ethyl acetate extract of C. singueana stem bark 
4.4.4 Results 
Analysis of the α-glucosidase and α-amylase inhibitory effects of the fractions revealed that the more 
polar fractions demonstrated significantly (P<0.05) higher inhibitory effects than the less polar fractions. 
However, within the more polar fractions, the α-glucosidase and α-amylase inhibitory activities 
demonstrated by the acetone fraction was significantly (P<0.05) higher than the other solvent fractions 
(Table 4.4.1). Based on the high activity of the acetone fraction in most of the assays described above, it 
was selected for further in vivo studies. 
Table 4.4.1:  IC50 values for the inhibition of α-glucosidase and α-amylase by various solvent fractions of 
the ethyl acetate extract of C. singueana stem bark  
Fractions/standard IC50 (µg/ml) 
α-glucosidase α-amylase 
Aqueous 80.99± 0.97c 157.24 ± 4.96b 
Acetone 67.58 ± 3.59b 108.36 ± 2.64a 
Dichloromethane 175.59 ± 1.68d 769.54 ± 165.71d 
Hexane 278.66 ± 48.64e NIL 
Acarbose 55.59 ± 5.22a 256.66 ± 20.52c 
The results are expressed as mean ± SD of triplicate determinations. a-eValues with different alphabets along a 
column are significantly different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05).  
 
The mean food and fluid consumption per day per rat over the seven week experimental period is 
presented in Figure 4.4.1. The food and fluid intakes of the DBC group was significantly higher (P<0.05) 
compared to NC and NCT groups; however the CSAF treated groups consumed an insignificantly 
(P>0.05) lower food and fluid than the DBC group. The fluid intake of DCH group was markedly lower 




Figure 4.4.1: Food and fluid intake of the different groups during the experimental period. Data are 
presented as mean ± SD of eight animals. a-bValues with different letters over the bars for a given 
parameter are significantly different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
No significant difference in the body weight among the different animal groups during the first 2 weeks 
of the experiment was observed. However, the body weight gains of the diabetic groups were 
significantly lower compared to NC and NCT groups during the entire experimental period (Figure 
4.4.2).
 
Figure 4.4.2: Mean body weight gain for all groups of experimental animals over the seven weeks 
experimental period. Data are presented as the mean ± SD of eight animals. a-bValues with different letters 






































































The blood glucose concentrations of the diabetic groups were significantly higher than the NC and NCT 
groups at week 1, however, as soon as the intervention started, the DCL and DCH groups maintained a 
significantly lower (P<0.05) blood glucose levels than the DBC group throughout the experimental period 
(Figure 4.4.3). The blood glucose lowering effect of the fraction seems to be dose dependent because the 
DCH had a relatively lower blood glucose levels than DCL throughout the intervention period. These 
results also suggest the significant effects of CSAF on both  non-fasting (week 1-4) and fasting blood 
glucose (week 5) levels compared to DBC group (Figure 4.4.3). 
 
Figure 4.4.3: Weekly blood glucose concentrations (post induction) of different animal groups. Data are 
presented as the mean ± SD of eight animals. a-cValues with different letters for a given week are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The data for OGTT are shown in Figure 4.4.4. The glucose tolerance abilities of DCL and DCH groups 
were significantly (P<0.05) better than the DBC group during the entire experimental period. Even better 
glucose tolerance was observed for DCH group compared to the metformin consuming DMF group at 120 
min point of the glucose tolerance test. The glucose tolerance ability of DCH group was also significantly 















































Figure 4.4.4: Oral glucose tolerance test (OGTT) for all groups of animals in the last week of the 
experimental period. Data are presented as the mean ± SD of eight animals. a-dValues with different letters 
for a given time are significantly different from each other (Tukey’s-HSD multiple range post hoc test, 
P<0.05) 
 
Table 4.4.2 presents the data for serum insulin and fructosamine concentrations as well as the computed 
HOMA-IR and HOMA-β scores. A significantly (P<0.05) higher serum insulin concentration and better 
β-cell function (HOMA-β) were recorded in the DCL and DCH groups in comparison to DBC group. 
However, the serum fructosamine levels and insulin resistance (HOMA-IR) were markedly decreased in 
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Table 4.4.2: Serum insulin and fructosamine concentrations as well as HOMA-IR and HOMA-β scores at 
the end of the experimental period 
 NC DBC DCL DCH DMF NCT 
Serum insulin 
(pmol/L) 
153.1± 9.9b 64.2±29.9a  119.7±17.8b 138.3±12.6b 119.2±13.0b 140.4±17.8b 
Serum fructosamine 
(µmol/L) 
196.3±5.6a 258.4±10.9b 268.4±14.1b 214.4±28.9ab 253.8±30.4b 185.0±8.4a 
HOMA-IR 4.9 ±1.1a 16.2±5.7b 13.0±5.7b 13.4± 4.9b 9.8±3.8b 4.6±0.7a 
HOMA-β 304.1±53.7d 9.68±5.2a 20.3±4.7b 32.8±16.7bc 54.9±27.5c 232.4±55.5d 
Data are presented as the mean ± SD of eight animals. a-dValues with different letters along a row are significantly 
different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The results for liver weights and liver glycogen levels are presented in Table 4.4.3 and there were no 
significant differences (P>0.05) in the liver weights of all groups of experimental rats but the relative liver 
weights of the diabetic groups were significantly higher than NC and NCT groups. The DCL, DCH and 
DMF groups had insignificantly (P>0.05) lower relative liver weights in comparison to the DBC group. A 
significantly higher liver glycogen contents were detected in the NC, DCL, DCH and DMF groups 
compared to DBC and NCT groups. 
 
Table 4.4.3: Liver weights and liver glycogen concentrations in different animal groups at the end of the 
experimental period 
 NC DBC DCL DCH DMF NCT 
Liver weight (g) 11.8±2.4 10.9±1.9 10.6±1.2 9.9± 0.8 10.4±1.7 10.8±1.4 
Relative liver weight (%) 3.3±0.3a 3.9±0.2b 3.8±0.1b 3.8±0.2b 3.7±0.1b 3.1±0.1a 
Liver glycogen (mg/g tissue) 3.5±0.8c 1.54±0.1a 3.2±0.2bc 2.7±0.2b 2.7±0.4b 1.5 ±0.6a 
Data are presented as the mean ± SD of eight animals. a-cValues with different letters along a row are significantly 








The concentrations of the serum lipids are presented in Figure 4.4.5. Although there were no significant 
differences in the concentrations of total cholesterol and LDL cholesterol among the experimental groups, 
the DBC had relatively higher values which were reduced in the DCL and DCH groups. The DBC group 
also recorded a significantly lower level of HDL cholesterol compared to the DCL and DCH groups. 
Furthermore, T2D caused a significant increase in the serum triglycerides which was ameliorated in the 
DCL, DCH and DMF groups. 
 
Figure 4.4.5: The serum lipid profile in different animal groups at the end of the experimental period. 
Data are presented as the mean ± SD of eight animals. a-bValues with different letters for a given 
parameter are significantly different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The data for serum AST, ALT, ALP, urea and creatinine concentrations are presented in Table 4.4.4. The 
serum levels of ALT, ALP and urea were significantly elevated in the DBC group compared to NC group 
but the DCL, DCH and DMF groups recorded significantly lower values of these biochemical parameters 
when compared to the DBC group (Table 4.4.4). Conversely, relatively higher serum levels of creatinine 
was observed in the DMF group compared to the DBC group whereas no significant difference was 




































Table 4.4.4: Serum biochemical parameters for all groups of animals at the end of experimental period  
 NC DBC DCL DCH DMF NCT 
AST (U/L) 88.0±14.9 73.6±7.6 78.3±4.9 76.2±3.6 88.7±17.9 86.0±13.7 
ALT (U/L) 56.3±12.6a 77.8±4.6b 64.6±9.2a 62.3±9.3a 63.3±18.2a 48.5±15.4a 
ALP (U/L) 188.8±19.9b 898.6±174.5d 320.4±25.8c 344.6±45.4c 472.0±74.9c 117.5±12.5a 
Urea (mg/dl) 48.0±6.2b 93.0±16.4c 69.2±10.7bc 78.0±10.9bc 42.0±11.8ab 30.2±4.5a 
Creatinine 
(µg/dl) 
582.0±70.5ab 485.0±40.4ab 570.0±104.6ab 545.0±84.1ab 675.0±95.2b 470.0±67.8a 
 Data are presented as the mean ± SD of eight animals. a-dValues with different letters along a row are significantly 
different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 
In the histopathological examination of the pancreas, the DBC group had a reduced number of β-cells 
which were highly dispersed compared with the NC group. Higher number of β-cells  was observed in the 
DCL and DMF groups compared to the DBC group although the size of the islets were morphologically 
smaller in size compared to the NC group (Figure 4.4.6). 
             
       
Figure 4.4.6: Representative histopathological examinations of the pancreas of different experimental groups at the 
end of the experiment. The NC had high number of β-cells while the DBC had highly dispersed and 
morphologically deformed β-cells. The DCL, DCH and DMF groups had higher number of β-cells (compared to 
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The structure of the active compound was determined as 3β-O-acetyl betulinic acid (Figure 4.4.7) from 
its 1H and 13C NMR data (Appendix 1 and 2) and by comparison of the data with the data reported in the 
literature [65]. Analysis of α-glucosidase and α-amylase inhibitory activity of 3β-O-acetyl betulinic acid 
revealed that the compound is a potent inhibitor of α-glucosidase and α-amylase activity with IC50 values 
of 45.12 ± 3.47 and 98.52 ± 2.816 µg/ml respectively. Furthermore, enzyme kinetics studies revealed that 
3β-O-acetyl betulinic acid exerts a non-competitive inhibition pattern on both enzymes thereby 
decreasing the Vmax of the enzymes while the KM remained unchanged (Figure 4.4.8). The computed 
















Figure 4.4.7: The structure of 3β-O-acetyl betulinic acid isolated from the acetone fraction of Cassia 











Figure 4.4.8: Lineweaver-Burke’s plot for α-glucosidase (A) and α-amylase (B) catalyzed reactions in the 
presence and absence of 3β-O-acetyl betulinic acid as an inhibitor 
 
4.4.5 Discussion 
The development of anti-diabetic agents that are devoid of adverse effects is still a challenge to the health 
care systems globally. Thus, medicinal plants are constantly being explored with the hope of developing a 
relatively safe antidiabetic plant-based product alone or in combination with other agents [66]. In the 
present study, we reported the anti-diabetic activity of an acetone fraction of the stem bark of Cassia 
singueana in a newly developed model of T2D. Cassia singueana is used for the traditional remedy of 
diabetes mellitus and the acetone fraction was selected for the study based on the higher -glucosidase 
and -amylase inhibitory activity showed by the fraction as compared to other solvent fractions.  
Polyphagia and polydipsia with concomitant reduction of body weight are major symptoms of diabetes 
























































parameters are usually dependent on energy expenditure, urinary excretion and catabolic processes among 
others.  Treatment with the fraction did not completely reverse the T2D-induced polyphagia, polydipsia 
and weight loss (Figures 4.4.1 and 4.4.2) possibly because the experimental period was short for the 
reversal of these parameters due to their dependency on other metabolic parameters.  
Fasting or postprandial hyperglycemia is a common pathogenesis of T2D which is induced by insulin 
resistance and partial pancreatic β cell destruction [68]. Effective control of the blood glucose 
concentration is a vital step in ameliorating diabetic complications and enhancing the quality of life in 
type 2 diabetic patients [69]. In the present study, oral treatment of diabetic animals with the CSAF 
resulted in a significant, consistent and dose dependent decrease in blood glucose levels throughout the 
experimental period, indicating its potent anti-diabetic activity. Furthermore, in the OGTT analysis, better 
glucose tolerance abilities were observed in the CSAF treated groups than the DBC group. These results 
could be linked to the potent -glucosidase and -amylase inhibitory activity exhibited by the fraction 
which could cause a decrease in the digestion of carbohydrates and intestinal absorption of sugar [70]. On 
the other hand, the CSAF stimulated insulin secretions and improved pancreatic β-cell function whereas 
insulin resistance was not affected. Based on the foregoing observations, it is logical to suggest that the 
mechanism of anti-T2D action of the CSAF is elicited through delaying glucose absorption, improving β 
cell function and stimulating insulin secretions rather than by increasing insulin sensitivity. Interestingly, 
the above hypothesis was further supported by the histopathological examinations of the pancreatic islets 
where CSAF groups had more as well as healthier pancreatic islets than the DBC group. The CSAF was 
found to have high in vitro anti-oxidative activity (data not shown) and thus, we speculated that the 
protection of the pancreatic islets could be mediated through an anti-oxidative dependent mechanism 
because oxidative stress is an important biological phenomenon in the process of pancreatic β-cell 
damage in T2D [71]. The serum fructosamine level is a measure of early protein glycation which is 
formed by the covalent binding of glucose to serum proteins via a non-enzymatic glycation reaction [72, 
73]. It predicts the overall metabolic control of diabetes over the preceding 2–3 weeks. Although, the 
result was not significant, CSAF treatments tended to ameliorate the T2D-induced elevation in serum 
fructosamine level especially in the DCH group. 
Previous studies reported contradictory findings on the effect of diabetes on liver weights. Some workers 
have shown an increase in hepatic weight in animals as well as humans while others have reported no 
change [74]. Our findings revealed that relative but not absolute liver weights were elevated by the 
disease and was not significantly reversed by the treatments. Hepatic glycogenesis is associated with 
extracellular glucose concentration and insulin availability. In vivo glycogen metabolism is regulated by a 
multifunctional enzyme glycogen synthase and glycogen phosphorylase [75]. Reduced hepatic glycogen 
reserve in diabetic animals has been attributed to reduced glycogen synthase activity and increased 
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glycogen phosphorylase activity. Thus, the ability of the CSAF to restore the depleted glycogen reserves 
in diabetic animals could indicate that the fraction also decreases the activity of glycogen phosphorylase 
and/or increases glycogen synthase activity. This could further suggest that the fraction not only acts as 
insulin secretagogue but also by inhibiting hepatic glycogenolysis thereby reducing an upsurge in blood 
glucose concentrations. 
Profound changes in the serum lipid and lipoprotein profile with an increased risk in cardiovascular 
diseases is associated with T2D. Hyperlipidemia is a well-known complication in diabetic patients 
characterized by increased cholesterol and triglycerides levels as well as changes in lipoprotein 
composition [76]. This hyperlipidemia is mainly as a result of uncontrolled actions of lipolytic hormones 
on the fat depots that arise from the impairment of insulin secretions in the diabetic state. In our study, 
serum total and LDL-cholesterols were relatively elevated but triglycerides were significantly increased in 
the untreated diabetic rats. Interestingly, the CSAF treated diabetic groups had relatively lower serum 
lipid concentrations than the untreated control for these lipid parameters. This observation is possibly 
linked to the stimulation of insulin secretion by the fraction which could modulate the actions of the 
lipolytic hormones in fat reserves.  
The serum levels of ALT and ALP but not AST were significantly increased in the untreated diabetic 
animals indicating impaired liver function, which is obviously due to hepatocellular necrosis. Diabetic  
complications  such  as  increased  ketogenesis and gluconeogenesis  may  be  due to elevated  
aminotransferase activities  [77]. Therefore, restoration of these biomarker enzymes towards normal level 
indicates decreased diabetic complications in the CSAF treated groups. Furthermore, the fraction reversed 
the T2D-induced increase in serum urea level which could suggest decreased renal impairments 
associated with diabetic complications. Apart from assessing renal damage, creatinine was reported to be 
a predictor for T2D and insulin resistance [78]. Creatinine is a product of creatine metabolism which 
mostly occur in skeletal muscle, the major center for the action of insulin and subsequent glucose 
disposal. Muscle mass has been proposed to inversely correlate with insulin resistance but directly 
correlate to serum creatinine. Thus, the serum creatinine could be a reliable marker to assess insulin 
resistance [78]. Thus, previous studies have demonstrated lower serum creatinine level in T2D human 
subjects compared to normal individuals [78, 79] which corroborates with our findings. It is thus possible 
to suggest that the insignificant decrease in the insulin resistance (HOMA-IR) of DCL and DCH groups 
compared to the DBC group also led to an insignificant elevation in the serum creatinine levels in these 
groups.  
In order to investigate the possible bioactive compounds that might play a role in eliciting the above-
mentioned anti-diabetic activity of CSAF, we isolated 3β-O-acetyl betulinic acid and subjected it to in 
vitro -glucosidase and -amylase inhibitory assays. Results from the studies indicated that 3β-O-acetyl 
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betulinic acid isolated from CSAF is a potent inhibitor of -glucosidase and -amylase which is mediated 
through non-competitive patterns for both enzymes. This indicates that 3β-O-acetyl betulinic acid binds 
-glucosidase and -amylase at separate site(s) of the enzyme (rather than the active sites) but caused 
conformational modification at the active sites thereby preventing effective binding of the substrates. This 
type of inhibition could further suggest that the compound could interact with the enzyme-substrate 
complexes [57]. 
In summary, data from the study suggest that the acetone fraction of the stem bark of C. singueana has a 
strong potent anti-T2D activity which could also ameliorate other diabetes-related complications. The 
mechanism of action is mediated through inhibition of carbohydrate-hydrolysing enzymes, modulation of 
β-cell function and stimulation of insulin secretions while 3β-O-acetyl betulinic acid is a possible 
bioactive anti-T2D agent in the fraction.  
. 
Postscript: In order to further explore the possible mechanism of anti-diabetic action of the fraction, the 
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Preface: This article describes the in vivo anti-oxidative status of the serum and organs collected from the 
rats in the above experiment.  
 
4.5.1. Abstract 
The effects of oral administration of the acetone fraction derived from the ethyl acetate extract of Cassia 
singueana stem bark (CSAF) on the oxidative stress parameters of the serum and organs of type 2 
diabetic rats were investigated. Type 2 diabetes was found to induce oxidative stress in the serum, liver, 
kidney, heart and pancreas as evidenced by the significant (P<0.05) increase in the levels of thiobarbituric 
acid reactive substances (TBARS) and significant (P<0.05) decreases in the levels of glutathione, 
superoxide dismutase (SOD) and catalase. However, treatment with CSAF ameliorated T2D-changes in 
all these parameters for the serum and organs under investigation. The effects of the CSAF on this 
parameters was dose dependent as treatment with a high dose of 300 mg/kg bw recorded a significant 
(P<0.05) effect for all the parameters except the TBARS level of the heart whereas low dose (150 mg/kg 
bw) treatment achieved less potent effects. It was concluded that the CSAF contains phytochemicals that 
could modulate oxidative stress in type 2 diabetic rats. 
 
4.5.2. Introduction 
Reactive oxygen species are products of aerobic metabolism which are continuously produced under 
normal metabolic conditions but become deleterious when overproduced or the enzymatic and non-
enzymatic anti-oxidative defense system is attenuated leading to a process called oxidative stress [80]. 
Chronic hyperglycemia is a hallmark in the pathophysiology of diabetes mellitus and is implicated as a 
vital contributory factor in the initiation and progression of most of the secondary complications 
associated with the disease [62]. In type 2 diabetes (T2D), hyperglycemia induces oxidative stress via 
multiple pathways which include glucose autooxidation, increased metabolic flux of the polyol (sorbitol) 
pathway, activation of protein kinase C, increased generation of advanced glycation end products, 
activation of protein kinase C and increased hexosamine pathway flux [40, 81]. The oxidative stress is 
thus considered as an important unifying mechanism that plays major roles in all aspects of T2D 
pathology that include pancreatic β cell dysfunction, microvascular and macrovascular complications [39, 
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40, 82]. Thus, anti-oxidative agents, which are able to modulate the hyperglycemia-induced oxidative 
stress, are beneficial, and anti-diabetic drugs with anti-oxidative potential would certainly have a higher 
therapeutic value. 
Cassia singueana Delile, also known as golden shower, is a member of the family Caesalpiniaceae and is 
commonly used by African traditional medical practitioners to treat several diseases [1]. In northern 
Nigeria, the plant is commonly exploited for the traditional management of diabetes mellitus [3] as well 
as bathes nursing mothers. In a previous study, we subjected different solvent crude extracts of the stem 
bark, root and leaves of the plant to anti-oxidative activity assays using several models and reported that 
the ethyl acetate extract of the stem bark had the highest anti-oxidative activity among all other extracts 
[48]. Subsequently, we subjected the ethyl acetate extract of the stem bark to solvent-solvent fractionation 
and found the acetone fraction (among other solvent fractions) had the best in vitro α-glucosidase and α-
amylase inhibitory activities as well as significant anti-hyperglycemic and insulinotropic effects in a T2D 
model of rats (see above article 4.4.). Furthermore, the fraction was found to ameliorate most of the T2D-
induced alterations in metabolic parameters including some indices of T2D complications. It is thus 
possible that the fraction exerts its actions, wholly or in part, via an anti-oxidative dependent mechanism. 
Therefore, in the present study, the effects of the fraction on the anti-oxidative status of the serum, liver, 
kidney, heart and pancreas of type 2 diabetic rats were investigated considering the crucial role of 
oxidative stress in the progression and complications of T2D. 
4.5.3 Materials and methods 
See Chapter two sub sections 2.3-2.4 pages (34-36); 2.7.1-2.7.5 (pages 41-42); and 2.7.8 (2.7.8.1-2.7.8.4) 
pages 44-45 for details that affect C. singueana.  
4.5.4 Results 
The T2D was found to significantly (P<0.05) increase the TBARS levels and significantly decrease the 
glutathione, SOD and catalase levels in the liver, kidney, heart, pancreas and serum. However, the CSAF 
treatment ameliorated these T2D-induced changes in the liver. The ameliorative effects seem to be dose-
dependent because all the changes were significant (P<0.05) in the DCH group (Table 4.5.1).  Also, the 
CSAF treatment significantly (P<0.05) boosted the kidney level of glutathione and catalase but 
insignificantly (P>0.05) reduced the disease-induced increase in kidney TBARS level. The SOD level 
was also boosted in the kidney of the CSAF-treated diabetic rats but the effect was only significant in the 





Table 4.5.1: Effects of CSAF on hepatic lipid peroxidation and anti-oxidant status of type 2 diabetic rats 
 NC DBC DCL DCH DMF NCT 
TBARS (µM) 10.6±3.0a 33.9±4.9b 31.7±7.7b 14.8±4.1a 35.9±9.5b 16.9±3.3a 
Glutathione (µM) 120.8±6.0c 29.9±9.3a 82.6±17.6b 86.7±29.9b 73.6±10.2b 103.1±26.6bc 
SOD (nmol/min) 25.5±5.3b 12.4±1.6a 14.9±4.6ab 20.5±3.9b 17.5 ±5.2ab 23.2±7.0b 
Catalase(µmol/min) 16.5±0.9c 1.5±0.3a 6.0±1.8b 9.3±1.9b 1.7±0.6a 7.4± 5.9ab 
The results are expressed as the mean ± SD of five animals. a-cData with different alphabets along a row are 
significantly different (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Table 4.5.2: Effects of CSAF on kidney lipid peroxidation and anti-oxidant status of type 2 diabetic rats 
 NC DBC DCL DCH DMF NCT 
TBARS (µM) 14.1±5.8a 40.8±12.5b 27.1±9.9ab 21.5±6.0ab 33.4±10.0b 18.6±6.2ab 
Glutathione (µM) 68.2±20.8ab 46.0±8.6a 92.7±23.1b 69.9± 9.3b 70.8±10.4b 52.9±3.9a 
SOD (nmol/min) 16.1±3.4b 6.8±1.5a 9.2±2.7ab 11.2±2.2b 11.5±4.4ab 16.7±5.8b 
Catalase (µmol/min) 1.7±0.3b  0.9±0.2a 1.8±0.6b 2.2±0.5b 1.6±0.4b 1.4±0.8ab 
The results are expressed as the mean ± SD of five animals. a-cData with different alphabets along a row are 
significantly different (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The data for the effects of the CSAF treatment on the heart oxidative stress parameters of type 2 diabetic 
rats also indicated that the treatment significantly (P<0.05) ameliorated the T2D-induced changes in heart 
TBARS level as well as glutathione and SOD levels. The catalase level of the heart was boosted 
compared to the DBC group but the effect was only significant (P<0.05) in the DCH group (Table 4.5.3).  
Table 4.5.3: Effects of CSAF on lipid peroxidation and anti-oxidant status in the heart of type 2 diabetic 
rats 
 NC DBC DCL DCH DMF NCT 
TBARS (µM) 9.4±2.6a 24.6±8.8b 24.2±7.7b 20.7±7.4b 33.9±5.9b 9.1±4.6ab 
Glutathione (µM) 122.2±22.0c 48.6±14.6a 77.3±13.4b 70.1±2.8b 79.2±18.3ab 109.9±5.9c 
SOD (nmol/min)  15.2±4.0b 5.8±1.2a 10.2±2.6b 10.5±2.0b 12.8±2.0b 13.5±3.6b 
Catalase(µmol/min) 2.1±0.5b 0.9±0.2a 1.4±0.6ab 1.8±0.4b 1.4±0.4ab 1.9±0.5b 
The results are expressed as the mean ± SD of five animals. a-cData with different alphabets along a row are 
significantly different (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The pancreatic levels of SOD and catalase were also significantly (P<0.05) higher in the DCL and DCH 
groups than the DBC group but the pancreatic glutathione level was significantly (P<0.05) higher in the 




Table 4.5.4: Effects of CSAF on pancreatic lipid peroxidation and anti-oxidant status of type 2 diabetic 
rats  
 NC DBC DCL DCH DMF NCT 
TBARS (µM) 6.0±1.2a 35.7±9.1c 24.3±6.3bc 16.2±3.8b 18.4±4.4b 10.1±4.2ab 
Glutathione (µM) 80.0±8.1d 6.2±3.5a 7.5±1.2a 22.9±7.9b 37.3±8.6bc 43.9±11.2c 
SOD(nmol/min) 2.6± 0.5c 0.4± 0.2a 0.8±0.2b 1.2±0.4bc 1.0±0.5bc 2.0±0.7c 
Catalase (µmol/min) 0.7±0.2b 0.35±0.04a 0.81±0.29b 0.9±0.2b 1.11±0.2b 0.9±0.3b 
The results are expressed as the mean ± SD of five animals. a-cData with different alphabets along a row 
are significantly different (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Table 4.5.5 presents the modulatory effects of the CSAF treatment on the serum oxidative stress 
parameters of type 2 diabetic rats. Although the CSAF treatment was able to prevent the T2D-induced 
changes in all the parameters but significant results were only observed for glutathione and SOD levels in 
both DCL and DCH groups. The T2D-induced changes in TBARS and catalase levels were significantly 
(P<0.05) reversed in the DCH group only. 
Table 4.5.5: Effects of CSAF on serum lipid peroxidation and anti-oxidant status of type 2 diabetic rats 
 NC DBC DCL DCH DMF NCT 
TBARS (µM) 63.0±15.2a  201.2±19.4c 138.1±48.2bc 134.4±26.4b 142.0±32.0b 66.3±22.7a 
Glutathione (µM) 84.5±7.7e 19.9±2.5a 30.7±7.2b 42.3±10.7bc 65.2±6.8d 54.1±3.8c 
SOD (nmol/min) 18.1±2.4d 0.9± 0.2a 2.1±0.7b 4.3±0.5c 3.2±0.7bc 12.1±3.4d 
Catalase (µmol/min) 3.6±0.8c 1.5±0.4a 1.9±0.4ab 2.9±0.8b 2.4±0.5b 3.1±0.6bc 
The results are expressed as the mean ± SD of five animals. a-dData with different alphabets along a row 
are significantly different (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
4.5.5 Discussion 
The anti-oxidative status of the serum and the various organs of the CSAF treated diabetic rats were 
investigated to determine, whether or not, the anti-diabetic effects of the fraction in various organs was 
elicited through an anti-oxidative-related phenomenon.  
Insulin resistance and hepatic and renal damages are established features of T2D and were linked to the 
induction of oxidative stress during the disease [41, 83]. The CSAF treatment was able to reduce the 
degree of insulin resistance and the organs damages (see manuscript 4.4 above) as well as alleviate the 
T2D-induced oxidative stress in these organs. Based  on the above statements, it is logical to deduce, 
although without a correlation analysis, that the effects of the CSAF on the insulin resistance and liver 
and kidney damages is related  to the modulatory effects of the fraction on the anti-oxidant status.   
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Cardiomyopathy and other cardiovascular complications associated with T2D are common secondary 
diabetic complications that are linked to oxidative stress in numerous studies [84, 85]. Therefore, agents 
that could impede the oxidative stress process in the heart during diabetes would ultimately be beneficial 
to the patients. Interestingly, the CSAF treatment was able to boost the anti-oxidative status in the heart, 
suggesting its beneficial effects. This could, perhaps, explain our observation on the ability of the CSAF 
to maintain the weight of the heart to near-normal (data not shown) despite the decrease in the heart 
weight caused by the diabetes (data not shown). 
The observed effects of CSAF on the pancreatic anti-oxidative parameters suggest that the fraction 
protected the pancreas from oxidative attack which consequently leads to an improvement in the function 
of the pancreas and the β-cells.  This is evident by the higher serum insulin concentrations, improved β 
cell function and higher number of β-cells recorded in the CSAF treated diabetic rats in comparison to the 
diabetic control. Thus, considering the crucial role of oxidative stress in the pathogenesis of pancreatic β 
cell dysfunction, it is possible to surmise that CSAF acts via an anti-oxidative dependent mechanism to 
prevent pancreatic β cell dysfunction and consequently improved the diabetic condition.  
Taken the findings of this study as a whole, it is evident that CSAF could modulate the anti-oxidative 
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5.0 THE ANTI-OXIDATIVE AND ANTI-DIABETIC ACTIVITIES OF 
Parkia biglobosa IN VITRO AND IN VIVO  
5.1.1 Parkia biglobosa A. Jacq (Mimosaceae) 
 
Figure 5.1: Parkia biglobosa A. Jacq (Mimosaceae); common names: African locust bean tree (English); 
Dorawa (Hausa, Nigeria); Caoubier African (French); Narehi (Fulani, Nigeria); Mkunde (Swahili, 
Tanzania). Photo: Mohammed Auwal Ibrahim (2013), Zaria, Nigeria 
5.1.2 Background 
It is a medium sized tree that make up to 20-30 m height with spreading branches that are usually gnarled. 
It has thick bark which is usually charred. The leaves are bi-pinnate (up to 36 cm long) with 6-11 pairs of 
pinnae. The plant produces flowers of about 17 mm long that are well anchored to stamens as well as a 
carbohydrate-rich yellowish fruit which is commonly consumed. The seeds are embedded in yellowish 
endocarp and when fermented, they are extensively used as cooking condiment in West Africa under 
various names such as dawa dawa in Nigeria and afitin in Benin republic.  The habitat of this species lies 
between 5oN and 15oN from Senegal (west Africa) to southern Sudan (North Africa) and Uganda (East 
Africa).  
 
5.1.3 Ethnomedicinal uses 
Documented ethnobotanical survey reveals that the plant is used to treat various types of wounds, pain 
and fungal infections in Mali [1]. Also, various parts of the plant are used in the treatment of a number of 
ailments in Nigeria such as bronchitis, pneumonia, diarrhea, sores and ulcers [2]. Reports from Ghana 
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reveal that the medicinal uses of the plant include toothache, rheumatism, schistosomiasis, leprosy, fever, 
burns and skin infections [3]. In an investigation from Burkina faso, the stem bark is successfully used in 
the treatment of jaundice, amoebiasis, cough, conjunctivitis and dermatosis in addition to most of the 
other ailments listed in other reports [4]. Moreover, rural villagers from the Oio region of Guinea Bissau 
reported that the smoke of the seed capsules of the plant is effective as mosquito repellant [5]. More 
relevant to this dissertation, ethnopharmacological surveys have indicated that the plant is exploited in the 
treatment of diabetes mellitus in northern Nigeria [6] and central region of Togo [7].  
 
5.1.4 Biological activities 
The most highly investigated biological activity of different parts of P. biglobosa is antibacterial activity 
using different bacteria species. Millogo-Kone et al. [4] studied the activity of extracts from the stem bark 
of the plant against three species of Shigellae isolated from hospitals in Burkina Faso and found that the 
hydroalcoholic extract was more active than aqueous extract particularly against S. dysenteriae. In a 
subsequent comparative study, the same research group further reported that the hydroalcoholic extract of 
the stem bark is more effective than extracts from the leaf against clinical isolates of enterobacteria [8]. In 
another study, aqueous extract of the root was reported to have a broader spectrum of antibacterial 
activity than corresponding extracts from other parts [2]. In a more recent study from South Africa, 
solvent fractions prepared from the crude methanolic extract of the stem bark was reported to possess 
antimicrobial properties which favourably compared with those of streptomycin [9]. The antivenom 
activity of the hydroalcoholic extract of the stem bark has also been investigated where it was found to 
inhibit the pathological effects of N. nigricolis venom as well as protected mice from death caused by E. 
ocellatus venom [10]. Preliminary analgesic and anti-inflammatory activities of stem bark extracts was 
investigated where the hexane extract was found to possess marked analgesic activity in an abdominal 
writhing test in mice [11]. In an effort to validate the anti-diarrhoeal activity of some plants, Agunu et al. 
[12] reported 100% protection by water-methanol extract of the plant against castor-oil induced diarrhoea. 
Conversely, semi ethanolic extracts from different parts of P. biglobosa did not induce any changes in 
corticosteroid secretion in rat [13]. The wound healing potentials of the plant was also validated [14] 
where the stem bark extracts of the plant were found to promote in vitro wound healing via stimulation of 
fibroblasts. Despite the extensive use of the leaves of this plant in traditional medicine, the only 
comprehensive investigation performed on this part is its antihypertensive properties of the procyanidin-
rich fraction which was reported to cause redox-sensitive endothelium-dependent relaxation involving 
NO and EDHF in porcine coronary artery [15]. The fermented seed extracts were also investigated for 
pharmacological activities. For example, Odetola et al. [16] demonstrated the preliminary hypoglycemic 







Most reports on the phytochemistry of P. biglobosa involves preliminary phytochemical screening where 
alkaloids, tannins, flavonoids, saponins, steroids and glycosides were reported in different extracts 
derived from the plant [2, 9, 17]. The only detailed phytochemistry study performed on the plant  reported 
the isolation of lupeol, 4-O-methyl-epi-gallocatechin, epi-gallocatechin, epi-catechin 3-O-gallate, long 
chain ester of trans-ferulic acid as well as an unsaparable mixture of long chain cis-ferulates [18].  
 
This study is aimed to comprehensively investigate the anti-diabetic activity of this plant using in vitro 
and in vivo models. To accomplish this, various solvent crude extracts of the stem bark, root and leaves of 
the plant were subjected to detailed in vitro anti-oxidative studies (using four models) from where the 
ethanolic extract of the leaves was found to have the best activity. Subsequently, the ethanolic extract of 
the leaves was fractionated across various solvents and the fractions were subjected to the anti-oxidative 
as well as -glucosidase and -amylase inhibitory studies where the butanol fraction was found to have 
the best anti-oxidative and enzymes inhibitory activities. Thus, the butanol fraction was investigated for in 
vivo anti-diabetic activity in type 2 diabetes rats model as well as the possible mechanism of action. A 













5.2 In vitro anti-oxidative activities of the various parts of Parkia biglobosa 
and GC-MS analysis of extracts with high activity  
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Preface: As the first preliminary study, the in vitro anti-oxidative activities of the crude solvents extracts 
from the stem bark, root and leaves of the plant were investigated in this article. The article has been 
published in the journal ‘’African Journal of Traditional, Complementary and Alternative Medicine’’ 
2013, Vol. 10 issue 5, page 283-291. 
 
5.2.1 Abstract  
The anti-oxidative activities of sequentially extracted solvent fractions of different parts of P. biglobosa 
were investigated using four complementary in vitro assays. Our findings indicated that all extracts had 
electron donating and free radical scavenging activities but the ethanol (EtOH) extracts from all the parts 
demonstrated more promising anti-oxidative effects in these experimental models. Apart from the 
aqueous extracts of the stem bark and leaves, all other extracts exhibited hydroxyl radical scavenging 
(HRS) activity but the stem bark ethyl acetate (EtOAc) extract and EtOH extracts of the root and leaves 
possessed more powerful HRS activity than other corresponding extracts in the parts. Further, nitric oxide 
(NO) inhibition activities were observed in all the extracts except the EtOAc extract of the stem bark 
which showed pro-oxidative activity. However, the EtOH extract of the stem bark and root as well as the 
EtOAc extract of the leaves displayed more potent anti-NO activity than other extracts in the parts. The 
GC-MS analysis of the EtOH extracts revealed that the most abundant phytochemicals are pyrogallol 
derivatives. Data from this study suggest that the EtOH extracts from different parts of P. biglobosa 
contained potent anti-oxidative agents and pyrogallol could be the main bioactive constituent.  
 
5.2.2 Introduction 
Reactive oxygen species (ROS) and free radicals are generated via normal biochemical and physiological 
processes in living system and are quenched by a cascade of endogenous antioxidant systems in the body 
[19]. Excess generation of such free radicals and/or inactivation of the endogenous anti-oxidative systems 
usually shift the ROS/antioxidants balance in favor of stress, a phenomenon called oxidative stress (OS) 
[20]. The OS is implicated as a crucial factor in the pathogenesis of a number of diseases which include 
hypertension, cardiovascular diseases, diabetes mellitus and other metabolic syndromes [21]. 
 
The application of medicinal plant resources for the management of various diseases continues to be an 
important component of the health care delivery system, especially in Africa where more than 5400 
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medicinal plants were reported to have over 16,300 medicinal uses [22]. The role of these medicinal 
plants on drug discovery is impressive because most of the currently available clinically active drugs are 
either directly discovered from natural products or have a natural product pharmacophore [23].   
 
Parkia biglobosa (Jacq.) Benth. (Mimosaceae), commonly known as the African locust bean tree, is 
native to Nigeria alongside other West African countries. The fermented seeds are well appreciated as 
condiments in cooking under various names such as ‘dawadawa’ in Nigeria. All of the different parts of 
this plant are used by traditional healers to cure several metabolic or non-metabolic disorders like 
hypertension, haemorrhages and dermatosis [2,15]. A recent ethnopharmacological survey in northern 
Nigeria also revealed that the stem bark part of the plant was among the most commonly used plants for 
the traditional healing of diabetes mellitus [6]. The analgesic and anti-inflammatory [11], antivenom [10], 
antidiarrhoeal [12], antibacterial [8], vasorelaxant [15], and wound healing [14] activities of extracts from 
different parts of this plant have been demonstrated. Furthermore, the fermented seed extract was also 
reported to possess hypoglycemic activity in a type 1 diabetes model of rats [16].  Although several 
studies were investigated to examine the above-mentioned effects of this plant, however the anti-oxidative 
effects have not been examined either in vitro or in vivo despite its extensive use for the treatment of 
diabetes mellitus, an OS associated metabolic disorder. 
Hence, our present study was firstly designed to conduct a comprehensive investigation on the anti-
oxidative effects of the various solvent extracts of the stem bark, root and leaves of this plant with a view 
to find compound(s) that could be used to ameliorate the OS mediated metabolic disorders. Based on the 
results of anti-oxidative activities, the most promising anti-oxidative extracts were subjected to GC-MS 
analysis in order to identify the phytochemicals contained therein. 
 
5.2.3 Materials and methods 
Please refer to the chapter 2 sub sections 2.3 – 2.5 page 35-38 for detailed material and method that affect 
P. biglobosa 
 
5.2.4 Results  
Higher yields of EtOAc and EtOH extracts were obtained from the leaves in comparison to the stem bark 
and roots, however the aqueous extract from the stem bark had the highest yield among the different plant 
parts. The EtOH extracts contained a significantly (P<0.05) higher amount of total polyphenols than other 






Table 5.2.1: Percentage yield and total polyphenol content of various solvent extracts of P. biglobosa 
parts 
 
The results are expressed as mean ± SD of triplicate determinations. a-hDifferent superscript alphabets within a 
column indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The EtOH extracts of the stem bark and leaves had significantly higher (P<0.05) total reducing power 
(GAE) than trolox and other solvents extracts in these parts at all concentrations. The EtOH extracts of 
the stem bark and leaves also had significantly higher (P<0.05) total reducing power than ascorbic acid at 
most concentrations tested. Extracts obtained from the root demonstrated weaker reducing power that 













Samples % Yield Total polyphenol 
(mg/g GAE) 
   
Stem bark   
EtOAc 0.74 57.76 ± 0.88e 
EtOH 4.80 114.77 ± 0.99g 
Aqueous 3.98 50.96 ± 0.37d 
   
Root   
EtOAc 0.17 0.47 ± 0.04a 
EtOH 0.15 168.98 ± 11.32h 
Aqueous 1.55 8.95 ± 0.78b 
   
Leaves   
EtOAc 1.54 32.41 ± 0.17c 
EtOH 4.95 84.57 ± 1.06f 
Aqueous 3.32 31.37 ± 0.65c 
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15  30 60 120 240 
Stem bark      
EtOAc 2.89 ± 0.95b 30.98 ± 1.11e 22.44 ± 1.14e 40.66 ± 1.33f 70.42 ± 4.68f 
EtOH 44.11 ± 1.30g 45.60 ± 2.45f 39.65 ± 1.33g 61.71 ± 1.14h 108.76 ± 9.07i 
Aqueous 27.69 ± 3.39f 23.93 ± 4.54d 25.88 ± 0.88ef 51.63 ± 5.69g 77.11 ±1.00g 
      
Root      
EtOAc 0.00 ± 0.00a 0.11 ± 0.01a 0.70 ± 0.24a 1.64 ± 0.17a 2.99 ± 0.46a 
EtOH 5.55 ± 1.12c 4.35 ± 2.66b 4.92 ± 0.45b 11.87 ± 2.39c 16.27 ± 1.05b 
Aqueous 5.15 ± 2.02c 7.38 ± 0.20c 3.94 ± 0.63b 5.98 ± 1.80b 15.79 ± 1.10b 
      
Leaves      
EtOAc 3.30 ± 1.12bc 5.60 ± 1.50bc 7.73 ± 0.55c 15.42 ± 0.65d 25.01 ± 0.38c 
EtOH 29.59 ± 6.45f 44.50 ± 6.38f 36.79 ± 2.82g 68.25 ± 3.39i 94.82 ± 0.85h 
Aqueous 11.74 ± 3.01d 15.79 ± 1.01d 15.59 ± 1.31d 25.70 ± 3.02e 48.36 ± 3.29d 
      
Ascorbic acid 31.50 ± 4.92f 32.66 ± 3.00e 35.62 ± 5.51g 52.56 ± 5.43g 89.95 ± 6.21h 
Trolox 17.84 ± 1.86e 20.88 ± 7.33d 24.42 ± 3.95ef 29.61 ± 1.96e 52.77 ± 0.90e 
The results are expressed as mean ± SD values of triplicate determinations. a-iDifferent superscript alphabets within 
a column indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The scavenging effects of the different solvent extracts of P. biglobosa parts on DPPH radical are 
presented in Figure 5.2.1. While all the extracts demonstrated the ability to scavenge DPPH radicals as 
manifested by the concentration-dependent increase in the percentage inhibitions, the EtOH extracts of 
the stem bark and root displayed significantly higher (P<0.05) radical scavenging activity than other 
extracts within these parts at higher concentrations (60-240 µg/ml) and the difference insignificant 
(P>0.05) compared to the standard antioxidants in some cases. Interestingly, the EtOH extract of the 
leaves extract maintained >90% free radical scavenging activity at 30-240 µg/ml. It is important to note 
that the IC50 values of the aqueous extracts of the root and leaves and the EtOH extract of the stem bark 






Figure 5.2.1: DPPH radical scavenging activity of stem bark (A), root (B) and leaves (C) extracts of P. 
biglobosa. The results are expressed as mean ± SD of triplicate determinations. a-eDifferent alphabets over 
the ars on a given concentration of each extract indicate significant difference (Tukey’s-HSD multiple 
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The results of the HRS assay indicated that all extracts could scavenge hydroxyl radicals generated by 
Fenton’s reaction except the aqueous extracts of the stem bark and leaves which displayed pro-oxidative 
tendencies at all concentrations tested (Table 5.2.3). Although all organic extracts obtained from the stem 
bark and root exhibited a non-concentration dependent pattern of HRS activity, the EtOAc and EtOH 
extracts of the stem bark displayed significantly higher (P<0.05) activity at 15-60 µg/ml and 120-240 
µg/ml respectively, than other extracts. It is also noteworthy that the EtOH extract of the root consistently 
demonstrated a significantly higher (P<0.05) HRS activity than other extracts in this part. Contrary to 
this, the EtOAc extract of the leaves displayed a significantly higher (P<0.05) hydroxyl radical inhibition 
than other extracts in this part at all concentrations and an activity that inversely correlates with 
concentration was observed with the EtOH extract of the leaves. 





15  30 60 120 240 
Stem bark      
EtOAc 20.93 ± 0.85f 39.10 ± 0.68e 19.30 ± 1.48d 8.71 ± 0.40c -5.57 ± 0.37b 
EtOH 0.00 ± 0.00c 10.31 ± 5.49c 17.38 ± 3.00d 33.79 ± 7.69e 28.10 ± 11.80e 
Aqueous -33.31 ± 0.97b -51.73 ± 3.25b -69.62 ± 2.00a -100.00 ± 0.00a -100.00 ±0.00a 
      
Root      
EtOAc 0.80 ± 0.07d 12.39 ± 3.07c 9.76 ± 1.07c 24.61 ± 1.37d,e 22.39 ± 1.96d,e 
EtOH 46.00 ± 2.86h 48.82 ± 2.73f 51.41 ± 1.01f 44.79 ± 0.78f 38.63 ± 0.39e,f 
Aqueous 19.07 ± 0.28e 27.87 ± 0.74d 26.67 ± 0.96e 30.75 ± 1.34e 28.40±2.90e 
      
Leaves      
EtOAc 64.69 ± 1.57j  68.62 ±14.25g 78.81 ± 0.81g 85.02 ± 0.27h 88.63 ± 0.70g 
EtOH 29.00 ± 1.32g 15.32 ± 0.31c 7.98 ± 0.57b 1.88 ± 0.23b 1.06 ± 0.23c 
Aqueous -41.26 ± 1.25a -60.90 ± 3.39a -81.80 ± 13.10a -100.00 ± 0.00a -100.00 ± 0.00a 
      
Trolox 57.32 ± 2.95i 73.11 ± 1.44g 76.04 ± 2.05g 80.09 ± 3.93g 79.82 ± 3.50h 
The results are expressed as mean ± SD values of triplicate determinations. a-iDifferent superscript alphabets for 
values within a column indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Table 5.2.4 presents the NO inhibition activities of solvents extracts of P. biglobosa parts.  Apart from 
the EtOAc extract of the stem bark, all other extracts were found to exhibit NO inhibition activity. The 
aqueous and EtOH extracts of the stem bark and root as well as the EtOAc and aqueous extracts of the 
leaves demonstrated a non-concentration dependent NO inhibition effects while the EtOH extract of the 
leaves showed an NO inhibition activity which inversely correlates with concentration. Furthermore, the 
EtOH extracts of the stem bark and root as well as the EtOAc extract of the leaves possessed lower IC50 




Table 5.2.4: Percentage NO scavenging activities of extracts from various parts P. biglobosa 
Extracts Concentration (µg/ml) 
15  30 60 120 240 
Stem bark      
EtOAc -24.74 ± 2..31a -47.96 ± 1.53a -47.96 ± 16.07a -100.00 ± 0.00a -100.00 ± 0.00a 
EtOH 55.47 ± 7.54g 50.78 ± 3.67f 31.60 ± 9.42e 36.91 ± 8.00c 43.45 ± 1.82e 
Aqueous 10.73 ± 0.72d 18.53 ±0.69d 33.40 ± 1.33e 32.22 ± 5.05c 22.51 ± 1.14b 
      
Root      
EtOAc 0.00 ± 0.00b 0.00 ± 0.00b 0.00 ± 0.00b 14.57 ± 7.66b 24.71 ± 2.93b,c 
EtOH 34.39 ± 2.45f 49.67 ± 0.85f 48.73 ± 0.88e,f 39.55 ± 1.62c,d  29.08 ± 0.73d 
Aqueous 28.92 ± 1.78e 32.36 ± 0.65e 14.61 ± 2.20c 20.20 ± 6.75b 38.49 ± 6.05e 
      
Leaves      
EtOAc 61.06 ± 4.96g,h 63.54 ± 6.89g 62.74 ± 14.33f,g,h 42.53 ± 9.34c,d,f 60.51 ± 2.86g 
EtOH 73.45 ± 1.98i 64.88 ± 7.31g  65.19 ± 3.97h  15.03 ± 6.28b 18.02 ± 3.29b 
Aqueous 15.19 ± 7.08d 32.45 ± 1.23e 41.30 ± 7.71e 51.67 ± 3.82f 39.36 ± 4.67e 
      
Ascorbic acid 47.81 ± 0.51g 50.97 ± 1.35f 52.82 ± 1.35g 56.72 ± 3.69f,g 64.08 ± 4.25g 
Gallic acid 4.43 ± 2.69c 7.52 ± 1.11c 25.74 ± 0.44d,e 27.66 ± 1.91b,c 31.70 ± 2.51d 
Trolox 66.30 ± 1.23h 65.51 ± 1.27g 63.39 ± 1.84h 59.53 ± 1.81g 52.21 ± 2.47f 
The results are expressed as mean ± SD values of triplicate determinations. a-iDifferent superscript alphabets for 
values within a column indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
















ND means not determined and P means the extract showed pro-oxidative properties in the experimental 




DPPH HRS NO 
Stem bark    
EtOAc 24.43 3.63 P 
EtOH 1.37 979.22 18.29 
Aqueous 22.34 P 8.69* 
    
Root    
EtOAc 177.39 52.79 5.71* 
EtOH 34.78 13.21 2.36 
Aqueous 7.60 118.16* >1** 
    
Leaves    
EtOAc 51.69 3.13 4.64 
EtOH 4.26 1.18 52.54 
Aqueous 1.83 P 252.43 
    
Ascorbic acid 2.56 ND 26.28 
Gallic acid 1.27 ND 1.03 
Trolox 5.04 2.61 599.21 
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Based on the anti-oxidative activities, the EtOH extracts were selected for GC-MS analysis (Figure 
5.2.2). The major peak detected in the chromatogram of the EtOH extracts of the stem bark and root were 
due to those of a 1,2,3-trioxygenated benzene compound (pyragallol) with a hydroxy, methoxy and 
acetoxy group at each of the oxygenated positions, while an additional phloroglucinol derivative with the 
same substituents as well as an alloside of the pyrogallol derivative and two sugars, 3-O-methyl-D-
fructose and 4-O-methyl-mannose were detected in the EtOH extract of the leaves (Table 5.2.6). The 
exact pyrogallol and phloroglucinol derivatives were not detected by the library of the instrument. 
Nevertheless, a parent ion at M+ 182 is evident in the mass spectrum as well as fragments at m/z 167 and 
125 for the loss of the methyl group and the loss of the methyl and acyl groups respectively.  The 
resultant fragmentation pattern at m/z 125 and below is consistent with that of pyrogallol and therefore the 


















Stem bark    
Pyrogallol derivative (acetoxy, hydroxyl and methoxy 
substituents) 
9.76 182 100 
    
Root    
Pyrogallol derivative (acetoxy, hydroxyl and methoxy 
substituents) 
9.73 182 100 
    
Leaves    
Pyrogallol derivative (acetoxy, hydroxyl and methoxy 
substituents) 
9.76 182 52.27 
*Pyragallol derivative - alloside  11.36 ND 3.19 
Phloroglucinol derivative 12.54 182 0.46 
3-O-methyl-D-fructose 13.78 194.18 25.33 
4-O-methyl mannose 13.92 194.18 6.92 
* The molecular ion was not detected but the fragmentation pattern is indicative of the compound. 
5.2.5 Discussion 
The genus Parkia comprises of over 70 species across the world but only a preliminary report on the 
antioxidant activity of a single plant (P. speciosa) from the genus appears in the literature [24]. 
Ethnobotanical surveys have indicated that different parts of P. biglobosa are used in the traditional 
treatment of diabetes mellitus and other diseases whose pathogeneses are, in part, linked to OS. This 
study investigated the anti-oxidative activities of various solvent extracts from different parts of P. 
biglobosa as a prelude to finding agent(s) that could be used to ameliorate OS mediated metabolic 
disorders.  
 
In the present study, four experimental models for in vitro anti-oxidative studies were used because a 
single model cannot give a full evaluation of the anti-oxidative capabilities of the different extracts tested 
due to the multiple mechanisms via which antioxidant compounds act. The total reducing ability of the 
extracts was measured as Fe3+–Fe2+ transformation using the procedure of Oyaizu [25]. Thus, the 
reducing power of an extract or compound could be a vital marker of its potential anti-oxidative activity 
and therefore the FRAP method is a viable procedure to investigate the anti-oxidative activity of different 
extracts and/or compounds. The strong reducing capacity of the stem bark and leaves EtOH extracts 
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indicate that the phytochemical components of this plant with high redox potential, at least in these parts, 
are EtOH extractable. 
 
The DPPH radical is a nitrogen-containing free radical which undergoes reduction through electron or 
hydrogen donation and changes color from violet to yellow. Agents which can undergo this reaction are 
considered as free radical scavengers and antioxidants [26]. The high DPPH radical scavenging effects of 
the different solvent extracts, especially the EtOH extracts that were comparable to standard antioxidants 
used in most cases, suggest that these extracts possess high proton donating ability which could make 
then free radical inhibitors. However, the EtOH extracts of the stem bark and leaves as well as the 
aqueous extracts of the leaves exhibited stronger DPPH radicals quenching ability with lower IC50 values 
than trolox. The computed IC50 values for the EtOH extract of the stem bark (1.37 µg/ml) and aqueous 
extract of the leaves (1.83 µg/ml) is especially remarkable because only a few authors [27] reported such 
low IC50 values as found with these extracts in spite of hundreds of reports on the DPPH radical 
scavenging effects of extracts from plants in various continents of the world. This could further indicate 
that these extracts contain powerful free radical scavenging phytochemicals that might have the ability to 
inhibit free radical upsurge as well as OS and therefore might be valuable as curative or preventing agents 
for the treatment diseases associated with radicals.  
 
The hydroxyl radicals are highly potent reactive free radicals generated in living organisms and have been 
implicated as detrimental species that can cause damage to all life essential biomolecules [28]. Thus, 
agents with excellent scavenging effects toward hydroxyl radicals would be important in treating diseases 
where OS is important for the disease initiation and/or progression. From the present study, all organic 
extracts from the various parts of P. biglobosa contain phytochemicals with hydroxyl radical inhibition 
activity but the activity is more pronounced in the EtOH extracts except in that of the stem bark. The non-
concentration dependent pattern of HRS activity displayed by the organic extracts of the stem bark and 
root as well as the reciprocal activity by the EtOH extract of the leaves could be attributed to a hormesis 
phenomenon by these extracts in this experimental model. Hormesis is a dose-response relationship for a 
single endpoint that is associated with changes of response between high and low dosages of biological 
agents, chemicals or any other agent that could initiate a response [29] and its occurrence has been 
documented in numerous biological, toxicological and pharmacological investigations [30]. The 
foregoing therefore indicates that maximum scavenging activity towards hydroxyl radicals by these 
extracts occur at optimal points. On the other hand, the pro-oxidative activities of the aqueous extract of 
the stem bark and leaves in the hydroxyl radical based anti-oxidative model further indicated the need to 
use a multi method approach before a definite statement can be made on the anti-oxidative effects of a 




Nitric oxide is a free radical produced by macrophages, endothelial cells or neurons and has been 
associated with the regulating a number of physiological processes [31]. High concentration of NO is 
implicated in the pathology of several diseases including T2D [32]. Excess NO reacts oxygen to produce 
peroxy nitrite anions and nitrite, which serve as free radicals [33]. In the present study, the incubation of 
sodium nitroprusside leads to a time-dependent nitrite generation [34], which was scavenged by all the 
tested extracts except the EtoAc extract of the stem bark. This could be linked to the anti-NO 
phytochemicals (mostly phenolics) in the extracts which could affect the NO-oxygen reaction, thereby 
diminishing the nitrite generation. Further, the hormetic responses shown by some extracts toward 
scavenging NO indicate that the anti-NO principles have some optimal points of effective inhibition 
and/or antagonism occurs with other phytochemicals at certain concentrations.  
Polyphenols are a well-known class of secondary metabolites with anti-oxidative activities. This is mostly 
linked to their high redox abilities that play crucial role in absorbing and scavenging free radicals, 
inhibiting triplet and singlet oxygen as well as decomposing peroxides [35]. Although correlation analysis 
was not performed, our results tend to suggest strong positive correlation between the polyphenolic 
content and anti-oxidative activity because a broad view of the results indicates that the EtOH extracts 
with highest polyphenolic content within the plants demonstrated a higher anti-oxidative activity with no 
pro-oxidative activity in any of the experimental models used. Thus, these extracts were further subjected 
to direct GC-MS analysis. It is evident from the results that a pyrogallol derivative is the only 
phytochemical detected in the stem bark and root sample of the plant and could therefore be the main 
bioactive anti-oxidative agent. However, the presence of the pyrogallol derivative peaks coupled with 
other phenolics in the leaf sample could account for the observed higher anti-oxidative activities in this 
part of the plant. On a general note, the observed quantitative difference in the anti-oxidative activities 
among the various parts of this plant could be attributed to the variations in concentrations and 
compositions of the anti-oxidative principles in the different parts.  
 
From the results of this study, we can conclude that the EtOH extracts of the various parts of P. biglobosa 
contain more potent anti-oxidative agents than other extracts and that a pyrogallol derivative could be the 
main bioactive agent. Future work would entail isolating the pyrogallol derivative and other phenolics as 
well as evaluating the anti-oxidative activity of the pure isolates and mixtures of isolates. 
Postscript: From the above experiment, the crude ethanol extract from the leaves was found to have 
relatively higher anti-oxidative activity that cuts across various types of radicals than other extracts. It was 
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Preface: In this sub-chapter, solvent-solvent fractionation of the crude ethanol extract from the leaves 
was carried out and the solvent fractions were investigated for anti-oxidative and α-glucosidase and α-
amylase inhibitory activities. The inhibitory mechanism of the most active (butanol) fraction and the 
bioactive phytochemicals were also investigated. This article is yet to be submitted to the supervisors for 
proof reading and eventual submission for publication. 
 
5.3.1 Abstract 
The in vitro anti-oxidative as well as the α-glucosidase and α-amylase inhibitory effects of various solvent 
fractions derived from the crude ethanol extract of Parkia biglobosa leaves were investigated. Crude 
ethanol extract of the leaves of P. biglobosa was subjected to solvent-solvent partitioning which yielded a 
butanol fraction with significantly (P<0.05) more potent anti-oxidative as well as α-glucosidase and α-
amylase activities than other solvent (aqueous, ethyl acetate, dichloromethane and hexane) fractions. 
Further kinetic studies on the inhibitory mechanism of the butanol fraction on α-glucosidase revealed a 
mixed inhibition pattern with inhibition binding constants (Ki) of 9.47 and 18.98 µg/ml for competitive 
and non-competitive inhibitions, respectively. However, the mechanism of α-amylase inhibition was non-
competitive with a Ki of 5.32 µg/ml. GC-MS analysis of the butanol fraction revealed that the main 
bioactive components are phenolics such as pyrogallol and methoxyeugenol. It was concluded that the 
butanol fraction contains potent anti-oxidative agents and inhibitors of α-glucosidase and α-amylase 
activities and could thus be useful therapeutic agents against diabetes mellitus.  
 
5.3.2 Introduction 
Diabetes mellitus could be defined as a heterogenous group of metabolic disorder associated with 
persistent hyperglycemia and derangement in the metabolism of major macromolecules resulting from 
anomalies in the secretion of insulin or its action [36]. At present, different pharmacological strategies are 
used in the treatment of the disease in addition to life style modification. These include stimulation of 
insulin, inhibition of gluconeogenesis, increasing peripheral insulin sensitivity and delaying glucose 
absorption from the intestine. One of the beneficial therapeutic approaches to delay glucose absorption is 
by decreasing the activity of carbohydrate-hydrolyzing enzymes such as α-amylase and α-glucosidase 
[37] which would consequently retard the release of glucose from complex dietary carbohydrates to the 




Available scientific evidences have shown that hyperglycemia induces oxidative stress and this 
phenomenon is regarded as the common biological event that plays vital roles in all aspects of the 
diabetes pathogenesis such as insulin resistance, pancreatic β cell dysfunction as well as macrovascular 
and microvascular complications [38-40]. Based on the foregoing, research on diabetes therapy has 
focused attention on the search for novel agents with potent anti-oxidative activities that could also 
decrease postprandial hyperglycemia via α-amylase and α-glucosidase inhibition, thereby providing a 
holistic therapeutic approach to control hyperglycemia and other diabetic complications resulting from 
oxidative stress. 
Traditional medicinal plants play an essential role in the healthcare delivery systems of many parts of the 
world as well as in drug discovery [23]. According to World Health Organization (WHO), approximately 
60% of the total population of the world depends, directly or indirectly, on traditional medicinal plants 
[41]. A survey of plant-derived pure compounds used as drugs in countries hosting WHO-Traditional 
Medicine Centers indicated that, out of the 122 compounds so far identified, 80% were used for the same 
or related ethnomedical purposes and were derived from only 94 plant species. Furthermore, 60% of the 
anticancer drugs and 75% of the anti-infectious disease drugs approved from 1981-2002, were originally 
derived from natural sources [42] whereas 61% of all new chemical entities introduced worldwide as 
drugs during the same period could be traced to natural products [43]. Indeed, the widely used anti-
diabetic drug metformin was originally developed from a medicinal plant [44]. Thus, investigating 
medicinal plants for anti-oxidative agents with potent α-amylase and α-glucosidase inhibitory activities is 
an appealing alternative. 
 
Parkia biglobosa (Jacq.) Benth. (Mimosaceae) is known as the African locust bean tree and native to 
West African countries. It is highly reputed for numerous medicinal values [1, 8] and all of the different 
parts of the plant are used by traditional healers to cure several metabolic or non-metabolic disorders such 
as hypertension, haemorrhages diarrhea, ulcers and dermatosis [2, 15]. Also, the fermented seeds of the 
plant are also frequently used as natural nutritional condiment with hypoglycemic activity [16]. Recent 
ethnopharmacological surveys also revealed that the plant is among the most commonly utilized plants in 
the traditional remedy of diabetes mellitus in northern Nigeria [6] and the central region of Togo [7]. In 
order to systematically study the anti-diabetic potentials of the plant, we previously subjected different 
solvent crude extracts of the stem bark, root and leaf samples of the plant to anti-oxidative activity assays 
using several models and found that the ethanol crude extract of the leaves had the most potent anti-
oxidative activity among all other extracts [45]. In the present study, we further fractionated the crude 
ethanol extract of the leaves by solvent-solvent partitioning and then conducted a comprehensive study on 
the in vitro anti-oxidative as well as the α-glucosidase and α-amylase inhibitory effects of the fractions. 
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Additionally, we subjected the most bioactive fraction to GC-MS analysis in order to identify the 
phytochemicals contained therein.   
 
5.3.3 Materials and methods 
Please refer to the chapter 2 sub-sections 2.6.1-2.6.6 pages 38-40 for detailed material and methods that 
affect P. biglobosa 
5.3.4 Results 
The total phenolics were significantly higher (P<0.05) in the butanol fraction than other solvent fractions. 
The butanol fraction also recorded a significantly (P<0.05) higher DPPH and NO radicals scavenging 
activities than other solvent fractions (Table 5.3.1). However, the aqueous fraction was found to have 
significantly (P<0.05) higher total reducing capacity (Figure 5.3.1) and hydroxyl radical scavenging 
activity than other fractions (Table 5.3.1).   
 
Figure 5.3.1: Total reducing power (gallic acid equivalent) of different solvent fractions of the ethanol 
extract of P. biglobosa leaves. The results are expressed as mean ± SD of triplicate determinations. a-
eDifferent alphabets presented for a given concentration indicate significant difference (Tukey’s-HSD 
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Table 5.3.1: IC50 values of various solvent fractions of ethanol extract of P. biglobosa leaves in different 
anti-oxidative models 






Aqueous 68.75 ± 0.75d 20.30 ± 1.46e 13.97 ± 3.16b 1734.38 ± 58.69f 
Butanol 82.66 ± 5.51e 16.05 ± 0.74d 44.05 ± 3.12c 227.63 ± 34.96b 
Ethyl acetate 32.73 ± 0.59c 43.15 ± 3.26f 160.42 ± 25.93e 3285.96 ± 1085.47g 
Dichloromethane 11.51 ± 0.52b 78.64 ± 0.82g 76.46 ± 5.17d 302.75 ± 21.58c 
Hexane 2.54 ± 0.37a 348.35 ± 48.40h 195.51 ± 10.08f 3697.62 ± 267.73g 
     
Ascorbic acid - 2.56 ± 0.26b ND 26.40 ± 6.46a 
Gallic acid - 1.40 ± 0.43a ND 1053.48 ± 239.92e 
Trolox - 8.47 ± 2.88c 3.23 ± 0.49a 629.76 ± 63.98d 
The results are expressed as mean ± SD values of triplicate determinations. a-hDifferent superscript alphabets along a 
column indicate significant difference (Tukey’s-HSD multiple range post hoc test, p<0.05).  
 
Data from the α-glucosidase and α-amylase inhibitory actions revealed that all the fractions could inhibit 
the carbohydrate digesting enzymes in a dose dependent pattern (Figure 5.3.2) but the butanol fraction 
was also found to possess significantly (P<0.05) more potent α-glucosidase and α-amylase inhibitory 
phytochemicals as evidenced by the significantly (P<0.05) lower IC50 values compared to other fractions 
(Table 5.3.2). Based on the high activity of the butanol fraction in most of the assays described above, it 







Figure 5.3.2: α-glucosidase (A) and α-amylase (B) inhibitory actions of different solvent fractions of the 
ethanol extract of P. biglobosa leaves. The results are expressed as mean ± SD of triplicate 
determinations. a-eDifferent alphabets over the bars for a given concentration  indicate significant 
difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Table 5.3.2:  IC50 values for the inhibition of α-glucosidase and α-amylase by various solvent fractions of 
the ethanol extract of P. biglobosa leaves 
Fractions/standard IC50 (µg/ml) 
α-glucosidase α-amylase 
Aqueous 21.08 ± 3.12b 120.23 ± 4.58b 
Butanol 13.28 ± 1.33a 58.00 ± 0.80a 
Ethyl acetate 22.31 ± 3.12b 318.90 ± 32.41d 
Dichloromethane 32.43 ± 8.40c 488.80 ± 88.37e 
Hexane 48.80 ± 5.96d 6615.49 ± 768.31f 
Acarbose 55.59 ± 5.22d 256.66 ± 20.52c 
The results are expressed as mean ± SD of triplicate determinations. a-eDifferent alphabets along a column indicate 
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Steady state kinetic analysis was used to delineate the inhibitory mechanism of the fraction on both 
enzymes and the findings indicated that the α-glucosidase was inhibited by the fraction using a mixed 
inhibition pattern (Figure 5.3.3A) with inhibition binding constants (Ki) of 9.47 and 18.98 µg/ml for 
competitive and non-competitive inhibitions respectively (Table 5.3.3). On the other hand, the α-amylase 
was non-competitively inhibited by the fraction (Figure 5.3.3B) with a Ki of 5.32 µg/ml.  
 
 
Figure 5.3.3: Lineweaver-Burke’s plot of α-glucosidase (A) and α-amylase (B) catalysed reactions in the 
presence and absence of the butanol fraction obtained from the ethanol extract of P. biglobosa leaves. 
Table 5.3.3: Effects of the butanol fraction derived from the ethanol extract of P. biglobosa leaves (30 
μg/ml) on some kinetic parameters of α-glucosidase and α-amylase 
Kinetic parameters α-glucosidase α-amylase 
control + butanol fraction control + butanol fraction  
KM  2.00*  8.33*  0.25#  1.66#  
Vmax (μmol/min) 655.09 253.55 33.70 33.70 
Ki (μg/ml) - 9.47 (competitive) 
18.98 (non-competitive) 
- 5.32 























































In order to identify the possible bioactive agents of this potent fraction, GC-MS analysis was conducted 
and the chromatogram is shown in Figure 5.3.4. The major peaks detected were those of pyrogallol, 
methoxyeugenol, 3-(1-isopropyl-but-3-enyloxy)-butyric acid and sugars (Table 5.3.4) which were 
identified by their fragmentation pattern in conjunction with the NIST library. 
 
Figure 5.3.4: GC-MS chromatogram of the butanol fraction derived from the ethanol extract of P. 
biglobosa leaves 
 
Table 5.3.4: Identified components of the butanol fraction derived from the ethanol extract of P. 
biglobosa leaves by GC-MS 




1 Pyrogallol 9.57 126.10 
2 D-Allose 11.21 180.15 
3 Methoxyeugenol 13.46 194.10 
4 3-O-methyl-fructose 13.62 194.18 
5 3-(1-isopropyl-but-3-enyloxy)-butyric acid 14.30 167.10 





The traditional use of P. biglobosa in the treatment of diabetes mellitus [6,7] prompted us to conduct a 
systematic study to investigate the anti-diabetic potentials of the plant. In a previous study, it was found 
that the leaves ethanolic extract had the best anti-oxidative activity among other solvent crude extracts 







ethanol extract of the leaves elicited remarkable anti-oxidative as well as α-glucosidase and α-amylase 
inhibitory effects. 
 
Sequential partitioning of the crude ethanol extract of the leaves across solvents of varying polarity was 
aimed at separating the polar phytochemicals from the non-polar ones for detailed investigation. Thus, the 
recovered fractions were subjected to in vitro anti-oxidative activity assays using different models 
because a single method cannot give a full evaluation of the anti-oxidative capabilities due to the 
involvement of multiple mechanisms in the induction of oxidative stress. The total reducing power of 
phytochemicals is considered as a reliable marker of their anti-oxidative potential. The reductants inhibit 
the chain reaction of free radicals by donating hydrogen atoms to the radical molecules. Free radicals are 
known to be a major factor in cellular damages in biological systems and DPPH method has been used to 
investigate the free radical scavenging effects of natural anti-oxidative agents. On the other hand, 
hydroxyl radicals are also extremely reactive species that can damage any biological molecule available 
in living cells [28] and NO is an unstable species which reacts with oxygen to generate the reactive nitrite 
and peroxynitrite anions [33]. All these radicals are implicated in the development of diabetes and 
associated complications [32]. From the present study, the aqueous fraction had the best total reducing 
power and hydroxyl radical scavenging activity while the butanol fraction had the best DPPH and NO 
radicals scavenging activities and this observation could suggest preferential difference in the response of 
the phytochemicals to the different anti-oxidative models. Furthermore, the findings suggests that the 
more polar (butanol and aqueous) fractions contain strong phytochemicals that could inhibit free radical 
upsurge and oxidative stress in diseases where the phenomenon is important mechanism of pathogenesis 
such as diabetes. 
All the solvent fractions inhibited α-glucosidase and α-amylase dose dependently which suggest that these 
fractions could slow down the initial hydrolysis of starch and other complex polysaccharides to 
oligosaccharides as well as the subsequent hydrolysis of the oligosaccharides to glucose for intestinal 
absorption and blood circulation [37]. This would obviously decrease the liberation of glucose from 
complex dietary carbohydrates to the bloodstream, thereby impeding postprandial hyperglycemia. 
However, the butanol fraction demonstrated the best α-glucosidase and α-amylase inhibitory effects 
which were mediated through mixed and non-competitive inhibition patterns respectively. The inhibitory 
pattern exerted on α-glucosidase indicates that the butanol fraction contain powerful inhibitors that were 
able to bind both at the active site and at an allosteric site of the enzyme [46] both the computed inhibition 
binding constants for competitive and non-competitive inhibitions suggest that the inhibitory constituents 
are more oriented to active site binding. On the other hand, the observed inhibitory pattern on α-amylase 
suggests binding at an allosteric site by the inhibitory phytochemicals which could consequently cause 
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conformational modification at the active site, thereby preventing the effective binding of the starch and 
resulting in decreased α-amylase activity [47].    
Phenolics are the major plants constituents responsible for anti-oxidative activity and are also known to 
inhibit some enzymatic activity such as α-glucosidase and α-amylase [48]. Interestingly, the butanol 
fraction had the highest phenolics content as well as the most potent α-glucosidase and α-amylase 
inhibitory activities among other fractions. It could thus imply, although without a correlation analysis, 
that phenolics play a vital role in the enzymes inhibitory activities of this fraction. This is supported by 
previous studies which reported that the α-glucosidase and α-amylase inhibitory effects of Ocimum 
basilicum, Citrus maxima, cinnamon and tea extracts are mediated by phenolics [48-51]. Furthermore, 
GC-MS analysis also revealed that the butanol fraction contained some phenolics which include 
pyrogallol and methoxyeugenol. Indeed, a phenolic peak is the most prominent peak (1) in the GC-MS 
chromatogram. Thus, while not discounting the possible contribution of other phytocomponents, it is 
reasonable to suggest that phenolics act individually or synergistically to bring about the observed 
inhibitory effects. 
In conclusion, our data suggests that the butanol fraction derived from the crude ethanol extract of the 
leaves of P. biglobosa contains powerful anti-oxidative agents and inhibitors of α-glucosidase and α-
amylase which could be exploited for the development of holistic therapeutic strategy for the control of 
postprandial hyperglycemia and other diabetic complications while phenolics could be the main bioactive 
agents. We are currently conducting a comprehensive investigation on the anti-diabetic activity of the 
butanol fraction in type 2 diabetic rats as well as isolating some pure compounds from it. 
 
Postscript: From the above studies, the butanol fraction had the best α-glucosidase and α-amylase effects 











5.4 Butanol fraction of Parkia biglobosa leaves modulates β cell functions, 
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Preface: This article reports the detailed in vivo anti-diabetic studies of the butanol fraction and the 
isolation of the possible bioactive anti-diabetic compound. It is yet to be submitted for publication.  
5.4.1 Abstract 
This study investigated the anti-diabetic effects and the mechanism of action of the butanol fraction of 
Parkia biglobosa leaves (PBBF) in a type 2 diabetes (T2D) rats model as well as the isolation of possible 
bioactive compound from the fraction. T2D was induced in rats by feeding with a 10% fructose solution 
ad libitum for two weeks followed by intraperitoneal injection of 40 mg/kg bw streptozotocin and the 
animals were treated with 150 and 300 mg/kg bw of the fraction for four weeks. The PBBF treatments 
significantly (P<0.05) decreased the blood glucose concentrations and enhances the glucose tolerance 
capacity compared to untreated diabetic rats. Furthermore, the treatments were found to improve β-cell 
function, stimulate insulin secretions, decrease insulin resistance, restore liver glycogen, ameliorate serum 
lipids alterations and prevent hepatic and renal damages compared to untreated diabetic rats. 
Phytochemical analysis of the fraction led to the isolation to lupeol which inhibited -glucosidase and -
amylase with IC50 values of 45.12 ± 3.47 and 256.47 ± 16.47 µg/ml. Kinetic studies revealed that lupeol 
is a non-competitive inhibitor of -glucosidase and an uncompetitive inhibitor of -amylase. The findings 
of this study suggest that PBBF possessed remarkable anti-T2D activity which is mediated through 
modulation of β-cell function and stimulation of insulin secretion while lupeol is an important bioactive 
anti-T2D agent in the fraction. 
 
5.4.2 Introduction 
Type 2 diabetes (T2D) is a complex, heterogenous and polygenic disorder associated with insulin 
resistance and pancreatic β-cell dysfunction [52]. Impaired postprandial insulin secretion due to 
functional defects and the loss of surviving pancreatic β-cells leads to hyperglycemia and a subsequent 
decline in insulin sensitivity [53].  At present, the use of insulin secretagogues and sensitizers as well as 
of inhibitors of carbohydrate-hydrolyzing enzymes such as α-glucosidase and α-amylase are the 
commonly exploited approach for the treatment of the disease [37]. Although a number of antidiabetic 
drugs are currently used for T2D treatment, adverse reactions and side effects are serious impediments to 
their use [54]. Recently, many researchers are searching medicinal plants or dietary interventions to 
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prevent or treat T2D. In this context, African medicinal plants may provide the much needed alternative 
therapies because of their multiple health benefits [22]. 
Parkia biglobosa (Jacq.) Benth. Is also called the African locust bean tree and belongs to the family 
Mimosaceae which is native to Nigeria and other West African countries. It is highly reputed for 
numerous medicinal values [1,8] and all of the different plant’s part are exploited in traditional medicine 
to cure several metabolic or non-metabolic disorders such as hypertension, haemorrhages and dermatitis 
[2, 15]. Also, the fermented seeds of the plant are also frequently used as natural nutritional condiment 
with different local names such as ‘afitin’ in Benin, nététou’ in Senegal, and dawadawa in Nigeria [15]. 
Scientific reports have validated the analgesic and anti-inflammatory [11], antivenom [10], antidiarrhoeal 
[12], antibacterial [8], vasorelaxant [15], wound healing [14] and anti-oxidative [45] activities of extracts 
from various parts of the plant.  
On the other hand, ethnopharmacological surveys revealed that P. biglobosa is commonly used in the 
traditional remedy of diabetes mellitus in northern Nigeria [6] and the central region of Togo [7]. In a 
previous study, the fermented seed extract was also reported to possess hypoglycemic activity in an 
alloxan-induced type 1 diabetes model of rats [16]. However, the anti-diabetic effects of the parts of the 
plant which are actually used for the traditional management of diabetes mellitus have not yet been 
examined either in humans or experimental animal models of T2D.  
Hence, the present study was conducted to comprehensively evaluate the in vivo anti-diabetic activity of 
the butanol fraction of P. Biglobosa leaves in a T2D model of rats as well as to isolate a pure α-
glucosidase and α-amylase inhibitory compound from the fraction. Additionally, the mechanism of α-
glucosidase and α-amylase inhibition by the active compound was determined using the enzyme kinetics 
approach. 
5.4.3 Materials and methods 
Please refer to the chapter 2 sub-sections 2.3-2.4 (pages 35-36);  2.6.1-2.6.4 (pages 38-40); 2.7.1-2.7.7 
pages (40-43); 2.8.2 page 46 for detailed materials and methods that affect P. biglobosa. However, the 
group codes DFL, DFH and NFT used in the chapter two are replaced with DPL, DPH and NPT 
respectively. PBBF refers to the butanol fraction derived from the crude ethanol extract of P. biglobosa  
leaves. 
5.4.4 Results 
The DBC group had significantly higher mean feed and fluid intake than the NC group while the PBBF-
treated groups had relatively lower feed and fluid intakes compared to the DBC group. The PBBF 
treatment did not significantly (P<0.05) affect the feed and fluid intakes of normal rats (Figure 5.4.1). 
Body weight gain was significantly retarded in the DBC group but the PBBF treatment caused an 
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insignificant (P>0.05) increase in the body weight gain especially in the last three weeks of the 
experiment (Figure 5.4.2).  
 
Figure 5.4.1: Feed and fluid intakes of different groups of during the experimental period. The results are 
expressed as the mean ± SD of eight animals. a-cDifferent alphabets over the bars for a given parameter 
indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Figure 5.4.2: Mean body weight gain for all groups of experimental animals over the seven weeks 
experimental period. The results are expressed as the mean ± SD of eight animals. a-cDifferent alphabets 
for a given week indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The profile of the weekly NFBG levels indicated that all diabetic groups had an elevated blood glucose 
level at the first week after induction (Figure 5.4.3). However, the PBBF treatment significantly (P<0.05) 
decreased the T2D-induced elevation in NFBG in the first week after treatment and the pattern was 
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brought to near normal and was significantly (P<0.05) lowered compared to the DPH group. In the 
OGTT, a rise in blood glucose levels was observed in all animal groups after 30 min of glucose 
administration but thereafter, the PBBF-treated groups recorded a significantly lowered blood glucose 
levels compared to the DBC group which was maintained throughout the 120 min experiment (Figure 
5.4.4). Also, the DPL group recorded significantly (P<0.05) better glucose tolerance ability compared to 
the DPH group. The serum insulin concentrations and β-cell function (HOMA-β) of the DBC group were 
significantly (P<0.05) lowered compared to the NC group but the PBBF-treated groups recorded 
significantly (P<0.05) higher insulin levels and β-cell function than the DBC group (Table 5.4.1). Indeed, 
the DPL group had a significantly higher (P<0.05) insulin concentration than normal rats. Conversely, 
serum fructosamine concentration and insulin resistance (HOMA-IR) were significantly (P<0.05) 




Figure 5.4.3: The effects of different doses of PBBF on weekly blood glucose levels (post induction). 
Results are expressed as the mean ± SD of eight animals a-eDifferent alphabets for a given week indicate 
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Figure 5.4.4: Oral glucose tolerance test (OGTT) for all groups of animals in the last week of the 
experiment. Results are expressed as the mean ± SD (n=8). a-dDifferent alphabets for a given time indicate 
significant difference from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Table 5.4.1: Serum  insulin and fructosamine concentrations, indices of hepatic and renal damages as 
well as computed HOMA-IR and HOMA-β scores for the animal groups at the end of the experiment 
 NC DBC DPL DPH DMF NPT 
Serum insulin 
(pmol/L) 




196.3 ±5.5a 258.4±10.9b 240.2±26.5b 243.0±21.5b 253.8 ±30.3b 195.1 ±18.6a 
HOMA-IR 4.9±1.1a 16.2 ± 5.6b 8.1±3.8b 9.6±2.51b 9.8 ± 3.7b 5.1 ± 0.7a 
HOMA-β 304.1±53.7d 9.6±5.2a 106.8±46.4c 28.6±12.2b 54.8±27.5bc 299.9±83.3d 
AST (U/L) 88.0 ± 14.8 73.6±7.6 79.6±12.5 73.7±8.8 88.6 ± 17.8 80.1±7.9 
ALT (U/L) 56.3 ± 12.6a 77.7±4.5b 75.8±22.1ab 71.0±12.9ab 63.3 ± 18.1ab 48.85 ± 8.1a 
ALP (U/L) 188.8±19.8a 898.6±174.5c 333.8±26.1b 426.6±87.6b 472.0±74.9b 155.4±48.6a 
Urea (mg/dl) 48.0 ± 6.2a 93.0±16.4b 53.5±18.7a 63.4±20.4ab 42.0±11.7a 41.63±9.37a 
Creatinine (µg/dl) 582.0±70.5ab 485.0±40.4a 548.3±36.0ab 555.0±52.3ab 675.0 ±95.2b 471.2±42.9a 
The results are expressed as the mean ± SD (n=8).  a-dDifferent superscript alphabets along a row indicate significant 
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The data for the liver weights and glycogen concentration of the experimental animals is presented in 
Table 5.4.2. No significant differences in the absolute liver weights of all groups of animals were 
observed, however, the relative liver weights of the diabetic groups were significantly higher than NC and 
NPT groups. The PBBF-treated groups recorded a significantly lower (P<0.05) relative liver weight in 
comparison to DBC group. The liver glycogen store was significantly (P<0.05) depleted in the DBC 
group compared to the NC group but the PBBF treatment significantly (P<0.05) boosted the liver 
glycogen reserves in the diabetic animals. 
 
Table 5.4.2: The effects of different doses of PBBF on liver weights and liver glycogen concentrations of 
type 2 diabetic rats 
 NC DBC DPL DPH DMF NPT 
Liver weight (g) 11.8±2.4 10.9± 1.9 11.2± 0.9  9.9±0.4 10.4±1.7 10.7±1.4 
Relative liver weight (%) 3.3±0.3a 3.9± 0.2c 3.6± 0.2b 3.6±0.2b 3.7±0.1b 3.1±0.2a 
Liver glycogen (mg/g tissue) 3.5±0.8bc 1.5±0.1a 3.7± 0.6c 2.6±0.3b 2.6±0.4b 2.6±0.4b 
Results are expressed as mean ± SD (n=8). a-cDifferent alphabets along a row indicate significant difference 
(Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Table 5.4.3 presents the serum lipid profile of all groups of experimental animals. Both PBBF and T2D 
did not significantly affect total and LDL cholesterols except in the DPH group which had significantly 
(P<0.05) higher total cholesterol in comparison to NC group. On the contrary, DBC group had a 
significantly (P<0.05) lower concentration of HDL-cholesterol which was boosted in the PBBF treated 
diabetic groups. Furthermore, T2D caused a significant (P<0.05) elevation in the level of serum 
triglycerides which was ameliorated in the PBBF treated diabetic groups. Results of other indices of 
diabetic complications also indicated that the T2D-induced increase in ALT, ALP and urea were 
ameliorated by the PBBF treatments (Table 5.4.1). Moreover, relatively lower serum levels of AST and 












Table 5.4.3: The effects of different doses of PBBF on serum lipid profiles of type 2 diabetic rats 
Serum lipids NC DBC DPL DPH DMF NPT 
   (mg/dl)    
Total cholesterol 66.3±6.4a 76.3±10.6ab 73.5±5.8ab 81.4±5.9b 74.6±12.1ab 69.1±16.4ab 
HDL cholesterol 31.0±9.6b 19.8±1.6a 26.3±4.3b 25.8±3.5b 28.1±5.4b 27.2±8.8ab 
LDL cholesterol 19.9±5.4a 27.5±4.3a 22.2±4.9a 30.3±9.4a 25.9±7.4a 17.1±5.1a 
Triglycerides 102.5±27.5a 184.8±40.9b 113.2±39.1ab 118.2±34.2ab 120.1±27.4ab 111.3±28.2a 
Results are expressed as mean ± SD (n=8). a-bDifferent alphabets along a row indicate significant difference 
(Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Histopathological examination of the pancreas indicated massive destruction of pancreatic islets with 
small number of β cells in the DBC group compared to NC. However, the PBBF treatments protected the 
T2D-associated destruction of β cells because larger islets with higher number of β cell were detected in 
the DPL and DPH groups. It is also noteworthy that the DPL group had more β cells than DPH group but 
they appear morphologically healthier in the DPH group than the DPL (Figure 5.4.5). 
 
  
       
Figure 5.4.5: Histopathological pictures of the pancreas of different experimental groups at the end of the 
experiment. The NC had high number of β-cell while the DBC had highly dispersed and morphologically 
deformed β-cells. The DPL, DPH and DMF groups had higher number of β-cells compared to DBC. 
Higher dose of the PBBF causes slight damage to pancreatic islets as well as the β-cells as evidenced in 
the NPT group. 
 
NC DBC DPL 
DPH DMF NPT 
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The structure of the active compound was identified as lupeol (Figure 5.4.6) through detailed 
spectroscopic analysis and confirmed by comparison with data from the literature [55, 56]. The 1H NMR 
spectrum showed two doublet resonances at δ 4.66 and 4.54 corresponding to the germinal olefinic 
protons (H-29a and H29b) of the ring D isopropenyl side chain (Appendix 3). The H-3 oxygenated proton 
was seen at δ 3.20 and the methyl resonances between δ 0.70 and δ 1.70.  The 13C NMR resonances at δ 
150.94 and δ 109.32, attributed to the olefinic carbon atoms and the oxygenated carbon resonance at δ 












Figure 5.4.6: Structure of the lupeol isolated from the butanol fraction of P.biglobosa leaves  
Results from the inhibitory effects of lupeol on -glucosidase and -amylase catalyzed reactions revealed 
that the compound inhibited the enzymes with IC50 values of 45.12 ± 3.47 and 256.47 ± 16.47 µg/ml for 
-glucosidase and -amylase inhibitions respectively. Using the enzyme kinetic approach, lupeol was 
found to be a non-competitive inhibitor of -glucosidase with Vmax decreasing from 655.09 μmol/min to 
56.84 μmol/min while the KM remained unchanged at 2 mM (Figure 5.4.7A). On the other hand, lupeol 
displayed an uncompetitive inhibition pattern for -amylase inhibition thereby decreasing both the Vmax 
and KM of the enzyme (Figure 5.4.7B). The Vmax decreased from  33.70 μmol/min to 0.75 μmol/min 















Figure 5.4.7: Lineweaver-Burke’s plot for α-glucosidase (A) and α-amylase (B) catalysed reactions in the 
presence and absence of lupeol as an inhibitor 
5.4.5 Discussion 
A preliminary study on the hypoglycemic and antihyperlipidemic activities of the fermented seeds of P. 
biglobosa has been reported [16]. So far, information on the anti-T2D activity and the mechanism of 
action from traditionally used parts of P. biglobosa does not appear in the literature. The present study 
demonstrated that the butanol fraction of P. biglobosa stem bark possesses exceptionally high anti-T2D 
effect which is mediated through stimulation of β-cell function and insulin secretion.  
 
The observed effects of PBBF on polyphagia, polydipsia, and body weight loss caused by T2D suggest 
that the fraction has a tendency to reverse these alterations caused by the disease. Shorter experimental 
period may be the reason for the insignificant amelioration of T2D-induced polyphagia and polydipsia as 
well as body weight gain.  
 
Fasting or postprandial hyperglycemia is a common pathogenesis of T2D which is induced by insulin 
















































a vital position in preventing diabetic complications as well as enhancing the living standard of  type  2  
diabetic patients  [58]. The ability of PBBF to effectively and consistently control the hyperglycemia in 
diabetic animals could be attributed to anti-hyperglycemic, rather than hypoglycemic, activity because the 
PBBF treatment did not lower the blood glucose level of normal rats.  In addition to the remarkable anti-
hyperglycemic effects, the PBBF treatment also resulted in an improvement of glucose tolerance which 
could be associated with the increased insulin secretions [59] and/or relatively lower insulin resistance 
observed in the PBBF-treated animals and this is known to promote more glucose uptake by cells.   
 
The effects of PBBF on serum insulin levels, HOMA-IR and HOMA-β scores as well as pancreatic 
histopathology were determined partly to give an insight into the mechanism of action. The elevated 
serum insulin levels in diabetic animals observed in the PBBF-treated diabetic animals suggest that the 
fraction is an insulin secretagogue whereas the relatively lower HOMA-IR in PBBF treated groups 
indicates that the fraction affects the peripheral insulin resistance. However, HOMA-β scores and 
pancreatic histopathology indicated that the fraction prevents T2D-induced pancreatic β-cell destruction 
and improves their functions.  It seems therefore that, the anti-hyperglycemic activity of the fraction is 
related to both pancreatic (modulation of β-cells to increase the secretion of insulin) and extra pancreatic 
(glucose utilization at the peripheral tissues) mechanisms and/or the observed potent -glucosidase and 
-amylase inhibitory activities shown by the fraction (see manuscript 5.3 above). The anti-diabetic 
activity of a number of plant materials were reported to be through interference with gastrointestinal 
glucose absorption [60], insulinotropic action [61] or by promoting the regeneration of pancreatic β-cells 
[62]. Fructosamine is a product of protein glycation at an early stage which undergoes oxidative cleavage 
resulting in the formation of advanced glycation end products causing diabetic complications [63]. It is a 
useful indicator in monitoring middle term changes after alterations in the management of diabetes. Our 
study indicated that the PBBF relatively lowered the serum fructosamine which could suggest that the 
fraction interrupts the glycation cascade, thereby reducing the risk of diabetic complications.  
 
The most important form of glucose storage is in the form of glycogen and its levels in different tissues 
especially the skeletal muscle provides a clear reflection of the activity of insulin. Insulin promotes 
intracellular glycogen deposition by stimulating glycogen synthase and inhibiting glycogen 
phosphorylase [64]. Thus, the reduced glycogen store in the DBC group may be attributed to the reduced 
insulin secretion with corresponding decrease in glycogen synthase activity and increase in glycogen 
phosphorylase activity. Based on the above, we speculated that the restoration of liver glycogen level in 
the PBBF treated animals might be linked to the insulinotropic activity of the fraction which could 




Although the results were not significant, an increasing tendency in the serum total and LDL cholesterols 
was observed in the DBC group. On the other hand, significant hypertriglyceridemia was also observed in 
the DBC compared to the NC group. The observed increase in serum lipids in diabetic animals is linked 
to the sensitivity of fatty acid mobilization (from adipose tissue) to the action of insulin. One of the most 
powerful actions of insulin is to reduce the process of lipolysis in the tissues [65]. Indeed, an increase in 
serum insulin level by only 5 IU/ml could inhibit lipolysis by 50%, while a decrease in insulin levels 
could profoundly accelerate tissue lipolysis [66]. Therefore, we also linked the observed restoration of 
these serum lipids in the PBBF treated groups to the insulinotropic action of the fraction which may result 
in the inhibition of lipolysis with a corresponding decrease in the serum lipids. Moreover, the result 
suggests that the PBBF has a tendency to reduce T2D-associated complications such as coronary heart 
disease. 
 
The serum levels of ALT and ALP but not AST were significantly increased in the untreated diabetic 
animals indicating impaired liver function, which is due to hepatocellular necrosis. Diabetic  
complications  such  as  increased  gluconeogenesis  and ketogenesis  is usually associated with elevated  
transaminase  activities  [67].  Therefore, restoration  of  these  biomarker  enzymes towards  normal  
level  indicates  decreased  diabetic  complications in PBBF treated groups. Furthermore, the fraction 
reversed the T2D-induced increase in serum urea level which could suggest decreased renal impairments 
associated with diabetic complications. Apart from assessing renal damage, creatinine was reported to be 
a predictor for T2D and insulin resistance [68]. Creatinine is a product of creatine metabolism which 
mostly occur in skeletal muscle, the major center for the action of insulin and subsequent glucose 
disposal. Muscle mass has been proposed to inversely correlate with insulin resistance but directly 
correlate with serum creatinine. Thus, the serum creatinine could be a reliable marker to assess insulin 
resistance [68]. Indeed, previous studies have demonstrated lower serum creatinine level in T2D human 
subjects compared to normal individuals [68] which corroborates with our findings. It is thus plausible to 
suggest that the relatively lower insulin resistance (HOMA-IR) of the PBBF treated diabetic rats 
compared to the DBC group translated to a relatively elevated serum creatinine levels in these groups.  
The anti-diabetic effects of DPL group were better than DPH group in most of the parameters measured 
in this study. One of the possible reasons for this observation might be the toxicological effects of the 
PBBF at higher dose (300 mg/kg bw) which was reflected in the histopathological results of the NPT 
group where pancreatic islets were slightly damage. This could eventually lead to a reduced function of 
the pancreas and ultimately decrease the overall anti-diabetic effects of the fraction at the high dose. 
Another possible explanation for the observation is that the fraction underwent hormesis phenomenon.  
Hormesis is a dose-response relationship for a single endpoint that is associated with changes of 
responses between high and low dosages of biological molecules, chemicals, or any other agent that can 
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initiate a response [29] and its occurrence has been documented in numerous biological, toxicological and 
pharmacological investigations [30].  
After the anti-T2D of the PBBF was confirmed by in vivo studies, we attempted to investigate the 
potential bioactive anti-T2D agents in the fraction. A pentacyclic triterpene, lupeol was isolated from the 
PBBF and was subjected to in vitro -glucosidase and -amylase inhibitory assays. Although previous 
studies have demonstrated the -glucosidase and -amylase inhibitory activity of lupeol isolated from 
other plants [69, 70], we further investigated the mechanism of the inhibitions using the enzyme kinetics 
approach, which to our knowledge had not been done previously. Results from the enzyme kinetics 
studies indicated that lupeol mediates -glucosidase and -amylase inhibitory action through non-
competitive and uncompetitive inhibition patterns respectively. These suggest that lupeol binds both to 
the free -glucosidase protein or the α-glucosidase-pNPG complex and consequently reduces the rate of 
product formation. Conversely, lupeol decreased the rate of starch hydrolysis only through binding to the 
-amylase-starch complex. 
In summary, results from this study suggest that treatment of diabetic animals with the butanol fraction of 
P. biglobosa leaves leads to the stimulation of β-cell function and insulin secretion with a corresponding 
decrease in postprandial blood glucose levels and other T2D-associated complications whilst a dose of 
150 mg/kg bw was more effective than 300 mg/kg bw possibly due to toxicological effects of the fraction 
at a higher dose. Furthermore, lupeol could be involved in decreasing postprandial hyperglycemia through 
-glucosidase and -amylase inhibitions. 
Postscript: In order to further explore the possible mechanism of anti-diabetic action of the butanol 
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Preface: This article describes the in vivo anti-oxidative status of the serum and organs collected from the 
rats in the above experiment to determine whether an anti-oxidative dependent mechanism is involved in 
the anti-diabetic effects of the fraction.  
 
5.5.1 Abstract 
The effects of a butanol fraction of Parkia biglobosa leaves (PBBF) on the antioxidant status of the 
serum, liver, kidney, heart and pancreas of type 2 diabetic rats were investigated. Type 2 diabetes (T2D) 
was found to induce oxidative stress as manifested by a significant (P<0.05) increase in the thiobarbituric 
acid reactive substances (TBARS) and significant (P<0.05) decrease in the glutathione, superoxide 
dismutase (SOD) and catalase in the serum and organs under study. However, the PBBF treatment 
significantly (P<0.05) ameliorated the T2D-induced changes in the TBARS levels glutathione, SOD and 
catalase in the serum, liver and pancreas of the type 2 diabetic rats.  In the kidney, the T2D-decrease in 
glutathione, SOD and catalase was significantly ameliorated by the PBBF treatment but the reduction in 
TBARS level was not significant (P>0.05). In the heart, the T2D-induced changes in TBARS level, 
glutathione and SOD were significantly (P<0.05) ameliorated but the increase in catalase level was not 
significant (P>0.05). It was concluded that PBBF contains therapeutically active phytochemicals that 
could modulate oxidative stress associated with T2D. 
 
5.5.2 Introduction 
Hyperglycemia is a hallmark of diabetes mellitus and has been implicated in the pathogenesis of macro 
and microvascular complications associated with the disease [36]. This is achieved via auto-oxidation of 
glucose and non-enzymatic protein glycation leading to the generation of advanced glycation end 
products as well as activation of protein kinase C which consequently results in excess free radicals in the 
body [20]. These highly reactive species attack membrane phospholipids and proteins leading to lipid 
peroxidation and a decrease in the levels of endogenous enzymatic (glutathione) and non-enzymatic 
(catalase, superoxide dismutase) antioxidants, a phenomenon called oxidative stress [20]. Thus, oxidative 
stress holds a central position in the secondary complications associated with diabetes mellitus and indeed 
all other aspects of the disease pathogenesis such as insulin resistance and pancreatic β cell dysfunction 




Parkia biglobosa (Jacq.) Benth (Mimosaceae) is a traditional medicinal plant commonly exploited  in the 
treatment of diabetes mellitus in Nigeria and Togo [6, 7]. In order to validate the claim, we conducted 
preliminary in vitro anti-oxidative studies on various crude extracts of the stem bark, root and leaf 
samples of the plant using complementary assays [45] and observed that the crude ethanol extract of the 
leaves had the best anti-oxidative activity. In a follow up study, butanol fraction obtained from the crude 
ethanol extract of the leaves, was subjected to an in vivo anti-diabetic study in a T2D rats model where it 
demonstrated potent anti-hyperglycemic activity and improved β-cell function, stimulated insulin 
secretions, decreased peripheral insulin resistance, ameliorated serum lipids alterations as well as 
prevented liver and kidney damages associated with T2D (see 5.4 above). In order to further probe, 
whether or not, the observed remarkable anti-diabetic activity was mediated through an anti-oxidative 
dependent mechanism, in the present study, the in vivo anti-oxidative status of the serum, liver, kidney, 
heart and pancreas of type 2 diabetic animals treated with the fraction was investigated. 
5.5.3 Materials and methods 
Please refer to the chapter two sub sections 2.3-2.4 (pages 35-36); 2.7.1-2.7.5 page 41-42; and 2.7.8 
(2.7.8.1-2.7.8.4) page 44-45 for detailed materials and methods that affect P. biglobosa 
5.5.4 Results 
The TBARS level in the liver and kidney of the DBC group were significantly (P<0.05) higher than NC 
group but the DPH group recorded lower levels of TBARS than the DBC group and the difference was 
significant (P<0.05) in the liver (Table 5.5.1) and not the kidney (Table 5.5.2). The glutathione, SOD and 
catalase levels in the liver and kidney were significantly (P<0.05) lowered in the DBC group compared to 
the NC group but the DPL and DPH groups had significantly (P<0.05) higher levels of glutathione, SOD 
and catalase in both liver (Table 5.5.1) and kidney (Table 5.5.2) compared to the DBC group.  
Table 5.5.1: Effects of PBBF on hepatic lipid peroxidation and anti-oxidant status of type 2 diabetic rats 
 NC DBC DPL DPH DMF NPT 
TBARS (µM) 10.61±3.02a 33.8 ±4.96c 31.78±5.65c 23.89±6.59bc 35.94±9.46c 17.82±2.23b 
Glutathione (µM) 120.82±6.01c 29.99±9.34a  137.45±15.06c 75.28±10.28b 73.62±10.22b 81.64±12.90b 
Superoxide dismutase 
(nmol/min) 
25.54±5.28b 12.37±1.62a 21.49±4.62b 21.81±6.06b 17.53±5.15ab 19.14±5.45b 
Catalase (µmol/min) 16.5 ±0.92c 1.54±0.27a 8.57±2.12b 13.14±3.39b 1.67±0.57a 20.05 ±4.37c 
Results are expressed as mean ± SD (n=5). a-cDifferent superscript alphabets along a row indicate significant 




Table 5.5.2: Effects of PBBF on kidney lipid peroxidation and anti-oxidant status of type 2 diabetic rats 
 NC DBC DPL DPH DMF NPT 
TBARS (µM) 14.1±5.8a 40.8±12.5b 48.2±13.5b 33.7±9.9b 33.4±10.0b 10.0±3.9a 
Glutathione (µM) 68.2±20.8b 46.0±8.6a 89.8±19.5b 113.9±8.7c 70.8±10.4b 121.6±10.1c 
Superoxide dismutase 
(nmol/min) 
16.1±3.4c 6.8±1.5a 7.6±1.8b 13.0±2.6c 11.5±4.4bc 9.9±2.8bc 
Catalase (µmol/min) 1.7±0.3 b 0.9±0.2a 3.2±0.9c 2.6±0.2c 1.6±0.4b 1.9±0.3b 
Results are expressed as mean ± SD (n=5). a-cDifferent superscripts alphabets along a row indicate significant 
difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
In the serum, heart and pancreas, the DBC group also had significantly (P<0.05) higher levels of TBARS 
as well as significantly (P<0.05) lower levels of glutathione, SOD and catalase than the NC group (Table 
5.5.3-5.5.5). However, the DPL and DPH groups recorded significantly (P<0.05) higher levels of TBARS 
as well as significantly (P<0.05) lower levels of glutathione and SOD in the serum (Table 5.5.3), heart 
(Table 5.5.4) and pancreas (Table 5.5.5) compared to the DBC group. Catalase was significantly 
(P<0.05) elevated in the pancreas and serum of the DPL and DPH groups (Table 5.5.4 & 5.5.5) but was 
significantly (P<0.05) elevated in the heart of the DPH group only (Table 5.5.3).  
 
Table 5.5.3: Effects of PBBF on lipid peroxidation and anti-oxidant status in the heart of type 2 diabetic 
rats 
 NC DBC DPL DPH DMF NPT 
TBARS (µM) 9.4±2.6ab 24.6±8.8c 9.1±1.7b 11.7±3.6b 33.9±5.9c 6.0±1.2a 
Glutathione (µM) 122.2±22.0c 48.6±14.6a 92.7±10.6b 117.3±9.4c 79.2±18.3ab 107.8±5.9bc 
Superoxide dismutase 
(nmol/min) 
15.2±4.0c 5.8±1.2a 9.3±1.2b 14.8±2.9c 12.8±2.0c 10.9±1.8bc 
Catalase (µmol/min) 2.1±0.5b 0.9±0.2a 1.0±0.1a 1.2±0.6ab 1.4±0.4ab 1.9±0.4b 
Results are expressed as mean ± SD (n=5). a-cDifferent alphabets along a row indicate significant difference 








Table 5.5.4: Effects of PBBF on pancreatic lipid peroxidation and anti-oxidant status of type 2 diabetic 
rats 
 NC DBC DPL DPH DMF NPT 
TBARS (µM) 6.0±1.2a 35.7±9.1d 12.2±2.6c 9.0±1.8bc 18.4±4.4c 8.5± 0.5b 
Glutathione (µM) 80.0±8.1d 6.2±3.5a 22.3±3.5b 27.4±5.4bc 37.3±8.6c 63.5±16.1d 
Superoxide dismutase 
(nmol/min) 
2.6±0.5d 0.4±0.2a 1.6±0.06c 0.7±0.2b 1.0±0.5bc 2.1±0.5cd 
Catalase (µmol/min) 0.7±0.2b 0.35±0.04a 1.4±0.3c 1.3±0.2c 1.11±0.2c 0.7±0.08b 
Results are expressed as mean ± SD (n=5). a-dDifferent superscripts alphabets along a row indicate significant 
difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Table 5.5.5: Effects of PBBF on serum lipid peroxidation and anti-oxidant status of type 2 diabetic rats 
 NC DBC DPL DPH DMF NPT 
TBARS (µM) 63.0±15.2a  201.2±19.4d 103.4±18.9c 148.0±17.3c 142.0±32.0c 31.1±13.3b 
Glutathione (µM) 84.5±7.7d 19.9±2.5a 41.2±6.6b 48.3±6.9b 65.2±6.8c 47.0±7.9b 
Superoxide dismutase 
(nmol/min) 
18.1±2.4d 0.9±0.2a 13.8±3.1d 7.1±1.6c 3.2±0.7b 14.5±2.4d 
Catalase (µmol/min) 3.6±0.8bc 1.5±0.4a 2.8±0.1b 3.8±0.4c 2.4±0.5b 3.9±0.3c 
Results are expressed as mean ± SD (n=5). a-dDifferent superscript alphabets along a row indicate significant 
difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
5.5.5 Discussion 
The present study demonstrated that the butanol fraction of P. biglobosa leaves possess potent in vivo 
anti-oxidative activity in a T2D model of rats.  
 
Glutathione is the most important in vivo antioxidant biomolecule and serves as the first line of defense 
against reactive oxygen species whereas SOD and catalase are the two major antioxidant defense enzymes 
that catalyze the detoxification superoxide radicals to hydrogen peroxides which is subsequently 
decompose to water [71]. The PBBF treatment was found to increase the levels of glutathione, SOD and 
catalase in the serum and organs of diabetic rats which suggests that the fraction possesses bioactive 
phytochemicals that could boost these endogenous anti-oxidant reserves under diabetic condition as well 
as prevent T2D-induced lipid peroxidation in the blood and various organs of the body.   
Oxidative stress has been reported to play a major role in insulin resistance, hepatic and kidney damages 
associated with diabetes [71, 40] and in our previous study, the PBBF was found to significantly reduce 
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the severity of these T2D-associated complications (see 5.4 above). Thus, the ability of the PBBF to 
retard the development of oxidative stress in the liver and kidney of diabetic animals suggests that the 
amelioration of the T2D-induced insulin resistance, hepatic and kidney damages by the fraction was 
mediated through an anti-oxidative dependent mechanism. 
Cardiovascular complications are associated with T2D and are usually caused by alterations in serum 
lipids profile during diabetes [72]. Thus, exploration of the biochemical events occurring at cardiac 
tissues during diabetes may ultimately provide a clue to the management of cardiovascular diseases 
associated with T2D. The observed effects of PBBF on the heart anti-oxidant parameters suggest that the 
fraction was able to reduce an oxidative attack to the heart resulting from increased serum lipids. 
Hyperlipidemia has been reported to be an important factor that enhances the formation of lipid peroxides 
and the development of oxidative stress in T2D [73] and in our previous study, we observed an anti-
hyperlipidemic activity of the PBBF in diabetic rats (see 5.4 above). Based on the foregoing, it is possible 
to surmise that the detrimental effects of the T2D-induced hyperlipidemia to the cardiac tissues were 
reversed via an anti-oxidative dependent mechanism. 
A number of studies have reported that pancreas has a very limited amount of ROS detoxifying enzymes 
(catalase and superoxide dismutase) which makes it highly susceptible to oxidative damage [38, 74]. 
Indeed, this phenomenon is a major event responsible for pancreatic β-cell death and subsequent decline 
in insulin secretion [75]. Interestingly, our findings also suggest that the pancreas has a lower amount of 
anti-oxidant enzymes compared to other organs. The observed effects of the PBBF on the pancreatic 
antioxidant parameters indicate that the fraction is capable of reducing the number of pancreatic β-cell 
death and associated hypoinsulinemia. Thus, this observation could provide a biochemical rationale for 
the higher serum insulin levels, β-cell function (HOMA- β) and β-cell number in PBBF-treated diabetic 
rats compared to diabetic controls (see 5.4 above). 
Taken the results of this study as a whole, it also appeared that the low dose treatment (150 mg/kg bw) 
confer better protection against T2D-oxidative stress than the high dose (300 mg/kg bw) which 
corroborates with the findings on the anti-diabetic effects of the two doses (see 5.4 above). This 
seemingly linear relationship is indeed very interesting because it provides strong evidence of a linkage 
between the anti-diabetic effects and in vivo anti-oxidative activity which further supports the earlier 
assertions on the involvement of anti-oxidative dependent processes in the overall anti-diabetic effects of 
the fraction. 
In conclusion, findings from this study revealed that PBBF, especially at a low dose of 150 mg/kg bw, is 
therapeutically active in alleviating T2D-induced oxidative stress in various organs of the body and this 
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6.0 THE ANTI-OXIDATIVE AND ANTI-DIABETIC ACTIVITY 
OF Khaya senegalensis IN VITRO AND IN VIVO  
 
Preface: This sub section (6.1.1-6.1.5) on the brief review of Khaya senegalensis is a synopsis of an 
accepted book chapter that I wrote during the course of this PhD study. However, due to space 
constraints, the entire book chapter was not presented in this dissertation. The reference to the book 
chapter is as follows: 
 
Ibrahim M. A. and Islam M. S. (2013). Biological activities, phytochemistry and industrial potentials of 
Khaya senegalensis (Meliaceae) A. Juss. In Medicinal Plants: Phytochemistry, Pharmacology and 
Therapeutics, Volume 3: page 213-234. M/S Daya Publication house, New Delhi, India. 
 
6.1.1 Khaya senegalensis (Meliaceae) A. Juss 
 
Figure 6.1: Khaya senegalensis (Meliaceae) A. Juss: African Mahogany (English); Cailcedrat (French); 
mkangazi (Swahili); Ogonwo (Yoruba, Nigeria); Madachi (Hausa, Nigeria); Ono (Igbo, Nigeria). Photo: 
Mohammed Auwal Ibrahim (2013), Zaria, Nigeria 
 
6.1.2 Background 
Khaya senegalensis is an evergreen tree that makes up to 15-30 m high. The leaves are compound 
approximately 13-33 cm. It occurs naturally in the tropics of 19 central African countries discontinuously 
from Senegal and neighboring countries in the west (mostly between about 8°N and 15°N but extending 
to about 6°N in Nigeria) through to Sudan and Uganda in the east where it extends southward to about 
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2°45'N. This distribution covers a wide range of climatic, altitudinal, ecological and edaphic conditions. 
Throughout its natural range, K . senegalensis has been exploited for timber, which is used for fine 
furniture, construction, and fuel. It was one of the first west African forest tree species to be imported by 
Europeans due to its excellent timber and veneer [1]. Apart from the wood and timber uses of this plant, 
more relevant to this dissertation, is the medicinal application of this species in the treatment of various 
tropical diseases. 
 
6.1.3 Ethnomedicinal uses 
Almost all parts of the plant are claimed to cure a multitude of tropical diseases prevalent in the areas 
where it grows and as such, it is considered as a primary health care facility to millions of Africans. In an 
ethnobotanical survey, Atawodi et al. [2] reported that among all other plants, K. senegalensis was the 
most commonly used plant for the treatment of trypanosomiasis in Kaduna state of Nigeria where the 
disease is prevalent. Similarly, in a survey of Ghanian herbal market, K. senegalensis was among the 
medicinal plants that had highest market demand where the bark is used as blood tonic, aphrodisiac and 
for treating fever and malaria [3]. Reports from northern Cote-d ‘Ivoire also indicate that the stem bark of 
K. senegalensis is among the highly utilized medicinal plants for the treatment of wounds, diarrhea and 
dysentery [4]. Furthermore, a study on herbal remedies among the Tem tribe of Togo also suggests that K. 
senegalensis was among the list of plants used to cure several diseases such as malaria, anemia and 
gastrointestinal diseases [5]. Another ethnobotanical study from north western Nigeria also indicated that 
K. senegalensis is highly ranked in the list of medicinal plants used for the traditional management of 
diabetes mellitus [6]. 
 
6.1.4 Biological activities 
The most widely scientifically validated pharmacological property of K. senegalensis extracts is perhaps, 
the antitrypanosomal activity. Atawodi et al. [7] and Wurochekke and Nok [8] demonstrated that extracts 
from K. senegalensis had the best in vitro antitrypanosomal activity using different species of 
trypanosomes. Subsequently, an in vivo activity of stem bark extracts of the plant against T. brucei [9] and 
T. evansi [10] was reported. More recently, Ibrahim et al. [11] reported the in vivo antitrypanosomal 
activity of a phenolics rich fraction of the stem bark where phloroglucinol and 3,4-(dihydroxyphenyl) 
acetic acid were identified as the possible bioactive compounds. The anti-malarial and antihelminthic 
activities of extracts of this plant were also validated where the stem bark extracts were found to inhibit 
the proliferation of Plasmodium falciparum [12] as well as mediate the killing of both intestinal and 
abdominal gastrointestinal nematode parasites [13]. Furthermore, the antibacterial and anti-inflammatory 
activities of the plant were also investigated. For example, Kone et al. [4] which demonstrated that 
ethanolic extract of K. senegalensis stem bark was among the ten most active plant extracts (out of fifty) 
against some antibiotic resistant bacteria strains and a freeze dried aqueous extract of the plant  was 
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shown to reduce carrageenan- and croton oil-induced oedema [14,15]. The antioxidant activity of the stem 
bark, root and leaf samples of the plant has also been reported using 2-deoxyguanosine and 
hypoxanthine/xanthine assays and the stem bark possessed the possessed the highest antioxidant activity 
[16]. Preliminary investigations on the larvicidal [17], pesticidal [18], anti-cancer [19] and anti-anemic 
[20] activities of the plant’s extracts have also been reported. Recently, preliminary anti-diabetic study 
was performed on the plant where the aqueous stem bark extract of K. senegalensis was found to reduce 
the fasting blood glucose levels of alloxan induced type 1 diabetes model of rats [21].  
 
6.1.5 Phytochemistry 
The major bioactive compounds isolated from different parts and extracts of K. senegalensis are 
limonoids. The first limonoid isolated from K. senegalensis in 1996 was khayanolide limonoids [22] 
which was followed by the isolation of a novel limonoid, 2,6-dihydroxyfissinolide and two known 
limonoids, fissinolide and methyl 3b-acetoxy-6-hydroxy-1-oxomeliac-14-enoate from the bark of the 
plant [23].  In 2001, another research group identified the presence of two mexicanolide-type limonoids 
named khayanone and  2-hydroxyseneganolide  as well as one rearranged phragmalin limonoid 1-O-
acetylkhayanolide A [24]. This is followed by the isolation of three new modified limonoids from the 
acetone extract of K. senegalensis bark which were named khayanolide D, khayanolide E and 
khayanoside [25]. Subsequently, a number of related limonoids were isolated and characterized from 
various parts of the plant [26-28]. Apart from limonoids, the only group of phytochemicals isolated from 
K. senegalensis are dimeric proanthocyanidins fisetinidol-(4α,6)-catechin (proanthocyanidin B3) and 
catechin-(4α,8)-catechin [29].  
 
In order to elaborately validate the folkloric claim for anti-diabetic activity of this plant (as earlier 
mentioned), a systematic and comprehensive investigation on the anti-diabetic activity of this plant using 
in vitro and in vivo models was carried out. Initially, various solvent crude extracts of the stem bark, root 
and leaves of the plant were subjected to detailed in vitro anti-oxidative studies (using four models) from 
where the ethanol extract of the root was found to have the best activity. Subsequently, the ethanol extract 
of the root was fractionated across various solvents and the fractions were subjected to in vitro anti-
oxidative and -glucosidase and -amylase inhibitory studies where the butanol fraction was found to 
have the best anti-oxidative and enzymes inhibitory activities. Thus, the butanol fraction was investigated 
for in vivo anti-diabetic activity in a type 2 diabetes model of rats as well as the possible mechanism of 
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Preface: The in vitro anti-oxidative activities of the stem bark, root and leaves of the plant were 
investigated in this article. Subsequently, the crude extract was partitioned and the recovered the solvent 
fractions were investigated for anti-oxidative and α-glucosidase and α-amylase inhibitory activities. This 
article has been submitted for publication to ‘’Acta Pharmaceutica’’ and is currently under review. 
 
6.2.1 Abstract 
This study evaluated the in vitro anti-oxidative activities of Khaya senegalensis extracts and the inhibitory 
effects of some solvent fractions on α-glucosidase and α-amylase activities. The stem bark, root and leaf 
samples of the plant were sequentially extracted with ethyl acetate, ethanol and water and then tested for 
anti-oxidative activity in a series of in vitro models. Our findings revealed that the ethanolic extract of the 
root had the most potent reducing power and could scavenge DPPH, hydroxyl and nitric oxide radicals. 
Solvent-solvent fractionation of the root ethanolic extract yielded a butanol fraction that possessed more 
potent anti-oxidative activity than other (aqueous, ethyl acetate and dichloromethane) fractions. 
Furthermore, the butanol fraction had significantly higher (P<0.05) α-glucosidase and α-amylase 
inhibitory activities among other fractions with IC50 values of 2.89 ± 0.46 and 97.51 ± 5.72 μg/ml for α-
glucosidase and α-amylase inhibitions respectively. Enzyme kinetic studies indicated that the butanol 
fraction is a non-competitive inhibitor for α-glucosidase with an inhibition binding constant (Ki) of 1.30 
μg/ml and a competitive inhibitor of α-amylase with a Ki of 7.50 μg/ml. GC-MS analysis revealed that 
the butanol fraction contains pyrogallol and phloroglucinol derivatives. Data from this study suggest that 
the butanol fraction derived from the ethanolic extract of K. senegalensis root possessed excellent anti-
oxidative as well as α-glucosidase and α-amylase inhibitory activities while pyrogallol and phloroglucinol 
derivatives could be the bioactive constituents. The results provide a strong motivation for further detailed 
in vivo study on the fraction. 
 
6.2.2 Introduction  
Diabetes mellitus is one of the major global public health problems and its prevalence is currently 
increasing at an alarming rate. According to the International Diabetes Federation (IDF), about 366 
million people are living with diabetes and this figure is projected to increase to 552 million by the year 
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2030 [30]. Between the two major types of diabetes, type 2 diabetes (T2D) is most prevalent and accounts 
for > 95% of the total diabetic population worldwide.  Type 2 diabetes (T2D) is a heterogeneous disorder 
characterized by a progressive decline in insulin action (insulin resistance), followed by the inability of 
pancreatic β-cells to compensate for insulin resistance (β-cell dysfunction) leading to hyperglycemia [31] 
and oxidative stress is a major contributor to the β cell damage [32].  
 
Oxidative stress refers to the existence of products called free radicals (molecules possessing an unpaired 
electron) and reactive oxygen species (ROS), which are formed in normal physiological processes but 
become deleterious when they are not quenched by a cascade of antioxidants systems. This can result 
either from an overproduction of ROS or from the inactivation of the antioxidants (AO), thereby shifting 
the ROS/AO balance in favor of stress [33]. In T2D, hyperglycemia induces generation of free radicals, 
including ROS, hydroxyl and nitric oxide (NO) radicals [34] which are responsible for oxidative stress 
induced pancreatic β cell destruction as well as the activation of all major pathways underlying the 
different components of chronic vascular diabetic complications such as glycation, sorbitol pathways 
among others [33]. The concept of oxidative stress as an important trigger, and postprandial 
hyperglycemia in the onset and progression of diabetes offer a unique therapeutic strategy for the 
treatment of T2D and for reducing chronic vascular complications [35]. Current therapeutic strategy for 
the control of postprandial hyperglycemia is the inhibition of two members of exo-acting glycoside 
hydrolase (α-glucosidase and α-amylase), resulting in aggressive delay of carbohydrate digestion to 
absorbable monosaccharides [36]. Starch and other complex polysaccharides are hydrolyzed by α-
amylase to oligosaccharides that are further hydrolyzed to liberate glucose by intestinal α-glucosidase 
before being absorbed into the intestinal epithelium and entering blood circulation.  Therefore, α-
glucosidase and α-amylase inhibitors will ultimately reduce the flow of glucose from complex dietary 
carbohydrates into the bloodstream, diminishing the postprandial hyperglycemia. However, the leading 
glucosidase inhibitors, acarbose and miglitol, are often reported to produce diarrhea and other intestinal 
disturbances, with corresponding bloating, flatulence, cramping and abdominal pain [37]. Randomized 
controlled trials with glucosidase inhibitors report these gastrointestinal side effects as the most common 
reason for noncompliance and early subject withdrawal [38]. Interestingly, plant based agents were 
reported to be a more acceptable source of glucosidase inhibitors due to their low cost and relatively 
better safety levels, including a lower incidence of serious gastrointestinal side effects [39].The foregoing 
therefore makes research on diabetes therapy to focus attention on the search for alternative agents with 
potent anti-oxidative properties which could also decrease postprandial hyperglycemia, thereby providing 





Khaya senegalensis (Desr.) A. Juss, also known as African mahogany, is a member of the Meliaceae 
family and highly reputed for numerous medicinal effects. Ethnopharmacological surveys revealed that 
the stem bark, root and leaves of the plant are used in the traditional treatment of diabetes, malaria, 
anemia, diarrhea, gastrointestinal diseases, fever amongst others [3, 6]. The antitrypanosomal [9], 
antioxidant [16] and anticancer [19] activities of different parts of the plant have been demonstrated. 
Furthermore, some preliminary investigations have reported the anti-hyperglycemic activity of the 
aqueous stem bark extract of this plant in a type 1 diabetes model of rats [21] as well as an in vitro α-
amylase inhibitory potential [40]. However, the complete anti-oxidative and -glucosidase or -amylase 
inhibitory activity of the extracts from different parts of this plant has not been evaluated till today. 
Hence, in this study, we conducted a comprehensive and systematic investigation on the in vitro anti-
oxidative as well as α-glucosidase and α-amylase inhibitory activities of various extracts and solvent 
fractions of K. senegalensis using different in vitro models. 
6.2.3 Materials and Methods 




The ethanolic extracts were found to contain a significantly (P<0.05) higher amount of total phenolics 
than other extracts with the highest amount being present in the ethanolic extract of the stem bark (Table 
6.2.1). The total reducing power (in terms of percentage gallic acid equivalent) of the various extracts 
from the stem bark, root and leaves of K. senegalensis was compared to ascorbic acid and trolox (Figure 
6.2.1). While all the solvent extracts from the various parts of K. senegalensis demonstrated Fe3+- Fe2+ 
reductive ability but the ethanolic extract of the root exhibited a significantly (P<0.05) higher reducing 













Figure 6.2.1: Total reducing power (relative to gallic acid) of stem bark (A), root (B) and leaves (C) 
extracts of K. senegalensis. Data are presented as mean ± SD of triplicate determinations. a-dDifferent 
alphabets presented for a given concentration of each extract indicate significant difference (Tukey’s-
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The anti-oxidative activities (using DPPH, HRS and NO models) of the extracts from the different parts 
of K. senegalensis are summarized in Table 6.2.1. All the extracts from the plant scavenged DPPH 
radicals, however the ethanolic extracts of the stem bark and root as well as the aqueous extract of the 
leaves displayed a statistically similar but significantly (P<0.05) higher DPPH radical scavenging activity 
than all other extracts from the plant. Furthermore, all the extracts could scavenge hydroxyl radicals 
generated by the Fenton’s reaction except the ethyl acetate extracts of the stem bark and leaves which 
showed pro-oxidative tendencies in this model. The ethyl acetate extract of the root showed the best 
activity with the ethanolic extracts also showing good activity. The highest NO scavenging activity was 
observed with the ethanolic extract of the leaves followed by the stem bark aqueous extract and ethanolic 
extract of the root. Thus, a close analysis of the results obtained from the total reducing power assay and 
the three models for anti-oxidative studies revealed that the ethanolic extract of the root had a high anti-
oxidative activity that reasonably cuts across all the models used and therefore, it was selected for the 
next step of the experiment. 
Table 6.2.1: Percentage yield, total phenolics and IC50 values of various extracts of K. senegalensis parts 
in different anti-oxidative models 
The results are expressed as mean ± SD values of triplicate determinations. a-hDifferent superscript alphabets along a 
column indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05). ND means not 
determined and P means the extract showed pro-oxidative properties in the experimental model.  
 
Using solvent-solvent fractionation, the ethanolic extract of the root was fractionated to obtain a 
dichloromethane, ethyl acetate, butanol and aqueous fractions. The butanol fraction had a significantly 
(P<0.05) higher total reducing power (Figure 6.2.2) and DPPH radical scavenging activity (Table 6.2.2) 
 
Samples 




DPPH HRS NO 
Stem bark      
Ethyl acetate 1.36 50.62 ± 0.08c 7.15 ± 2.12c P 3205.41 ± 760.44h 
Ethanol 4.75 107.31 ± 3.05g 1.99 ± 0.87a 2.08 ± 0.28a 63.75 ± 4.81c 
Aqueous 3.51 59.64 ± 1.03d 195.01 ± 45.60f 15.13 ± 1.25d 28.50 ± 7.71b 
      
Root      
Ethyl acetate 0.98 13.70 ± 0.37b 48.20 ± 3.47e 1.68 ± 0.27a 95.32 ± 6.08d 
Ethanol 2.91 97.76 ± 0.66f 1.59 ± 0.64a 2.18 ± 0.45a 29.23 ± 1.87b 
Aqueous 2.66 58.32 ± 1.76d 22.71 ± 3.47d 4.85 ± 0.61c 192.70 ± 33.91e 
      
Leaves      
Ethyl acetate 1.43 12.08 ± 0.12a 44.67 ± 4.62e P 47.75 ± 5.92c 
Ethanol 2.99 77.38 ± 1.27e 3.25 ± 0.57b 2.44 ± 0.53ab 6.92 ± 1.42a 
Aqueous 3.82 14.08 ± 0.74b 1.40 ± 0.22a 59.31 ± 12.43e 183.45 ±15.18e  
      
Ascorbic acid - - 2.56 ± 0.26ab ND 26.40 ± 6.46b 
Gallic acid - - 1.40 ± 0.43a ND 1053.48 ± 239.92g 
Trolox - - 8.47 ± 2.88c 3.23 ± 0.49b 629.76 ± 63.98f 
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than other fractions. However, the ethyl acetate and dichloromethane fractions had significantly higher 
(P<0.05) hydroxyl and NO radicals scavenging activities respectively, than other fractions (Table 6.2.2).  
 
Figure  6.2.2:  Total reducing power (relative to gallic acid) of different solvent fractions of K. 
senegalensis root ethanolic extract. The results are expressed as mean ± SD of triplicate determinations. a-
dDifferent alphabets presented for a given concentration for each extract indicate significant difference 
(Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Table 6.2.2: IC50 values of various solvent fractions of ethanolic extract of K. senegalensis root in 
different anti-oxidative models 
Fractions Total phenolics 
(mg/g GAE) 
IC50 (µg/ml) 
DPPH Hydroxyl radical Nitric oxide 
Aqueous 128.23 ± 1.73b 27.71 ± 0.87b 62.45 ± 0.72c 6.92 ± 0.4c* 
Butanol 201.24 ± 4.64d 3.11 ± 0.77a 41.20 ± 2.27b 35.89 ± 3.24d* 
Ethyl acetate 182.15 ± 2.78c 3.78 ± 1.12a 31.53 ± 4.22a 3.58 ± 0.5b* 
Dichloromethane 7.71 ± 3.30a 91.00 ± 1.09c 58.31 ± 4.74c 1042.84 ± 40.28a 
The results are expressed as mean±SD values of triplicate determinations. a-dDifferent superscript alphabets along a 
column indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05).*Unit was expressed in 
mg/ml. 
Figure 6.2.3 shows the inhibition of α-glucosidase and α-amylase by the fractions of ethanolic extract of 
the root. All the fractions inhibited α-glucosidase and α-amylase activities in vitro in a dose dependent 
pattern. The more polar (aqueous and butanol) fractions consistently maintained higher inhibitory 
activities against the enzymes than the less polar (ethyl acetate and dichloromethane) fractions. 
Furthermore, as shown by the IC50 values, the butanol fraction had a significantly (P<0.05) higher 
inhibitory activity than other fractions with IC50 values of  2.89 ± 0.46 and 97.51 ± 5.72 μg/ml for α-
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Figure 6.2.3: α-glucosidase (A) and α-amylase (B) inhibitory activities of different solvent fractions of 
ethanolic extract of K. senegalensis root. The results are expressed as mean ± SD of triplicate 
determinations. a-eDifferent superscripts alphabets over the bars for a given concentration indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Table 6.2.3:  IC50 values for the inhibition of α-glucosidase and α-amylase by various solvent fractions of 
ethanolic extract of K. senegalensis root  
Fractions/standard IC50 (µg/ml) 
α-glucosidase α-amylase 
Aqueous  5.15 ± 1.10b 130.23 ± 12.90b 
Butanol 2.89 ± 0.46a 97.51 ± 5.72a 
Ethyl acetate 23.89 ± 0.70c 394.97 ± 13.46d 
Dichloromethane 91.23 ± 2.17e 154.64 ± 6.67e* 
Acarbose 55.59 ± 5.22d 256.66 ± 20.52c 
The results are expressed as mean ± SD of triplicate determinations. a-eDifferent superscripts alphabets along a 
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The enzyme kinetic studies revealed that the butanol fraction is a non-competitive inhibitor of α-
glucosidase with Vmax decreasing from 655.09 μmol/min to 27.38 μmol/min. The KM remained 
unchanged at 2.00 mM and the computed Ki value for inhibiting α-glucosidase was 1.30 μg/ml (Figure 
6.2.4A). Conversely, the mechanism of inhibition of α-amylase by the butanol fraction revealed a 
competitive inhibition pattern with a KM value of 1.25% and 0.25% in the presence and absence of the 
inhibitor respectively. The Vmax of the α-amylase was not affected (33.70 μmol/min) and Ki for 




Figure 6.2.4: Lineweaver-Burke’s plot of α-glucosidase (A) and α-amylase (B) catalysed reactions in the 
presence and absence of the butanol fraction derived from the K. senegalensis root ethanolic extract 
 
The GC-MS chromatogram of the butanol fraction is presented in Figure 6.2.5. The major peaks detected 
in the chromatogram of the butanol fraction were those of the chromones 7,8-dihydroxy-2,3-
dihydrochromone (1), 5,7-dihydroxychromone (2),  p-anilinophenol hydrochloride (3) and 3-ethyl-5-(3-

















































fragmentation patterns and in conjunction with the NIST library (Figure 6.2.6). The retention time and 
molecular mass of the detected phytochemicals are provided in Table 6.2.4. 
 
















































Table 6.2.4: Identified components of butanol fraction of K. senegalensis root ethanolic extract by GC-
MS 




1 7,8-dihydroxy-2,3-dihydrochromone 9.35 181 
2 5,7-dihydroxychromone 12.53 179 




§ means annotated peak number on the GC-MS chromatogram 
6.2.5 Discussion 
The roles of oxidative stress and hyperglycemia as underlying factors in the pathogenesis of T2D and 
associated complications have been fully elucidated in several previous studies [41, 42]. Therefore, the 
use of potent anti-oxidative agents and inhibitors of carbohydrate digesting enzymes (α-glucosidase and 
α-amylase) will provide a holistic therapeutic strategy for the control of postprandial blood glucose levels, 
T2D and chronic vascular complications. This study revealed that the butanol fraction of ethanolic extract 
of the root of K. senegalensis, a plant commonly used for the treatment of diabetes in Nigeria [6] 
contained powerful anti-oxidative agents as well as inhibitors of α-glucosidase and α-amylase. 
 
 Four experimental models for in vitro anti-oxidative studies were used because a single model cannot 
give a full evaluation of the anti-oxidative capabilities of the different extracts tested due to the 
involvement of multiple mechanisms. The total reducing power was measured by the reduction of Fe3+–
Fe2+ in the presence of the extracts using the method of Oyaizu [43]. The reducing capacity of an 
extract/compound may serve as a significant indicator of its potential antioxidant activity. Using this 
method, the ethanolic extract of the root displayed a consistently higher reducing power than the other 
extracts. Free radicals are known to be a major factor contributing to biological damages and DPPH has 
been used to evaluate the free radical scavenging activity of natural AO. Hydroxyl radicals are also 
extremely reactive species capable of damaging any biological molecule found in living systems [44] and 
NO is an unstable species which reacts with oxygen to generate nitrite and peroxynitrite anions [45] All 
these radicals are implicated in the pathogenesis of T2D [34] From the present study, the ethanolic extract 
of the root contain better group(s) of phytochemical(s) which could reasonably scavenge all the various 
forms of the reactive species tested. This further suggests that the phytochemical components of this plant 
with high redox potentials, at least in this part, are ethanol extractable. Guided by these activities, solvent 




The butanol fraction partitioned from the ethanolic extract of the root was shown to possess better 
antioxidant and scavenging activities than other fractions across the experimental models used. This is 
indicative of the presence of powerful phytochemical(s) that might have the ability to inhibit free radical 
upsurge as well as oxidative stress. These phytochemicals, either in pure form or in combination could be 
useful therapeutic agents for treating oxidative stress based metabolic disorders.  
 
The control of postprandial hyperglycemia is believed to be important in the treatment of diabetes and 
prevention of cardiovascular complications. One of the therapeutic approaches to this control is to retard 
glucose absorption by inhibiting carbohydrate hydrolysing enzymes, such as α- amylase and α-
glucosidase, in the digestive organs [36]. All the fractions from the ethanol extract of the root inhibited α-
glucosidase in a dose dependent manner. Inhibition of this enzyme would slow down the breakdown of 
disaccharides to liberate glucose; thereby reducing glucose absorption from the small intestine [46]. 
However, the butanol fraction exhibited stronger α-glucosidase inhibitory activity with especially 
remarkable IC50 value (2.89 ± 0.46 µg/ml). In spite of abundant reports on the α-glucosidase inhibitory 
activities of extracts and pure compounds from plants in different parts of the world, only a few authors 
[47] reported such a low IC50 value as found with the butanol fraction in our study. This observation 
might not be unconnected to the high phenolics content recorded in this fraction because polyphenolic 
fractions from plants have been shown to inhibit α-glucosidase activity allowing for tighter control of 
blood glucose [48]. Furthermore, Mai et al. [49] reported a strong positive correlation between 
polyphenolic content and α-glucosidase inhibitory effects of 28 extracts from Vietnamese edible plants 
but also suggested that the enzymatic inhibition might depend on the type of the polyphenolics. In the 
same vein, the butanol fraction had the highest α-amylase inhibitory activity which suggests the presence 
of better group(s) of phytochemicals that could inhibit the breakdown of complex carbohydrates to 
oligosaccharides, thereby diminishing the effect of carbohydrate consumption on postprandial 
hyperglycemia. Moreover, the observed higher α-glucosidase inhibitory activity of the butanol fraction 
over the corresponding α-amylase activity is of great pharmaceutical interest. This is because some of the 
side effects associated with the currently available drugs for the management of T2D are linked with the 
excessive inhibition of α-amylase activity [35]. 
 
The mechanism of α-glucosidase inhibition by the butanol fraction revealed a non-competitive inhibition 
pattern which indicates that the fraction binds the α-glucosidase at separate site(s) of the enzyme (rather 
than the active site) but caused conformational modification at the active site, thereby preventing effective 
binding of the pNPG and consequently reduced the α-glucosidase activity. It further suggests that the 
fraction contains some phytochemicals that are capable of interacting with the α-glucosidase-pNPG 
complex [50]. On the contrary, the pattern of α-amylase inhibition by the fraction suggests that the active 
site of the enzyme is directly involved in the inhibitory action and the fraction most likely contains some 
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phytochemical(s) that could serve as substrate analogues, thereby competing for the active site of α-
amylase [51].  
Phenolics are very important constituents among the secondary metabolites of plants because of their 
multiple biological effects and direct contribution to anti-oxidative and α-glucosidase inhibitory activities 
[49]. While not discounting the possible contributions of the other detected phytochemicals, it is possible 
to suggest that the bioactive agents of the butanol fraction contain phenolic groups such as those present 
in the two chromones 1 and 2 identified by GC-MS. 
The results of this study suggests that the butanol fraction derived from the ethanolic extract of K. 
senegalensis root contain the most potent α-glucosidase and α-amylase inhibitory agents and the 
identified phenolics could be the bioactive agents hence can be investigated as novel anti-diabetic 
therapeutic.  
Postscript: From the above studies, the butanol fraction had the best α-glucosidase and α-amylase effects 
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Preface: This article reports the detailed in vivo anti-diabetic studies of the butanol fraction and the 




The present study was conducted to examine the anti-diabetic activity of butanol fraction of Khaya 
senegalensis root (KSBF) in a type 2 diabetes (T2D) model of rats as well as the possible bioactive 
compound from the fraction. T2D was induced by feeding rats with 10 % fructose solution ad libitum for 
two weeks followed by intraperitoneal injection of 40 mg/kg bw streptozotocin and the animals were 
treated with 150 and 300 mg/kg bw of the fraction for five days in a week. The KSBF treatment, at 300 
mg/kg bw, significantly (P<0.05) lowered blood glucose level, improved oral glucose tolerance ability 
and β cell function (HOMA-β), decreased insulin resistance (HOMA-IR), stimulated hepatic glycogen 
synthesis, ameliorated serum lipids alterations and prevented hepatic and renal damages compared to 
untreated diabetic rats. Additionally, the fraction was found to insignificantly (P>0.05) improve weight 
gain, decrease feed and fluid intakes, stimulate insulin secretions and lower serum fructosamine 
concentrations compared to untreated diabetic rats. Bioassay guided fractionation of the fraction led to the 
isolation of bicyclo [2.2.0]hexane-2,3,5-triol which strongly inhibited -glucosidase and -amylase with 
IC50 values of 45.87 ± 6.46 and 63.28 ± 10.10 µg/ml respectively. Further kinetic studies revealed that the 
compound is a non-competitive inhibitor of -glucosidase and -amylase activities.  Data from the study 
suggests that orally administered KSBF, at 300 mg/kg bw, possess remarkable anti-T2D activity and 
could ameliorate some diabetes-associated complications while bicyclo [2.2.0]hexane-2,3,5-triol is an 
important bioactive anti-diabetic agent in the fraction. 
 
6.3.2 Introduction 
Diabetes mellitus is a heterogeneous group of metabolic disorder characterized by high blood glucose 
levels (hyperglycemia) with alterations in carbohydrate, lipid and protein metabolism resulting from 
defects in insulin secretion and/or action [52]. Current estimation for the prevalence of diabetes stands at 
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366 million people which is projected to reach 552 million by the year 2030 [30] while type 2 diabetes 
(T2D) accounts for >90% of all the diabetic cases. T2D is a complex, heterogenous and polygenic disease 
characterized mainly by insulin resistance and pancreatic β cell dysfunction [53]. A number of theories 
have been proposed to explain the pathogenesis of insulin resistance and pancreatic β cell dysfunction but 
oxidative stress, through a single unifying mechanism of reactive oxygen species production, is regarded 
as the common biological player for the two main pathogenic features of T2D and also plays vital roles in 
other aspects of diabetes pathology [54-56], thereby making it a potential therapeutic target. At present, 
T2D is predominantly managed with sulfonylureas and biguanides but α-glucosidase inhibitors are still 
considered as vital therapeutic option especially in the developing world [36]. Unfortunately, none of the 
multiple therapeutic agents designed for the management of diabetes is not without undesirable side 
effects such as diarrhea, nausea and liver failure [37].  
 
For centuries, several medicinal plants or their extracts are traditionally used in the treatment of diabetes 
with limited side effects. In this modern era, these medicinal plants also continue to play an essential role 
in modern drug discovery. Indeed, the widely used anti-diabetic drug metformin was originally developed 
from a medicinal plant, Galega officinalis [57]. Apart from providing chemical leads for novel anti-T2D 
drugs, some of these medicinal plants are currently available for sale in some African markets as 
standardized herbal products (in crude form) after approval by relevant authorities [58]. Based on the 
above, there is growing research interest on African traditional herbal medicines for possible exploitation 
either directly as standardized anti-diabetic herbal products or indirectly by providing novel chemical 
leads for the development of newer alternative therapies for the treatment of T2D. 
Khaya senegalensis A. Juss (Meliaceae), also known as African mahogany, is a large tree growing mainly 
in the sub-Saharan Africa and highly reputed for numerous medicinal activities [27]. The plant has been 
reported to produce an array of limonoids with fascinating pharmacological activities such as 
antiplasmodial,  anticancer, antifeedant and antifungal properties [25-27]. Polyphenolic compounds such 
as catechin, rutin and procyanidins with significant antioxidant activities were also identified in different 
parts of the plant by HPLC [16]. More recently, Ibrahim et al. [11] reported that phloroglucinol and 3,4-
(dihydroxyphenyl) acetic acid-enriched fraction from the stem bark of the plant elicited antitrypanosomal 
activity and ameliorated the trypanosome-induced anemia and organ damage.  
Ethnobotanical surveys have revealed that K. senegalensis is among the most commonly used plants for 
the traditional treatment of diabetes in northwestern part of Nigeria and central region of Togo [6]. 
Preliminary in vitro α-amylase inhibitory potential as well as anti-hyperglycemic activity of the stem bark 
aqueous extract of the plant in a type 1 diabetes model of rats have been demonstrated [21, 40]. However, 
a comprehensive anti-diabetic study on any part of this plant has not yet been conducted either in humans 
or experimental models of T2D. 
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In a preliminary screening, we subjected different solvent crude extracts of the stem bark, root and leaves 
of the plant to anti-oxidative activity assays using several models and found that the ethanolic extract of 
the root had the best anti-oxidative activity among all other extracts. Hence, in the present study, the 
ethanolic extract of the root was further fractionated across solvents of different polarity and a butanol 
fraction derived from it, was subjected to a comprehensive in vivo anti-diabetic study in a T2D model of 
rats. Additionally, we isolated a pure bicyclo [2.2.0] hexane-2,3,5-triol as a possible bioactive anti-
diabetic compound from the fraction. 
6.3.3 Materials and methods 
Please refer to chapter two sub-sections 2.3-2.4 (pages 35-36); 2.7.1-2.7.7 (pages 40-43) and 2.8.3 page 
46 for detailed materials and methods that affect K. senegalensis. However, the group codes DFL, DFH 
and NFT used in the chapter two are replaced with DKL, DKH and NKT respectively. KSBF refers to the 
butanol fraction of K. senegalanesis root. 
6.3.4 Results 
The mean feed and fluid intake as well as weekly body weight changes of all animals were monitored 
during the experiment. Compared with the normal rats, significantly (P<0.05) higher feed and fluid 
intakes with lower body weight gains were recorded in the diabetic rats. Administration of KSBF to the 
diabetic rats insignificantly (P>0.05) decreased the feed and fluid intake compared to the untreated 
diabetic rats (Figure 6.3.1). However, the body weight loss recorded in diabetic rats was insignificantly 
restored in the DKH group only while DKL group had relatively lower body weight gain than DBC group 
in the last four weeks of the experiment (Figure 6.3.2).  
 
Figure 6.3.1: Feed and fluid intakes of different groups of during the experimental period. Data are 
presented as the mean ± SD of eight animals. a-bDifferent superscript alphabets over the bars for a given 




































Figure 6.3.2: Mean body weight gain for all groups of experimental animals over the seven weeks 
experimental period.  The results are expressed as the mean ± SD of eight animals. a-cDifferent alphabets 
for a given week indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The profiles of weekly NFBG levels in all groups of experimental rats indicated that normal rats (NC and 
NKT groups) maintained an NFBG level of about 7.0 mmol/L throughout the experiment while all 
diabetic rats had an elevated NFBG level. However, treatment of the diabetic rats with KSBF decreased 
the T2D-induced increase in NFBG. The effect of the treatment on NFBG is more pronounced in DKH 
than DKL groups (Figure 6.3.3). Indeed, a sharp and significant decrease (P<0.05) in the FBG level was 
observed in the DKH group compared to the DBC group at the last week of the experiment. The data for 
OGTT are shown in Figure 6.3.4. At 0 and 30 min, the blood glucose concentrations of the diabetic 
groups were significantly (P<0.05) higher than the NC group. There was no significant difference 
(P<0.05) between the glucose tolerance ability of DKL and DBC groups during the entire experimental 
period but the DKH group had a significantly (P<0.05) better glucose tolerance ability compared to the 
DBC group. In fact, statistically similar glucose tolerance ability was observed between DKH and DMF 


































Figure 6.3.3: Weekly blood glucose concentrations (post induction) of different animal groups. The 
results are presented as the mean ± SD of eight animals. a-cDifferent alphabets for a given week indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
 
Figure 6.3.4: Oral glucose tolerance test (OGTT) for all groups of animals in the last week of 
experimental period. The results are expressed as the mean ± SD of eight animals. a-cDifferent alphabets 
for a given time indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The serum insulin concentrations of the DBC group were significantly (P<0.05) lowered compared to NC 
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than the DBC group (Table 6.3.1). HOMA-IR score was significantly (P<0.05) higher while HOMA-β 
score was significantly lower in the DBC group compared to the NC group. However, the DKH group 
had a significantly (P<0.05) ameliorated HOMA-IR and HOMA- β scores while statistically similar, 
though relatively better, results were recorded in the DKL group compared to DBC group. Also, T2D 
caused a significant (P<0.05) elevation in serum fructosamine concentration which was not significantly 
(P>0.05) reversed in the KSBF treated diabetic groups.  
Table 6.3.1: Serum insulin and fructosamine concentrations as well as computed HOMA-IR and HOMA-
β scores for different animal groups at the end of the experimental period 
 NC DBC DKL DKH DMF NKT 
Serum insulin 
(pmol/L) 
153.1±9.9c 64.2±29.9a 74.5±20.3a 84.6±18.9a 119.2±13.0b 162.3±7.5c 
Serum fructosamine 
(µmol/L) 
196.3±5.6a 258.4±10.9b 245.6±8.8b 239.2±2.3b 253.8±30.4b 209.1±20.9ab 
HOMA-IR 4.96±1.0ab 16.2±5.7c 11.8±2.3c 3.3±0.53a 9.8±3.8c 5.3±0.6b 
HOMA-β 304.07±53.72c 9.7±5.2a 15.8±3.7a 27.5±4.4b 54.9±27.5b 289.9±107.8c 
The results are expressed as the mean ± SD of eight animals. a-cDifferent alphabets along a row indicate significant 
difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
HOMA-IR = [(Fasting serum insulin in U/L x Fasting blood glucose in mmol/L) / 22.5] 
HOMA-β = (Fasting serum insulin in U/L x 20 / Fasting blood glucose in mmol/L – 3.5) 
Conversion factor: insulin (1U/L = 7.174 pmol/l) 
 
There were no significant differences in the absolute liver weights of all groups of experimental rats but 
the relative liver weights of the diabetic groups were higher than NC and NKT groups (Table 6.3.2). The 
KSBF treatments did not significantly (P>0.05) affect the relative liver weights in all the experimental 
animals. The liver glycogen content was significantly (P<0.05) depleted in the DBC group compared to 
the NC group but the KSBF treatment significantly (P<0.05) boosted the liver glycogen reserves in the 









Table 6.3.2: Liver weights and liver glycogen concentrations in different animal groups at the end of the 
experimental period 
 NC DBC DKL DKH DMF NKT 
Liver weight (g) 11.8±2.4 10.9±1.9 10.4±0.9 11.1±1.8 10.4±1.7 11.7±1.4 
Relative liver weight (%) 3.3±0.3a 3.9±0.2b 3.9±0.2ab 4.0±0.3b 3.7±0.1a 3.3±0.3a 
Liver glycogen (mg/g tissue) 3.5±0.8b 1.5±0.1a 3.4±1.0b 2.9±1.1b 2.6±0.4b 3.3±0.5b 
The results are expressed as the mean ± SD of eight animals. a-bDifferent superscripts alphabets along a row indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The serum lipid profiles and other biochemical parameters are presented in Table 6.3.3. The DBC group 
had relatively higher levels of total and LDL cholesterols (compared to the NC group) which were 
reduced in the DKL and DKH groups. Conversely, the DBC group had a significantly (P<0.05) lower 
level of HDL-cholesterol which was boosted in the KSBF treated groups. Furthermore, significantly 
(P<0.05) higher triglycerides concentration was recorded in the DBC group which was also decreased in 
the KSBF-treated diabetic rats. Results of other indices of diabetic complications indicated that the serum 
level of AST was neither affected by the T2D nor the KSBF treatments but serum ALT, ALP and urea 
levels were significantly elevated (P<0.05) in the DBC group compared to the NC group. However, the 
KSBF treatments significantly (P<0.05) ameliorated the T2D-induced increase in ALP and urea levels 
whereas the increase in ALT level was significantly ameliorated in the DKH group only. It is noteworthy 
that the KSBF-treated groups had a significantly lower urea levels than the NC group. Relatively lower 




















Table 6.3.3: Serum lipid profiles and other biochemical parameters in different animal groups at the end 
of the experimental period 
 NC DBC DKL DKH DMF NKT 
Total cholesterol 
(mg/dl) 
66.3±6.4ab 76.3±10.62b 54.2±8.5a 68.8±12.7ab 74.6±12.1b 62.8±11.3ab 
HDL cholesterol 
(mg/dl) 
31.0±9.6b 19.8±1.6a 23.5±6.8ab 24.2±5.6ab 28.1±5.4ab 34.4±8.6b 
LDL cholesterol 
(mg/dl) 
19.9±5.4ab 27.5±4.3b 22.4±8.2ab 25.6±8.8ab 25.9±7.4ab 16.3±5.9a 
Triglycerides 
(mg/dl) 
102.5±27.5a 184.8±40.9b 163.8±37.7ab 105.0±12.9a 120.1±27.4ab 92.0±30.5a 
AST (U/L) 88.0±14.8 73.6±7.6 80.0±15.5 82.0±18.0 88.7±17.9 81.9±6.8 
ALT (U/L) 56.3±12.6a 77.8±4.6b 69.0±6.2ab 67.2±4.8ab 63.3±18.2ab 47.0±5.5a 
ALP (U/L) 188.8±19.9a 898.6±174.5c 547.3±196.2b 378.6±124.1b 472.0±74.9b 174.1±35.1a 
Urea (mg/dl) 48.0±6.2b 93.0±16.4c 22.7±6.0a 25.8±3.9a 42.0±11.8b 20.9±6.6a 
Creatinine (µg/dl) 582.0±70.5ab 485.0±40.4a 560.0±71.1ab 554.0±26.1b 675.0±95.2b 551.7±75.7ab 
The results are expressed as the mean ± SD of eight animals. a-cDifferent superscripts alphabets along a row indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Histopathological examination of the pancreatic sections revealed a reduction in the size of pancreatic 
islets as well as the number of β cells per islet count in the DBC group compared to the NC group. 
However, the KSBF treatments protected the T2D-associated destruction of β cells because larger islets 
with higher number of β-cell were detected in the DKL and DKH groups compared to DBC group, 




















Figure 6.3.5: Histopathological pictures of the pancreas of different experimental groups at the end of the 
experiment. The NC had large islets with high number of β-cell while the DBC had smaller islets and 
morphologically deformed β-cells. The DKL, DKH and DMF groups had relatively larger islets with 
higher number of β-cells compared to DBC.  
The isolated compound was identified as bicyclo[2.2.0]hexane-2,3,5triol (Figure 6.3.6) through detailed 
spectral analysis that includes 1H NMR, 13C NMR, 1H-1H COSY, 1H-1H NOESY, HSQC and HMBC 
NMR spectra (Appendix 5-11) as well as mass spectroscopy. The 1H NMR spectrum showed the presence 
of a triplet at δH 0.83 (2H-6, J = 7.4 Hz) which corresponded to a methylene carbon resonance at δC 14.3 
in the 13C NMR spectrum.  The proton resonance is actually two coalesced doublets (a doublet for each of 
the protons in the methylene group) since the two protons are non-equivalent.  This resonance was seen 
coupled to the multiplet methine resonance at δH 1.28 (H-1), which was coupled in turn to the other 
methine resonance at δH 1.46 (H-4), leading to a C6-C1-C4 system. There were two other multiplet peaks 
in the oxygenated region of the spectrum at δH 3.39 (2H) and δH 3.55 (1H).  The H-4 resonance was 
coupled to the resonance at δH 3.39, which was assigned to the two oxygenated methine groups at H-3 and 
H-5.  This proton peak had corresponding carbon resonances at δC 72.2 and 73.3 (C-3 and C-5 
respectively).  The other multiplet resonance at δH 3.55 was assigned to H-2.  HMBC correlations 
between C-1 and H-3/5, C-4 and H-3/5, and C-2 and H-3/5 as well as correlations between C-1 and 2H-6 
and C-4 and 2H-6 support the proposed structure. 
NC DBC DKL 












Figure 6.3.6: Structure of the possible anti-diabetic agent (bicyclo [2.2.0] hexane-2,3,5-triol) isolated 
from the butanol fraction of K. senegalensis root through bioassay guided isolation 
Analysis of α-glucosidase and α-amylase inhibitory activity of the bicyclo [2.2.0] hexane-2,3,5-triol 
revealed that the compound is a potent inhibitor of α-glucosidase and α-amylase activity with IC50 values 
of 45.87 ± 6.46 and 63.28 ± 10.10 µg/ml respectively. Furthermore, enzyme kinetics studies revealed that 
the compound exerts non-competitive inhibition pattern on both enzymes thereby decreasing the Vmax of 
the enzymes while the KM remained unchanged (Figure 6.3.7). For α-glucosidase, the Vmax was reduced 
from 655.09 μmol/min to 66.52 μmol/min and the KM remained unchanged at 2mM while for α-amylase, 




Figure 6.3.7: Lineweaver-Burke’s plot for α-glucosidase (A) and α-amylase (B) catalysed reactions in the 
presence and absence of bicyclo [2.2.0] hexane-2,3,5-triol as an inhibitor 
 
6.3.5 Discussion 
Khaya senegalensis is traditionally used in the management of diabetes in some West African countries 
[6]. Earlier workers have reported preliminary studies on the in vitro -amylase inhibitory activity as well 
as an anti-hyperglycemic activity of the stem bark of the plant in a type 1 diabetes model of rats [21,40]. 
In the present study, we performed a detailed study on the in vivo anti-diabetic activity of the butanol 
fraction of K. senegalensis root in a newly developed model of T2D as well as isolation of a possible 
bioactive anti-diabetic agent from the fraction.  
 
Polyphagia and polydipsia with concomitant reduction of body weight are major symptoms of diabetes 
mellitus [59] which were also evidently observed in the diabetic groups of our experiment. Treatment 
with KSBF did not completely prevent the T2D-induced changes in these physico-metabolic parameters 


















































Elevated fasting or postprandial hyperglycemia is the hallmark of T2D and causes life-threatening 
complications linked to the disease. Consequently, maintaining glucose homeostasis is essential in 
preventing the detrimental effects of hyperglycemia and its associated complications [60]. In our study, at 
a dose of 300 mg/kg bw, the KSBF displayed remarkable anti-hyperglycemic, and not hypoglycemic, 
activity because the fraction did not cause any decrease in the blood glucose level of normal rats. 
Furthermore, the fraction improved glucose tolerance abilities, lowered peripheral insulin resistance, 
stimulated pancreatic β cell function with mild insulinotropic effect as well as ameliorated the diabetes-
induced damage to pancreatic architecture. Taken together, it seems that, in addition to the potent -
glucosidase inhibitory activity of the fraction, the anti-diabetic activity of the fraction is mediated through 
both pancreatic (protection and modulation of β-cells to increase insulin secretion) and other extra 
pancreatic (peripheral utilization of glucose) mechanisms. The anti-diabetic activity of a number of plant 
materials were reported to be through interference with gastrointestinal glucose absorption [61], 
insulinotropic action [62] or by promoting the regeneration of pancreatic β-cells [63].  
Another important feature of experimentally induced diabetes is a reduction in the liver glycogen level 
[64] which is caused by reduced activity of glycogen synthase and increased glycogen phosphorylase 
activity during the disease. Previous studies have demonstrated that a number of plant materials [65, 66] 
elicited an anti-diabetic activity partly through stimulation of hepatic glycogenesis. Thus, the significantly 
higher liver glycogen content recorded in the KSBF treated groups compared to the DBC group (Table 
6.3.2) indicated that the anti-diabetic activity of the KSBF was also mediated not only through the earlier 
postulated mechanisms but also by stimulating hepatic glycogenesis and/or inhibiting glycogenolysis, 
thereby reducing an upsurge in blood glucose levels (Figure 6.3.2). 
 
Type 2 diabetes is associated with profound changes in the serum lipid and lipoprotein profile with an 
increased risk in coronary heart diseases [67]. The LDL transports cholesterol to the peripheral tissues 
where it is deposited while HDL transports cholesterol from peripheral tissues to the liver and facilitate its 
metabolism as well as excretion. Thus, elevation of serum LDL-cholesterol indicates the development of 
atherogenic process while increased HDL-cholesterol decrease the risk of coronary diseases [68]. Thus, 
the ability of KSBF to relatively reduce total cholesterol, triglycerides, LDL-cholesterol and elevate 
HDL-cholesterol in the serum of diabetic animals suggests that, in addition to the anti-diabetic activity, 
the fraction also has a tendency to reduce T2D-associated complications such as coronary heart disease. 
This is partly supported by the lowered serum fructosamine level detected in the KSBF treated diabetic 
animals which also suggest that the fraction interrupts proteins glycation cascades, thereby reducing the 
risk of diabetic complications [69]. Results from other indices of diabetic complications also indicated 
that the T2D caused a significant increase in serum levels of ALT and ALP indicating impaired liver 
function as well as urea which denotes renal function. Interestingly, the fraction also restored these 
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biomarkers (to varying degrees) suggesting the protection of hepatic and renal damages associated with 
diabetic complications. On the other hand, lower serum creatinine concentration was found in the DBC 
group compared to NC group (Table 6.3.3) which corroborates with findings in human based studies 
[70]. Lower serum creatinine level was reported to be a predictor of insulin resistance [70]. It is thus 
plausible to suggest that the ability of KSBF to effectively reduce insulin resistance could be linked to the 
relatively elevated creatinine levels detected in the KSBF-treated diabetic groups compared to the DBC 
group. 
 
After the anti-T2D of the KSBF was investigated by in vivo studies, phytochemical analysis for the 
potential bioactive anti-diabetic agent in the fraction was further conducted which led to the isolation of 
bicyclo [2.2.0]hexane-2,3,5-triol. This is the first time the compound was isolated from any part of K. 
senegalensis. Indeed, apart from a report on the isolation of dimeric proanthocyanidins [29] from the stem 
bark of the plant, all other studies on the phytochemistry of this plant reported mainly on limonoids [25-
27].  Interestingly, the compound was found to be a potent inhibitor of the two enzymes (-glucosidase 
and -amylase) in in vitro models suggesting that the compound could lead to a reduction in postprandial 
hyperglycemic shoot up. Furthermore, kinetic delineation of α-glucosidase and -amylase inhibitions 
indicated non-competitive patterns for both enzymes. These indicate that bicyclo [2.2.0]hexane-2,3,5-triol 
binds -glucosidase and -amylase at separate site(s) of the enzyme (rather than the active sites) but 
caused conformational modification at the active sites thereby preventing effective binding of the 
substrates. This type of inhibition could further suggest that the compound could interact with the 
enzyme-substrate complexes [50]. 
In conclusion, data from the study revealed that the butanol fraction of K.senegalensis root (at a dose of 
300 mg/kg bw) has anti-T2D activity which is mediated possibly through modulation of β-cell function, 
stimulation of peripheral insulin sensitivity and hepatic glycogenesis. Furthermore, the fraction was able 
to ameliorate some of the diabetes-associated complications and bicyclo [2.2.0]hexane-2,3,5-triol is a 
possible anti-diabetic agent in the fraction. Our future work will focus on detailed studies on the 
molecular mechanism(s) for the observed results.  
 
 
Postscript: In order to further explore the possible mechanism of anti-diabetic action of the butanol 





6.4 Attenuation of in vivo antioxidant status could be involved in the anti-
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Preface: This article describes the in vivo anti-oxidative status of the serum and organs collected from the 
rats in the above experiment to give an insight into the possible mechanism of action from oxidative stress 
point of view. This sub section is also not yet submitted for publication. 
6.4.1 Abstract 
The effects of the butanol fraction of Khaya senegalensis root (KSBF) on the anti-oxidant status of the 
liver, kidney, heart, pancreas and serum of type 2 diabetic rats were investigated. Rats were induced with 
type 2 diabetes (T2D) and treated with 150 and 300 mg/kg body weight (bw) of the KSBF. The levels of 
thiobarbituric acid reactive substances (TBARS), glutathione, superoxide dismutase (SOD) and catalase 
in the selected organs and serum were determined at the end of the experiment. The T2D was found to 
significantly (P<0.05) increase the TBARS levels and significantly (P<0.05) decrease the glutathione, 
SOD and catalase in the serum and organs compared to normal rats. However, the KSBF treatment caused 
a dose dependent decrease in the TBARS levels of the serum and organs of type 2 diabetic rats. 
Furthermore, the KSBF treatment ameliorated the T2D-induced depletion in glutathione, SOD and 
catalase in the serum and organs in a dose dependent fashion. It was concluded that the KSBF alleviated 
T2D-induced oxidative stress which could be relevant for the treatment of T2D by the fraction. 
6.4.2 Introduction 
Diabetes mellitus is a complex polygenic disease with multiple aetiologies that poses threat to the global 
health system. At present, oxidative stress is considered to be the most serious contributor to the onset and 
progression of the disease [35]. Our body is naturally endowed with a number of defense systems against 
oxidative damage but impairment of glutathione metabolism and other endogenous non-protein anti-
oxidants as well as attenuation of anti-oxidant enzymes occur in diabetic conditions [33] and this is 
regarded as a vital pathogenic mechanism for the disease [41]. 
 
Khaya senegalensis A. Juss (Meliaceae) is an African medicinal plant commonly used in the traditional 
treatment of several metabolic diseases including diabetes mellitus in Nigeria [6]. Preliminary in vitro α-
amylase inhibitory potential as well as anti-hyperglycemic activity of the stem bark aqueous extract of the 
plant in a type 1 diabetes model of rats have been demonstrated [21, 40]. However, our interest is to 
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comprehensively study the anti-diabetic potentials of this plant as well as the possible molecular 
mechanism(s) involved in the observed activity of the plant. Hence, in a previous study (see 6.2 above), 
we subjected the various crude solvents extracts from the stem bark, root and leaf samples of the plant to 
a series of in vitro anti-oxidative assays and reported that the ethanolic extract of the root had the most 
potent anti-oxidative activities that reasonably cuts across various models. Subsequently, the crude 
ethanolic extract of the root was subjected to solvent-solvent partitioning and found that the butanol 
fraction contain the most potent anti-oxidative and α-glucosidase and α-amylase inhibitory 
phytochemicals in in vitro models (see 6.2 above). Based on the foregoing observations, the butanol 
fraction was investigated for in vivo anti-diabetic activity in a type 2 diabetes model of rats where it was 
found to lower blood glucose levels, improve oral glucose tolerance ability and β-cell function (HOMA-
β), stimulate insulin secretions, decrease peripheral insulin resistance (HOMA-IR), ameliorate serum 
lipids alterations as well as prevent liver and kidney damages associated with the disease (see 6.3 above). 
Thus, considering the crucial role of oxidative stress in the pathogenesis of diabetes and its complications, 
the present study was conducted to investigate, whether or not, attenuation of in vivo antioxidant status 
plays a role in the observed anti-diabetic activity of the butanol fraction of K. senegalensis root. 
6.4.3 Materials and methods 
Please refer to the chapter two sub sections 2.3-2.4 (pages 35-36); 2.7.1-2.7.5 (pages 40-42); and 2.7.8 
(2.7.8.1-2.7.8.4) pages 44-45 for detailed material and methods that affect K. senegalensis. 
 
6.4.4 Results 
The TBARS levels in the serum and all organs investigated in this study were significantly (P<0.05) 
higher in the DBC group compared to the NC group while the glutathione, SOD and catalase levels were 
significantly (P<0.05) lower in the DBC group than the NC group. The DKL and DKH groups had 
significantly (P<0.05) lower levels of hepatic TBARS and significantly (P<0.05) higher levels of hepatic 
glutathione and catalase than the DBC group. SOD was also significantly (P<0.05) boosted in the DKH 









Table 6.4.1: Effects of KSBF on hepatic lipid peroxidation and anti-oxidant status of type 2 diabetic rats 
 NC DBC DKL DKH DMF NKT 
TBARS (µM) 10.6±3.0a 33.9±4.9c 27.8±2.5c 22.2±2.0b 35.9±9.5bc 13.6±4.8a 
Glutathione (µM) 120.8±6.0d 29.9±9.3a  90.2±3.6c 98.3±6.2c 73.6±10.2b 104.5±9.9d 
Superoxide dismutase 
(nmol/min) 
25.5± 5.3b 12.4±1.6a 16.5±5.7ab 19.1±4.4b 17.5±5.2ab 24.2±3.1b 
Catalase (µmol/min) 16.5±0.9c 1.54±0.3a 6.6±1.6b 8.3±1.8b 1.7±0.6a 9.8±1.8b 
The results are expressed as the mean ± SD of five animals. a-dDifferent superscript alphabets along a row indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
Also, the DKL and DKH groups had significantly (P<0.05) lower levels of kidney TBARS but 
significantly (P<0.05) higher levels of SOD and catalase than the DBC group. The glutathione level in the 
kidney was significantly (P<0.05) elevated in the DKH and not DKL group (Table 6.4.2).  
Table 6.4.2: Effects of KSBF on kidney lipid peroxidation and anti-oxidant status of type 2 diabetic rats 
 NC DBC DKL DKH DMF NKT 
TBARS (µM) 14.1±5.8a 40.8±12.5d 33.4±5.6c 26.0±1.9b 33.4±10.0bc 17.9±5.3a 
Glutathione (µM) 68.2±20.8ab 46.0±8.6a 40.6±7.3a 67.9±9.7b 70.8±10.4b 63.3±5.5b 
Superoxide dismutase 
(nmol/min) 
16.1±3.4bc 6.8±1.5a 10.2±1.5b 11.6±2.2b 11.5±4.4ab 18.1±3.8c 
Catalase (µmol/min) 1.7±0.3b  0.9±0.2a 1.7±0.4b 2.1±0.4bc 1.6±0.4b 2.9±0.3c 
The results are expressed as the mean ± SD of five animals. a-dDifferent superscript alphabets along a row indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
The levels of the TBARS and anti-oxidant parameters in the heart of the DKL group was not significantly 
(P>0.05) different from the DBC group. However, the DKH group recorded significantly (P<0.05) lower 
levels of TBARS and higher levels of glutathione than the DBC group. Relatively higher levels of SOD 








Table 6.4.3: Effects of KSBF on lipid peroxidation and anti-oxidant status in the heart of type 2 diabetic 
rats 
 NC DBC DKL DKH DMF NKT 
TBARS (µM) 9.36±2.60a 24.60±8.83b 13.50±3.68ab 8.28±1.98a 33.92±5.89b 8.03±2.06a 
Glutathione (µM) 122.23±22.00c 48.57±14.60a 74.03±14.64ab 91.94±5.25b 79.21±18.30ab 94.97±6.32bc 
Superoxide dismutase 
(nmol/min) 
15.24±4.02b 5.76±1.23a 8.40±2.55a 9.07±2.43ab 12.83±2.01b 16.24±3.84b 
Catalase (µmol/min) 2.10±0.48b 0.93±0.20a 1.29±0.25a 1.34±0.36a 1.44±0.42a 3.29±1.06b 
The results are expressed as the mean ± SD of five animals. a-cDifferent superscripts alphabets along a row indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
 
The TBARS levels in the pancreas was insignificantly (P>0.05) lowered, but the glutathione and catalase 
levels were significantly (P<0.05) higher in the DKL and DKH groups than the DBC group (Table 6.4.4).   
 
Table 6.4.4: Effects of KSBF on pancreatic lipid peroxidation and anti-oxidant status of type 2 diabetic 
rats 
 NC DBC DKL DKH DMF NKT 
TBARS (µM) 6.0±1.2a 35.7±9.1c 26.1±8.6bc 22.6±2.4bc 18.4±4.4b 7.8±1.9a 
Glutathione (µM) 80.0±.09cd 6.2±3.5a 58.7±11.1c 86.5±6.8d 37.3±8.6b 71.7±12.2cd 
Superoxide dismutase 
(nmol/min) 
2.6±0.5c 0.4±0.2a 0.4±0.02a 0.9±0.2b 1.0±0.5b 2.8±0.6c 
Catalase (µmol/min) 0.7±0.2c 0.35±0.04a 0.43±0.03b 1.0±0.3cd 1.1±0.2d 1.5±0.4d 
The results are expressed as the mean ± SD of eight animals. a-dDifferent superscripts alphabets along a row indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
In the serum, a significantly higher (P<0.05) levels of glutathione, SOD and catalase were observed in the 
DKL and DKH groups than the DBC group whereas TBARS level was significantly (P<0.05) lower in the 






Table 6.4.5: Effects of KSBF on serum lipid peroxidation and anti-oxidant status of type 2 diabetic rats  
 NC DBC DKL DKH DMF NKT 
TBARS (µM) 63.0±15.2a  201.2±19.4c 147.9±36.6bc  111.9±18.9b 142.0±32.0b 83.5±12.9a 
Glutathione (µM) 84.5±7.7c 19.9±2.5a 77.8±6.1bc 79.5±3.4bc 65.2±6.8b 67.3±13.9b 
Superoxide dismutase 
(nmol/min) 
18.1±2.42d 0.9±0.2a 8.2±2.6c 11.2±2.0c 3.2±0.7b 15.9±3.8cd 
Catalase (µmol/min) 3.6±0.8c 1.5±0.4a 2.5±0.3b 2.7±0.6bc 2.4±0.5b 3.1±0.9b 
The results are expressed as the mean ± SD of eight animals. a-dDifferent superscripts alphabets along a row indicate 
significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
6.4.5 Discussion 
One of the possible mechanisms of anti-diabetic action of phytochemicals is via attenuation of in vivo 
anti-oxidative status. Therefore, the anti-oxidant parameters of serum and vital body organs of KSBF 
treated diabetic rats were investigated to unravel the possible involvement of anti-oxidant activity to the 
overall anti-diabetic activity of the fraction. 
Analysis of the entire data generated in this study indicates that the KSBF effectively ameliorated the 
T2D-induced oxidative stress in the blood and vital body organs in a dose dependent pattern. 
Interestingly, similar pattern was observed for the anti-T2D of the fraction in the previous study (see 6.3 
above), suggesting a possible correlation between the two phenomenon.  
The attenuation of the hepatic and kidney anti-oxidant parameters by the KSBF indicates that the fraction 
could reduce the oxidative damage to these vital organs and consequently might ameliorate oxidative 
stress- associated pathological complications in diabetes such as liver and kidney damages as well as 
insulin resistance. In the previous anti-diabetic study (see 6.3 above), we found that KSBF was able to 
ameliorate the above mentioned complications in type 2 diabetic rats. Hyperlipidemia has been reported 
to be an important contributory factor for the development of oxidative stress as well as cardiovascular 
complications in T2D [71]. Thus, the observed effects of KSBF on the heart anti-oxidant parameters 
could indicate the beneficial effects of KSBF in alleviating the hyperlipidemia-induced oxidative stress 
which might consequently be useful in the management of cardiovascular diseases associated with T2D. 
The KSBF treatment also boosted the endogenous anti-oxidant reserves in the pancreas which could go a 
long way to reduce the susceptibility of the organ to oxidative attack and consequently improved its 
function. Interestingly, this hypothesis is supported by the mild insulinotropism, improved β-cell function 
and higher number of β-cells demonstrated in KSBF treated type 2 diabetic rats (see 6.3 above). Based on 
the above discussion coupled with the vital role of oxidative stress in the pathogenesis of pancreatic β-cell 
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dysfunction [72], we speculated that the mode of action of KSBF in the pancreas of diabetic animals is 
related to the attenuation of the anti-oxidants status. 
We thus concluded that KSBF treatment attenuated the oxidative stress in various organs of type 2 
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7.0 THE IN VITRO ANTI-OXIDATIVE AND ANTI-DIABETIC ACTIVITY 
OF Vitex doniana 
7.1.1 Vitex doniana (Verbanaceae) 
 
Figure 7.1: Vitex doniana (Verbanaceae); common names: African black plum (English); Dinya (Hausa, 
Nigeria); Orin la (Yoruba, Nigeria); mfudu (Swahili, Tanzania); kashilumbulu (Lunda, Zambia and 
Angola); munyamazi (Luganda, Uganda); utakiri (Igbo, Nigeria), mfutu (Nyanja, Malawi). Photo: 
Mohammed Auwal Ibrahim (2013), Zaria, Nigeria 
7.1.2 Background 
Vitex doniana is a widespread deciduous tree that makes up to 8 -18 m high. The stem bark of the plant is 
usually rough and pale brown whereas the leaves are usually pale greyish-green of approximately 14-34 
cm long. The fruits are drupe, black, edible and sweet which made them highly palatable for consumption 
as snack [1]. Indeed, the fruits are sold in large quantities at various local markets. Vitex doniana is 
widely distributed in tropical West African countries such as Nigeria, Niger and Senegal. It also extended 
eastward to Uganda, Kenya and Tanzania [2]. The plant is also available in some Southern African 
countries such as Angola, Namibia, Zambia and Botswana. 
 
7.1.3 Ethnomedicinal uses 
Different parts of Vitex doniana are used in folkloric medicine for the treatment of a number of diseases. 
Aqueous extract of the leaves have been reported to be useful in the traditional treatment of stomachache, 
diarrhea, dysentery, epilepsy and other psychiatric disorders [2-4]. The stem bark of the plant is used for 
the traditional management of postpartum bleeding in nursing mothers [5] and also as chewing sticks [6].  
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Ethnopharmacological survey from northwestern Nigeria indicates that the stem bark of the plant is used 
for the traditional treatment of diabetes mellitus [7]. 
 
7.1.4 Biological activities 
Different parts of V. doniana have been investigated for a number of pharmacological activities. The 
antibacterial activity of the stem bark was reported where the extract demonstrated potent activity against 
medically and dentally relevant bacteria [6]. Different solvent extracts of the leaves of the plant were 
reported to possess antibacterial activity against S. typhi and E. coli [8]. In a comparative study, the crude 
ethanol extracts of various parts of the plant were found to have a broad spectrum antibacterial activity. 
Upon fractionation, only fractions retained most of the activity which was attributed to the presence of 
cardiac glycosides and tannins [9].  Other biological investigations on the stem bark extract of the plant 
demonstrated a non-dose dependent anti-diarrhoeal activity of the methanol extract [5] and a dose 
dependent hepatoprotective activity of an aqueous extract [1]. Furthermore, the aqueous extract was 
found to induce graded uterine muscle contractions and potentiated the contractile effects of 
prostaglandins and oxytocin [5]. The in vitro antitrypanosomal activity of the stem bark extracts were also 
reported [10]. For the root part of the plant, an aqueous extract was found to induce potent depressant 
activity on peripheral and central nervous system [11] whereas the methanol extract was found to reduce 
exploratory and stereo-typic behavior but potentiated pentobarbital sleeping time [6]. Leaves of V. 
doniana have also been investigated for several biological activities. The anti-helminthic and 
hepatoprotective activities of the aqueous extracts were reported [1, 12]. Also, the leaves exhibited anti-
inflammatory and analgesic activities through the inhibition of prostaglandin synthesis [2]; a myelo-
protective activity in Wistar rats [13] and an antioxidant activity [14]. In a reproductive study, 
consumption of the plant by wild baboons was linked to a reduced reproductive function [15]. For the 
fruits of V. doniana, preliminary investigations revealed that the fruits possess anti-oxidative activity [16].  
 
7.1.5 Phytochemistry 
Information on detailed isolation and structural elucidation of a compound from any part of V. doniana 
does not appear in the literature. However, preliminary analysis on the isolation of -terpineol has been 
described [9]. Qualitative phytochemical screening of the leaves indicates the presence of saponins, 
tannins, flavonoids, terpenoids, anthraquinones and alkaloids [2, 14]. 
 
In order to validate the folkloric claim for anti-diabetic activity of this plant (as earlier mentioned), a 
systematic and comprehensive investigation on the anti-diabetic activity of this plant using in vitro and in 
vivo models was intended but due to unforeseen circumstances in terms of the availability of the plant 
material, only the in vitro anti-oxidative and -glucosidase and -amylase inhibitory studies of the plant 
were investigated.  
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7.2 Anti-oxidative, α-glucosidase and α-amylase inhibitory activity of Vitex 
doniana: possible exploitation in the management of type 2 diabetes 
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Preface: The in vitro anti-oxidative activities of the stem bark, root and leaves of the plant were 
investigated in this article. Subsequently, the crude extract was partitioned and the recovered the solvent 
fractions were investigated for anti-oxidative and α-glucosidase and α-amylase inhibitory activities. The 
phytochemical content of the most active fraction was analyzed by GC-MS. This article has been 
submitted for publication to ‘Records of Natural Product’’ and is currently under review. 
 
7.2.1 Abstract 
Vitex doniana is an important African medicinal plant traditionally used for the treatment of many 
diseases including type 2 diabetes (T2D). In this study, ethyl acetate, ethanol and aqueous extracts of the 
stem bark, root and leaf of V. doniana were analyzed for in vitro anti-oxidative activity and the results 
indicated that the ethanolic extract of the leaves had the best anti-oxidative activity. Subsequently, the 
ethanolic extract of the leaves was partitioned between hexane, dichloromethane, ethyl acetate and water. 
The aqueous fraction had a significantly (P<0.05) higher phenolic content and also showed the best anti-
oxidative activity within the fractions. Furthermore, the aqueous fraction demonstrated significantly 
(P<0.05) more potent inhibitory activities against α-glucosidase and α-amylase than other fractions. 
Steady state kinetic analysis revealed that the aqueous fraction inhibited both α -glucosidase and α-
amylase activities in a non-competitive manner with inhibition binding constant (Ki) values of 5.93 and 
167.44 µg/ml, respectively. Analysis of the aqueous fraction by GC-MS showed the presence of 
resorcinol, 4-hydroxybenzoic acid, 3,4,5 trimethoxy phenol and 2,4'-dihydroxychalcone identified by 
their mass fragmentation patterns and comparison to standard spectra. The results obtained from this 






Despite extensive research efforts, the incidence of diabetes is still increasing at an alarming rate with 
over 346 million people affected worldwide and the number is expected to rise to 544 million people in 
2030 [17, 18]. Prolonged diabetes leads to serious damage to many of the body’s physiological processes 
and causes a number of medical complications, such as cardiovascular disease, stroke, atherosclerosis, 
blindness, kidney damage, lower-limb amputations among many others [18,19].  Among the two major 
types of diabetes, type 2 diabetes (T2D) accounts for 90-95% of the total diabetic patients worldwide. It is 
a heterogeneous disorder characterized by a progressive decline in insulin action (insulin resistance), 
followed by the inability of pancreatic β-cells to compensate for insulin resistance (β-cell dysfunction) 
which leads to hyperglycemia [20]. 
 
Prolonged hyperglycemia leads to the auto-oxidation of glucose and formation of advanced glycated end 
products which are involved in the generation of reactive oxygen species (ROS) that cause lipid 
peroxidation and play an important role in the production of secondary complications in T2D [21]. 
Oxidative stress is believed to be a common pathway linking diverse mechanisms for the pathogenesis of 
microvascular and macrovascular complications of diabetes [22]. Therefore, the use of antioxidants could 
be exploited in the treatment of T2D and prevention of its chronic vascular complications [23]. Another 
therapeutic approach commonly exploited  in the management of T2D is decreasing the postprandial rise 
of blood glucose level by impeding glucose absorption in the digestive tract through inhibition of 
carbohydrate hydrolyzing enzymes (α-glucosidase and α-amylase) [24]. Combined actions of α-
glucosidase and α-amylase enzymes are responsible for hydrolysis of starch, complex carbohydrates and 
oligosaccharides to glucose and other monosaccharides which are then absorbed in the intestinal 
epithelium and enter into the blood circulation [25]. Therefore, α-glucosidase and α-amylase inhibitors 
will ultimately reduce the flow of glucose from complex dietary carbohydrates into the bloodstream, 
diminishing the postprandial hyperglycemia.    
 
At present, many clinical drugs are used as α-glucosidase inhibitors; however, severe side effects such as 
diarrhea, flatulance, lactic acid intoxication and other gastrointestinal problems are associated with their 
intake [26, 27]. Randomized controlled trials with glucosidase inhibitors report these gastrointestinal side 
effects as the most common reason for noncompliance and early subject withdrawal [28]. Interestingly, 
plant based agents were reported to be a more acceptable source of glucosidase inhibitors due to their low 
cost and non-toxic nature, including a low incidence of serious gastrointestinal side effects [29, 30].  On 
the other hand, synthetic anti-oxidative agents, such as butylated hydroxyanisole (BHA), butylated 
hydroxytoluene (BHT), propylgallate (PG), and tertiobutylhydroxytoluene exhibit potent free radical 
scavenging effects but they induce liver damage and carcinogenesis in laboratory animals [31, 32]. Based 
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on the above, recourse to plants as sources of antioxidants and α-glucosidase inhibitors becomes an 
appealing alternative.  
 
Vitex doniana (Verbanaceae) commonly called African black plum is widely distributed in tropical West 
Africa. Various parts of the plant are used by traditional medicine practitioners in Nigeria for the 
management and treatment of several disorders which include rheumatism, hypertension, cancer, and 
inflammatory diseases. An ethnobotanical study also revealed that the plant leaves are used in the 
treatment of diabetes mellitus in northern Nigeria [7]. The myelo- and hepatoprotective as well as the 
analgesic and antitrypanosomal activities of the leaf extracts have also been reported in several recent 
studies [1-2; 10, 13]. The stem bark of the plant was found to induce graded uterine muscle contractions 
[5] and demonstrated antidiarrhoeal and antibacterial activities [3, 6, 9]. Furthermore, natural 
consumption of the plant was linked to reduced reproductive function of wild baboons [15]. A recent 
preliminary study also reported the antioxidant potential of the methanolic extract from the leaves of this 
plant [14]. However, the detailed anti-oxidative effects of different parts of this plant using various 
extracts and solvent fractions as well as the inhibitory effects on the carbohydrate digesting enzymes are 
still unknown, despite the traditional use of the plant in the management of diabetes. 
 
Hence our current study conducted a comprehensive and systematic investigation on the in vitro anti-
oxidative as well as α-glucosidase and α-amylase inhibitory activities of various extracts and solvent 
fractions of V. doniana with a view to find new alternative agent(s) that could provide a holistic avenue to 
control postprandial hyperglycemia and other diabetic complications.  
 
7.2.3 Materials and Methods 
Please refer to chapter two sub-sections 2.3-2.6 page 35-38; 2.6.1-2.6.6 page 38-40 for detailed materials 
and methods that affect V. doniana 
 
7.2.4 Results 
The ethanolic extract of the leaves was found to contain a significantly (P<0.05) higher amount of total 
phenolics than other crude extracts from the different parts of the plant (Table 7.2.1). All the stem bark 
extracts displayed a weak and statistically similar (P<0.05) total reducing power (GAE) compared to 
ascorbic acid and trolox. For the roots, the ethyl acetate extract had significantly (P<0.05) higher reducing 
power than other extracts at all concentrations. The ethanolic extract of the leaves demonstrated a 











The results are expressed as mean ± SD values of triplicate determinations. a-gDifferent superscript alphabets along a 
column indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05) 
 
 
Crude extracts % Yield Total polyphenol 
(mg/g GAE) 
   
Stem bark   
Ethyl acetate  0.26 0.86 ± 0.03a 
Ethanolic 0.53 4.38 ± 0.38c 
Aqueous 0.67 10.65 ± 0.62d 
   
Root   
Ethyl acetate 0.11 17.75 ± 0.64e 
Ethanolic 0.42 29.04 ± 3.88f 
Aqueous 0.51 19.92 ± 2.15e 
   
Leaves   
Ethyl acetate 0.29 9.76 ± 1.83d 
Ethanolic 0.22 50.90 ± 6.06g 






Figure 7.2.1: Percentage total reducing power (gallic acid equivalent) of crude extracts of stem bark (A), 
root (B) and leaves (C) of Vitex doniana parts. Data are presented as mean ± SD of triplicate 
determinations.  a-dDifferent alphabets presented for a given concentration of each extract indicate 
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The calculated IC50 values for the different anti-oxidative models are presented in Table 7.2.2. According 
to the IC50 values, the DPPH radical scavenging activities of the various extracts of V. doniana parts 
indicated that the stem bark extracts had weaker free radicals quenching ability than extracts from other 
parts of the plant (Table 7.2.2). Crude ethanolic and aqueous extracts of the root as well as the ethanolic 
extract of the leaves demonstrated the strongest and statistically similar (P<0.05) free radical scavenging 
activity among all the crude extracts from the plant. The best HRS activity was observed with ethyl 
acetate extract of the root (IC50 = 2.22 ± 0.15 µg/ml) and the ethanolic extract of the leaves (IC50 = 2.72 ± 
0.60 µg/ml). Furthermore, in the NO scavenging assay, the ethanolic extract of the leaves showed a 
significantly higher (P<0.05) scavenging activity towards the generated NO radicals than other extracts 
from the plant (Table 7.2.2). A close analysis of the results obtained from the four different models for 
anti-oxidative studies indicated that the ethanolic extract of the leaves had the highest anti-oxidative 











































The results are expressed as mean ± SD values of triplicate determinations. a-kDifferent superscript alphabets along a 
column indicate significant difference (Tukey’s-HSD multiple range post hoc test, P<0.05). ND means not 
determined. *Unit was expressed in mg/ml. **Unit was expressed in g/ml.  
 
Using solvent-solvent partitioning, hexane, dichloromethane, ethyl acetate and aqueous fractions were 
obtained. All the fractions possessed reducing power ability but the aqueous fraction displayed the best 
activity in this model (Figure 7.2.2). However, the results of the DPPH radical scavenging activity 
showed that the ethyl acetate fraction had a significantly higher (P<0.05) free radical scavenging activity 
than the aqueous and dichloromethane fractions (Table 7.2.3). The results also indicated that the hexane 
fraction did not contain free radical scavenging phytochemicals. Among the four fractions, only the 




DPPH HRS NO 
Stem bark    
Ethyl acetate 13.70 ± 1.18h* 2.43 ± 0.22i** 298.79 ± 56.05e 
Ethanol 170.88 ± 12.40f 7.51 ± 0.90c 4.47 ± 0.13j* 
Aqueous 128.93 ± 19.41e 467.54 ± 63.40g 192.10 ± 31.16d 
    
Root    
Ethyl acetate 47.38 ± 7.84d 2.22 ± 0.15a 10.02 ± 1.52k* 
Ethanol 2.36 ± 0.34b 37.66 ± 5.15d 549.87 ± 58.84f 
Aqueous 1.96 ± 0.16ab 99.66 ± 10.25e 691.22 ± 6.53fg 
    
Leaves    
Ethyl acetate 103.63 ± 5.45e 371.86 ± 23.28f 2.17 ± 0.22i* 
Ethanol 2.64 ± 0.76b 2.72 ± 0.60a 45.94 ± 3.04b 
Aqueous 6.49 ± 0.10g* 1.37 ± 0.08h* 76.39 ± 6.45c 
    
Ascorbic acid 2.56 ± 0.26b ND 26.40 ± 6.46a 
Gallic acid 1.40 ± 0.43a ND 1.05 ± 0.23h* 
Trolox 8.47 ± 2.88c 3.23 ± 0.49ab 629.76 ± 63.98f 
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significantly (P>0.05) different from each other in the HRS activity assay whereas the aqueous fraction 
showed a significantly higher (P<0.05) NO scavenging activity than the ethyl acetate fraction (Table 
7.2.3).  
 
Figure  7.2.2:  Percentage total reducing power (gallic acid equivalent) of different solvent fractions of 
ethanolic extract of V. doniana leaves. Data are presented as mean ± SD of triplicate determinations. a-
eValues with different letters presented for a given concentration are significantly different from each 
other (Tukey’s-HSD multiple range post hoc test, P<0.05). 
 
Table 7.2.3: IC50 values of various solvent fractions of ethanolic extract of V. doniana leaves in different 
anti-oxidative models 
Fractions Total phenolics 
(mg/g GAE) 
IC50 (µg/ml) 
DPPH HRS NO 
Aqueous 32.57 ± 2.11a 67.42 ± 1.54b 81.26 ± 1.92 210.29 ± 12.20a 
Ethyl acetate 24.81 ± 0.68b 52.73 ± 0.39a 77.93 ± 4.44 697.49 ± 27.71b 
Dichloromethane 9.27 ± 1.34c 92.06 ± 0.44c NIL NIL 
Hexane NIL NIL NIL NIL 
The results are expressed as mean ± SD values of triplicate determinations. a-cDifferent superscript alphabets along a 
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The α-glucosidase and α-amylase inhibitory activities of the different solvent fractions of the ethanolic 
extract of the leaves are shown in Figure 7.2.3. With the exception of hexane fraction, all other fractions 
inhibited α-glucosidase and α-amylase in vitro (Figure 7.2.3) but judging from the IC50 values, the 
aqueous fraction also displayed a significantly (P<0.05) higher  α-glucosidase and α-amylase inhibitory 
activities than other fractions (Table 7.2.4).  
 
Figure 7.2.3: α-glucosidase (A) and α-amylase (B) inhibitory activities of different solvent fractions of 
ethanolic extract of V. doniana leaves. The results are expressed as mean ± SD of triplicate 
determinations. a-dDifferent alphabets over the bars for a given concentration indicate significant 



















































































Table 7.2.4:  IC50 values for the inhibition of α-glucosidase and α-amylase by various solvent fractions of 
ethanolic extract of V. doniana leaves  
Fractions/standard IC50 (µg/ml) 
α-glucosidase α-amylase 
Aqueous  41.26 ± 4.25a 729.31 ± 145.76b 
Ethyl acetate 61.98 ± 4.81b 1.67 ± 0.10c* 
Dichloromethane 91.37 ± 5.22c 7.27 ± 0.33d* 
Hexane NIL NIL 
Acarbose 55.59 ± 5.22b 256.66 ± 20.52a 
The results are expressed as mean ± SD of triplicate determinations. a-dDifferent superscript alphabets 
within a column for a given parameter indicate significant difference (Tukey’s-HSD multiple range post 
hoc test, P<0.05). *Unit was expressed in mg/ml. 
 
 Steady state kinetic analysis from the initial velocity studies of α-glucosidase using pNPG as substrate 
gave a KM and Vmax of 2.00 mM and 655.09 μmol/min respectively whereas a KM and Vmax of 0.25 % 
and 33.70 μmol/min respectively, were computed for α-amylase using starch as the substrate. Delineation 
of the type of inhibition exerted by the aqueous fraction revealed that α-glucosidase and α-amylase are 
non-competitively (Figure 7.2.4) inhibited, albeit at different rates, with Ki values of 5.93 and 167.44 









Figure 7.2.4: Lineweaver-Burke’s plot of α-glucosidase (A) and α-amylase (B) catalyzed reactions in the 
presence and absence of the aqueous fraction derived from the V. doniana leaves ethanolic extract 
Table 7.2.5: Effect of aqueous fraction (60 μg/ml) of ethanolic extract of V. doniana leaves on some 
kinetic parameters of α-glucosidase and α-amylase 
Kinetic parameters α-glucosidase α-amylase 
Control + aqueous fraction Control + aqueous fraction  
KM  2.00*  2.00*  0.25#  0.25#  
Vmax (μmol/min) 655.09 58.96 33.70 24.81 
Ki (µg/ml) - 5.93 - 167.44 






















































Based on the above results, the aqueous fraction was subjected to GC-MS analysis in order to identify the 
components of the fraction. From the experiment, the reasonably identified compounds in the fraction 
were mainly phenolic compounds such as resorcinol, 4-hydroxybenzoic acid, 3,4,5 trimethoxy phenol and 
2,4'-dihydroxychalcone (Figure 7.2.5 and Table 7.2.6). 
Table 7.2.6: Components of the aqueous fraction of V. doniana leaves ethanolic extract identified 





8.05 Resorcinol 110.1 
11.43 4-hydroxy benzoic acid 138.1 
12.36 3,4,5-trimethoxy phenol 184.2 


















Figure 7.2.5: The chemical structures of the compounds identified in the aqueous fraction of the ethanolic 




Type 2 diabetes is linked to oxidative stress-mediated complications as well as hyperglycemia which are 
regarded as important underlying factors for the pathogenesis of the disease [33]. Thus, agents that can 
scavenge free radicals and have strong antioxidant as well as α-glucosidase and α-amylase inhibitory 
properties play a significant role in the treatment and prevention of T2D and related complications.  In the 
present study, the stem bark, root and leaves of different solvent extracts of V. doniana were evaluated for 
their anti-oxidative property which led to the fractionation of the ethanolic extract of the leaves as well as 
investigation of the anti-oxidative and α-glucosidase and α-amylase inhibitory activity of the fractions.  
  
Four complementary assays were performed to evaluate the anti-oxidative activities of the extracts 
because a single model cannot give a full evaluation of the anti-oxidative capabilities of the different 
extracts tested due to the involvement of multiple mechanisms. The total reducing power of a compound 
serves as a significant indicator of its antioxidant potential. The reductants terminate the free radical chain 
reaction by donating hydrogen atoms to the radical molecules. Free radicals are known to be a major 
factor in cellular damages in biological systems and DPPH method has been used to evaluate the free 
radical scavenging activity of natural antioxidants. On the other hand, hydroxyl radicals are also 
extremely reactive species capable of damaging any biological molecule found in living systems [34] and 
NO is an unstable species which reacts with oxygen to generate the reactive nitrite and peroxynitrite 
anions [35]. All these radicals are implicated in the pathogenesis of T2D [36]. Findings from this 
investigation revealed that among the various solvent crude extracts of the different parts of V. doniana, 
the ethanolic extract of the leaves possessed better antioxidant activity having reasonably high scavenging 
activity toward the various forms of radicals. This observation supports the traditional use of the leaves of 
V. doniana by traditional healers for the management of T2D and other radical pathologies as opposed to 
the other parts of the plant. Hence, the ethanolic extract of the leaves was selected for further fractionation 
based on its anti-oxidative activities. 
 
Evaluation of the different fractions from the ethanol extract of the leaves indicated that the aqueous 
fraction had the best anti-oxidative activity amongst the fraction but the activity was less potent than what 
was observed for the crude ethanolic extract. This suggests that not all anti-oxidative components were 
concentrated in the aqueous fraction and other less polar components also contribute to the overall anti-
oxidative activity. Nevertheless, at least among the fractions, the aqueous fraction seems to contain the 
most powerful phytochemical(s) that could be useful therapeutic agents for treating oxidative stress based 
metabolic disorders including T2D. Moreover, the observed anti-oxidative activity is linked to the highest 
phenolic content recorded in this fraction because phenolic compounds are the major constituents in 




Analysis of the α-glucosidase inhibitory activity of the fractions also demonstrated that the aqueous 
fraction contains the most powerful inhibitors against this enzyme which could slow down the breakdown 
of disaccharides to liberate glucose; thereby reducing glucose absorption from the small intestine [38]. 
This consequently suppresses the postprandial rise in the blood glucose level. The observation could be 
linked to the high phenolic content recorded in this fraction since polyphenolic fractions from plants have 
been shown to inhibit α-glucosidase activity and allow for a tight control of blood glucose [39].  Indeed, 
some isolated phenolics have been reported to be the main bioactive anti-diabetic agents of Brickellia 
cavanillesii [40] and Garcinia mangostana [41] and the activity was mediated through the inhibition of α-
glucosidase. Furthermore, Mai et al. [42] reported a strong positive correlation between polyphenolic 
content and α -glucosidase inhibitory effects of 28 extracts from Vietnamese edible plants. In the same 
vein, the aqueous fraction had the highest α-amylase inhibitory activity amongst the fractions. Humans 
have five α-amylase genes, three encoding salivary α-amylase and two encoding pancreatic α-amylase. 
Both salivary and pancreatic α-amylases are composed of a single polypeptide chain of 496 amino acids 
with high degree of amino acid sequence similarity of  97% overall identical residues and 92% in the 
catalytic domain [24]. These similarities suggest that the aqueous fraction could interact with both 
isozymes through a similar pattern to slow down the breakdown of complex carbohydrates to 
oligosaccharides, thereby diminishing the effect of carbohydrates consumption on postprandial 
hyperglycemia. Although the α-amylase inhibitory activity of the aqueous fraction was lower than the 
reference drug acarbose, but keeping in mind the multiple health benefits of herbal medicines, this finding 
may provide further scope for investigation. 
 
Kinetic delineation of the α-glucosidase and α-amylase inhibitions indicated that the aqueous fraction 
inhibited the enzymes in a non-competitive manner suggesting that the bioactive ingredient(s) bind to the 
enzymes at separate site(s) of the enzyme (rather than the active site) but caused conformational 
modification at the active site which prevented the effective binding of the substrates to the enzymes. It 
could further suggest that the fraction contains some phytochemicals capable of interacting with the α-
glucosidase-pNPG and α-amylase-starch complexes [43]. Similarly, recent studies have shown that some 
isolated phenolics such as 6-hydroxyacetyl-5-hydroxy-2,2-dimethyl-2H-chromene, fucofuroeckol A and 
Dioxinodehydroeckol exhibited potent α-glucosidase inhibitions in a non-competitive manner [40,44]. 
Interestingly, our GC-MS analysis also revealed that the aqueous fraction mainly contains phenolic 
compounds such as resorcinol, 4 hydroxybenzoic acid and 3,4,5 trimethoxy phenol and 2,4'-
dihydroxychalcone. It could thus imply that the observed α-glucosidase and α-amylase inhibitions of this 
fraction is mediated by these phenolics acting individually or synergistically. The identification of the 
chalcone in the fraction is also interesting in that chalcones are biosynthetic precursors to the flavonoids 




The data obtained from this study suggest that the V. doniana leaves contain phenolic compounds that 
could serve as anti-oxidative agents and inhibitors of α-glucosidase and α-amylase which could be 
exploited for the development of a holistic therapeutic strategy for the control of postprandial blood 
glucose levels, T2D and chronic vascular complications. However, the determination of the specific role 
of each phenolic compound awaits further work on the isolation of these compounds and conducting 
detailed intervention trials in a T2D model of rats.  
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Postscript: From the above studies, the aqueous fraction derived from the crude ethanolic extract of the 
leaves had the best in vitro anti-diabetic potentials. Unfortunately however, due to the low yield and 
unavailability of the leaves of this plant (for more extraction) as at the time needed, this plant was not 
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8.0 GENERAL DISCUSSIONS AND CONCLUSIONS 
8.1 General discussions 
Diabetes mellitus affects more than 14 million people in Africa, accounting for approximately 4.3% of 
average adults and responsible for about 401 000 death in the continent [1]. It inflicts a major socio 
economic problem, especially to the patients. Currently, different therapeutic approaches are used to 
control the disease using synthetic anti-diabetic drugs in addition to life style modification. Unfortunately 
however, most of the available anti-diabetic drugs are costly and not readily affordable to the majority of 
the affected population. Interestingly, the continent is endowed with tremendous medicinal plants that are 
explored for the folkloric treatment of the disease. These medicinal plants include Ziziphus mucronata, 
Cassia singueana, Parkia biglobosa, Khaya senegalensis and Vitex doniana [2, 3]. Thus, this study was 
undertaken to validate the traditional use of these plants in the treatment of diabetes which would provide 
a scientific basis for the subsequent standardization and commercialization of these medicinal plants as 
anti-diabetic herbal products (in crude form) after approval by relevant authorities. Furthermore, the study 
was aimed to identify the possible bioactive anti-diabetic compounds from these medicinal plants as a 
prelude to the development of novel plant-derived anti-diabetic drugs which are considered safer than 
chemically-originated drugs. 
 
In order to achieve the set goals, the stem bark, root and leaves of each of the afore-mentioned plants 
were initially subjected to a thorough investigation for in vitro anti-oxidative activity. This is because of 
the vital role of oxidative stress to the two main pathogenic features of diabetes (insulin resistance and 
pancreatic β-cell dysfunction) as well as other aspects of diabetes complications [4-6]. Thus, the best anti-
oxidative crude extracts were selected for further studies. The selection was made in comparison to other 
extracts within a plant and not across plants.  
Ziziphus mucronata was the first plant under study which had a crude ethanolic extract of the root with 
remarkable in vitro anti-oxidative activity. Upon fractionation, this crude extract yielded a butanol 
fraction with high in vitro anti-oxidative as well as α-glucosidase and α-amylase inhibitory activities. In 
spite of these activities of the butanol fraction, the in vivo anti-diabetic activity of this fraction was not as 
powerful as expected. Indeed, among all the four fractions investigated for in vivo anti-diabetic activity in 
this study, this butanol fraction demonstrated the weakest anti-diabetic effects despite its ability to 
ameliorate oxidative stress in some organs of diabetic animals. These observations suggest that the 
alleviation of oxidative stress is not strong enough to reverse the alterations of diabetes related parameters 
possibly because some phytochemicals might have lost their activity due to xenobiotic metabolic 
processes that could convert bioactive compounds to inactive ones [7]. It is also possible that the 
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bioavailability of the bioactive phytochemicals was highly limited. In the GC-MS analysis, phenolics 
were identified as the main bioactive phytochemicals and coincidentally, a pure phenolic compound (2,7-
dihydroxy-4H-1-benzopyran-4-one) with potent α-glucosidase and α-amylase inhibitory activities was 
subsequently isolated from the fraction and characterized. The 2,7-dihydroxy-4H-1-benzopyran-4-one 
inhibited α-glucosidase and α-amylase in uncompetitive and non-competitive patterns respectively, which 
were different from the mixed inhibition patterns observed for the entire fraction. This observation 
suggests that other phytochemical components of the fraction contribute to the inhibition of the two 
enzymes. Based on the above discussions, it appears that standardisation and commercialisation of this 
part of the plant (in crude form) as anti-diabetic herbal remedy might not be a promising venture because 
of the weak activity. However, on a positive note, the fraction yielded a pure bioactive compound that 
could be exploited for the development of novel plant-derived anti-diabetic drugs. 
Cassia singueana was the second plant under study. The crude ethyl acetate extract of the stem bark 
yielded an acetone fraction with higher in vitro anti-oxidative as well as α-glucosidase and α-amylase 
inhibitory effects compared to other solvent fractions. Subsequently, the fraction retained its anti-diabetic 
effects in a dose dependent fashion with no toxic effects in vivo and was also able ameliorate most of the 
diabetes associated complications which were linked to the observed results under in vitro conditions. The 
foregoing suggests the stability and safety of the bioactive compounds of the fraction. Although the GC-
MS analysis detected mainly phenolics as the bioactive ingredients but the bioassay guided isolation led 
to a pentacyclic triterpene, 3β-O-acetyl betulinic acid. This underscores the need to isolate, characterize 
and test a pure compound before a definite statement is made on the bioactive phytochemicals in a plant 
material. The difference in the mechanism of α-glucosidase and α-amylase inhibitions could also attest to 
the earlier assertion. Thus, taken the results of in vitro and in vivo studies as a whole, the C. singueana 
stem bark has the potentials for standardisation as anti-diabetic herbal product. 
For P. biglobosa, crude ethanolic extract of the leaves had the best anti-oxidative activity and upon 
fractionation, a butanol fraction had the best in vitro anti-oxidative as well as α-glucosidase and α-
amylase inhibitory effects compared to other solvent fractions. In the in vivo studies, this fraction 
demonstrated remarkable anti-diabetic effects. More interestingly, the fraction seems to work via multiple 
mechanisms that involve the established modes of actions of most of the anti-diabetic therapies. This 
could be a trace of evidence for synergism among the phytochemical constituents of the fraction.  It is 
also noteworthy to state that, in comparison to the fractions from other plants under study, this fraction 
demonstrated the best in vivo anti-diabetic effects.  However, from the phytochemistry view point, similar 
observations to the C. singueana fraction were made where the GC-MS analysis detected mainly 
phenolics and sugars but a pentacyclic triterpene, lupeol was isolated as the α-glucosidase and α-amylase 
inhibitory phytochemical. Furthermore, the mechanism of α-glucosidase and α-amylase inhibitions 
between the fraction and lupeol was different which agrees with the earlier suggestion on possible 
253 
 
synergism. Considering the fact that this fraction was derived from the leaves and coupled with its 
remarkable anti-diabetic effects, this part of the plant presents a good opportunity for possible 
standardisation as anti-diabetic herbal remedy which could subsequently be commercialised. The fraction 
also further confirmed that lupeol has an anti-diabetic potential. 
The butanol fraction derived from the crude ethanolic extract of K. senegalensis root was the last fraction 
in the in vivo studies because it had the best in vitro activities among other solvent fractions. The in vivo 
studies also demonstrated that the fraction has dose-dependent anti-diabetic effects which were also 
mediated through multiple mechanisms. However, the anti-diabetic effects are generally not as potent as 
those of P. biglobosa fraction. The GC-MS analysis detected an array of phenolic compounds as the 
phytochemical constituents of the fraction and subsequently, the bioassay guided isolation led to a 
phenolic-like, simple (6 carbon) and rarely-isolated compound, bicyclo [2.2.0] hexane-2,3,5-triol. This 
compound inhibited α-glucosidase, but not α-amylase, in the same pattern as the butanol fraction which 
also indicate possible synergism with other phytochemicals. However, the synergism in this fraction did 
not seem to be as powerful as what was observed in the P. biglobosa fraction because in this case, at least 
the pattern of inhibition against one enzyme is similar. Generally, results from this plant also 
demonstrated its potential for further standardization. More interestingly, this fraction yielded a rarely 
encountered compound in natural product chemistry and it possessed potent α-glucosidase and α-amylase 
inhibitory activities. 
8.2 General conclusions 
Among the five plants solvent fractions investigated in this work, three of the fractions have demonstrated 
remarkable and more effective, in some cases, similar in vivo anti-diabetic effects than a commonly used 
standard anti-diabetic drug, metformin. These fractions did not show signs of toxicity for most of the 
parameters measured in this investigation. The study identified the possible bioactive anti-diabetic 
compounds (in their pure form) from the selected fractions. The findings are important for the relevant 
government agencies, pharmaceutical industries, scientific community and poor diabetic patients because 
it might open an avenue for the development of viable and cost effective anti-diabetic herbal products 
and/or novel plant-derived anti-diabetic drugs. 
 
8.3 Recommendations 
Massive investment of human and financial resources to conduct a large human based clinical study may 
be worthwhile as it will confirm the efficacy of the plant samples in humans for eventual standardisation 
and commercialization as herbal products. The identified bioactive compounds should be subjected to a 
thorough in vivo anti-diabetic study as conducted with the fractions in this study. This may eventually 
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Appendix 1: 1H NMR spectrum of 3β-O-acetyl betulinic acid isolated from the acetone fraction of 
C.singueana stem bark. 
 
 
Appendix 2: 13C NMR spectrum of 3β-O-acetyl betulinic acid isolated from the acetone fraction of 




Appendix 3: 1H NMR spectrum of lupeol isolated from the butanol fraction of P. biglobosa leaves 
 
 





Appendix 5: 1H NMR spectrum of bicyclo [2.2.0]hexane-2,3,5-triol isolated from the butanol fraction of 
K. senegalensis root 
 
  
Appendix 6: 13C NMR spectrum of bicyclo [2.2.0]hexane-2,3,5-triol isolated from the butanol fraction of 





Appendix 7: DEPT spectra of bicyclo [2.2.0]hexane-2,3,5-triol isolated from the butanol fraction of K. 
senegalensis root 
 






Appendix 9:  NOESY spectrum of bicyclo [2.2.0]hexane-2,3,5-triol isolated from the butanol fraction of 
K. senegalensis root 
 
 
Appendix 10: HSQC correlation of bicyclo [2.2.0]hexane-2,3,5-triol isolated from the butanol fraction of 





Appendix 11: HMBC correlation of bicyclo [2.2.0]hexane-2,3,5-triol isolated from the butanol fraction 





Appendix 12: The ethical clearance letter obtained from the University animal ethics sub-committee to 
conduct the in vivo intervention trial 
